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ABSTRACT 
The causal role of human papillomavirus (HPV) in oropharyngeal squamous cell carcinoma (OSCC) 
has been well established. The work presented in this thesis sets out to explore the information 
available about HPV-OSCC and examine the psychosocial issues associated with a diagnosis of 
HPV-OSCC.  
Six studies were carried out between 2013 and 2016. Study 1 systematically reviewed the existing 
literature examining the psychosocial impact of HPV-OSCC in patients (n=10 studies) and current 
knowledge of the relationship between HPV and OSCC (n=41 studies). Study 2 was a content 
analysis examining the media coverage in the UK of the link between HPV and OSCC (n=112 
articles). Study 3 was a qualitative study with health professionals caring for HNC patients (n=15). 
Study 4 was an extension of study 3, developing a survey for dissemination among health 
professionals working with HPV-OSCC patients (n=260). Both studies explored their experiences of 
and attitudes to discussing HPV with their patients, with study 4 additionally measuring knowledge 
of HPV-OSCC. Study 5 was a qualitative study with patients diagnosed with HPV-OSCC (n=20) and 
with some of these patients’ partners (n=12), examining their experiences around the diagnosis of 
HPV-OSCC. Study 6 involved the development of an information booklet about HPV-OSCC, based 
on the findings of studies 1-5.  
The existing literature examining the psychosocial impact of HPV-OSCC provided limited evidence 
about the impact of HPV in OSCC patients. Knowledge of HPV in OSCC was not well known across 
most populations, and the HPV-OSCC content presented in the media lacked basic facts about 
HPV. The increasing incidence of HPV-OSCC was a significant issue for health professionals and 
key messages to communicate to HPV-OSCC were found. Reactions about HPV were mixed 
among participants whose cancer or partners’ cancer was caused by HPV. An information booklet 
developed about HPV-OSCC was well received by patients and health professionals and could act 
as a discussion tool to provide patients with evidence-based information. De-escalation of treatment 
in the future may help minimise some of the negative psychosocial outcomes associated with HPV-
OSCC and improve long-term functioning. 
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CHAPTER 1. EPIDEMIOLOGY 
Human papillomavirus (HPV), the leading cause of cervical cancer, has increasingly been 
recognised as a cause of head and neck cancer (HNC). The increasing number of HPV-related 
HNC cases have implications both for health professionals in clinical practice, for the patient 
and for the patient’s family. There is a depth of understanding of the role of HPV in cervical 
cancer, but as yet, in comparison there is still a sparse amount of understanding of the natural 
history of HPV in HNC and a lack of research examining the psychosocial impact of a diagnosis 
of HPV-related HNC. The term ‘psychosocial’ is used throughout this thesis in reference to 
cognitive, social, emotional and behavioural implications of the diagnosis of HPV.  
This chapter presents the epidemiology and risk factors of both HNC and HPV-related HNC, 
and what implications this might hold for treatment of HNC patients in the future. Chapters 2 
and 3 will present evidence of the psychosocial impact of HNC and of HPV in the context of 
cervical cancer screening. Theoretical approaches which may be useful for future research will 
also be considered. 
1.1 Head and neck cancer 
The term HNC covers cancers found in the lip, oral cavity, nose and paranasal sinuses, 
nasopharynx, oropharynx, hypopharynx and larynx (Syrjanen, 2004). HNCs are usually found in 
squamous cells that line the moist, mucosal surfaces inside the head and neck. This includes 
the mouth, nose and throat. Therefore the most common type of HNC is squamous cell 
carcinoma (SCC), accounting for about 90% of HNCs (Kim, King, & Agulnik, 2010). HNC is the 
sixth most common type of cancer in the world, with approximately 600,000 new cases 
diagnosed worldwide each year (Ferlay et al., 2010).  
1.1.1 Terminology  
As described above, the term HNC encompasses a range of anatomical sites in the head and 
neck. The term HNC covers all cancers of the head and neck, whereas other terms such as oral 
cancer, mouth cancer, throat cancer and oropharyngeal cancers include specific anatomical 
sites. These terms are often used interchangeably and although oropharyngeal cancer will be 
CHAPTER 1 – EPIDEMIOLOGY 
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the type of HNC that will be focused on throughout this thesis, some of the studies did not 
specifically recruit using oropharyngeal cancer as a criterion and so for these studies, the 
broader term of HNC has been used to encompass all cancers of the head and neck. Also when 
citing previous research, the term will be dependent on the type of cancer presented in the 
study.  
Figure 1.1 illustrates the parts of the head and neck where oropharyngeal squamous cell 
carcinoma (OSCC) occurs and Table 1.1 demonstrates which anatomical sites are included in 
the different terminologies. The International Classification of Diseases (ICD) was produced by 
the World Health Organisation (WHO) and provides a diagnostic tool for epidemiology, health 
management and clinical purposes. The ICD-10 is the latest version of the diagnostic tool and 
Table 1.2 clarifies the codes assigned to HNCs, with those codes assigned to OSCCs in bold. 
1.1.2 Oropharyngeal cancer 
Oropharyngeal cancers are those HNCs located in the soft palate, base of the tongue, side 
walls of the throat (tonsils) or the back wall of the throat (Macmillan Cancer Support, 2013). 
SCCs account for the majority of oropharyngeal cancers. Symptoms can include a painless 
swelling or lump in the neck, a sore throat or tongue, earache, difficulty swallowing or moving 
the mouth and jaw, changes in a patient’s voice, bad breath and unexplained weight loss 
(Macmillan Cancer Support, 2013).  
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Figure 1.1: Showing the parts of the head and neck where oropharyngeal cancers occur 
 
Areas where oropharyngeal cancer can occur  
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Table 1.1: Explaining the terminology behind the anatomical sites 
 
Common terminology 
Anatomical site 
Head and 
neck cancer 
Oral cancer 
Oropharyngeal 
cancer 
Mouth 
cancer 
Throat 
cancer 
Oral cavity (including 
lip, floor of mouth, 
buccal mucosa, 
gingiva, hard palate 
and mobile part of the 
tongue) 
x x  x  
Nose and paranasal 
sinuses 
x     
Nasopharynx x    x 
Oropharynx (including 
base of tongue, 
tonsils, soft palate, 
back wall of throat) 
x x x  x 
Hypopharynx  x x    
Larynx x    x 
Laryngopharynx     x 
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Table 1.2: International Classification of Diseases for head and neck cancer 
ICD-10 code Site description 
C00-C14 Malignant neoplasm of lip, oral cavity and pharynx 
C00 Malignant neoplasm of lip 
C01 Malignant neoplasm of base of tongue 
C02 Malignant neoplasm of other and unspecified parts of tongue 
C03 Malignant neoplasm of gum 
C04 Malignant neoplasm of floor of mouth 
C05 Malignant neoplasm of palate 
C06 Malignant neoplasm of other and unspecified parts of mouth 
C07 Malignant neoplasm of parotid gland 
C08 Malignant neoplasm of other and unspecified major salivary glands 
C09 Malignant neoplasm of tonsil 
C10 Malignant neoplasm of oropharynx 
C11 Malignant neoplasm of nasopharynx 
C12 Malignant neoplasm of pyriform sinus 
C13 Malignant neoplasm of hypopharynx 
C14 Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and 
pharynx 
C30 Malignant neoplasm of nasal cavity and middle ear 
C31 Malignant neoplasm of accessory sinuses 
C32 Malignant neoplasm of larynx 
The codes in bold are those assigned to OSCC  
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1.1.2.1 Staging 
When diagnosing oropharyngeal cancer, the stage of the tumour influences treatment options 
and prognosis. Table 1.3 shows the Tumour Node Metastases (TNM) staging given to 
oropharyngeal cancers. This staging system includes Tumour (T) stages for the size of the 
primary tumour and whether this has spread to any tissues of the oral cavity or oropharynx, 
Node (N) stages for the extent that the cancer has spread to regional lymph nodes, and 
Metastases (M) stages for whether the cancer has metastasised (spread to other parts of the 
body). The numbers that appear after the stages indicate the degree of severity, from 0-4 for T 
stage, 0-3 for N stage and 0 or 1 for M stage, with the greater the number indicating greater 
severity. When each of these stages have been summarised, patients are given an overall 
stage for their cancer, which are dependent on combinations of TNM (Table 1.4). For example, 
if a tumour is small (< 2cm; T1 stage) and has not spread to nearby (N0 stage) or other parts of 
the body (M0 stage), then the patient would be diagnosed with early stage I cancer, whereas if 
the tumour is any size (any T stage), has or has not spread locally (any N stage), but has 
spread to distant sites (M1 stage), this patient would be diagnosed with advanced stage IVC 
cancer.  
Table 1.3: TNM stages for oropharyngeal cancer: Information taken from 
http://www.cancer.org/cancer/oralcavityandoropharyngealcancer/detailedguide/oral-cavity-and-
oropharyngeal-cancer-staging (American Cancer Society, 2014) 
Table 1.4: Staging for oropharyngeal cancer: Information taken from 
http://www.cancer.org/cancer/oralcavityandoropharyngealcancer/detailedguide/oral-cavity-and-
oropharyngeal-cancer-staging (American Cancer Society, 2014) 
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1.2 Risk factors for HNC 
1.2.1 Traditional risk factors of HNC 
Causes of HNC are traditionally known to be related to lifestyle, such as through the 
consumption of tobacco and alcohol. The typical patients are older men (>65) (Hammerlid, 
Persson, Sullivan, & Westin, 1999) of lower socioeconomic status (Conway et al., 2008). 
Studies have shown over half of HNCs in the UK are caused by smoking (Parkin, 2011b) and 
almost a third are caused by drinking alcohol (Parkin, 2011c). More common in Asia, chewing 
tobacco or betel quid is also known to cause HNC. Studies have shown that the risk of HNC 
decreases with increasing time since giving up smoking or drinking alcohol (Marron et al., 
2010). Alcohol and smoking remain the most important causes of HNC worldwide (Serra-
Majem, 2016; Soerjomataram, De Vries, Pukkala, & Coebergh, 2007).  
Poor diet and poor dental hygiene have also been shown to be risk factors for HNC, but as 
these are also usually associated with areas of lower socioeconomic position, it is difficult to rule 
out this as a confounding variable (Gillison, 2007; Guha et al., 2007). 
1.2.2 Human papillomavirus 
Human papillomavirus, or HPV as it is more commonly known, is a common sexually 
transmitted infection which can be contracted through both skin-to-skin and sexual contact. 
There are over 100 variants of HPV (Parkin, Bray, Ferlay, & Pisani, 2005). High-risk 
carcinogenic types of HPV include HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 
and 82 (Munoz, Bosch, Sanjosé, Herrero, & Castellsagué, 2003), with HPV16 and HPV18 being 
the most well recognised. High-risk sexually transmitted HPV types are thought to be 
responsible for up to 5% of cancers worldwide, including cervical, anal, penile, vaginal, vulva 
and some OSCCs (Parkin & Bray, 2006). Those classified as low-risk such as HPV6 and 11 are 
rarely associated with malignant disease and are implicated as causes of genital warts. In 
anogenital HPV, most people clear high-risk types within a year and low-risk types in less than a 
year (Schiffman & Kjaer, 2003). Most sexually active people will contract HPV at some point in 
their lives (Fakhry & D’Souza, 2013). 
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1.2.2.1 HPV-positive head and neck cancers 
First suggested in 1983 (Syrjänen, Syrjänen, Lamberg, Pyrhönen, & Nuutinen, 1983) the 
aetiological role of HPV in OSCC has now been well established through epidemiological 
studies (Gillison et al., 2012; Mehanna, Beech, Nicholson, El-Hariry, & McConkey, 2013; 
Näsman et al., 2009; Rietbergen et al., 2013). Studies found associations between HPV and 
HNC as early as 1997 (Paz, Cook, Odom-Maryon, Xie, & Wilczynski, 1997), with a study in 
1998 specifically finding HPV16 to be associated with OSCC (Wilczynski, Lin, Xie, & Paz, 
1998). A seminal study confirmed the causal association of HPV in OSCC, through a 
retrospective analysis of tumour tissues of patients diagnosed with HNC (Gillison et al., 2000). 
The rate of HPV in the oropharynx has been shown to be consistently higher than in the oral 
cavity, larynx or hypopharynx (Sturgis & Cinciripini, 2007). A large international study found 
22.4% oropharyngeal, 4.4% oral cavity and 3.5% larynx were HPV-positive and that HPV16 was 
largely the most common type (Castellsagué et al., 2016). A meta-analysis of 60 studies across 
26 countries showed 26% of 5046 HNC cases were HPV-positive. HPV was found in 36% of 
OSCCs, 23% of oral cancers and 24% or laryngeal cancers (Kreimer, Clifford, Boyle, & 
Franceschi, 2005). The tonsil and the base of tongue are the two areas of the oropharynx where 
HPV is more commonly found and are the tumour sites responsible for the increasing proportion 
of OSCCs (Dahlstrom et al., 2013). One explanation for this is that the properties of the mucosa 
found in these areas is similar to that of the properties of the mucosa in the cervix (Kreimer et 
al., 2005).  
HPV-OSCC appears to be biologically and clinically distinct from other HNCs (Marur, D’Souza, 
Westra, & Forastiere, 2010) and although the natural history of oral HPV is not well understood, 
it is thought to differ from that of cervical HPV (D’Souza, Kreimer, et al., 2007). Studies 
examining the persistence of oral HPV over time have been with limited numbers of participants 
and have not analysed by HPV-type, so have been unable to estimate the incidence or 
clearance rates of oral HPV (D’Souza, Fakhry, et al., 2007). Risk factors for oral HPV have also 
been shown to significantly differ from cervical HPV. There is no established clinical 
infrastructure for screening or for the understanding of precancerous lesions, unlike in cervical 
cancer. There is still much to learn about HPV-OSCCs, in particular about its natural history and 
its progression from oral HPV to HPV-OSCC.  
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HPV-positive patients typically present at an advanced nodal stage (see  
Table 1.4) (Gillison et al., 2008; Khode, Dwivedi, Rhys-Evans, & Kazi, 2014) and as a result 
have stage IV disease. This may be due to the challenges associated with the distinct nature of 
HPV-OSCC from other HNCs, being asymptomatic, and the changing demographic of patient 
without the common risk factors. T and N stage combined with smoking history are the most 
important prognostic factors (Ang et al., 2010; O’Sullivan et al., 2013) in the TNM staging 
system. Health professionals may lack suspicion of HNC due to the patient having a negative 
smoking history and there may be an absence of signs and symptoms in early disease. Other 
delays may occur due to inadequate training or equipment and detection methods (Lewis et al 
2015). It is therefore important for health professionals to not be dismissive of younger patients 
(~ 55 years of age) (Dahlstrom et al., 2013) who present to their general practitioner (GP) with 
potential symptoms of HNC such as a sore throat, a swelling or a sore that does not heal, and 
who are either non-smokers or non-drinkers. These patients should be considered highly 
suspicious for HPV-OSCC (Gillison et al., 2000). 
Despite TNM staging characterising many of these tumours as locoregionally advanced, the 
prognosis for these cancers caused by HPV is more in line with earlier staged cancers which 
have not been caused by HPV (Paz et al., 1997). They have different causes, risk factors and 
survival outcomes. Recently, it has been recognised that a new staging system is needed for 
HPV-OSCC due to the better outcomes in these patients despite the advanced nodal stage and 
consequently, more advanced overall stage (Dahlstrom, Garden, William, Lim, & Sturgis, 2016). 
For HPV-positive HNC patients, the T stage has been shown to have more prognostic value 
(Ward et al., 2015) and for HPV-negative HNC patients, the N category has been shown to 
have more prognostic value (Hong et al., 2013). Table 1.5 illustrates some of the distinct 
differences between HPV-positive and HPV-negative HNCs.   
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Table 1.5: Comparison of HPV-negative and HPV-positive HNC 
Characteristics HPV-negative HPV-positive 
Site All sites Tonsil, base of tongue 
Risk factors Tobacco/alcohol Sexual behaviour 
Co-factors Poor oral hygiene Marijuana use 
Age Older cohorts Younger cohorts 
Sex 3:1 men 3:1 men 
Incidence Decreasing Increasing 
Stage Variable Early T stage, advanced N 
stage 
Histology Keratinized Basaloid/poorly differentiated 
p16 Decreased expression Increased expression 
Permission to reproduce this has been granted by UBM. Source: Adapted from (Lewis, Kang, 
Levine, & Maghami, 2015) 
HPV-OSCCs occur more in men than women, with a ratio of 3:1, but this ratio varies across 
countries (Combes, Chen, & Franceschi, 2014). The typical patients are younger (<65), white 
men, married, educated and employed (Gillison et al., 2008; Marur et al., 2010). Patients tend 
otherwise to be in good health, without any traditional risk factors or comorbid disorders 
(Gillison et al., 2008; Lin et al., 2013; Marur et al., 2010). Although lower rates of smoking are 
seen among HPV-OSCC patients, many patients are current or former smokers (60-70%) and 
true non-smokers account for the minority (Ang et al., 2010; Gillison et al., 2012; O’Sullivan et 
al., 2013).  
The evidence presented shows the changing demographic of HNC patients and how HPV-
related OSCC is clinically and biologically distinct from other HNCs. These studies also 
demonstrate that there is still a lot that is not known about HPV-OSCC.  
  
CHAPTER 1 – EPIDEMIOLOGY 
35 
 
1.2.2.2 Risk factors for HPV-related HNC 
Sexual behaviour 
Moving on to look at the risk factors associated with HPV-OSCC, a number of studies have 
found a greater lifetime number of sexual (>26) and oral sex partners (>6) to be associated with 
increased risk of oral HPV infection (Blomberg, Nielsen, Munk, & Kjaer, 2011; D’Souza, 
Agrawal, Halpern, Bodison, & Gillison, 2009; D’Souza, Kreimer, et al., 2007; Fakhry, Gillison, & 
D’Souza, 2014; Farsi et al., 2015; Gillison et al., 2008) due to greater exposure to HPV. In a 
cross-sectional study with a control patient group from an outpatient otolaryngology clinic as 
one population and university students as a second population, evidence of oral HPV infection 
was found in oral samples of men who reported never having oral sex (D’Souza et al., 2009), 
suggesting that oral sex may not be the only route of transmission for oral HPV infection. The 
results from this study are not population-based and can therefore not be generalised, however 
the authors did find comparable levels of sexual activity in these samples compared to a large 
population based study discussed below.  
The National Health and Nutrition Examination Survey (NHANES) is a large population-based 
USA study which detected oral HPV through oral samples of over 2000 men and 2000 women 
and sexual behaviour information through an audio computer-assisted interview. Men were 
found to have a significantly higher number of lifetime oral and vaginal sexual partners 
compared to women and to have a higher prevalence of oral HPV16. Although men and women 
aged 30-59 were more likely to have performed oral sex compared to those 60-69, oral HPV16 
prevalence was similar (D’Souza, Cullen, Bowie, Thorpe, & Fakhry, 2014). This study concluded 
that oral sexual behaviour was the primary predictor of oral HPV16 infection, as after oral sexual 
behaviour was controlled for, age-cohort and race were no longer associated with oral HPV16.  
It has been hypothesised that performing oral sex on a woman results in a higher level of oral 
HPV exposure compared to oral sex on a male because of the viral load of HPV being higher in 
the female genital mucosa than the male genital mucosa/skin (Pytynia, Dahlstrom, & Sturgis, 
2014). It was also thought that there may be some differences in local immune responses in the 
cervix and oral cavity of women which may explain the differences in prevalence of oral and 
cervical HPV and consequent oral exposure to infection (Fakhry et al., 2013). Another study 
using data from the NHANES found that for each additional sexual partner, men were at a 
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three-fold greater risk for high-risk oral HPV than women, supporting the hypothesis of higher 
transmission rates from females to males than from males to females (Giuliano et al., 2015). 
These authors report on a series of five longitudinal studies which have shown the transmission 
of HPV from men to women to have a lower incidence than from women to men. Prevalence of 
oral HPV also plateaued at different stages for men and women, being approximately 15 oral 
sex partners for men and approximately five oral sex partners for women, demonstrating there 
is a lower threshold at which point prevalence does not increase among women. This is 
hypothesised to be due to natural seroconversion rates of HPV being higher in women than in 
men, potentially due to greater exposure to genital HPV. The differences in HPV-OSCC 
prevalence between men and women may also be due to men smoking more heavily (see 
below) and for longer durations than women (Combes et al., 2014). 
Open-mouthed kissing is also thought to be a route of transmission for HPV (D’Souza et al., 
2009; Pickard, Xiao, Broutian, He, & Gillison, 2012), specifically having at least 16 open mouth 
kissing partners (Fu et al., 2015). These studies were all carried out with university students and 
so may not be representative of the general population, but could be representative of student 
populations. These results need to be replicated in a general population-based study.  
Smoking 
Another factor which has been shown to raise the odds of persistent oral HPV is current 
smoking (D’Souza, Kreimer, et al., 2007; Kreimer & Chaturvedi, 2011). Oral HPV16 prevalence 
has been found to be greater in current tobacco users compared with never or former tobacco 
users (Fakhry, Gillison, et al., 2014), having been shown to have immunosuppressive effects 
(Sopori, 2002). Higher odds of HPV were found in current than never smokers (Anantharaman 
et al., 2016), but smoking increased the risk of OSCC independent of HPV status. Current 
tobacco users were also found to be more likely to have other risk factors for HNC as they were 
male, younger, less-educated and had a higher number of oral sexual partners (Fakhry, 
Gillison, et al., 2014). 
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Human Immunodeficiency Virus (HIV) 
Studies with HIV patients have indicated that HIV may increase the persistence and progression 
of HPV-related HNC (D’Souza, Carey, et al., 2014; Picard et al., 2016). Having a CD4 (white 
blood cells which organise the immune system’s response to bacterial, fungal and viral 
infections) count of <500 (and therefore showing some damage to your immune system) have 
been shown to be associated with persistence of oral HPV infection (D’Souza, Fakhry, et al., 
2007). D’Souza and colleagues found HPV detected in 30% of HIV HNCs and 64% of OSCCs. 
HIV-positive HNC patients were also more likely to be male, younger, nonwhite and current 
smokers (D’Souza, Carey, et al., 2014) showing some similar attributes to the general 
population for both HPV-related and tobacco or alcohol-related HNCs.  
In summary, sexual behaviour is thought to be the most important risk factor for HPV-OSCC, 
with smoking and HIV having potential interactive affects.  
1.2.3 Determining oral HPV status in tumours  
Focusing on the different methods used to determine the HPV status of a tumour, an important 
finding is that the biology of HPV-OSCC is distinct from HPV-negative HNC (Nevens & Nuyts, 
2015). A few different methods are currently being used to determine the HPV status of a 
tumour. In-situ hybridization (ISH) uses histology specimens to identify specific segments of 
nucleic acids and specific DNA or RNA sequences and has moderate sensitivity but high 
specificity (Schlecht et al., 2011). Polymerase chain reaction (PCR) involves testing the DNA of 
biopsy specimens for HPV and has high sensitivity but low specificity (Jung et al., 2010). As a 
surrogate test immunohistochemical (IHC) involves staining for p16 and has high sensitivity but 
moderate specificity (Jordan et al., 2012). There is no ‘gold standard’ test, but the most 
commonly used tests are ISH and PCR, with HPV DNA methods being found to be the most 
objective and reliable (Bussu et al., 2014). p16 IHC is widely used in clinical practice (Nevens & 
Nuyts, 2015) as p16 is commonly used as a surrogate marker for HPV. p16 expression has 
been found to occur in a small percentage (5-8%) of HPV-negative head and neck SCCs (Liang 
et al., 2012) demonstrating that this method is not always reliable.  
Testing for HPV is not routinely carried out in the UK, but recent guidelines have been published 
for doing so (National Institute for Care and Excellence, 2016), as there are in the USA (Pfister 
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et al., 2012). The UK and USA recommend testing the tumour for HPV using IHC staining for 
p16. In Canada, Cancer Care Ontario has recommended that all adult patients with OSCC 
should be tested for HPV and as p16 ISH has demonstrated high sensitivity, that HPV status in 
OSCC should be determined using this method (Lacchetti et al., 2013). 
Although HPV is being tested for more routinely, treatment and care methods are not currently 
being modified on the basis of HPV status unless patients are enrolled into clinical trials. Also, 
the mere presence of HPV DNA in these methods is not enough for causality to be established; 
the detection of oncogenic proteins in HPV and events such as p16 overexpression is essential 
for inferring causality.  
1.2.4 Prevalence of oral HPV infections  
General population 
Now considering methods to determine oral HPV in a healthy population, there is no ‘gold 
standard’ test, but those commonly used are oral swabs/scrapes, oral rinses and saliva 
samples. Prevalence rates range dependent on the oral sampling method used, from 6.9% 
using oral scrapes (Herrero et al., 2003) to 18.3% with saliva samples (Montaldo et al., 2007). 
A systematic review of oral HPV prevalence in healthy individuals included studies that detected 
oral HPV DNA in around 4000 cancer-free participants and estimated prevalence of 4.5% for 
any HPV infection and 1.3% for oral HPV16 (Kreimer et al., 2010). Oral HPV16 accounted for 
28% of HPV detected in the oral region. Estimates of the prevalence of any oral HPV infection 
from other studies range from 1.0% and 1.6% in healthy males (Kreimer et al., 2011) to 2.4% in 
a sample of young (aged 18-30) men and women (Pickard et al., 2012). At any given time, it 
has been estimated that approximately 7% of the USA population has an oral HPV infection 
(Gillison et al., 2012; Pickard et al., 2012). These are estimates and the variations in prevalence 
are likely due to different testing methods, as described above.  
In a population-based, cross-sectional study in the USA, a bimodal distribution was found for 
the prevalence of oral HPV infection in over 5,500 participants (Gillison et al., 2012). The overall 
prevalence of oral HPV infection between 2009 and 2010 was 6.9% and prevalence of oral HPV 
infection peaked in the 30-34 and 60-64 age groups. Prevalence was also found to be higher in 
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men than women, for both any oral HPV infection and oral HPV16. It is not possible to compare 
these estimates across countries as they are not available. 
HPV-OSCC patients 
Looking at the prevalence of oral HPV infection in OSCC patients, a large study in the USA 
using cancer registry data found oral oncogenic HPV infection to peak bimodally at 25-30 years 
and at 50-60 years, with a median age of 63 at diagnosis (Chaturvedi, Engels, Anderson, & 
Gillison, 2008). This led the authors to estimate a latency period between oral HPV infection 
and an HPV-OSCC diagnosis of approximately 10-30 years, under the assumption that either 
peak in prevalence could contribute to risk.  
In the United States, HPV is detected in two thirds of OSCCs (American Cancer Society, 2013) 
and the high-risk type HPV16 has been implicated in over 90% of HPV-positive tumours 
(D’Souza, Kreimer, et al., 2007; Gillison et al., 2000). Only a small number are caused by other 
HPV types such as HPV18, 31, 33, 35, 52 and 58 (Chaturvedi et al., 2011) but the associations 
with other high-risk types remain unclear (Michaud et al., 2014). In patients with HPV16, HPV18 
and HPV33 were found to be significantly associated with OSCC (Michaud et al., 2014). In the 
UK the number of OSCCs caused by HPV has been estimated at 14% (Parkin, 2011a) but this 
figure is now out-of-date. A few studies have demonstrated HPV16 infection to precede those 
later diagnosed with HPV-positive HNC. A Nordic cohort study showed in those patients later 
diagnosed with HNC, prevalence of HPV16 seropositivity was almost twice as high compared to 
control participants (Mork et al., 2001). This has also been found in other studies (Hansson et 
al., 2005; Smith et al., 2004). 
It is difficult to assess prevalence rates over time as no large scale studies have followed the 
dynamics of oral HPV infection in the general population for longer than one year. The largest 
prospective study to date examined oral HPV infection among 1626 adult males with a median 
follow-up of 12.7 months (Kreimer et al., 2013). Four per cent of men had a new oral HPV 
infection, with a median duration of infection of 6.9 months, and less than 1% of men developed 
an oral HPV16 infection with a median duration of 7.3 months. The majority of infections had 
cleared or were below the threshold of detection by 18 months. 
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Summary 
Prevalence studies show the overall prevalence of oral HPV is low, but the estimates can vary 
due to the different testing methods mentioned above and the populations it is measured in. 
Oral HPV has also been shown to demonstrate bimodal peaks at around 30 years of age and 
60 years of age. Longitudinal studies are needed to assess how prevalence of oral HPV 
changes and also a reliable, standardised test is needed to detect oral HPV in both the general 
population and in the tumours of patients.  
1.2.5 Concordance of oral and genital HPV 
Some studies have investigated both oral and genital specimens to look for concordance 
between different anatomical sites and investigate whether HPV can be transmitted across the 
two sites. In a sample of over 2200 men in rural China, the prevalence of HPV in the oral cavity 
was 6.7% and 16.9% for the external genitalia (Liu et al., 2015). HPV was found in both in the 
oral cavity and the external genitalia of 43 men; 60.5% of these had an identical HPV type at 
both sites. The authors concluded that the risk of oral HPV infection was higher among men 
with genital HPV infection than among uninfected men, and that having multiple lifetime sexual 
partners was a significant risk factor for oral-genital HPV coinfection. In contrast, in a small 
sample (n=151) of HIV negative men who have sex with men (MSM) at a sexual health clinic in 
the UK, oral rinse and anogenital samples found prevalence of any oral HPV to be 13.7% and 
any anogenital HPV to be 64.9%. High-risk HPV types were found in 5.9% of oral HPV and 
34.4% of anogenital samples (King et al., 2015). These authors found no concordance between 
HPV types detected in both oral and anogenital sites.  
Another small sample (n=34 heterosexual couples) study taking place in South Africa at an HIV 
testing centre found similar oral HPV prevalence in women (12%) and men (18%) (Vogt, Gravitt, 
Martinson, Hoffmann, & D’Souza, 2013). Oncogenic HPV types were found in 4% of oral, 26% 
of penile and 74% of vaginal samples. HPV16 was found in 1% of oral, 12% of penile and 21% 
of vaginal samples. Thirty-five per cent of couples had at least one type-specific concordant 
vaginal-penile HPV infection, but only one of nine couples who had oral HPV, had concordant 
oral-oral infection. The concordance of oral-genital HPV infection was higher, with 67% of men 
and 25% of women with oral HPV infection having a partner with a concordant genital HPV 
infection. Data from this study supports the hypothesis of the transmission of vaginal HPV 
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infection to the oral cavity during oral sex. Another study found that partners of patients with 
HPV-OSCC have a similar prevalence of high-risk oral HPV infection to the general population 
(1.2%; D’Souza, Gross, et al., 2014). 
It is important to carry out concordance studies to help us understand the risk of transmission 
among partners and from one body site to another. The limited data available currently is 
inconclusive and limited in its ability to generalise due to small samples and non-population 
based studies. The studies do demonstrate consistently that prevalence of oral HPV is lower 
than the prevalence of genital HPV.  
1.3 Incidence rates and timeline of progression of HNC 
1.3.1 Incidence of HNC 
In the UK, approximately 11,200 new cases of HNC are diagnosed each year (ISD Scotland, 
2013; Northern Ireland Cancer Registry, 2013; Office of National Statistics, 2013; Welsh Cancer 
Intelligence and Surveillance Unit, 2013), around 25% of which are classified as base of tongue, 
tonsil or OSCCs. The incidence of HNCs in the UK has increased over the last few decades and 
Figure 1.2 shows data from the cancer registries in England, Scotland, Wales and Northern 
Ireland. Incidence rates in England have risen by 58% from 1995 to 2011 (Louie, Mehanna, & 
Sasieni, 2015). Figures in Scotland have risen by approximately 51% from 1990 to 2014, in 
Wales by approximately 47% from 2001 to 2014 and by approximately 25% in Northern Ireland 
between 1993 and 2014. Figures for oral cancer show it was the 14th most common cancer in 
the UK in 2013, being the 11th most common cancer in males and the 16th most common cancer 
in females. One in 75 men and one in 150 women will be diagnosed with oral cancer during 
their lifetime (Cancer Research UK, 2016).  
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Looking specifically at oropharyngeal cancers, figures for the incidence of oropharyngeal 
cancers in England and Scotland show an increase in the number of people diagnosed from 
1998 to 2013 (Figure 1.3). In England the incidence of oropharyngeal cancers has risen more 
dramatically than for any other HNC and the increasing trend has paralleled that of genital warts 
and genital herpes (Louie et al., 2015). Figures for oropharyngeal cancers in England include 
ICD-10 codes C01, C09 and C10 and in Scotland, the cancer registry additionally included the 
codes C02.4, C05.1 and C05.2. Figures were not available separately for the ICD-10 codes 
relating to oropharyngeal cancers in Northern Ireland or Wales.  
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 Figure 1.2: Incidence of head and neck cancers in the UK 
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The incidence of HNCs in the USA has been declining over the last three decades due to a 
decrease in the consumption of tobacco (Enomoto, Bann, Hollenbeak, & Goldenberg, 2016). 
Figures show that nearly 25% of HNCs that are now being diagnosed in the USA, are 
independent of tobacco use (de Martel et al., 2012). Between 1983 and 2004, a significant 
decrease in incidence has been found in sites unrelated to HPV (tongue, gum, floor of mouth, 
palate, other/unspecified parts of the mouth), but there was a significant increase in incidence at 
HPV-OSCC sites in the same time period (1973-2004) (Chaturvedi et al., 2008). The largest 
increase in these cancers was found in white men in their 40’s or 50’s.  
In an analysis of 23 countries, an increasing incidence of OSCC has been found between 1983 
and 2002 in men aged 60 years or younger. This trend was seen in countries including the 
USA, Australia, Denmark, UK, Slovakia and Canada (Chaturvedi et al., 2013). These increases 
were not seen in Colombia, India, the Philippines and Thailand. This may be due to differences 
in sexual behaviour practices which are relevant for oral HPV exposure in these developing 
countries (Chaturvedi et al., 2013). Figure 1.4 shows the incidence rates per 100,000 across the 
decades, from the 1970’s to 2000.  
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Figure 1.3: Incidence of oropharyngeal cancers in England and Scotland 
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Figure 1.4: Incidence rates of OSCC in different countries by decade 
Permission to reproduce this has been granted by Wiley. Source: Gooi, Chan, & Fakhry, 2016 
1.3.2 Incidence and prevalence of HPV-OSCC  
Incidence of HPV-OSCC 
Moving on to the incidence rates for HPV-OSCC, in the UK these have doubled from 1 per 
100,000 to 2.3 per 100,000 in just over a decade (Mehanna, Olaleye, & Licitra, 2012). The 
declining incidence of HPV-negative OSCC due to decreasing rates of smoking, means that 
HPV-OSCC now constitutes an increasing proportion of OSCCs overall (Chaturvedi et al., 
2011). Studies have shown HPV-OSCC to be prevalent worldwide and incidence rates are 
expected to rise (Chaturvedi et al., 2008) with numbers in the USA set to surpass the numbers 
of cervical cancer cases by 2020 if the current trend continues (Chaturvedi et al., 2011). It has 
also been projected that by 2030, half of all HNCs will be related to HPV (Chaturvedi et al., 
2011).  
As Figure 1.2 shows, the overall incidence of HNCs in England increased during 2002-2014. 
During 2002-2011, 69% of patients were males, but significant increases were found in males 
and females and in those aged 60 or over. Cancers of the oropharynx, base of tongue and 
tonsil were found to significantly increase by 47.1% in males and 37.5% in females. The HPV 
status of these cancers was unknown, but as a large proportion of these cancer subtypes have 
been found to be HPV-related, these could be HPV-associated cancers (McCarthy, Field, 
Rajlawat, Field, & Marcus, 2015).  
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Prevalence of HPV-OSCC 
In Sweden, data from the cancer registry have demonstrated that the detection of HPV DNA 
taken from tonsillar SCC had increased from 68% from 2000-2002 to 93% in 2006-2007 
(Näsman et al., 2009). Data from the USA shows the prevalence of HPV in OSCC has 
significantly increased from 16.3% between 1984 and 1989, to 71.7% between 2000 and 2004 
(Chaturvedi et al., 2011). A meta-analysis confirmed the data from these two studies, with 
prevalence increasing significantly in North America and Europe. The rate of increase in Europe 
has been faster than in North America, increasing from 35.3% before 2000 to 73.1% in 2009 
(Mehanna et al., 2013). Across all studies, the prevalence of HPV in OSCC increased from 
40.5% before 2000, to 64.3% between 2000 and 2004 and 72.2% between 2005 and 2009. 
Worldwide it is estimated that 21,400 (25.6%) of OSCCs are attributed to HPV (de Martel et al., 
2012). 
A recent large systematic review of the prevalence of HPV in OSCC, accessed data from 105 
articles, with data on over 9500 specimens in 23 nations. The review found a significant 
percentage increase of HPV-OSCC from pre-1995 to present, with this being 20.6% worldwide, 
21.6% in North America and 21.5% in Europe (Stein et al., 2015).  
The data presented in this section shows a substantial increase in the incidence and prevalence 
of HPV-OSCCs over the last 20 years, particularly in countries such as the USA, UK and 
Sweden. If these trends continue to increase at the current rate, the rate of HPV-OSCC could 
surpass that of cervical cancer by 2020.  
1.4 HPV Vaccination 
The HPV vaccine was approved by the Food and Drug Administration (FDA) as a primary 
prevention strategy against cervical cancer in 2006 and introduced into the UK in 2008, offered 
initially to girls. As genital HPV is sexually transmitted, it is necessary to vaccinate before sexual 
debut. Between 2008 and 2012, the UK administered the HPV vaccine three-dose schedule 
through a school-based programme for girls aged 12-13 with the bivalent vaccine (Cervarix), 
which prevents HPV types 16 and 18. In 2012, the school-based programme switched to the 
quadrivalent vaccine (Gardasil) which prevents HPV types 6, 11, 16 and 18. In the UK, since 
September 2014, the school-based programme implemented the two-dose schedule. The two-
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dose schedule was introduced after an endorsement from the WHO in 2014 (World Health 
Organisation, 2014), with the recommended interval between the doses to be six months apart.  
Since the approval of the HPV vaccine, a number of countries have chosen to introduce it, 
alongside a national vaccination programme for adolescent girls. By 2012, 19 out of the 29 
countries in the EU had introduced national vaccination programmes (European Centre for 
Disease Prevention and Control, 2012). In Australia since 2013, the national programme 
additionally introduced the HPV vaccine to boys (Australian Government Department of Health, 
2016) and the HPV vaccine is recommended for boys in the USA and Canada.  
The HPV vaccine has also recently been approved for use in men who have sex with men 
(MSM) aged up to 45 (Joint Committee on Vaccination and Immunisation, 2015) and a pilot has 
recently been announced to offer the HPV vaccine in appointments at some Genitourinary 
Medicine and HIV clinics in England. The vaccine is not yet recommended by the NHS for use 
in school-aged boys which has caused a great deal of debate and controversy, resulting in the 
development of groups now campaigning for gender neutral vaccination, such as HPV Action 
(HPV Action, 2013).  
In December 2014, the FDA approved a nonavalent (Gardasil 9) vaccine, which now covers an 
additional five high-risk HPV types 31, 33, 45, 52, 58. The nonavalent vaccine is currently only 
licensed with the three-dose schedule. These currently available vaccines are preventative and 
so do not help to clear already acquired infections or decrease the incidence of abnormal 
cytology associated with HPV (Hildesheim et al., 2016; Takes et al., 2015). 
Evidence of effectiveness of the HPV vaccination  
Since the introduction of the HPV vaccine, evidence has already been published demonstrating 
the effectiveness of the vaccine on reducing the cases of genital warts and also cases of 
cervical lesions (Australia Institute of Health and Welfare, 2014; Herweijer et al., 2016; 
Hofstetter, Ompad, Stockwell, Rosenthal, & Soren, 2016; Markowitz et al., 2013; Mesher et al., 
2013; Munoz et al., 2010; Skinner et al., 2016). There is also evidence that the vaccine can 
provide some cross-protection to other types of HPV that are not specifically protected against 
in the vaccine (Skinner et al., 2016). Studies are demonstrating reductions of HPV infections in 
men (Bollerup et al., 2016; Giuliano et al., 2011; Goldstone et al., 2013), demonstrating 
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evidence of herd protection in heterosexual men (Bollerup et al., 2016) and efficacy of the HPV 
vaccine in both heterosexual and MSM men (Giuliano et al., 2011; Goldstone et al., 2013).    
Vaccination against oral HPV infection 
Vaccine efficacy against oral HPV infection and OSCC has not been fully evaluated. A study 
conducted as part of the Costa Rica HPV vaccine trial measured oral HPV prevalence in 
women and found oral HPV16/18 to have a lower prevalence in vaccinated women (1/2910) 
than those in the placebo (hepatitis A vaccine) group (15/2924), but the number of infections 
found in either group were small and this was only measured at one time point, 4 years after 
vaccination (Herrero et al., 2013). 
These studies suggest that there is some evidence supporting the possibility that the HPV 
vaccine may prove to be effective in reducing the incidence of oral HPV, the effects of which will 
not be seen for years to come due to the higher average age demonstrated in OSCC compared 
to cervical cancer (Gillison et al., 2013). As the majority of HPV-related OSCC cases are caused 
by HPV16 and HPV18, which are high-risk HPV types included in both the Cervarix and 
Gardasil vaccines, it is reasonable to expect that these vaccines might be able to also prevent 
oral HPV16/18 infection (Takes et al., 2015). Clinical trials evaluating the efficacy of HPV 
vaccines for the prevention of oral HPV infection are difficult to carry out as there is a lack of 
data regarding rates of incidence and clearance of oral HPV infection (Gillison et al., 2013). 
1.5 Survival rates of HPV-related HNC worldwide and the UK 
The majority of HNCs are referred to a specialist by GPs (Health and Social Care Information 
Centre, 2013); however general dental practitioners also have an important role to play. As yet, 
no effective screening programme exists to detect HPV-OSCC. This is because there is not yet 
the ability to detect precancerous lesions or subclinical/early-stage HNCs (Gillison, Chaturvedi, 
Anderson, & Fakhry, 2015). It is also important to remember that there is no established 
intervention for reducing cancer incidence, cancer mortality or screening for HNC. Early 
diagnosis is crucial in HNC and stage I or II disease have much better two year survival rates 
compared to those diagnosed at advanced stages III and IV (Rusthoven et al., 2010). After 
exploring screening strategies with the equivalent of a ‘Pap-test’ for the oropharynx, authors 
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concluded it may not be feasible due to limitations in sampling (Fakhry, Rosenthal, Clark, & 
Gillison, 2011). 
Survival rates for HPV-positive patients compared to HPV-negative patients are considerably 
improved, with the median survival of HPV-positive patients being almost 4 years, compared to 
less than 3 years for HPV-negative patients (Gillison et al., 2000). The 3 year overall survival 
rate in HPV-positive patients was shown to be 82.4% compared with 57.1% in HPV-negative 
patients (Ang et al., 2010). Five year survival rates in the same groups range from 75-80% in 
HPV-positive patients compared with 45-50% in HPV-negative patients (Ang et al., 2010). In a 
prospective analysis of patients with stage III or IV OSCC, patients with an HPV-positive tumour 
status had higher overall-survival and progression free survival at 2 years compared to HPV-
negative patients (Fakhry et al., 2008). The effects of HPV-positive tumour status still remained 
independently associated with a reduced mortality risk after controlling for age, tumour stage 
and comorbidities.  
In a sample of over 500 OSCC patients in a USA study, 5 year survival was found to be better 
in patients with HPV16 than other HPV types and those who were HPV-negative (Goodman et 
al., 2015). 
Figure 1.5 shows the results from a retrospective analysis which divided patients with stage III 
and stage IV OSCC into risk of death categories (Ang et al., 2010). The groups were classified 
as: 
 Low risk (93% 3 year survival) 
o HPV+, smoked less than 10 pack years 
o HPV+, smoked more than 10 pack years, diagnosed at low clinical staging (N0-
N2a) 
 Intermediate risk (70.8% 3 year survival) 
o HPV+, smoked more than 10 pack years, diagnosed at intermediate clinical 
staging (N2b-N3) 
o HPV-, smoked less than 10 pack years, diagnosed at intermediate tumour 
stage 
 High risk (46.2% 3 year survival) 
o HPV- and either T4 or >10 year pack history  
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Figure 1.5: Risk stratification for OSCC 
Permission to reproduce this has been granted by UBM. Source: Lewis et al., 2015 
Survival and treatment 
When comparing survival in HPV-positive and HPV-negative OSCC by treatment, significantly 
worse outcomes were found for HPV-negative patients when they were treated with primary 
radiation compared with primary surgery (Wang, Liu, Gornbein, & Nguyen, 2015). No 
differences were found for HPV-positive patients between primary radiation and primary 
surgery.  
Looking at survival in patients with nonmetastatic OSCC treated with radiotherapy between 
2000 and 2010, lower 5 year overall survival was found in patients with a higher TNM stage who 
were also HPV-negative, but this was not the case for HPV-positive patients (Huang et al., 
2015). Five year survival dropped from 70% for stage I to 30% in stage IV for HPV-negative 
patients, but the decrease was not so drastic in the HPV-positive patients (stage I 88%, stage IV 
74%). 
Although HPV-OSCC patients have a favourable response to treatment, up to 30% experience 
recurrence (Guo et al., 2015) and the majority of recurrences occur within a year for both p16 
positive and p16 negative patients (Fakhry, Zhang, et al., 2014). HPV-OSCC patients have 
lower recurrence rates than their HPV-negative counterparts, but they have a higher proportion 
of recurrences that occur at distant sites and nontraditional sites, such as the kidney, brain and 
3 year OS     93%             70.8%              46.2% 
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skin (Huang et al., 2013; Müller et al., 2012). HPV-OSCC patients are also less likely to develop 
second primaries than their HPV-negative counterparts.  
There is a substantial amount of evidence to show that the survival rates for HPV-OSCC 
patients are more favourable than non-HPV related HNCs. This has both clinical and 
psychological implications which are discussed further in this thesis.  
1.6 Implications for treatment of HPV-related HNC 
HPV testing has been introduced as a clinical standard of care in OSCC in the USA, under the 
National Comprehensive Cancer Network (NCCN) guidelines (Pfister et al., 2012). 
Recommendations for HPV testing methods are variable, with the NCCN recommending using 
PCR or ISH and the College of American Pathologists recommend using ISH and/or detection 
of p16 IHC (see section 1.2.2). Testing tumours for HPV is also taking place in some UK centres 
as part of the diagnostic and treatment planning process (Roe, Drinnan, Carding, Harrington, & 
Nutting, 2014), and the National Institute for Health and Care Excellence (NICE) published 
recommendations in February 2016 to use p16 IHC for testing OSCC, but that it should only be 
regarded as positive if ‘there is strong nuclear and cytoplasmic staining in more than 70% of 
tumour cells’ (National Institute for Care and Excellence, 2016, section 1.5). The guidelines also 
recommend confirming HPV status using HPV DNA or ISH, but does not recommend de-
intensifying treatment in HPV-positive patients. Although there is evidence that prognosis differs 
with HPV status, this has not yet been integrated into the staging classification (Gillison et al., 
2000).  
The treatment for patients diagnosed with HPV-OSCC is currently the same as those with HPV-
negative OSCC. If patients are diagnosed at an early stage and their cancer is clinically 
confined to the oropharynx, surgical resection may be sufficient. Primary radiation is considered 
to be equivalent to surgery for these early stage cancers. If primary tumours are large or have 
regional nodal metastases, chemoradiation is frequently selected as treatment for OSCC. 
Surgical resection followed by adjuvant chemoradiation is also an option, as well as induction 
chemotherapy followed by chemoradiation (Posner et al., 2007).  
In the UK, most patients with HPV-OSCC present at an advanced stage (stage III and IV) and 
undergo multimodality treatment. This can include surgery and/or radiotherapy and/or 
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chemotherapy. Some patients receive triple-modality treatment, but single-modality therapy is 
recommended to be provided if possible to minimise toxicity (Roland & Paleri, 2011). Treatment 
can be associated with morbidity and occasional mortality (Bonner et al., 2010; Curran et al., 
2007). As patients diagnosed with HPV-OSCC have a much improved prognosis compared to 
their HPV-negative counterparts due to its responsiveness to treatment (Argiris et al., 2014; 
Ragin & Taioli, 2007), research is underway to explore ways to limit toxicity related to treatment 
and de-escalate treatment for patients with HPV-positive disease (Mehanna et al., 2012). This is 
being explored by reducing the number of treatment modalities and/or reducing intensity/dose of 
a given modality without compromising efficacy (Mirghani et al., 2015). Results from these trials 
will be expected in the next few years. In a study investigating oropharyngeal cancer patients’ 
preferences for receiving less invasive treatment, Brotherston and colleagues found that 
patients valued survival over quality of life (Brotherston et al., 2013).  
Many studies are underway to define de-escalation more precisely. As HPV-OSCC patients 
tend to be younger, it is important to also consider the long-term implications of treatment and 
whether this can be modified. Appendix 1.1 shows the current ongoing trials investigating the 
feasibility of deintensifying the treatment offered to HPV-OSCC patients. These trials include: 
radiation alone in risk-stratified OPSCC; decreased dose of radiation; substitution of cetuximab 
for cisplatin; and surgical resection followed by reduction/elimination of chemotherapy or 
radiation therapy (Roland & Paleri, 2011). 
1.7 Summary 
This chapter has provided the epidemiological context for this thesis. HNC affects over 11,000 
men and women in the UK each year.  An increasing number of these are OSCC caused by 
HPV; most commonly HPV16. This field is still in relative infancy and there are still a large 
number of unknowns regarding the progression of oral HPV to cancer as the natural history is 
not well understood. Although research from cervical cancer can be useful, key differences in 
incidence and prevalence have been established between cervical HPV and oral HPV. Patients 
diagnosed with HPV-OSCC tend to be younger, non-smokers and non-drinkers compared to 
those diagnosed due to the main risk factors of smoking and alcohol. Sexual behaviour has 
been strongly associated as a risk factor for the acquisition of oral HPV. There is hope that the 
HPV vaccine which is currently offered to girls in the UK when they are in year 8 at school could 
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also have an impact on oral HPV, however the effects of this will not be seen for another 45 
years. HPV-OSCC does appear to respond better to treatment than HPV-negative cancers and 
survival rates are much more favourable. This has led to a number of clinical trials investigating 
the possibility of offering patients with HPV-OSCC less intensive treatment, considering the 
long-term implications of current treatments on what are now younger patients. Chapter 2 
provides background into the psychosocial factors associated with HNCs and how health 
psychologists can use these findings to explore how patients diagnosed with HPV-OSCC may 
be impacted.
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CHAPTER 2. PSYCHOSOCIAL ISSUES RELATED TO HEAD 
AND NECK CANCERS 
The focus of this thesis is examining the psychosocial impact of human papillomavirus-
oropharyngeal squamous cell carcinoma (HPV-OSCC), therefore it is important to review the 
literature about the psychosocial impact of head and neck cancer (HNC) more generally and to 
consider the implications this has on the partner or caregiver of the patient. In this chapter I 
discuss the existing evidence exploring the psychosocial impact of HNC, including 
psychological distress, quality of life (QOL), disfigurement and dysfunction. 
2.1 Psychosocial impact of head and neck cancers1 
Cancer is often perceived as ‘a death sentence’ (Moser et al., 2014) with a recent general 
population study across the USA, Germany, France, Italy, Japan and the UK, showing 66% to 
indicate ‘death as a result of cancer’ as a great concern should they be diagnosed with cancer 
(Ramers-Verhoeven, Geipel, & Howie, 2013). A wealth of literature has found cancer to have a 
significant psychological impact on patients (Stanton, 2006) and the prevalence of clinically 
significant depression in cancer patients is greater than the general population (van’t Spijker, 
Trijsburg, & Duivenvoorden, 1997). A growing number of those diagnosed with cancer are 
surviving beyond 5 years and it is important to understand the psychosocial impact of diagnosis 
and treatment. Overall access to psychological services by cancer patients has been found to 
be low (Waller, Williams, Groff, Bultz, & Carlson, 2013).  
It has long been recognised that a diagnosis of HNC is associated with psychosocial distress. 
The term psychological distress encompasses depression, anxiety, and symptoms of acute 
stress (Shiraz, Rahtz, Bhui, Hutchison, & Korszun, 2014). A diagnosis of HNC is often described 
as highly traumatic (De Boer, McCormick, Pruyn, Ryckman, & van den Borne, 1999) due to 
disfigurement and loss of essential functions such as eating, speaking and breathing (Duffy et 
al., 2007). Patients have been shown to isolate themselves from their friends and family due to 
                                                     
1 The focus of this thesis is HPV-OSCC, but as this chapter is discussing the psychosocial issues related 
to head and neck cancer (HNC) more generally, the term HNC will be used in this chapter.  
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their appearance (Dhooper, 1985) and nearly 60% have said they have felt stigmatised or 
discounted because of their appearance (Strauss, 1989). Challenges and concerns associated 
with a diagnosis of HNC include changes to appearance, eating and drinking, communication, 
challenges to employment and finances, sexuality and coping (Chaturvedi, Shenoy, Prasad, 
Senthilnathan, & Premlatha, 1996; Penner, 2009). Challenges for family caregivers are also 
recognised (Penner, 2009), and one study found problem domains identified by HNC patients to 
be communicating with the partner, functioning in the family, and social and interpersonal 
relations (Rapoport, Kreitler, Chaitchik, Algor, & Weissler, 1993). Compared with laryngeal 
cancer patients, oral cancer patients had significantly more concerns about current illness, 
subjective evaluation of health, eating and chewing, social interactions, pain, and disfigurement 
(Chaturvedi et al., 1996).  
Body image is a key factor when considering the psychosocial impact of HNC. Figure 2.1 
illustrates a conceptual framework of body image in HNC patients developed on the basis of a 
review of the literature (Rhoten, Murphy, & Ridner, 2013). The framework proposes that 
diagnosis and treatment for HNC results in two main physical effects of disfigurement and 
dysfunction. The framework suggests that patients may have dysfunction and/or disfigurement 
at any time during their diagnosis and treatment pathway, the effect of which may be moderated 
by personal, social and environmental factors. The framework also acknowledges psychological 
and social outcomes, including QOL. This framework will structure my overview of the evidence 
of psychological outcomes, QOL and social outcomes and how these relate to disfigurement 
and dysfunction.  
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Figure 2.1: A conceptual framework of body image in head and neck cancer patients  
Permission to reproduce this has been granted by Elsevier. Source: Rhoten et al., 2013 
2.1.1 Psychological outcomes  
Studies measuring anxiety and depression in this patient population have used validated clinical 
tools, including the Hospital Anxiety and Depression Scale (HADS) (Zigmond & Snaith, 1983) 
and the mood and anxiety subscales of the validated University of Washington Quality of Life 
(UWQOL) measure (Hassan & Weymuller, 1993). The literature exploring the psychosocial 
impact of HNC on patients has yielded mixed results for anxiety, depression and QOL, but as a 
variety of measures are used to assess these psychological domains, it is difficult to compare 
findings across studies or conduct meta-analyses.  
Prevalence of psychological distress and patterns over time 
Table 2.1 summarises selected previous research with HNC patients that has reported anxiety 
and depression measured using the HADS and the UWQOL, so results can be compared with 
studies using the same measures. Levels of anxiety range from 16-22% (Hassanein, Musgrove, 
& Bradbury, 2005; Hutton & Williams, 2001; Kanatas, Ghazali, Lowe, & Rogers, 2012; Neilson 
et al., 2013) and levels of depression range from 5% reporting extreme depression one year 
post-treatment (Chen et al., 2013), to 29% being above the clinical threshold for depression 3 
weeks post-treatment (Neilson et al., 2013). A UK-based study showed elevated levels of 
CHAPTER 2 – PSYCHOSOCIAL IMPACT 
56 
 
depression and anxiety in both men and women compared to other studies with HNC patients 
(Shiraz et al., 2014). This may in part be due to their sample including 25% Asian cancer 
patients, who have been shown to have a more fatalistic attitude than patients from white British 
backgrounds (Roy et al., 2005). Longitudinal studies presented in Table 2.1 show levels of 
depression to change with time since diagnosis, with one study finding levels of depression at 
their highest 3 weeks post-treatment and levels of anxiety to be greatest 18 months post-
treatment (Neilson et al., 2013). Trends have also shown depression to decrease with time 
since illness onset and to be slightly less common among patients attending a support group 
(Hutton & Williams, 2001). A study measuring psychological distress in HNC patients 7-11 years 
after they had received curative treatment found levels of psychological distress was higher 
than anticipated (Bjordal & Kaasa, 1995), but as patients were no longer involved in the hospital 
system and receiving follow-up appointments, they were no longer being offered any systemic 
support or psychological treatment.  
Other studies using the HADS have shown depression to be higher than the UK norms for the 
general population, with anxiety being similar to UK norms for the general population (Clarke, 
Newell, Thompson, Harcourt, & Lindenmeyer, 2013) and 25% of HNC patients to have clinically 
significant distress levels (Henry et al., 2014). Depression, distress and anxiety have been 
found to be greatest in younger patients (Hutton & Williams, 2001; Kanatas et al., 2012; Neilson 
et al., 2013)
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Table 2.1: Examples of studies reporting anxiety and depression in head and neck cancer patients using the HADS and UWQOL 
   Scoring above clinical threshold  
Reference Sample Outcome measures Anxiety Depression Findings 
Hutton and 
Williams, 2001 
UK 
18 HNC patients being 
actively treated 
HADS (scores > 8 
=clinical threshold) 
22% 22%  Age significantly predicted distress 
and depression, but not anxiety or low 
self-esteem 
 Age did not predict clinically relevant 
anxiety or depression, but there was 
a trend for it to predict clinically 
important distress 
 Time since onset of illness was 
significantly associated with lessening 
of depression 
 Neither sex nor recurrence of illness 
was significantly associated with 
distress, anxiety, or depression 
Hassanein et 
al., 2005 
UK 
68 HNC patients who had 
received treatment for oral 
cancer between October 
1992 and October 1997 
HADS 
UWQOL 
EORTC QLQ-30 
Mental adjustment to 
cancer scale 
16%  19%  No significant differences between 
age, sex, site, stage and treatment 
modalities of the tumour 
 A strong negative association was 
found between anxiety and 
depression and poor head and neck 
specific functional measures 
 A strong positive association between 
ineffective coping strategies and 
anxiety and depression 
HADS=Hospital Anxiety and Depression Scale; UWQOL=University of Washington Quality of Life; EORTC QLQ-30=European Organisation for Research and Treatment of 
Cancer; PCI=Patient Concerns Inventory 
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Table 2.1: Examples of studies reporting anxiety and depression in head and neck cancer patients using the HADS and UWQOL (contd.) 
   Scoring above clinical threshold  
Reference Sample Outcome measures Anxiety Depression Findings 
Kanatas et al., 
2012 
UK 
204 HNC patients if 
disease-free and under 
routine follow-up at least 6 
weeks after completing 
treatment  
UWQOL 
PCI 
 
20% on UWQOL 
10% raised anxiety 
on PCI 
17% on 
UWQOL 
10% raised 
mood on PCI 
10% raised 
depression on 
PCI 
 More significant problems of anxiety 
and/or mood were reported on the 
UWQOL by younger patients  
Chen et al., 
2013 
USA 
211 HNSCC patients 
previously treated with 
radiotherapy and disease-
free with at least 1 year of 
follow-up; cross-sectional; 
120 at 3 years; 54 at 5 
years  
UWQOL (mood score 
of < 25 to indicate 
incidence of 
depression) 
 Somewhat 
depressed 
12% (1 year), 
8% (3 years), 
9% (5 years) 
Extremely 
depressed 
5% (1 year), 
7% (3 years), 
4% (5 years) 
 Only a small number were receiving 
medication in the form of 
antidepressants, or actively undergoing 
or seeking psychiatric care 
HADS=Hospital Anxiety and Depression Scale; UWQOL=University of Washington Quality of Life; EORTC QLQ-30=European Organisation for Research and Treatment of 
Cancer; PCI=Patient Concerns Inventory 
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Table 2.1: Examples of studies reporting anxiety and depression in head and neck cancer patients using the HADS and UWQOL (contd.) 
   Scoring above clinical threshold  
Reference Sample Outcome measures Anxiety Depression Findings 
Neilson et al., 
2013 
Australia 
101 first time HNC 
patients treated with 
radiotherapy with curative 
intent 
75 completed 3 week 
post-treatment 
37 completed 18 month 
post-treatment 
HADS (scores > 8 
=clinical threshold) 
20% Pre-treatment 
17% 3 weeks post-
treatment 
22% 18 months 
post-treatment 
15% Pre-
treatment 
29% 3 weeks 
post-
treatment 
8% 18 
months post-
treatment 
 The severity of physical symptoms 
associated with HNC tumours and 
treatment was a significant predictor of 
anxiety and depression scores (more 
physical symptoms associated with 
higher anxiety and depression scores) 
 Age of participants predicted anxiety 
and were higher in younger participants 
Shiraz et al., 
2014 
UK 
124 HNC patients from 
outpatient HNC clinics 
HADS (scores > 8 
=clinical threshold) 
Acute Stress Disorder 
Scale (ASD) 
48% women 
42% men 
35% women 
38% men 
 Acute stress was found in 8% of men 
and 33% of women 
 
HADS=Hospital Anxiety and Depression Scale; UWQOL=University of Washington Quality of Life; EORTC QLQ-30=European Organisation for Research and Treatment of 
Cancer; PCI=Patient Concerns Inventory 
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Predictors of psychological distress 
A study looking at the predictors of psychological distress in HNC patients found when 
comparing this patient population to patients with other cancers, HNC patients were frequently 
more distressed on more than one occasion post diagnosis (Singer et al., 2012). Patients 
undergoing surgery appear to report greater psychosocial impact when compared with 
alternative methods of treatment, as alternative treatments such as radiotherapy are associated 
with better functional outcomes (e.g. understandability of speech) (Allal, Nicoucar, Mach, & 
Dulguerov, 2003; De Boer et al., 1995; Taylor et al., 2004). A review of studies reporting patient-
reported outcomes in HNC found depression associated with loss of self-esteem, and a 
modified individual and social identity (Babin et al., 2008). 
Studies have presented findings on the support and information needs of HNC patients and 
found moderate to high levels of supportive care needs in the 6 months from the start of 
treatment (Chen et al., 2012). Highest information needs in patients occurred at the 
pretreatment stage, but the greatest overall and individual care needs occurred 2 months after 
starting radiotherapy or chemoradiotherapy. Supportive care needs were found to be higher in 
those without religious beliefs, those with a high educational level, high functional level, high 
overall physical symptom severity, and high baseline anxiety. Higher physical and daily living 
needs were significantly related to individual symptoms (Chen et al., 2012) and worsening 
physical symptoms have an adverse effect on psychosocial distress of patients (Badr, Gupta, 
Sikora, & Posner, 2014). Sixty-eight per cent of all patients in a cross-sectional survey reported 
they had unmet needs; the highest unmet needs being psychological (Henry et al., 2014). 
Maladaptive coping strategies of helplessness and fatalism were adopted by patients 
(Chaturvedi et al., 1996). Maladaptive coping strategies such as helplessness/hopelessness, 
anxious preoccupation and fatalism have been shown to be strongly associated with anxiety 
and depression (Hassanein et al., 2005). Qualitative work has found patients to describe a 
feeling of hopelessness and the loss of meaning in life in the context of their illness, feeling like 
they were fighting an endless battle (Moore, Chamberlain, & Khuri, 2004). Beliefs about how 
chronic the disease is has been shown to predict depression after treatment (Llewellyn, 
McGurk, & Weinman, 2007). Specifically looking at the relationship between anxiety, depression 
and coping strategies adopted by HNC patients, 6-12 months after their diagnosis, patients with 
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higher levels of anxiety and depression used ‘blame self’, ‘wishful thinking’ and ‘avoidance’ 
coping strategies (Elani & Allison, 2011). Conversely, benefit finding in HNC patients has also 
been reported, with moderate to high levels found in these patients (Harrington, McGurk, & 
Llewellyn, 2008). Benefit finding was independently positively associated with optimism and 
positive reappraisal.  
Examining patient’s ratings of disfigurement against psychosocial outcomes in HNC (Katz, Irish, 
Devins, Rodin, & Gullane, 2003) found women reported more depressive symptoms than men. 
Those reporting more depressive symptoms rated themselves as more disfigured, and 
individuals with social support reported higher psychological well-being. Social support was 
found to moderate disfigurement and psychological well-being in women but not men. Patients 
not returning to work after surgery have been found to find it more difficult to adapt 
psychologically (Terrell, Nanavati, Esclamado, Bradford, & Wolf, 1999).  
A study exploring the psychological impact of facial disfigurement on both HNC patients and 
their partners found scores on the HADS to be within normal range for patients and within 
normal range for depression in partners (Vickery, Latchford, Hewison, Bellew, & Feber, 2003). 
Partners had higher median scores for anxiety and these were classified as borderline clinical, 
demonstrating the experiences of illness and treatment are clearly different for partners. This 
group of patients did not have greater levels of psychological distress compared to other cancer 
patients. The degree of facial disfigurement has been found to be positively related to 
psychological distress and distress in reaction to unpleasant behaviour of others when patients 
did not feel confident in social interactions (Hagedoorn & Molleman, 2006). 
Another factor which could cause psychological distress in HNC patients is sexual function, also 
known in the literature as sexuality. A recent review about sexuality and HNC (Rhoten, 2016) 
found nine studies eligible for inclusion in the review, five of these with the specific aim to 
examine sexuality in patients with HNC (Low et al., 2009; Moreno et al., 2012; O’Brien, Roe, 
Low, Deyn, & Rogers, 2012; Rogers, Hazeldine, O’Brien, Lowe, & Roe, 2014; Singer et al., 
2008). The prevalence of HNC having a negative impact on sexual function ranged from 24% to 
100%, with 50% of that 100% reporting it to be an extremely negative impact (Moreno et al., 
2012). Two studies included in the review investigated the relationship between sexual function 
and QOL and found impaired sexual function was negatively associated with QOL (Psoter, 
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Aguilar, Levy, Baek, & Morse, 2012; Zwahlen et al., 2008). Issues with sexual relationships 
following treatment for HNC have also been reported by both patients and their partners (Low et 
al., 2009; Manne, Badr, & Kashy, 2012). Substantial problems were reported for sexual interest 
and enjoyment by one-third of respondents overall, and one-quarter for problems with intimacy 
that causes them some concern (Low et al., 2009). Problems with intimacy declined with age, 
from 36% in under 55 year olds, to only 6% in those aged 75 years or older. 
Fear of recurrence in HNC patients is another factor which could have a negative impact on the 
patient’s psychological health. Studies in this patient population have found the prevalence of 
significant fear of recurrence in a group of nearly 200 post-treatment HNC patients to be 35% 
and this remained stable over time (Ghazali et al., 2013). Being under 65 years of age, reporting 
anxiety and mood related problems as well as self-reporting fear of recurrence, were all 
predictors of having significant fear of recurrence. When looking at assessing fear of recurrence 
using the Patient Concern Inventory or the Fear of Recurrence questionnaire, fear of recurrence 
was selected as an issue by 42% of patients (Rogers, Scott, Lowe, Ozakinci, & Humphris, 
2010). It was not possible to predict which patients would report fear of recurrence by their 
clinical characteristics.  
Summary 
The research presented illustrates that there are a number of factors that contribute to HNC 
patients’ psychosocial distress with the most frequently measured outcomes being anxiety and 
depression. Understandably HNC patients exhibit higher levels of depression just after starting 
treatment as disabilities that arise from treatment for HNC have been described by patients as 
worse than the cancer itself (Burns, Chase, & Goodwin, 1987; Gamba et al., 1992). It is also 
evident that anxiety is more prevalent in younger cancer patients and those with more 
symptoms. It is important to note that psychological distress and QOL are not independent of 
each other (Bornbaum et al., 2012; de Graeff et al., 2000; Hammerlid et al., 1997). 
Psychological distress also interacts with disfigurement, dysfunction, coping, social support and 
sexual functioning in HNC patients.  
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2.1.2 Quality of life 
Although QOL is a widely used concept, it lacks a clear definition due to the different ways in 
which the term can be used. In the context of the health literature, health-related QOL (HRQOL) 
assesses physical, psychological and social domains (Llewellyn, McGurk, & Weinman, 2005) 
and QOL is defined by the Centers for Disease Control and Prevention as ‘a broad 
multidimensional concept that usually includes subjective evaluations of both positive and 
negative aspects of life’ (Centers for Disease Control and Prevention, 2016). In the health 
literature, QOL is commonly used as a psychological concept or as a medical outcome (Rejeski 
& Mihalko, 2001) and HRQOL has been stated to be important in Oncology because a patients’ 
well-being is substantially impacted by the disease and treatment (Secord et al., 2015). As 
previously stated, QOL is not independent from psychological distress and psychological 
distress can often predict QOL. Common general measures of QOL within the HNC population 
are the UWQOL and the European Organisation for Research and Treatment of Cancer QLQ 
(EORTC QLQ) (Aaronson et al., 1993), with a HNC specific version EORTC QLQ-H&N35 
(Bjordal et al., 2000). Specific HNC QOL measures have now been developed to include 
questions regarding some of the functional changes such as swallowing/eating and 
speaking/communication. 
Predictors of QOL 
QOL is commonly measured in HNC patients and has been the focus of some reviews (Dunne 
et al., 2016; Llewellyn et al., 2005; Moore, Ford, & Farah, 2014; Rogers, Ahad, & Murphy, 
2007). One review found the psychosocial variables of personality, social support, depressive 
symptoms, and satisfaction with consultation and information were associated with HRQOL, as 
well as behavioural factors such as consumption of alcohol and tobacco (Llewellyn et al., 2005). 
The support needs of patients in relation to QOL have also been reviewed and found these 
variables to relate to coping with both the psychosocial and physical aspects of radiotherapy 
(Moore et al., 2014). Aspects shown to cause a significant impact on QOL included depression, 
anxiety and malnutrition. The most recent review examined the evidence of associations 
between psychological factors and QOL (Dunne et al., 2016). The psychological variables more 
often measured were depression, anxiety and distress, and were found to have negative 
associations with QOL outcomes. Other psychological factors found to have associations with 
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QOL included coping, neuroticism and fear of recurrence. There are difficulties associated with 
measuring QOL, which include its lack of clear definition and lack of consistency in its 
measurement.  
Leventhal’s Common-Sense Model (CSM) proposes that patients’ representations of their 
illness guide coping mechanisms and outcomes such as QOL (see section 3.4.1.1) (Leventhal, 
Meyer, & Nerenz, 1980). In a study investigating the utility of this model as a framework for 
determining changes in outcomes over time, baseline illness and treatment beliefs were not 
predictive of HRQOL, individualised QOL, or anxiety 6-8 months after treatment (Llewellyn et 
al., 2007). The five dimensions of the CSM were found to be related to coping. The strongest 
relationship with identity was the use of venting and self-distraction, with the use of more coping 
strategies at 6-8 months; longer timeline beliefs were most strongly associated with planning 
and active coping at 6-8 months; stronger beliefs about consequences were associated with 
denial, venting and planning in the short-term, and self-distraction, denial and venting 
implemented at 6-8 months; stronger treatment concerns were associated with increasing levels 
of denial; and stronger emotional representations were most strongly associated with substance 
use, denial, self-distraction and planning. 
HNC patients were interviewed in a small qualitative study and their support needs were 
explored (Moore, Ford, & Farah, 2014). Patients were asked to describe their current QOL and 
their support needs post-treatment. In the first six to twelve months following treatment, QOL 
was affected by psychological distress such as depression and anxiety. Feelings of isolation 
were described following the loss of support from the hospital after treatment had finished. 
Support was sought from professional and personal networks during and after treatment and 
coping strategies were disrupted when patients were away from the hospital environment as 
they felt a loss of supportive care.  
In long-term survivors of HNC, objective measures of word intelligibility measured using the 
‘Assessment of Intelligibility of Dysarthric Speech’ (Yorkston & Beukelman, 1981) have been 
found to be significantly associated with factors affecting survivors QOL, such as enjoyment of 
recreation, perception of chewing and swallowing, willingness to eat in public and reported 
normalcy of diet (Meyer et al., 2004). Another study exploring the psychological impact of facial 
disfigurement in HNC patients found that although their QOL was lower than the general 
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population, it was comparable with other HNC samples (Vickery et al., 2003). Other research 
using the EORTC QLQC-30 showed overall global QOL in HNC patients to be satisfactory 
(Chaukar et al., 2009). 
Scores for QOL has been shown to be significantly better in patients diagnosed at an early 
stage and treated with surgery alone, compared with patients diagnosed at an advanced stage 
and given either radiation alone or multimodality treatment (Chaukar et al., 2009). 
Sociodemographic correlates with QOL 
A review of 35 articles provides an overview of sociodemographic predictors of QOL in HNC 
patients, as well as the functional and psychological outcomes associated with HNC (Babin et 
al., 2008). Being married, employed, having higher educational levels (Duffy et al., 2002) and no 
comorbidities (Fang et al., 2002), all tend to be associated with better QOL. Poorer ratings of 
QOL are found in younger patients. Patients from a lower socioeconomic position appear to 
present at a more advanced stage and have an increased number of disabilities associated with 
late stage diagnosis, having a significant effect on HRQOL. As these patients were also more 
likely to have jobs where physical strength was required, they were less inclined to attend 
rehabilitation as they did not want to accept change from the consequences of their treatment 
(Babin et al., 2008). This resulted in patients becoming disabled and unable to work, resulting in 
reduced QOL. 
Patterns of QOL over time 
QOL has been shown to be reduced even years after treatment (Meyer et al., 2004). The most 
significant changes in QOL in HNC survivors occur within the first year since diagnosis, with a 
lower QOL at one year post diagnosis being associated with a significantly increased risk of 
death (Mehanna & Morton, 2006). A study measuring QOL in HNC patients longitudinally at 
three, 12 and 24 months (Morton, 2003) found global QOL improved with time and patients 
coped well.  
Summary 
The findings from these research studies show there are a multitude of factors associated with 
QOL, with depression and anxiety being shown to be negatively associated with QOL. There 
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are also patient factors which can result in improved QOL, such as being married, employed 
and having a higher level of education. Younger patients were found to have lower QOL, as well 
as those who received multimodality treatment rather than single modality treatment. Support 
needs have also been shown to be influential in both QOL and psychological distress. QOL is 
related to function in HNC patients, with concerns around speech, chewing and swallowing 
affecting QOL. It is important to identify these factors, as alleviating them through medical, 
social or psychological interventions could result in HNC patients experiencing improved QOL.  
2.1.3 Social outcomes  
Social outcomes include those which affect the patient in the social context, such as social 
isolation and avoidance, shame and stigma, effects on relationships, and work. Social support 
has the potential to mitigate adverse social outcomes. Psychological distress has been found to 
be more common in HNC patients compared to other cancer patients, which might be due to 
their perception of less social support despite not asking for support from professionals (Singer 
et al., 2012). Having social support in the form of fellow patients during radiation was found to 
lead to less loneliness, reduction of uncertainty and reduced negative feelings (Egestad, 2013) 
and an increased feeling of control and self-esteem. It was also recognised that contact with 
fellow patients could lead to psychological distress, due to the emotions attached to being with 
someone who was seriously ill and sick from their treatment. In addition, patients sympathised 
with each other and therefore were effected when something happened to one of their fellow 
patients (Egestad, 2013). Social support has been found to be associated with fewer negative 
psychological symptoms and greater well-being in HNC patients (Bowers, 2008). A more recent 
study conducted in Japan confirmed this, finding patients who live with their family scored lower 
on the HADS than those who did not. Social distress, in this study defined as how much distress 
patients felt about their appearance following their surgery, was significantly positively 
associated with psychological distress and negatively associated with social support and self-
efficacy (Deno et al., 2012). Social support from friends was found to be positively influential on 
psychological distress, and social support from the family was not found to significantly 
influence social or psychological distress.  
Changes in communication are a key challenge associated with HNC following treatment 
(Chaturvedi et al., 1996; Penner, 2009; Rapoport et al., 1993). Qualitative studies with HNC 
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survivors have found communication to be a common theme emerging from the data (Lang, 
France, Williams, Humphris, & Wells, 2013; Parker et al., 2013; Swore Fletcher, Cohen, 
Schumacher, & Lydiatt, 2012). “Changes in communication” (Swore Fletcher et al., 2012), “living 
with the aftermath” (Parker et al., 2013) and “disruption to daily life” (Lang et al., 2013) were all 
themes reflecting the effect of treatment on communication which could result in patients feeling 
isolated, experiencing difficulties talking in groups, living with a persistent disability and also 
challenges to their confidence and self-esteem. The importance of social support was also 
reflected in these studies through “going deeper into life” (Swore Fletcher et al., 2012), “being 
supported” (Parker et al., 2013) and “sharing the burden” (Lang et al., 2013). Patients felt that it 
was important to be supported and that they would not have been able to do it alone, but some 
also reported feeling like they had become a burden (Parker et al., 2013). Social, recreational 
and sexual functioning have also all been shown to be negatively affected (De Boer et al., 
1999). These interviews were conducted with a small number of patients who ranged from 7 
months to 26 months after surgery, so there is the possibility that these themes may not be 
pertinent to HNC patients at all time points after their surgery. However, themes developed in a 
meta-synthesis reflected similar themes, and this included studies at various time points from 
pre-diagnosis to beyond treatment (Lang et al., 2013). 
Summary 
Common factors found to affect social outcomes of HNC patients included the amount of 
support they receive and problems with communication. Social support has been found to be 
associated with less psychological distress and greater well-being, yet some patients say they 
feel isolated and that they also do not want to be a burden. Having social support from fellow 
patients has been shown to reduce patients’ feelings of loneliness, but problems with 
communication can lead to patients isolating themselves due to having functional difficulties 
talking in groups and psychological difficulties with a lack of confidence and self-esteem.  
2.1.4 Disfigurement and dysfunction  
Disfigurement 
The term disfigurement is used to describe ‘visible and negative alteration in appearance 
caused by disruption of skin, soft tissue, or bony structures’ (Katz, Irish, Devins, Rodin, & 
CHAPTER 2 – PSYCHOSOCIAL IMPACT 
68 
 
Gullane, 2000, p136). Facial disfigurement, whether this be from the cancer itself or following 
surgery, has been considered the most stressful aspect of HNC (Koster & Bergsma, 1990; van 
Doorne, van Waas, & Bergsma, 1994). In 1983, Dropkin and colleagues developed the ‘Dropkin 
Disfigurement and Dysfunction Scale’ to measure the severity of visible disfigurement and 
dysfunction after surgery for HNC (Dropkin, Malgady, Scott, Oberst, & Strong, 1983). In a study 
of 117 HNC patients who were about to undergo disfigurative surgery, the relationship between 
coping with surgical disfigurement/dysfunction and length of hospital stay was investigated. 
Coping effectiveness was diminished in these patients and the degree of surgical deficit ranged 
from mild to severe disfigurement and dysfunction. If patients were coping effectively before the 
surgery, this predicted post-surgery coping behaviour. In a cohort study of 75 of these patients, 
anxiety levels before surgery were extremely high (Dropkin, 1999).  
More recently, Katz and colleagues developed an observer-rated disfigurement scale with a 
single item to measure the degree of disfigurement on a nine-point likert scale (Katz et al., 
2000). Patients then rated their disfigurement using five items, a single item for patient 
appearance and ten items for dysfunction, all rated on a seven-point likert scale. Ratings of 
disfigurement by surgeons and nonsurgeons were found to significantly correlate with patients’ 
ratings, indicating reliability between patients’ self-reports and ratings from their healthcare 
team.  
Reviewing QOL instruments used to assess the impact of disfigurement in HNC patients, the 
UWQOL was considered the instrument most well developed and validated to clinically evaluate 
appearance problems in HNC patients compared to the Head and Neck Survey, the EORTC 
QLQ-H&N35, the Derriford Appearance Scale 59 and the Derriford Appearance Scale 24 (Djan 
& Penington, 2013). Studies using the UWQOL and Derriford appearance scale have shown 
around 40% to indicate some concern about their appearance (Katre, Johnson, Humphris, 
Lowe, & Rogers, 2008; Millsopp et al., 2006). Additionally, 5% indicated they feel significant 
disfigurement and although this limits their activities, they still get out (Katre et al., 2008). The 
mean score for disfigurement on a patient-rated disfigurement scale with possible scores from 5 
to 35, was 15.68, but scores ranged across the entire breadth of the scale (Katz et al., 2000).  
In a study using the Derriford Appearance Scale 24, females reported higher appearance-
related distress than females in the general population and male HNC survivors (Clarke et al., 
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2013). At baseline, both fear of negative evaluation and dispositional optimism were significant 
predictors of appearance-related adjustment, with dispositional optimism remaining a significant 
predictor nine months later. Qualitative responses indicated that there is a link between 
appearance and disability, with patients describing how their difficulties with speaking and/or 
eating had a significant impact on how they appeared in public and how they were concerned 
about the visibility of their disfigurement in public. Coping strategies that patients found effective 
in managing their challenges about their appearance included hiding their disfigurement, 
focusing on positive aspects and reminding themselves they were lucky to be alive, and giving 
less importance to appearance (Clarke et al., 2013).  
A study interviewing nurses and their patients a few days and 6 months after surgery found 
patients moved through the process of disfigurement from becoming disfigured within the 
hospital setting and not feeling different to others, to being a disfigured person in the community 
after discharge and experiencing others’ silence, to becoming a person with a disfigurement, 
having alleviated the feeling of being left alone with disfigurement (Konradsen, Kirkevold, 
McCallin, Cayé-Thomasen, & Zoffmann, 2012). This process was described elsewhere as 
‘transitional cancer survivorship’ as patients adjust from being acute survivors to being extended 
or permanent survivors (Miller, Merry, & Miller, 2008). 
Identification of appearance-related concerns has been documented as being difficult in 
outpatient clinics due to them being busy, patients worrying it might take up too much of the 
doctor’s time, or the doctors being reluctant to discuss issues they may not feel comfortable or 
confident with (Flexen, Ghazali, Lowe, & Rogers, 2012). In a sample where 75% of patients with 
early stage HNC did not need radical and invasive treatment, appearance was a concern raised 
by patients on the Patient Concerns Inventory in 9% of consultations and as a problem by 
patients on the UWQOL in 10% of consultations. Thirty-four per cent of patients with 
appearance concerns on the UWQOL also indicated anxiety as a problem, with 12% of those 
indicating appearance concerns on the PCI wanting to discuss appearance, but had no problem 
with anxiety.  
Stigma and shame are also concepts that have been found to be pertinent through qualitative 
studies with HNC patients with disfigurement. Patients can feel stigma when others view their 
behaviour having caused the disease and/or when the disease results in visible disfigurement or 
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dysfunction (Crocker & Major, 1989; Sophie Lebel & Devins, 2008). A measure of Shame and 
Stigma for HNC was developed by Kissane and colleagues. Items loaded onto four factors of 
“sense of appearance”, “social and speech concerns”, “stigma” and “regret” (Kissane et al., 
2012) and was shown to be reliable and valid. Using a battery of stigma measures, self-blame 
was not found to predict stigma, but disfigurement predicted stigma (Lebel et al., 2013). 
In a review of the literature, nine studies examined body image as a psychological construct, 
with body image included as a study variable (Rhoten et al., 2013). In the first of a series of 
three studies, depression was found to predict body image issues (Fingeret, Vidrine, Reece, 
Gillenwater, & Gritz, 2010). The second study found 75% of patients reported body image 
concerns at some point since diagnosis and patients with speech and swallowing concerns had 
the highest number of body-related concerns and lower QOL than those with appearance-
related concerns (Fingeret, Hutcheson, Jensen, Urbauer, & Lewin, 2012). The third study of the 
series found predictors for decreased QOL included greater body image dissatisfaction, greater 
number of body image concerns and time since surgery (Fingeret et al., 2011). In a quasi-
experimental study, patients scheduled for surgery with flap reconstruction and receiving 
instructions in cosmetic rehabilitation, had improved satisfaction on the appearance evaluation, 
compared to patients receiving standard care (Huang & Liu, 2008). There was no overall 
change on body areas satisfaction, but higher satisfaction with patient’s body weight and face 
showed improvements at 12 weeks compared to baseline.  
Dysfunction 
Dysfunction refers to alterations in function, such as general functional deficits (e.g. fatigue), 
HNC specific functional deficits (e.g. loss of speech, swallowing) and loss of function in other 
areas such as the neck and shoulders (Rhoten et al., 2013). In a longitudinal study, HNC 
patients treated with surgery and/or radiotherapy showed limited deterioration of physical and 
role functioning and of many HNC symptoms at 6 months, as measured by the EORTC Head 
and Neck Cancer Module (de Graeff et al., 2000). Improvement was demonstrated after 6 
months and after 36 months, with only physical functioning and symptoms of tastes/smell, dry 
mouth and sticky saliva rated as worse than at baseline. Being female, having a more advanced 
cancer stage and receiving multimodality treatment were factors associated with more 
symptoms and worse functioning. Physical symptoms included speech problems, appetite loss, 
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fatigue, cough, dry mouth and throat and swallowing problems, as well as pain (Chaukar et al., 
2009; De Boer et al., 1999). Measuring head and neck dysfunction on a ten-item scale found 
the mean score to be 23.38, out of a possible 10 to 70 (Katz et al., 2000). 
Eating is a significant loss of function in HNC patients and those diagnosed with oropharyngeal 
tumours have been shown to have worse scores on the eating scale than tumours from other 
primary sites (Terrell et al., 1999). Patients often report difficulties in function around eating, 
communication and pain. 
As previously discussed in section 2.1.3, communication is a key challenge for patients 
following treatment. Research has demonstrated that concerns HNC patients have at the time 
of diagnosis differ from those long into survivorship (Meyer et al., 2004). Persistent concerns 
include those of speech intelligibility, with objective tests of communication found to correlate 
well with subjective self-perceptions of speech intelligibility (Meyer et al., 2004). 
Summary 
Disfigurement and dysfunction are two consequences of HNC which have the capability to 
cause psychological distress in patients by affecting body image (Figure 2.1). Women appear to 
have more appearance-related concerns than men and those receiving multimodality treatment 
have been shown to exhibit more symptoms and worse functioning than those receiving single 
modality treatment. The dysfunction related to HNC affects the fundamental human behaviours 
of eating and speaking which has a significant impact on how HNC patients appear in public.  
2.1.5 Summary of the psychosocial impact of HNC 
Reviews of the literature over the last 20 years have consistently provided evidence for the 
physical and psychological impact of HNC (De Boer et al., 1999; Dunne et al., 2016; Humphris 
& Ozakinci, 2006; Lang et al., 2013; Llewellyn et al., 2005; Moore et al., 2014; Rogers et al., 
2007). As these studies have shown, there are a number of factors which can predict 
psychological distress in HNC patients and psychological factors, social factors, QOL, 
disfigurement and dysfunction are all closely associated and affect one another. The constructs 
found through the research presented in this chapter to either contribute to or be a 
consequence of psychosocial distress in HNC patients are synthesised in Figure 2.2. The next 
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section focuses on interventions that have been developed to help improve psychological 
outcomes in HNC patients.  
 
Figure 2.2: Factors contributing to psychosocial distress in head and neck cancer 
2.2 Interventions 
Most of the psychosocial intervention studies carried out for HNC patients have included QOL, 
anxiety and/or depression as primary outcome measures. Some examples of interventions 
found through a search of the literature are summarised in Table 2.2 (D’Souza, Blouin, Zeitouni, 
Muller, & Allison, 2013; de Leeuw et al., 2013; Hammerlid et al., 1999; Handschel, Naujoks, 
Hofer, & Kruskemper, 2013; Jesse et al., 2015; Kangas, Milross, Taylor, & Bryant, 2012; 
Semple, Dunwoody, Kernohan, & McCaughan, 2009; van der Meulen et al., 2013; Vilela et al., 
2006). The interventions involved regular sessions for a designated period of time providing a 
supportive environment for patients and delivering interventions to improve psychosocial 
outcomes through psychoeducational programmes, supportive counselling and Cognitive 
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Behavioural Therapy. Some of the interventions were group-based and others were individual 
sessions. All these interventions were found to be effective at achieving improvements in 
psychological outcomes and in some of these interventions the results were maintained 
longitudinally (Kangas et al., 2012; Semple et al., 2009; van der Meulen et al., 2013). The 
designs of these intervention studies however, were a mixture of quasi-experimental, feasibility, 
cross-sectional and only two were randomised controlled trials (RCTs).  
An earlier review by Semple and colleagues suggested that there was evidence that 
psychosocial interventions generally provide an overall positive effect, but recognised that many 
of the studies had weaknesses in their methodology (Semple, Sullivan, Dunwoody, & Kernohan, 
2004). Some education alone intervention studies failed to achieve favourable results. A recent 
Cochrane review conducted to assess the effectiveness of psychological interventions for 
improving QOL and psychosocial well-being for HNC patients found seven trials, either RCTs or 
quasi-RCTs, with no evidence to suggest that psychosocial intervention promotes QOL, anxiety 
or depression following the interventions (Semple et al., 2013). None of the studies included in 
Table 2.2 were included in the Cochrane review, as one of the criterion of the Cochrane review 
was that the intervention had to be tested in an RCT or quasi-RCT. The intervention studies 
implementing an RCT design and presented in the table, were published after the search in the 
review had been conducted in December 2012.  
Although the interventions presented in Table 2.2 show promising results in their ability to 
achieve psychological improvements in HNC patients, only two of the intervention studies 
presented were tested in an RCT. As the review found interventions tested in either RCTs or 
quasi-RCTs to not be effective at achieving improvements in psychological outcomes, it may be 
that the other interventions presented here are flawed in their methodology. The review also 
showed that there is a paucity of research evaluating psychological interventions for this patient 
group. Therefore, there is a need for interventions to be tested within RCTs and to enable 
comparisons to be made more easily across interventions, standardised outcome measures 
need to be used. There may be a need to establish through RCTs, which factors are successful 
at achieving psychological improvements in order to develop an effective intervention. 
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Table 2.2: Interventions to improve psychological outcomes 
Reference Study design Sample Intervention Outcome measures Findings 
Hammerlid 
et al.,1999 
Sweden 
Feasibility and 
effectiveness  
 
13 newly diagnosed HNC 
patients living within 40km 
of the hospital; 34 control 
group those living further 
away 
14 HNC patients one year 
post-treatment for 
psychoeducational 
program 
Psychological group therapy 
(compared to control group) 
1.5hours a week for 2 
months, every second week 
for 2 months and once a 
month for 6 months  
Psychoeducational program  
EORTC QLQ-C30 
EORTC QLQ-H&N37 
HADS 
Diagnosis, 3 and 12 
months post-treatment 
 Patients receiving 
psychological group therapy 
showed greater 
improvements than control 
group 
 Greatest benefit in 
psychological group therapy 
group concerned emotional 
functioning 
 At 1 year follow-up the 
therapy group had improved 
considerably and fewer 
patients than in the control 
group were considered 
probably or possible cases 
of psychiatric morbidity 
 Most of the functioning 
variables and symptoms 
improved after 1-week 
psychoeducational 
programme 
EORTC QLQ-C30=European Organisation for Research and Treatment of Cancer core quality of life questionnaire; EORTC QLQ-H&N37=European Organisation for 
Research and Treatment of Cancer quality of life questionnaire head and neck cancer module; HADS=Hospital Anxiety and Depression Scale 
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Table 2.2: Interventions to improve psychological outcomes (contd.) 
Reference Study design Sample Intervention Outcome measures Findings 
Vilela et 
al., 2006 
Canada 
Feasibility 
study – 
prospective, 
nonrandomised 
design 
 
138 HNC patients; 
controls were matched to 
patients in the intervention 
group by stage of cancer 
and time since diagnosis 
Short-term 
psychoeducational coping 
strategies intervention 
(Nucare) 
QOL 
Depression 
Baseline, 3-4 months later 
 Intervention group showed 
improved physical and social 
functioning, global QOL, 
fatigue, sleep disturbance, 
depressive symptoms 
compared to the control 
group who showed no 
changes in QOL or 
depressive symptoms 
Semple et 
al., 2009 
Northern 
Ireland 
Quasi-
experimental 
design and 
compared to a 
control group 
 
54 HNC patients 
completed treatment with 
evidence of psychosocial 
dysfunction; 25 
intervention group, 29 
control group 
Psychosocial intervention 
with treatment approach 
based on psychoeducation 
and Cognitive Behavioural 
Therapy principles  
Minimum of 2 sessions, 
maximum of 6 (average 4) 
lasting up to 90 minutes, 
biweekly 
Control group – ongoing 
review at the 
multidisciplinary HNC 
outpatient clinic and 
involvement as appropriate 
with members of the HNC 
team 
HADS 
WASA scale 
HRQOL (UWQOLv4) 
1 week, 3 months post 
intervention 
 The intervention group 
showed a significant 
reduction in psychological 
distress, improved social 
functioning and improved 
QOL scores which remained 
into the 3 month follow-up 
period 
QOL=quality of life; HADS=Hospital Anxiety and Depression Scale; WASA=Work and Social Adjustment scale; HRQOL=health-related quality of life; UWQOL=University of 
Washington Quality of Life scale 
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Table 2.2: Interventions to improve psychological outcomes (contd.) 
Reference Study design Sample Intervention Outcome measures Findings 
Handschel et 
al., 2013 
Germany, 
Austria, 
Switzerland 
Cross-sectional  1652 HNC patients at 
post-operative care 
appointments  
Psychological interview Depressive state 
Anxiety 
 77.5% evaluated this as 
helpful 
 70.7% of patients did not 
want an interview 
 Patients who wanted a 
psychological interview but 
who did not receive one 
showed significantly worse 
QOL than those patients 
who did not want an 
interview 
 Interviews found to not 
meet the needs of the 
patient diminished QOL 
compared to not having an 
interview  
D’Souza 
2013 
Canada 
Non-
randomised 
controlled trial 
103 newly diagnosed 
HNC patients with stage 
III and IV primary or 
recurrent cancer; 50 
intervention, 53 control 
Tailored information (patient 
booklet, interactive computer 
booth, computer animation, 
DVD, database) compared to 
control intervention (no 
specific information 
resources, met with nurse for 
15-45 minutes) 
Distress thermometer 
HADS 
Baseline, 3 and 6 months 
 Lower levels of anxiety 
and depression were 
found in the intervention 
group than the control 
group 
 Younger subjects were 
more depressed than 
older subjects 
QOL=quality of life; HADS=Hospital Anxiety and Depression Scale 
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Table 2.2: Interventions to improve psychological outcomes (contd.) 
Reference Study design Sample Intervention Outcome measures Findings 
de Leeuw et 
al., 2013 
The 
Netherlands 
Quasi-
experimental, 
patients 
enrolled 
consecutively 
into two groups 
 
80 HNC patients treated 
with curative intent  
80 comparison group 
Nurse-led follow up 
consultation during first year 
post treatment; 6x30 minute 
nurse follow up consultations  
Comparison group received 
conventional care; 5 year 
routine control schedule with 
6x10 minute bimonthly visits 
to a head and neck surgeon 
in the first year post-
treatment 
Psychosocial adjustment 
measured using the 
Psychosocial Adjustment 
to Illness Scale-Self 
Report 
HRQOL measured using 
EORTC QLQ-C30 and 
QLQ-H&N35 
1, 6 and 12 months after 
treatment 
 Positive effects were found 
for the intervention group 
in HRQOL compared to 
conventional medical 
follow-up, but these were 
not significant  
 Greater improvements 
from baseline to 12 months 
in HRQOL scores were 
found in the intervention 
group compared to the 
comparison group at 12 
months  
 Scores were lower in both 
groups at 12 months 
compared to baseline for 
psychological adjustment  
HRQOL=health-related quality of life; EORTC QLQ-C30=European Organisation for Research and Treatment of Cancer core quality of life questionnaire; EORTC QLQ-
H&N37=European Organisation for Research and Treatment of Cancer quality of life questionnaire head and neck cancer module 
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Table 2.2: Interventions to improve psychological outcomes (contd. 
Reference Study design Sample Intervention Outcome measures Findings 
van der 
Meulen et 
al., 2013 
The 
Netherlands 
RCT 
 
205 HNC patients treated 
with curative intent; 103 
intervention group, 102 
control group 
Nurse counselling and after 
intervention (NUCAI) 
compared to usual care; 
problem focused and patient 
driven, aims to help patients 
manage the physical, 
psychological and social 
consequences of their 
disease and treatment; 
maximum 6 counselling 
sessions of 45-60 minutes 
every 2 months over 1 year 
Care as usual – bimonthly by 
HNC specialists aimed at the 
treatment of complications 
and the detection of 
recurrences or second 
primary tumours  
HADS 
HRQOL (EORTC QLQ-
C30 and EORTC 
QLQH&N35 
Depressive symptoms 
(CES-D) 
Baseline, 3, 6, 9, 12, 18, 
24 months post treatment 
completion 
 Intervention group at 12 
months showed significant 
improvement in emotional 
and physical functioning, 
pain, swallowing, social 
contact, mouth opening 
and depressive symptoms 
 Intervention group 
remained significantly 
better than the control 
group at 18 months in 
global QOL, role and 
emotional functioning, 
pain, swallowing, mouth 
opening and depressive 
symptoms and at 24 
months for emotional 
functioning and fatigue  
HADS=Hospital Anxiety and Depression Scale; HRQOL=health-related quality of life; EORTC QLQ-C30=European Organisation for Research and Treatment of Cancer 
core quality of life questionnaire; EORTC QLQ-H&N37=European Organisation for Research and Treatment of Cancer quality of life questionnaire head and neck cancer 
module; CES-D=Center for Epidemiologic Studies Depression Scale; QOL=quality of life 
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Table 2.2: Interventions to improve psychological outcomes (contd.) 
Reference Study design Sample Intervention Outcome measures Findings 
Kangas et 
al., 2013  
Australia 
Pilot RCT 35 primary, first-onset 
HNC patients aged 18-70 
recommended to receive 
primary or adjuvant 
radiotherapy; 21 CBT, 14 
supportive counselling 
Brief early CBT intervention 
evaluated against a non-
directive supportive 
counselling programme 
Both comprised 6x90 minute 
weekly sessions with 
structured homework 
activities and a 7th booster 
session conducted 4 weeks 
following session 6 
Acute cancer-related 
PTSD 
Anxiety (STAI) 
Depression (BDI) 
1, 6 and 12 months post-
intervention 
 Patients in both interventions 
reported declines in anxiety 
and depression over time 
and both were equal in their 
effects of reducing PTSD 
and enhancing perceived 
QOL 
 Effects maintained at 6 and 
12 months follow up 
Jesse et 
al., 2015 
USA 
Cross-sectional 
evaluation 
173 HNC patients 
psychiatrically evaluated 
by the integrated clinical 
health psychologist 
between May 2010 and 
August 2011 
Evaluation of integrated 
psychological care and 
perceived benefit  
Survey to determine 
whether perceived a 
benefit from having a 
psychologist integrated 
into HNC care 
 Perceived 
availability/accessibility 
 Effectiveness with 
distress management 
and QOL 
 Impact of help with 
medical care 
 Overall satisfaction 
 Psychologist integrated into 
the evaluation and treatment 
of HNC patients was well 
received by staff, patients 
and patient supports 
 Younger patients reported 
greater satisfaction than 
older patients 
 Patients with reported 
psychiatric histologies 
indicated more satisfaction 
in relation to managing 
distress than patients who 
denied psychiatric 
histologies  
 Current smokers tended to 
report lower satisfaction than 
past/never smokers 
PTSD=post-traumatic stress disorder; STAI=State-Trait Anxiety Inventory; BDI=Beck Depression Inventory; QOL=quality of life 
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2.3 Implications for the patients’ partner 
As previously demonstrated, accompanying a diagnosis of HNC is a multitude of functional 
deficits as well as psychosocial implications for the patient. Understandably friends and family of 
the patient diagnosed are integral in the care of the patient due to the functional and 
psychosocial impact of this diagnosis and often become known as informal caregivers. Studies 
exploring the impact of a HNC diagnosis on informal caregivers, more often focusing on the 
partner of the patient, have found substantial impact on a number of factors including financial, 
information needs and psychological distress. 
A recent review provided a thorough overview of psychological health of caregivers of HNC 
patients (Longacre, Ridge, Burtness, Galloway, & Fang, 2012), searching using different terms 
for head and neck cancer and for caregivers. Outcomes most frequently assessed in the studies 
included in the review were psychological distress, anxiety or depressive symptoms and 
caregiver perceived burden. A study measuring psychological distress with the HADS found 
20% of HNC caregivers reported psychological distress (Verdonck-de Leeuw et al., 2007) and 
in a study using the Global Mental Health scale, 38% reported moderate to high distress (Ross, 
Mosher, Ronis-Tobin, Hermele, & Ostroff, 2010). Two other studies also demonstrated anxiety 
symptoms suggestive of clinical anxiety in 30-40% of caregivers (Hodges & Humphris, 2009; 
Vickery et al., 2003) which is poorer than that found in the general population (Ostroff, Ross, 
Steinglass, & Ronis-tobin, 2004) and poorer than patients themselves (see section 2.1.1) 
(Hodges & Humphris, 2009; Vickery et al., 2003). Depressive symptoms were within the normal 
range (Hodges & Humphris, 2009; Vickery et al., 2003) and were equivalent to the general 
population. Caregivers also perceived moderate levels of caregiving burden (Chen et al., 2009) 
and expressed the need for psychological care for themselves to help them cope (Baghi et al., 
2007). The review summarises the key factors reported to be associated with poorer 
psychological health in HNC caregivers as caregiver sociodemographic factors, time since the 
patient diagnosis, hours of care, lifestyle modifications, patient needs and treatment-related 
factors, and cancer recurrence (Longacre et al., 2012).  
Further findings from the review presented mixed results for gender, age and educational level 
of the caregiver and their association with psychological health across studies. Confirmed in a 
couple of studies, caregiver psychological health appeared to be better with longer time since 
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diagnosis (Blood, Simpson, Dineen, Kauffman, & Raimondi, 1994; Ross et al., 2010) and poorer 
psychological health was associated with a greater number of hours caregiving (Ross et al., 
2010). In qualitative studies, the themes emerging which reflected how caregiving for HNC 
patients leads to modifications in lifestyle were around the transition “from spouse to supportive 
caregiver”, self-neglect and managing psychological distress, changes in lifestyle and restricted 
living, and an “altered sense of time lived” (Röing, Hirsch, & Holmstrom, 2008; Watt-Watson & 
Graydon, 1995). Additionally, concerns about effects on patients’ socialising were noted (Watt-
Watson & Graydon, 1995) and about their ability to continue providing care on an on-going 
basis (Mah & Johnston, 1993). Levels of caregiving burden were associated with the level of 
physical and daily living needs of the patient (Chen et al., 2009; Verdonck-de Leeuw et al., 
2007) but spousal distress was not associated with patient’s self-rated functional impairment 
(Verdonck-de Leeuw et al., 2007). Finally, one study found caregivers had higher fear of 
recurrence than the patients themselves and that this was associated with psychological 
distress (Hodges & Humphris, 2009). This review provides a comprehensive overview of studies 
conducted into the psychosocial health of caregivers for the HNC patient and provides a 
substantial insight into the impact of caregiving for this patient group.  
In studies published since the review, QOL in caregivers was found to decrease during the 
middle part of the patients’ treatment and caregiver burden increase over the course of the 
patients’ treatment (Badr et al., 2014; Nightingale, Lagorio, & Carnaby, 2014). Depression was 
also found to always be at lower levels in caregivers than patients. A systematic review of QOL 
in patient-caregiver dyads found no consensus in results (Sterba, Zapka, Cranos, Laursen, & 
Day, 2016).  
An increase in patient-rated head and neck specific symptoms has an adverse effect on the 
psychosocial distress in patients and caregivers (Badr et al., 2014). Caregivers reported 
moderately high to high resilience, 27% had scores suggestive of the presence of anxiety and 
10% had scores suggestive of the presence of depression (Simpson et al., 2015). Higher 
resilience was significantly associated with lower psychological distress and was independent of 
the severity of HNC.  
Qualitative studies have given examples of psychological support needs of caregivers, with 
caregivers wanting information, honesty and empathy from clinical staff (Richardson, Morton, & 
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Broadbent, 2015a) and that practical support is the most useful support at 6 months post-
diagnosis. Forty per cent of caregivers would have liked psychological support at diagnosis, and 
33% still wanted psychological support at 6 months. Caregivers wanted to improve their 
understanding by having more information about HNC and its treatment, be able to express 
emotion, fears and concerns, and to discuss coping strategies. Caregivers also described their 
psychological distress, lack of knowledge and support in an interview study with relatives of 
HNC patients experiencing pain (Schaller, Liedberg, & Larsson, 2014). Relatives described their 
struggle with the patient’s pain related to the treatment and in the context of their own situation. 
Relatives felt unable to relieve the patients’ pain, felt in need of support from the health care 
service, had their own emotions to deal with and their altered daily activities and family roles 
due to the illness and treatment. Coping strategies in patients with terminal HNC and their 
caregivers have been described as being able to cope individually, using internal resources to 
cope, coping through support from others and coping together as a dyad (Foxwell & Scott, 
2011). 
HNC can also impact on caregivers financially and can result in caregivers becoming either 
under or unemployed (Balfe et al., 2016). Those with large debts or ongoing expenses could be 
vulnerable to cancer-related financial pressures and having access to medical and/or social 
welfare benefits may help mitigate financial distress.  
Summary 
A diagnosis of HNC has been shown to have a significant impact on the caregiver, as well as 
the patient. Caregivers have shown levels of anxiety that are worse than the general population 
and the patients themselves, demonstrating the substantial significance becoming a caregiver 
for a HNC patient has. Caregivers not only need to deal with their own emotions, but also 
support the patient through their psychological and physical needs, and greater caregiving 
hours are associated with lower psychological health. Studies have shown that caregivers 
would like to receive psychological support and these results suggest that this is something 
which should be offered to caregivers, as well as patients.  
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2.4 Summary 
This chapter has presented a multitude of factors associated with psychosocial distress and 
QOL of HNC patients. A diagnosis of HNC is accompanied by long-term implications of 
treatment, often resulting in disfigurement and dysfunction. Interventions developed to help 
improve psychosocial distress have shown some promising results, but these need to be tested 
further and within RCTs. Friends and family of HNC patients are also significantly affected by 
the diagnosis and have their own emotional and practical needs and requirements for 
psychosocial support. The next chapter will focus on the psychosocial impact of the additional 
dimension of HPV as a causal factor, presenting findings in the cervical cancer screening 
context. 
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CHAPTER 3. PSYCHOSOCIAL ISSUES RELATING TO HPV IN 
CANCER  
The research previously reported in chapter 2 has demonstrated the significant psychosocial 
burden of a diagnosis of head and neck cancer (HNC) not only on the patient, but also on the 
patient’s caregiver. Human papillomavirus (HPV) is most well known for its association with 
cervical cancer and there has been a substantial amount of research carried out examining the 
psychosocial impact of HPV in the context of cervical cancer screening. As described in chapter 
1, the relationship between HPV and HNC has now been well established, but there is currently 
very little work carried out examining the psychosocial impact of HPV-related HNC. It is 
therefore important to present what we currently know about the impact of HPV in the cervical 
cancer screening context. This will provide some insight into the potential impact HNC patients 
may face when told this diagnosis, which will be in addition to the already significant burden of 
their HNC diagnosis.  
3.1 Psychosocial issues of HPV in the context of cervical cancer 
Research conducted in the cervical cancer context has been carried out as part of the 
population-based screening programme for cervical cancer. Within such research, women are 
told they have HPV and are at risk for cervical cancer, which differs from the context of my 
thesis as I examine the impact of HPV in patients diagnosed with cancer.  
3.1.1 Impact on relationships 
Early research in women with genital HPV showed a high percentage of sexual impairments 
after treatment, fear of cancer and a negative impact on the emotional relationship with a 
partner (Filiberti et al., 1993). Reasons for changes in their emotional relationship with partners 
were the disease itself, fear of infecting the partner, pain during intercourse and forced use of 
condoms. A reduction in sexual enjoyment and frequency of sex has also been reported 
(Clarke, Ebel, Catotti, & Stewart, 1996).  
Some women indicated that they had ceased sexual activity since learning of their HPV status. 
Disclosures in this sample of women focused on different aspects of HPV depending on who 
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they were disclosing to, with the focus being on its potential to lead to cervical cancer if talking 
to their mother or friends, and on its sexually transmitted nature if talking to their sexual partner 
(Daley et al., 2010). 
3.1.2 Psychological outcomes 
Based on the cervical cancer literature, an HPV infection can be accompanied by feelings of 
guilt, shame and depression (Clarke et al., 1996). A number of studies have found a substantial 
psychosocial impact associated with women testing positive for HPV. English-based centres 
participating in the piloting of HPV testing found women with borderline or mildly dyskaryotic 
smear results who were told they were HPV-positive, had significantly higher levels of anxiety, 
distress and concern compared to women who were HPV-negative, were not tested for HPV or 
were given normal results (Maissi et al., 2004). The women told they were HPV-positive also 
perceived themselves as being at a greater risk of developing cervical cancer than all other 
groups. Perceiving a greater risk of developing cervical cancer and not knowing the meaning of 
a smear result predicted anxiety, distress and concern, with younger age also being a predictor 
for anxiety. At six months after their results, the raised anxiety in the HPV-positive group and 
the differences between the groups for anxiety, distress and concern had disappeared (Maissi 
et al., 2005). Perceived risk of developing cervical cancer was higher in the HPV-positive and 
untested group at 6 months, compared to the HPV-negative or normal group. Concern about 
the smear test result was still elevated in women testing HPV-negative and was highest in those 
untested for HPV. Similar results were found in a cross-sectional survey in over 400 women 
where increased anxiety, distress and concern about sexual relationships were associated with 
testing positive for HPV and distress was markedly higher in women diagnosed with an 
abnormal smear accompanied by HPV (McCaffery et al., 2004). Anxiety and depression were 
both found to be elevated in a sample of Canadian women given an abnormal result compared 
to those given a normal result and this was clinically meaningful at 12 weeks (Drolet et al., 
2012). 
3.1.3 Knowledge of HPV and reactions to HPV diagnosis 
Qualitative studies carried out with women tested for HPV alongside either a smear or 
colposcopy found women knew very little about cervical cancer or HPV (Waller, McCaffery, 
Nazroo, & Wardle, 2005). Some women were aware that HPV was linked to sexual activity, but 
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not that cervical cancer was linked to sexual activity, and therefore were shocked to discover its 
association with a sexually transmitted infection. Reassurance was provided by knowledge that 
HPV is common, it has no symptoms, it can lie dormant for many years, can clear up by itself 
and there is no need to raise concerns among sexual partners (McCaffery & Irwig, 2005; Waller 
et al., 2005). 
Embarrassment, shame, fear and uncertainty have all been cited as initial reactions to a 
diagnosis of HPV (Taylor, Keller, & Egan, 1997). When specifically looking at data related to the 
diagnosis of HPV, being told of the HPV-positive nature of their test result was associated with 
adverse psychosocial consequences, primarily due to the sexually transmitted nature of HPV 
and its link to cervical cancer (McCaffery, Waller, Nazroo, & Wardle, 2006). Women felt stigma, 
anxiety, concern about their relationships and worry about disclosure of their test results to 
others. The terms ‘unclean’ and ‘dirty’ were used to describe some of the stigma they felt. Some 
women who were aware of the sexually transmitted nature of HPV, but who did not describe 
feelings of stigma, just saw it as an inevitable part of sexual activity. Those who were unaware 
of the sexually transmitted nature of HPV did not describe feelings of stigma. Questions were 
raised about where they had got the infection from and this sometimes led to women 
questioning if their partner had been unfaithful. Reports of receiving inconsistent information 
from health professionals contributed to their confusion and distress about the infection. 
Disclosing their HPV-positive result to their partner or family and friends was accompanied by 
anxiety and in some cases, in order to manage this anxiety, women chose not to disclose HPV 
(McCaffery et al., 2006). Similar results were found in the USA, with some women not intending 
to disclose their HPV-positive test result as they viewed this as stigmatising or shameful and 
were concerned it would be seen as a sign of having been unfaithful (Kahn et al., 2005). 
More recent research has supported these findings with higher scores of worry and concern 
found in women given an abnormal smear result with a HPV-positive result compared to an 
abnormal smear only (Kwan et al., 2011; Wang et al., 2010). In addition, an analysis of 
interviews conducted with women who had received an HPV-related diagnosis, found five 
themes of stigma, fear, self-blame, powerlessness and anger emerging from qualitative data 
(Daley et al., 2010). 
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3.1.4 Information needs 
In a research study conducted in Australia, women diagnosed with HPV after their smear test 
showed obvious confusion about HPV and what the HPV infection is, struggling to make sense 
of this information (McCaffery & Irwig, 2005). Many were confused about the association 
between high-risk HPV and genital warts which contributed to embarrassment and stigma they 
felt about HPV. Information needs of women were around transmission, prevention against 
catching and spreading the infection, importance of disclosing the HPV test result to future 
partners, how long the virus could lie dormant for and if it would completely clear, and how 
smoking could affect their cervical cancer risk. Almost all women said they had insufficient 
information about HPV and a high proportion looked for information elsewhere, most commonly 
on the internet. Women not understanding the information about their test result perceived 
themselves at higher risk of cervical cancer (McCaffery & Irwig, 2005). These findings were also 
found in Taiwan where women felt fearful of having cervical cancer and potentially infecting their 
partners, worry for themselves and their partner, and suspicion about the results or their 
partner’s faithfulness (Lin, Jeng, & Wang, 2011).  
A number of studies have found that a lack of information and uncertainty has contributed to 
feelings of anxiety, stigma and shame (Daley et al., 2008; Waller, Marlow, & Wardle, 2007), 
confusion and distress (Kosenko, Hurley, & Harvey, 2012; McCaffery et al., 2006; McCaffery & 
Irwig, 2005), and has resulted in perceiving a higher risk of cervical cancer (Drolet et al., 2012). 
Uncertainty documented by women was found to be around the meaning of their diagnosis, the 
potential progression of the infection, finances, not knowing the source of infection, disclosure to 
current and prospective sexual partners, insufficient information about the implications for sex 
and reproduction, and about whether the HPV vaccine would prevent against future infections 
with HPV (Kosenko et al., 2012).  
As a lack of information contributes to the negative psychosocial impact experienced by many 
women, it is important for health professionals to recognise this and address psychosocial and 
educational needs throughout the treatment and follow-up process, provide support to facilitate 
coping, and provide education to promote optimal self-care (Linnehan & Groce, 2000). 
Providing written information for patients to take home and refer back to and share with their 
family and friends has been seen as important to help ease uncertainty (Linnehan & Groce, 
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2000; Rubin & Tripsas, 2010). As the internet has also been cited as a popular source of health 
information, it is also important for evidence-based, accurate information to be made available 
online.  
3.2 Possible implications for patients diagnosed with HPV-related head 
and neck cancer 
For a patient diagnosed with HPV-OSCC they have been given a diagnosis of cancer and of a 
sexually transmitted infection, and told that their cancer has been caused by this sexually 
transmitted infection. As presented in section 3.1.2, women told of their diagnosis of HPV in the 
cervical cancer screening context indicated substantial psychosocial burden. Common patient 
concerns related to HPV in HNC have been documented to be how, when and why they got 
their cancer (Fakhry & D’Souza, 2013). The answers to these questions have implications both 
for the patient and their past, present or future partners. The answers to these questions are 
often complex and, due to a lack of available evidence, sometimes unanswerable (Chu, 
Genden, Posner, & Sikora, 2013). 
A small number of quantitative studies have begun to measure quality of life (QOL) and the 
informational and psychosocial needs of HPV-OSCC patients (Maxwell et al., 2013; Milbury, 
Rosenthal, El-Naggar, & Badr, 2013) which are discussed in chapter 4. A small qualitative study 
with HPV-OSCC survivors found that some felt stigma or embarrassment related to their 
diagnosis and that nearly half were worried about infecting their partner (Baxi et al., 2012). As 
discussed in section 1.2.4, some studies have found indications of transmission of oral high-risk 
HPV between partners (Agrawal et al., 2008; Haddad et al., 2008). One study found persistent 
oral HPV infection in one spouse to be a significant risk factor for oral HPV infection in the other 
partner (Rintala, Grénman, Puranen, & Syrjänen, 2006).  
As discussed earlier in section 2.1.1, younger age has been found to be a factor which 
contributes to psychosocial distress in HNC patients. As HPV-OSCC patients are more likely to 
be younger, it is possible that they may experience greater psychosocial distress than older 
patients with HPV-negative HNC. This also means that more parents of young children are 
being diagnosed with HPV-OSCC. A qualitative study found HNC patients with young children 
experienced fear of missing milestones in their children’s lives and fear of telling their children 
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about their diagnosis (Semple & McCance, 2010). The dysfunctional effects of treatment also 
had an impact on family activities and following treatment they had a desire to get back to day-
to-day life. Patients with HPV-OSCC who are younger are keen to return to their normal lives, 
which could also have implications for rehabilitation needs.  
3.3 Summary 
As chapters two and three have demonstrated, a diagnosis of HNC and a diagnosis of an HPV 
infection independently have a substantial negative psychosocial impact. Chapter two 
demonstrates the significant impact that a diagnosis of HNC has on the patient in terms of 
disfigurement and dysfunction associated with its treatment, affecting levels of psychological 
distress and quality of life, as well as how the patient perceives reactions from others and how 
their life has changed in a social context. A diagnosis of HPV-OSCC also has implications of 
caregiving responsibilities and a possible reduction in sexual intimacy between patients and 
their partners. The partner will also have their own informational needs alongside their fears and 
concerns. 
Chapter three provides evidence that in the cervical cancer screening context, a result which 
shows infection with HPV can result in psychosocial distress. Women receiving this result in the 
context of screening have expressed feelings of embarrassment, worry, and stigma and have 
been concerned about transmitting the infection to their partner or future partners. Although 
these findings are in the context of cervical cancer screening and in women being told of 
abnormal results, but not of a cancer diagnosis, these findings provide a substantial body of 
evidence and a starting point to exploring the psychological impact of HPV in other cancers. 
The evidence from both the cervical cancer screening and HNC literature suggests that the 
combination of these could lead to psychosocial distress in HPV-OSCC patients being 
amplified. A great number of factors contribute to psychosocial distress in HNC patients and 
there is an opportunity for health psychologists and behavioural medicine specialists to use their 
expertise to develop ways in which the impact of these factors could be alleviated.  
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3.4 Psychological theories 
Social cognition models are primarily focused on components which interact in a linear nature to 
predict health behaviours, such as attending for cervical cancer screening or being vaccinated 
against HPV. This includes models such as the Health Belief Model (Rosenstock, 1974) and 
The Theory of Planned Behaviour (Ajzen, 1991). Applying theory can help guide and focus 
research and can be useful in explaining health outcomes. Theory also allows knowledge to 
accumulate so that better models to understand behaviour can be developed. How patients 
cope and appraise illnesses cannot be explained by these models and therefore models are 
needed which take into account the dynamic processes involved. Understanding patients’ 
beliefs about their illness and how this impacts appraisal of their illness is important to ensure 
interventions to change behaviour can be targeted appropriately.  
3.4.1 Psychological models of illness perceptions/adjustment 
The use of psychological theory is scarce in research previously conducted examining the 
psychosocial impact of HNC. The dynamic process through which patients’ beliefs and 
appraisals of their illness influence their emotional outcomes is often termed ‘adjustment’. 
Adjustment has commonly been defined as ‘the presence or absence of diagnosed 
psychological disorder, psychological symptoms or negative mood’ (Stanton, Revenson, & 
Tennen, 2007, p568). Although my thesis is pragmatic and not theory-driven, I recognise that 
there are some useful theories of psychological adjustment which could be applied to examine 
the issues raised in this thesis and, where appropriate, these are drawn upon in the discussion 
sections of the empirical chapters. These theories of psychological adjustment are dynamic, 
examining patients’ beliefs and responses about an illness following the acquisition of new 
health information in changing contexts. Firstly, it is important to look at examples of theories 
which help explain how patients may understand their illness and how this may affect ways in 
which they cope with their illness.  
3.4.1.1 Common-Sense Model of Self-Regulation 
Leventhal’s Common-Sense Model of Self-Regulation (CSM) theorises that lay cognitive illness 
representations fall into five dimensions: identity, cause, consequences, timeline, curability or 
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controllability (Leventhal et al., 1980). In the context of this research, this refers to how patients 
understand their HNC diagnosis through these five dimensions.  
Identity is the label given to the health threat (e.g. cancer), as well as experiences of the threat 
such as any symptoms or functional changes; cause relates to patients’ perceptions of what 
might have determined their cancer (e.g. HPV); the consequences of the illness refer to the 
physical, psychological, social and economic impact that the illness may have on the patient’s 
life (e.g. loss of speech); timeline refers to the duration of the illness, including the development 
and the recovery (e.g. how long they may have cancer) and whether this is acute, chronic, or 
cyclical; curability or controllability refers to the extent to which the patient believes their illness 
can be prevented or treated (e.g. prognosis). The CSM assumes that these five dimensions 
explain how people attempt to cope with illness.  
The Illness Perception Questionnaire (IPQ) was developed as a quantitative measure of these 
dimensions (Weinman, Petrie, Moss-Morris, & Horne, 1996). More recently, the curability or 
controllability dimension of the CSM was extended to include personal and treatment control, 
illness coherence and emotional representations and the Revised Illness Perception 
Questionnaire (IPQ-R) was developed to include these dimensions (Moss-Morris et al., 2002). 
Personal control refers to how much a person feels in control of their own illness; treatment 
control is the perception of how effective the treatment will be on their illness; and illness 
coherence refers to how much understanding a person has about their illness. Emotional illness 
representations are recognised as an additional parallel process to cognitive illness 
representations and both are included in the CSM (Figure 3.1) (Leventhal et al., 1997). 
Emotional representations may include anger, anxiety or fear, and responses to these 
representations may include seeking social support or denying the existence of the illness. The 
model posits that both cognitive and emotional representations of illness influence coping 
strategies, the success of which are later appraised and may lead to the representation being 
adapted and a new coping strategy being implemented. Although the cognitive and emotional 
pathways are parallel processes, they also influence each other. 
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Figure 3.1: Common-Sense Model of Self-Regulation adapted from Leventhal et al., 1997 
These illness representations have mainly been applied to chronic illnesses and a recent 
systematic review found over 50 studies assessing illness representations in cancer patients 
using the IPQ, the IPQ-R and the Brief Illness Perception Questionnaire (B-IPQ; Broadbent, 
Petrie, Main, & Weinman, 2006) (Richardson, Schüz, Sanderson, Scott, & Schüz, 2016). This 
systematic review and meta-analysis found evidence of associations between illness 
representations, coping behaviours and cancer illness outcomes (Richardson et al., 2016). 
Specifically, those patients with a greater identity, timeline, consequences, emotional 
representations and lower personal control, treatment control and illness coherence adopted 
maladaptive coping strategies and experienced more negative illness outcomes such as higher 
anxiety. The reverse reflected adaptive coping behaviours and more positive illness outcomes, 
such as higher QOL.  
This theoretical framework has been applied in a few studies with HNC patients, using the IPQ-
R to predict fear of recurrence (Llewellyn, Weinman, McGurk, & Humphris, 2008) and QOL 
(Dempster et al., 2011; Llewellyn et al., 2007; Scharloo et al., 2005, 2010). The findings from 
these studies show various relationships exist between pretreatment illness perceptions with 
coping over time. For example, better QOL was associated with less belief of the disease being 
cyclical, lower internal disease attributions and lower emotional response to disease (Scharloo 
et al., 2005), and changes in depression and anxiety over time were associated with a change 
in illness perceptions, with illness perceptions and coping variables contributing to the majority 
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of explained variance in psychological distress (Dempster et al., 2011). Patients perceiving less 
severe consequences, more personal control, being more likely to understand their condition 
and being less likely to believe their HNC was caused by stress or poor emotional health were 
less likely to report poor psychological health (Dempster et al., 2011). This theoretical 
framework has limited evidence of use in HNC, but results thus far are suggestive that HNC 
patients’ illness representations may be useful in explaining psychological outcomes.  
3.4.2 Transactional Model of Stress and Coping 
As the CSM model suggests, patients’ illness representations influence how they cope with their 
illness. In the context of this thesis, coping influences how patients and their family members 
experience the diagnosis and the level of potential psychological impact. Problem-focused 
coping and emotion-focused coping have been suggested as strategies for coping with stress 
(Lazarus & Folkman, 1984). Problem-focused coping is aimed at the stressor (e.g. cancer) and 
emotion-focused coping is aimed at reducing distress (e.g. anxiety). Stress exists when a 
person is confronted with a stressor; for example a diagnosis of cancer that they are unable to 
manage. Coping refers to their efforts to deal with the stressor which can result in the removal 
of the stressor or a reduction of its adverse impact on the person. Lazarus and Folkman (1984) 
developed a framework to include dynamic processes involved in the appraisal of stress, which 
is known as the Transactional Model of Stress and Coping (Figure 3.2). This model views stress 
as a transaction between the person and the environment and involves both primary and 
secondary appraisals of the stressor (Wenzel, Glanz, & Lerman, 2002). The impact of the 
stressor is mediated by these appraisals, as well as the psychological, social and cultural 
context.  
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Figure 3.2: Transactional Model of Stress and Coping (Glanz and Schwartz., 2008) 
Primary appraisal is the judgement made as to whether an event, such as a cancer diagnosis, is 
controllable or stressful. Perceived susceptibility and perceived severity are two examples of 
primary appraisals. The model suggests that patients perceiving themselves to be at risk and 
perceiving the stressor to be severe will either encourage patients to cope with the stressor, or 
may lead patients becoming distressed. Motivational relevance refers to the impact the stressor 
may have on a person’s life and causal focus to how responsible a person might feel for the 
stressor. High motivational influence (e.g. perceiving a high impact on their life) and high causal 
focus (e.g. self-blame) may lead to anxiety, guilt and depression. Secondary appraisal refers to 
a person’s perception of whether they have the resources or ability to manage the stressor. 
Perceived control over outcomes and emotions, and a person’s self-efficacy, all contribute to a 
person’s appraisal of their ability to deal with the stressor.  
The association between these two appraisal systems and the outcome are mediated by 
problem and/or emotion-focused coping strategies, as discussed earlier. Problem-focused 
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strategies are predicted to be most useful for stressors that are perceived as controllable and 
emotion-focused for stressors that cannot be changed. Meaning-based coping strategies are 
also used to cope with health stressors and can induce positive emotion (Folkman, 1997). 
Active coping strategies have often been shown to have psychological benefits in comparison to 
avoidant or disengaging strategies (Carver et al., 1993; Fawzy et al., 1990). The outcomes refer 
to how the person has adapted to a stressor after their primary and secondary appraisals, 
mediated by coping strategies.  
This model has been applied in a small interview study of eight HNC patients as a framework to 
describe the appraisal and coping processes of these patients following their diagnosis (Moore 
et al., 2014). Environmental factors were found to be influential to patients’ appraisal and coping 
processes and structured support from health professionals positively impacted patients’ ability 
to cope during their treatment. Those patients who had less social support were found to have 
less effective coping strategies.  
3.4.3 Models of behaviour change 
The interaction between patients and health professionals in their discussions of HPV in the 
context of HNC, may be influential in shaping patients’ beliefs and appraisals about their 
diagnosis. As beliefs about illness can be shaped by information provided, it was important to 
draw on an all-encompassing model of behaviour to understand the components influential in 
discussing HPV and how these may be targeted in interventions. 
3.4.3.1 The Capability Opportunity Motivation-Behaviour Model 
The Capability Opportunity Motivation-Behaviour (COM-B) model is the central hub of the 
Behaviour Change Wheel (BCW), which was developed to provide a framework encompassing 
all the common features of previous behaviour change frameworks, and which is linked to a 
model of behaviour that can be broadly applied to any behaviour (Michie, van Stralen, & West, 
2011). The COM-B model is the starting point in the development of interventions, as it 
identifies the source of behaviour. The model posits that an individual’s capability, opportunity 
and motivation to enact a behaviour interact with each other to generate behaviour. Capability 
refers to an individual’s psychological and physical capacity to carry out the behaviour, which 
includes their knowledge and skills. Motivation involves reflective processes (e.g. attitudes and 
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beliefs), and automatic processes (e.g. wants and needs, desires). Opportunity reflects physical 
(e.g. time, resources, location) and social (e.g. social cues and cultural norms) factors.    
Figure 3.3 illustrates how these components interact and influence each other. This model can 
be used for the development of interventions aimed at changing behaviour. In the context of this 
thesis, the behaviour to be changed is health professionals discussing HPV with their patients 
(see chapter 7). 
 
 
3.4.3.2 The Information-Motivation-Behavioural Skills model 
The Information-Motivation-Behavioural Skills (IMB) model (Fisher & Fisher, 1992), asserts that 
behaviour-specific information, motivation and behavioural skills are necessary for an individual 
to perform a health behaviour. Information that is directly relevant to performing the health 
behaviour is necessary for performing that health behaviour. Motivation includes both personal 
(e.g. attitudes) and social motivations (e.g. perceived social support) for engaging in a health 
behaviour. Finally, behavioural skills include both objective skills and self-efficacy for performing 
the health behaviour. Figure 3.4 illustrates how these three components interact, with the 
interaction of information and motivation inducing behaviour change through behavioural skills. 
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Information and motivation can also work directly to induce behaviour change, which may be 
when the behavioural skills required to induce a behaviour change are more complex (Misovich, 
Martinez, Fisher, Bryan, & Catapano, 2003). In the context of this thesis, the health behaviour 
requiring a change is health professionals discussing HPV and this is illustrated in Figure 3.4.  
 
Figure 3.4: Information-Motivation-Behavioural Skills model (Fisher & Fisher, 1992) 
 
3.4.4 Summary 
The CSM and The Transactional Model of Stress and Coping provide a theoretical underpinning 
into our understanding of patients’ responses to illness and how these are appraised. The 
dynamic processes involved in these two models may help us understand patients’ 
representations after a diagnosis of HPV-OSCC, how these may influence their coping 
attempts, and how this may change over the period of their treatment and recovery. Theories of 
behaviour change such as the COM-B model are helpful for targeting areas in the development 
of interventions, such as those which may facilitate discussions of HPV between patients and 
health professionals.   
3.5 Aims of thesis 
As the evidence presented in the first three chapters of this thesis shows, there is potential for 
patients diagnosed with HPV-OSCC to experience significant psychological distress. However, 
with limited research specifically looking at this particular group, the extent to which 
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psychosocial distress is experienced by HPV-OSCC patients is unknown. In addition it is 
unclear what different populations know about HPV and HNC and what information they have 
been provided with by the media and health professionals; or the impact of an HPV-OSCC 
diagnosis on both patients and their partners. Using a series of studies implementing a range of 
methodology, this thesis will improve on our understanding of the psychosocial impact of HPV-
OSCC across different populations.  
More specifically, this thesis aims to: 
1. Review the existing literature exploring the psychosocial impact of HPV-OSCC on 
patients and knowledge of HPV and head and neck cancer among the public, patients 
and health professionals 
 
2. Examine the UK media for coverage of the link between HPV and head and neck 
cancer in order to establish the information presented to the public about HPV and head 
and neck cancer 
 
3. Explore the views and experiences of UK health professionals caring for patients with 
HPV-positive head and neck cancer 
 
4. Explore the views and experiences of patients diagnosed with HPV-positive head and 
neck cancer and their partners  
 
5. Develop information materials to provide information for patients diagnosed with HPV-
related head and neck cancer and partners of those diagnosed with HPV-related head 
and neck cancer 
These aims are addressed in a series of six studies, addressing the following research 
questions:  
Study 1: A systematic review of the literature 
1) What is the psychological impact of an HPV diagnosis in the context of head and neck 
cancer according to the existing literature? 
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2) What is known about HPV-related head and neck cancer in different population groups 
according to the existing literature? 
To provide context, rationale and background to my thesis, study 1 is a systematic review which 
examined the psychosocial literature in HPV-OSCC and the literature measuring the knowledge 
of the relationship between HPV and HNC. I was invited to write this systematic review for a 
special Head and Neck Oncology edition of Clinical Oncology. The database search was carried 
out in December 2014. 
Study 2: UK media coverage of the link between HPV and HNC 
3) How frequently has the relationship between HPV and HNC received coverage in the 
UK media? 
4) What information is included in media articles covering the relationship between HPV 
and HNC? 
At the time this study was conducted, my focus was on the interaction between health 
professionals and patients diagnosed with HPV-OSCC and the findings presented in study 3 
demonstrated some important messages that should be communicated about HPV. Due to the 
timely disclosure from Michael Douglas about his throat cancer being caused by HPV prior to 
the start of my PhD, this offered an opportunity to assess the content of the media at a time 
when HPV-related HNC was receiving a lot of media attention. Although this study does not fit 
directly with the other aims of the thesis, it was considered important and too good an 
opportunity to miss to establish what messages about HPV-OSCC were communicated to the 
general population through the media. These research questions were addressed using a 
content analysis of articles published in the media providing coverage of the relationship 
between HPV and HNC. The search was conducted in August 2014.  
Study 3: An exploratory interview study with health professionals 
5) What are the experiences and attitudes of health professionals in the UK about 
discussing HPV with HPV-OSCC patients? 
This study was needs driven and the starting point of my thesis, as my supervisor Dr Jo Waller 
was contacted by a health professional worried about the increasing number of HPV-OSCC 
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cases and was concerned about their ability to communicate to patients about HPV. This was 
therefore the first study conducted as part of my thesis and it adopted an exploratory qualitative 
study design to explore the experiences, attitudes and beliefs relating to HPV-OSCC in health 
professionals. This study was carried out in June 2013.  
Study 4: A survey of health professionals 
6) What are the experiences and attitudes of different groups of health professionals in the 
UK and Ireland who care for patients with HPV-OSCC? 
Due to the exploratory qualitative nature and small number of health professionals in study 3, 
this study involved the development of a survey based on the results from study 3.  A survey-
based quantitative study was carried out, designed to explore the knowledge, experiences, 
attitudes and beliefs relating to HPV-OSCC in a larger sample of different health professional 
groups. This study was carried out between October and December 2015.  
Study 5: A qualitative interview study with patients diagnosed with HPV-OSCC and their 
partners 
7) What is the psychosocial impact on patients being diagnosed with HPV-OSCC? 
8) What is the psychosocial impact on partners of patients who have been diagnosed with 
HPV-OSCC? 
The systematic review in study 1 showed limited literature available examining the psychosocial 
impact of HPV-OSCC and studies 3 and 4 demonstrated some of the concerns patients express 
to health professionals about HPV. Therefore a qualitative study with patients and their partners 
was designed to explore their experience of being diagnosed or of their partner being diagnosed 
with HPV-OSCC and what this may mean to them. This study was carried out between 
September and November 2015.  
Study 6: The development of patient information materials  
As the previous studies had found health professionals and patients to have information needs 
about HPV-OSCC, this study drew together the findings from all the previous studies, to design 
an information booklet to answer frequently asked questions of health professionals, patients 
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and their family members. This was also developed as a discussion tool to facilitate the 
discussion of HPV between health professionals, patients and their family members. The 
information booklet began development in December 2015 and was completed in April 2016.  
These studies are not presented in the order in which they were conducted, but are ordered in a 
way in which the narrative flows better. Figure 3.5 illustrates the dates each study was carried 
out.
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Figure 3.5: Timeline illustrating the dates each study was conducted 
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CHAPTER 4. A SYSTEMATIC REVIEW OF THE LITERATURE 
(STUDY 1) 
4.1 Introduction2 
As detailed in chapter 1, it is now clear that an increasing proportion of head and neck cancer 
(HNC) cases are caused by HPV (Gillison et al., 2012; Mehanna et al., 2013; Näsman et al., 
2009; Rietbergen et al., 2013). Chapter 2 presented evidence of a diagnosis of HNC being 
associated with a well recognised psychosocial impact, but research exploring this in patients 
with HPV-related HNC has yet to be synthesised.  
Also detailed in the previous chapters, we know from the cervical cancer literature that the 
sexually transmitted nature of HPV can lead to psychological challenges. As the link between 
HPV and HNC has been established, and HPV is sexually transmitted, there has been 
increasing recognition of the need for guidance on how to discuss HPV with patients (Chu et al., 
2013; Fakhry & D’Souza, 2013; Finnigan & Sikora, 2014). Sections 2.1, 2.2 and 3.1 of this 
thesis show the contribution of behavioural and psychological science to understanding and 
addressing psychosocial issues associated with both HNC and HPV. It is also important to 
assess knowledge of the association between HPV and HNC among different populations, to 
identify gaps in knowledge and inform communication strategies.   
Research has begun to explore what the public know about HPV and HNC and how an HPV 
diagnosis affects patients. Knowledge of HPV appears to have increased following the 
introduction of the HPV vaccination which is now offered to adolescents in most developed 
countries (Kelly, Leader, Mittermaier, Hornik, & Cappella, 2009; Patel, Jeve, Sherman, & Moss, 
2016). In the context of cervical cancer, an online survey of adults in the UK, USA and Australia 
following the introduction of the HPV vaccination showed 61% reported having heard of HPV 
(Marlow, Zimet, McCaffery, Ostini, & Waller, 2013). By contrast, public awareness of the signs 
and risk factors for HNC has been shown to be poor (Warnakulasuriya et al., 1999). In the HNC 
                                                     
2 The search for this study was conducted in December 2014. Literature available during this period which 
contributed to the rationale for this study is included in the introduction. Literature published after the 
analysis for this study was performed, is included in the discussion. A version of this chapter has been 
published in Clinical Oncology (Appendix 4.1). 
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clinical context, an overview paper has shown that few resources currently exist to answer 
patient’s concerns about how, when and why they got their cancer (Fakhry & D’Souza, 2013), 
the answers to which can have implications both for the patient and their past, present or future 
partners. 
My review draws together findings from the emerging literature and identifies priorities for a 
behavioural science research agenda in this field. The evidence from both the cervical cancer 
and HNC literature suggests that there may be greater psychological distress in these patients 
due to the combination of both a diagnosis of cancer and of HPV. The review aimed to answer 
the first two research questions of this thesis: 
1) What is the psychological impact of an HPV diagnosis in the context of HNC? 
2) What is known about HPV-related HNC in different population groups? 
4.2 Methods 
4.2.1 Search methods for identification of studies 
This systematic review followed the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines (Moher, Liberati, Tetzlaff, & Altman, 2009). I developed the 
search terms in consultation with a librarian at University College London and through extracting 
key terms from previous review papers and relevant primary research. The initial search terms 
covered 1) the two health conditions of interest (e.g. HPV, human papillomavirus, head and 
neck cancer) and 2) psychosocial outcomes of interest (e.g. psychosocial, depression, anxiety, 
quality of life). These psychosocial factors were chosen for the search based on previous 
reviews with HNC patients and a scoping exercise of the current literature. On examination of 
the papers found with the initial search strategy, it was evident that papers also being included 
were those which examined knowledge of the link between HPV and HNC. Therefore I added a 
third search term to the search strategy; 3) knowledge. It was deemed important to also assess 
knowledge of the relationship between HPV and HNC in different populations to identify groups 
where knowledge is limited and where communication campaigns could be targeted. Assessing 
knowledge in the population also helps to understand the amount of information people who are 
diagnosed with HPV and HNC may be receiving. The full search strategies and the number of 
papers found for each database are shown in Appendix 4.2. Initial search terms were later 
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refined based on common text words from relevant articles retrieved from the search. I 
accessed MEDLINE, Embase and PsycINFO databases through Ovid databases and searched 
from inception to present in December 2014. I adapted the search terms for CINAHL Plus and 
Web of Science. Boolean operators were used to combine terms such as ‘head and neck 
cancer OR oral cancer’ AND ‘human papillomavirus OR HPV’. These databases were chosen 
based on previous review papers in this field and because all databases complement each 
other and allow a broader scope of coverage. There were no language or date restrictions 
applied to the search. I searched the reference lists of included studies for additional relevant 
papers and the grey literature using OPENSIGLE (opensigle.inist.fr). No papers were found 
from the grey literature. I downloaded the results of the literature search into Endnote and 
removed any duplicate articles.  
4.2.2 Inclusion and exclusion criteria 
Studies were included if they 1) reported original research (qualitative or quantitative), 2) 
mentioned HPV and HNC, 3) measured an aspect of the psychosocial impact of the diagnosis 
of HPV-related HNC as the dependent variable and/or 4) measured knowledge of the 
association between HPV and HNC. Studies were excluded if they were not written in English, 
did not report original research or were conference abstracts.  
4.2.3 Selection procedure  
Dr Jo Waller and I screened all the titles of the articles and excluded articles if they were not 
written in the English language or were clearly irrelevant to the review. Disagreements were 
resolved by discussion and reasons for inclusion/exclusion were noted. Dr Laura Marlow and I 
screened all the abstracts of the remaining articles, looking more specifically for articles 
mentioning HPV. Authors of conference abstracts that appeared to meet the eligibility criteria 
were contacted to request a copy of the full paper if it was available. Those not submitted or 
published in peer-review journals were excluded and one author did not reply so this paper was 
also excluded. Disagreements were resolved by discussion and reasons for inclusion/exclusion 
were noted. Articles that appeared to meet the inclusion criteria based on the title and abstract 
screen were obtained for full-text review (Figure 4.1). Copies of articles that could not be 
assessed for relevance based on the title and abstract screen were also obtained to determine 
eligibility based on full-text review.  
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I conducted the full-text eligibility review with Dr Laura Marlow and we both independently 
recorded reasons for exclusion of papers. Reasons for excluding studies included the article not 
containing i) any original data relevant to our eligibility criteria, ii) not mentioning HPV or iii) not 
measuring the outcomes of interest as dependent variables. Using Scopus, I carried out forward 
citation searches for all papers obtained for full-text review and included those published up to 
August 2015. Dr Laura Marlow confirmed the eligibility of articles found through forward citation 
and reference searching. A summary of the data from all full-text articles was extracted (Table 
4.1 and Table 4.3) into Microsoft Excel. 
4.2.4 Quality assessment 
The quality of the studies was assessed using an amended version of NICE quality appraisal 
checklist for quantitative and qualitative studies (National Institute for Care and Excellence, 
2012) (Appendix 4.3 and 4.4). These checklists were selected for use in this review due to there 
being both a quantitative and qualitative checklist available and included items which fitted with 
the designs of these studies. Some of the items that were not relevant to the design were 
removed from the checklists. These checklists considered a range of factors which included 
whether the source population was well described, whether the outcome measures were 
reliable and relevant, whether the analytical methods were appropriate and whether the findings 
could be generalised to the source population. I conducted the quality assessment on all of the 
studies and Dr Laura Marlow assessed a random ten per cent selection. 
CHAPTER 4 – SYSTEMATIC REVIEW 
109 
 
 
Figure 4.1: Flow diagram of study selection adapted from Moher et al (2009) 
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4.2.5 Analysis 
Data from all included articles were recorded using a data extraction form. The data extraction 
form was developed for extracting the key sections of data from the articles and for assessing 
the quality of the studies. I developed a data extraction forms which used for both the articles 
measuring psychosocial outcomes and for the articles measuring knowledge (Appendix 4.5). 
The data extraction form was first tested with two articles from each domain and was deemed 
acceptable. Results from articles measuring psychosocial outcomes and knowledge are 
reported descriptively with comparisons drawn where appropriate. Qualitative findings are 
described separately.   
4.3 Results  
4.3.1 Search results 
The initial search returned 782 articles, which was reduced to 491 after the removal of 
duplicates. 448 were excluded on the basis of their title, leaving 43 abstracts to be reviewed. 
Once the articles had been screened by title and abstract, 25 were obtained for full-text review. 
An additional 37 articles were included after searching the reference lists, relevant review 
papers found through the search and searching forward citations of those already obtained for 
full-text review. Eleven articles were excluded during full-text review, leaving 51 papers in the 
final analysis. Figure 4.1 shows the study selection process. My supervisors (Dr Jo Waller and 
Dr Laura Marlow) and I agreed on the final papers included in the review. 
4.3.2 Studies assessing the psychosocial impact of HPV-related head and neck cancer 
Ten of the studies measured psychosocial outcomes (Table 4.1) (Baxi et al., 2012; Broglie et 
al., 2013; Durmus et al., 2014; Dziegielewski et al., 2013; Hess et al., 2014; Marcellusi et al., 
2014; Maxwell et al., 2013; Milbury et al., 2013; Sharma et al., 2012; Vainshtein et al., 2015). Of 
these, eight were conducted in the United States of America (USA) (Baxi et al., 2012; Durmus 
et al., 2014; Dziegielewski et al., 2013; Hess et al., 2014; Maxwell et al., 2013; Milbury et al., 
2013; Sharma et al., 2012; Vainshtein et al., 2015), one was conducted in Switzerland (Broglie 
et al., 2013) and one in Italy (Marcellusi et al., 2014). Quantitative studies used survey based 
methods (Broglie et al., 2013; Durmus et al., 2014; Dziegielewski et al., 2013; Marcellusi et al., 
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2014; Maxwell et al., 2013; Milbury et al., 2013; Sharma et al., 2012; Vainshtein et al., 2015) 
and one conducted an audit on medical records (Hess et al., 2014). One article collected 
qualitative data from individual interviews (Baxi et al., 2012). All articles were published between 
2012 and 2014. All studies reported patients’ HPV status, six of these were clinically verified 
and four were taken from patients’ medical records. In some studies, p16 expression was used 
as a marker of HPV status, but for simplicity I refer to patients as HPV-positive throughout the 
review.  
The psychosocial impact of HPV-related HNC was measured in patients at different time points 
in their care continuum from newly diagnosed (Broglie et al., 2013; Dziegielewski et al., 2013; 
Maxwell et al., 2013; Milbury et al., 2013; Sharma et al., 2012) to up to 5 year post treatment 
completion (Baxi et al., 2012). 
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Table 4.1: Psychosocial studies included in systematic review 
Reference 
Country 
Sample 
HPV/p16 
positive 
Study Design Outcomes/measures Relevant Findings 
Baxi et al., 
2012 
 
USA 
10 male 
survivors of 
HPV-OSCC 
between 1 and 5 
years treatment 
completion 
100% 
(HPV+) 
Qualitative 
semi-structured 
interviews 
Exploring the communication, 
comprehension and psychological 
impact of a diagnosis of HPV-
related oropharyngeal cancer 
- 3/10 felt a sense of stigma or embarrassment 
associated with their diagnosis 
- The cancer itself occasionally or always 
overshadowed the impact of HPV 
- 4/10 were concerned with potentially infecting a 
partner with HPV and one expressed concerns 
about re-infection 
- Survivors understood and were encouraged by 
positive prognostic implications of an HPV 
diagnosis 
Broglie et al., 
2013 
 
Switzerland 
98 survivors of 
oropharyngeal 
cancer a median 
of 67 months 
post treatment 
63.9% 
(p16+) 
Follow-up 
survey (postal) 
Quality of life: EORTC QLQ-C30 
and EORTC QLQ-H&N35 
- p16- patients had significantly lower scores on 
physical and role functions and had more 
complaints about feeling ill and pain than p16+ 
patients 
Durmus et al., 
2014 
 
USA 
22 patients at 
first head and 
neck cancer 
clinic visit; 2 
females, 20 
males 
80.9% 
(HPV+) 
95.2% 
(p16+) 
 
Longitudinal 
study: baseline 
(pre-
operatively), 3 
weeks, 3 
months, 6 
months and 12 
months 
 
Quality of life: Head and Neck 
Cancer Inventory 
- Speech, eating, aesthetics and social disruption 
scores at 3 weeks, 3 and 6 months were 
significantly lower than at baseline  
- Overall QOL still significantly lower than pre-
operative levels at 1 year 
- Significant declines in overall QOL at 3 months 
compared with 3 weeks 
- No significant impact on QOL outcomes by 
HPV status (HPV+ compared to HPV-) 
HPV, human papillomavirus; HNSCC, head and neck squamous cell carcinoma; EORTC, European Organisation for Research and Treatment of Cancer; UWQOL, University of Washington Quality 
of Life; HNQOL, Head and Neck Quality of Life; SF-36, Short Form 36; OSCC, Oropharyngeal squamous cell carcinoma. 
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Table 4.1: Psychosocial studies included in systematic review (contd.) 
 
 
Reference  
Country 
Sample 
HPV/p16 
positive 
Study Design Outcomes/measures Relevant Findings 
Dziegielewski 
et al., 2013 
 
USA 
87 patients at 
first new patient 
referral visit: 81 
included in 
analysis (71 
tested for HPV) 
72% 
(HPV+) 
 
85% 
(p16+) 
Prospective 
cohort study 
Quality of life: Head and Neck 
Cancer inventory 
- All health-related QOL scores declined at 3 
weeks; social and overall scores continued to 
drop and were the lowest at 3 months 
- Social and overall scores demonstrated at 12 
months greatest recovery significantly from 
baseline 
- No differences between HPV+ and HPV- 
patients on any of the QOL domains at 12 
months  
Hess et al., 
2014 
 
USA 
162 medical 
records - 
patients with 
locally advanced 
OSCC, known 
p16 status and 
treated by 
chemoradiation 
or primary 
surgery followed 
by adjuvant 
radiation 
therapy; 142 
men, 20 women 
69% 
(p16+) 
Audit of 
medical 
records 
Prevalence of anxiety disorder 
and major depression in patients 
with HPV+ and HPV- tumours 
- No significant differences between HPV+ and 
HPV- patients for rates of major depression or 
anxiety disorder  
- Higher prevalence of anxiety in HPV- patients 
HPV, human papillomavirus; HNSCC, head and neck squamous cell carcinoma; EORTC, European Organisation for Research and Treatment of Cancer; UWQOL, University of Washington 
Quality of Life; HNQOL, Head and Neck Quality of Life; SF-36, Short Form 36; OSCC, Oropharyngeal squamous cell carcinoma. 
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Reference  
Country 
Sample 
HPV/p16 
positive 
Study Design Outcomes/measures Relevant Findings 
Milbury et al., 
2013 
 
USA 
62 newly 
diagnosed 
HPV+ patients 
initiating 
radiotherapy 
98% 
(p16+) 
 
89% 
(HPV+) 
Cross-sectional 
survey 
Self-reported:  
- Feelings of keeping their HPV 
a secret from others 
- Disclosure of HPV to current 
sexual partner 
- Whether HPV increased 
partner’s risk of developing 
cancer 
- Whether they talked to 
partner about likelihood of 
transmission 
- How much knowledge of HPV 
as a cause had impacted their 
relationship 
- Distress  
- Self-blame  
- Approx. 30% showed marked distress 
- Distress levels were moderate 
- Patients reported low levels of behavioural 
self-blame 
- Blame and distress were significantly 
correlated  
- No significant differences regarding distress 
and self-blame in those self-declaring as HPV+ 
compared to those who did not or were unsure 
- 14% intended to keep it a secret from others 
and 3% did not tell their partner – reasons 
included embarrassment, stigma, and belief it 
is no-one else’s business 
- 41% said they had not discussed concerns 
regarding potential viral transmission to their 
partner 
- 8% thought their HPV had entirely increased 
their partners risk for developing cancer, 42% 
somewhat and 29% said it did not 
- 80% reported that the diagnosis had no 
negative impact, 14% reported a somewhat 
negative impact, 6% reported a completely 
negative impact on relationships 
HPV, human papillomavirus; HNSCC, head and neck squamous cell carcinoma; EORTC, European Organisation for Research and Treatment of Cancer; UWQOL, University of Washington 
Quality of Life; HNQOL, Head and Neck Quality of Life; SF-36, Short Form 36; OSCC, Oropharyngeal squamous cell carcinoma. 
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Reference  
Country 
Sample 
HPV/p16 
positive 
Study Design Outcomes/measures Relevant Findings 
Sharma et al., 
2012 
 
USA 
228 patients 
diagnosed with 
primary OSCC 
between 2003 
and 2010 
 
Group 1: 
(n=162) HPV- 
and low-risk 
HPV 
  
Group 2: (n=66) 
High-risk HPV+  
29% 
(HPV+) 
Longitudinal 
study: pre-
treatment, 
immediate 
post-treatment 
and one year 
post-treatment 
Quality of life: UWQOL 
- Pre-treatment QOL was significantly higher in 
patients who were HPV+ 
- Immediate post treatment scores were lower in 
HPV+ patients 
- Post treatment scores were similar between 
the two groups  
- Group 2 had a significantly larger decrease in 
QOL scores from pre-treatment to immediate 
post-treatment compared to group 1 
- The change in QOL scores from post-
treatment to 1 year post treatment was similar 
between the groups 
- HPV status was associated with pre-treatment 
QOL and a change in QOL from pre-treatment 
to immediate post treatment 
- Patients in group 2 did not have better 1 year 
QOL compared with group 1 
HPV, human papillomavirus; HNSCC, head and neck squamous cell carcinoma; EORTC, European Organisation for Research and Treatment of Cancer; UWQOL, University of Washington 
Quality of Life; HNQOL, Head and Neck Quality of Life; SF-36, Short Form 36; OSCC, Oropharyngeal squamous cell carcinoma. 
Table 4.1: Psychosocial studies included in systematic review (contd.) 
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Table 4.1: Psychosocial studies included in systematic review (contd.) 
Reference  
Country 
Sample 
HPV/p16 
positive 
Study Design Outcomes/measures Relevant Findings 
Vainshtein et 
al., 2015 
 
USA 
40 head and 
neck cancer 
survivors >2 
years after 
treatment: 34 
men, 6 women 
98% 
(HPV+) 
Follow-up 
survey (postal) 
Health-related quality of life: 
HNQOL, UWQOL, SF-36  
- Global HNQOL remained stable compared to 2 
year assessments for HNQOL and UWQOL 
- Clinically meaningful declines in global 
HRQOL from 2 year assessment were 
reported by 8% of patients by HNQOL and 
14% of patients by UWQOL 
- 8% on HNQOL and 11% on UWQOL reported 
meaningful improvements in global HNQOL 
- 84% and 75% of patients reported stable 
global HRQOL compared with 2 years by 
HNQOL and UWQOL 
- Overall physical and mental health mean 
scores on the SF-36 were comparable to US 
population norms in each HRQOL domain 
- Overall cohort experienced stable HNQOL 
scores and statistically worse UWQOL score 
compared to pre-treatment 
- Clinically meaningful declines were found in 
global HRQOL from pre-treatment by 8% on 
HNQOL and 30% on UWQOL 
HPV, human papillomavirus; HNSCC, head and neck squamous cell carcinoma; EORTC, European Organisation for Research and Treatment of Cancer; UWQOL, University of Washington 
Quality of Life; HNQOL, Head and Neck Quality of Life; SF-36, Short Form 36; OSCC, Oropharyngeal squamous cell carcinoma. 
 
 
 
CHAPTER 4 – SYSTEMATIC REVIEW 
117 
 
4.3.2.1 Psychological measures used 
QOL was the main outcome measure used in seven studies and was measured using a number 
of different tools. Six of these studies measuring QOL used at least one HNC specific measure 
(Table 4.2). Two studies used the Head and Neck Cancer Inventory (HNCI) (Durmus et al., 
2014; Dziegielewski et al., 2013), which is a validated 30-item survey measuring patient-
reported QOL status in speech, eating, aesthetics and social disruption. QOL measures 
previously discussed in chapter 2 were also used. Three studies used the UWQOL (Maxwell et 
al., 2013; Sharma et al., 2012; Vainshtein et al., 2015), which is a validated HNC-specific QOL 
questionnaire including 12 domains, with two subscales of physical and social-emotional 
functioning. One study used the European Organisation for Research and Treatment of Cancer 
(EORTC) HNC specific version (QLQ-H&N35) (Broglie et al., 2013), which includes seven 
scales measuring pain, swallowing, senses, speech, social eating, social contact and sexuality. 
One study used the Head and Neck Quality of Life (HNQOL) (Vainshtein et al., 2015), which 
measures the four domains of eating, communication, pain, and emotion.  
Generic QOL measures were used in three of these studies and included the Medical Outcome 
Study Short Form 36 (SF-36) which is a 36-item generic measure of health status split into 10 
domains (Vainshtein et al., 2015), the EQ-5D (Marcellusi et al., 2014), which has five 
dimensions of measuring QOL, and the EORTC general core questionnaire (QLQ-C30) 
measuring activity, physical and social functioning (Broglie et al., 2013). Other psychosocial 
measures used were the National Comprehensive Cancer Network’s distress thermometer, 
which uses a scale from 0 to 10 for patients to indicate how much distress they have been 
experiencing in the last week, and Glinder and Compas one-item measure of behavioural blame 
(Milbury et al., 2013) (i.e., “How much do you blame yourself for the kinds of things you did, that 
is, for any behaviors that may have led to your cancer?”).  
4.3.2.2 Findings of cross-sectional studies with a comparison group 
One study compared QOL in HPV-positive patients and HPV-negative patients using the 
EORTC QLQ-C30 (Broglie et al., 2013; Table 4.2). Patients with HPV-positive tumours were 
found to score significantly better on physical and role functions of the scale, but there were no 
significant differences between the groups in the emotional, social and global health functions of 
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the scale (Broglie et al., 2013). The numbers in each group were small however, so the study 
was unlikely to have had enough power to detect differences if they were not large. In an audit 
of medical records, Hess and colleagues (Hess et al., 2014) found there was a higher 
prevalence of anxiety in HPV-negative patients compared to HPV-positive patients, but rates of 
major depression or anxiety disorder did not differ significantly between the HPV-positive and 
HPV-negative groups. Another study compared QOL scores measured using the EQ-5D 
between HPV-positive patients and healthy subjects attending the same clinic for 
nonpathological reasons, matched to patients for sex and disease proportion (Marcellusi et al., 
2014). Overall QOL was significantly lower in HPV-positive patients than healthy subjects.  
4.3.2.3 Findings from longitudinal studies with a comparison group 
Four studies compared QOL between HPV-positive and HPV-negative patients at more than 
one time point (Durmus et al., 2014; Dziegielewski et al., 2013; Maxwell et al., 2013; Sharma et 
al., 2012). One study measuring QOL using the UWQOL (Maxwell et al., 2013), found overall 
QOL scores were better at each time point for HPV-positive patients than HPV-negative 
patients, with the differences being significant at baseline, 6 months and after 12 months. 
Another study measuring QOL using the UWQOL (Sharma et al., 2012) found pre-treatment 
QOL scores were significantly higher in HPV-positive patients compared to HPV-negative 
patients, lower (but not significantly) at immediate post-treatment, and similar at one year post-
treatment. QOL measured using the HNCI in one study found HPV-positive patients had higher 
QOL at baseline, but then lower QOL at 3 weeks, 3 months and 6 months compared to HPV-
negative patients (Durmus et al., 2014). Another study using the HNCI found HPV status was 
not associated with QOL outcomes at 12 months (Dziegielewski et al., 2013). Using data from 
the whole sample, clinically meaningful declines were found from baseline to 12 months in 
speech function, aesthetic attitude, eating function and attitude (Dziegielewski et al., 2013).  
Overall, these longitudinal studies found inconsistent results when comparing QOL in HPV-
positive patients and HPV-negative patients. Some reported HPV-positive patients with a 
combination of both higher and lower QOL scores than HPV-negative patients depending on the 
time points (n=3), with differences only significant when the QOL scores were higher in HPV-
positive patients. Others found no significant differences between the groups at any time point 
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(n=2). As these studies used a variety of time points at which to measure QOL after baseline 
and used different measures of QOL, this makes comparisons across studies difficult.  
4.3.2.4 Findings from studies with HPV-positive patients only  
Three studies did not include a comparison between HPV-positive patients and HPV-negative 
patients (Baxi et al., 2012; Milbury et al., 2013; Vainshtein et al., 2015). One study measured 
distress and self-blame in newly diagnosed HPV-positive patients (Milbury et al., 2013). Distress 
levels were found to be moderate (mean 3.38, range 0-9), with 30% showing clinically 
meaningful scores (scores above or equal to 4). Self-blame levels were found to be low (mean 
2.27, range 1-4). The second study measured QOL using the UWQOL, HNQOL and SF-36 and 
found summary scores remained stable between two years and long-term follow up (median of 
78 months following completion of treatment) (Vainshtein et al., 2015). Clinically meaningful 
(≥10 point change) declines in QOL measured using the UWQOL were found in 14% of 
patients, while 11% of patients reported clinically meaningful improvements. Summary scores 
on this measure between pre-treatment and long-term follow up were significantly worse. 
Clinically meaningful (≥10 point change) declines in QOL measured using the HNQOL were 
found in 8% of patients, with 8% of patients reporting clinically meaningful improvements. 
Summary scores on this measure remained stable between pre-treatment and long-term follow 
up. Scores on the SF-36 for long-term physical and mental health were comparable to the USA 
population norms (Vainshtein et al., 2015). The one qualitative study with HPV-positive HNC 
survivors reported that 3/10 cancer survivors felt a sense of stigma or shame associated with 
their diagnosis (Baxi et al., 2012). This study also found the top three emotional responses to 
their HPV diagnosis to be optimism (9/10), concern (8/10) and relief (7/10). Relief and optimism 
were responses reported as a consequence of the better prognosis for HPV-OSCC patients. 
Embarrassment, surprise, sadness and fear were all reported by 6/10 of the participants. Five of 
the eight participants who spoke about their sexual relationships, reported a decrease in 
intimacy with their partner, which were mostly to do with fear of transmitting HPV to their 
partner. Three of the participants had ceased deep-kissing or performing oral sex on their 
partners. All of these studies were conducted with small sample sizes, so it would be necessary 
to replicate these findings in larger samples to get more representative results and have the 
ability to draw some conclusions.  
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Table 4.2: Scores from psychosocial measures in HPV-related head and neck patients in 9* studies 
Reference Measure HPV+ HPV- 
Significant 
difference 
Broglie et al., 
2013 
Quality of life - EORTC QLQ-C30 (median score; scale range 0-100) 
Physical 100 86.67 0.001 
Role 100 91.67 0.03 
Emotional 91.67 83.33 NS 
Social 100 100 NS 
Global Health 
 
83.33 79.17 NS 
Durmus et al., 
2014 
Quality of life - HNCI (mean score; scale range 0-100) 
Baseline (pre-treatment) 
 
3 weeks 
 
3 months 
 
6 months 
  
12 months 
 
94 
 
79 
 
48 
 
63 
 
88 
75 
 
88 
 
58 
 
83 
 
/ 
NS 
 
NS 
 
NS 
 
NS 
 
NS 
Dziegielewski 
et al., 2013 
Quality of life - HNCI (mean score; scale range 0-100) 
12 months 
 
75 78 NS 
Maxwell et al., 
2013 
Quality of life – UWQOL (mean score across 12 domains; scale range 0-
100) 
Baseline (pre-treatment) 
 
2 months 
 
6 months 
 
12 months 
 
>12 months  
76 
 
57 
 
67 
 
69 
 
82 
 
50 
 
51 
 
59 
 
64 
 
65 
0.008 
 
NS 
 
0.034 
 
NS 
 
0.013 
Sharma et al., 
2012 
Quality of life – UWQOL (mean score across 12 domains; scale range 0-
100) 
Pre treatment 
 
Immediate post treatment 
 
Post treatment 
 
86 
 
63 
 
75 
79 
 
73 
 
77 
0.015 
 
NS 
 
NS 
Vainshtein et 
al., 2015 
Quality of life – UWQOL (mean score; scale range 0-100) 
Pre-treatment 
 
10 /  
24-months 
 
 
15.2 /  
Long-term 
 
16.5 /  
HNQOL (mean score; scale range 0-100) 
 
Pre-treatment 
 
15.1 /  
24-months 
 
9.5 /  
Long-term 
 
11.9 /  
Marcellusi et 
al., 2014 
EQ-5D (mean utility values)    
Women 
 
0.7 
(SD=0.2) 
/  
Men 
 
0.8 
(SD=0.2) 
/  
Hess et al., 
2014 
Major depression 
 
Anxiety disorder 
 
9% 
 
6% 
10% 
 
12% 
NS 
 
NS 
Milbury et al., 
2013 
Distress (mean; scale range) 
 
Self-blame (mean; scale range) 
 
3.38 (0-9) 
 
2.27 (1-4) 
/ 
 
/ 
 
*One reference not included as used qualitative methodology (Baxi et al., 2012); NS=not significant; 
SD=standard deviation 
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Table 4.3: Included studies measuring knowledge of HPV and head and neck cancer 
Reference 
Country 
Sample 
Response 
rate 
Study Design Outcomes/measures Relevant Findings 
Alami, El 
Sabbagh, & 
Hamdan, 
2013 
Jordan 
112 newly graduated 
medical and dental 
senior house officer level; 
49% dental degree, 51% 
medical 
Not 
reported 
Cross-sectional 
survey (in person) 
Knowledge of risk 
factors for oral cancer 
(e.g. Which of the 
following factors is 
considered an increased 
factor for oral cancer: 
Human papillomavirus as 
a response option) 
- HPV correctly recognised as a risk factor 
by 34% - more dental (47% vs 21%) than 
medical responded correctly 
Ashe, Elter, 
Southerland, 
Strauss, & 
Patton, 2006 
USA 
651 dental hygienists 
from North Carolina State 
Board of Dental 
Examiners 
53% 
Cross-sectional 
survey (postal) 
Knowledge of risk 
factors for oral cancer 
(e.g. In the United States, 
which of the following 
factors places an 
individual at high risk for 
oral cancer? Human 
papilloma virus as 
yes/no/don’t know option) 
- 47.1% recognised HPV as a risk factor for 
oral cancer 
- 32% felt patients are knowledgeable 
about oral cancer risk factors 
Boroumand, 
Garcia, 
Selwitz, & 
Goodman, 
2008 
USA 
248 1st, 2nd, 3rd and 4th 
year dental students at 
University of Maryland 
Baltimore College of 
Dental Surgery 
59.6% 
Cross-sectional 
survey (in person and 
postal) 
Knowledge of oral 
cancer risk factors 
- 30.8% 1st year, 89.1% 2nd year, 78.1% 
3rd year, 81.8% 4th year knew HPV a risk 
factor for oral cancer 
 
  
 
1
2
2
 
 
Reference 
Country 
Sample 
Response 
rate 
Study Design Outcomes/measures Relevant Findings 
Brewer, Ng, 
McRee, & 
Reiter, 20103 
USA 
609 men aged 18-59 
years from population-
based panel of US 
households: Men’s 
Health Study 
70% 
Cross-sectional 
survey (online) 
Awareness and 
knowledge 
 
Perceived knowledge 
 
Beliefs about causes of 
HPV-related disease 
- More men knew HPV can cause genital 
warts (41%) than oral cancer (23%) 
- 90% said knew little or nothing at all about 
oral cancer 
- 43% recognised infection with a virus as a 
potential cause of oral cancer (less than 
for anal cancer or genital warts) 
- Few believed sexual behaviours 
increases risk of oral cancer (23% having 
sex; 26% high number of sexual partners) 
Cannick, 
Horowitz, 
Drury, Reed, 
& Day, 2005 
USA 
163 dental students, 
Medical University of 
South Carolina 
79.1% 
Cross-sectional 
survey (in person) 
Knowledge of risk 
factors for HPV 
- 79.8% correctly recognised HPV as a risk 
factor 
Clovis, 
Horowitz, & 
Poel, 2002 
Canada 
670 dentists, British 
Columbia and Nova 
Scotia 
55.2% 
Cross-sectional 
survey (postal) 
Knowledge of risk 
factors for HPV 
- 53.1% correctly recognised human 
papillomavirus as a risk factor for oral 
cancer 
Colón-López 
et al., 2012 
Puerto Rico 
206 men in sexually 
transmitted disease clinic 
Not 
reported 
Cross-sectional 
survey (in person) 
HPV awareness, HPV 
knowledge  
(e.g. HPV is associated 
with oral cancer) 
- 27.4% recognised HPV infection has a 
role in oral cancer (HPV is associated 
with oral cancer) 
                                                     
3 These four papers use data from the same study 
Table 4.3: Included studies measuring knowledge of HPV and head and neck cancer (contd.) 
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Table 4.3: Included studies measuring knowledge of HPV and head and neck cancer (contd.) 
Reference 
Country 
Sample 
Response 
rate 
Study Design Outcomes/measures Relevant Findings 
Daley et al., 
2011 
USA 
 
17 dentists in 2 focus 
groups, 21 dental 
hygienists in 2 focus 
groups 
Not 
reported 
Qualitative focus 
groups 
Assess awareness of 
oral health providers 
regarding the HPV-oral 
cancer link  
Elicit attitudes and 
perceived role in 
screening for HPV-oral 
cancer lesions and 
discussing HPV as a 
contributing factor for 
oral cancer 
- Participants ranged from a complete lack 
of knowledge to understanding some 
intricacies of the HPV-oral cancer link 
- Shifts in dentistry practice were seen as a 
result of the HPV-oral cancer link and 
there was a desire for additional guidance 
from professional organisation on ways to 
manage screening for HPV-related oral 
cancer 
- Discomfort was expressed in discussing 
the HPV-oral cancer link with patients, 
with concerns about the appropriateness 
of HPV-oral cancer discussions with 
patients due to confidentiality and gender 
roles 
- Responses varied as to whether it was 
their role to discuss with patients  
Decuseara, 
MacCarthy, 
& Menezes, 
2011 
Ireland 
254 dentists 
Not 
reported 
Cross-sectional 
survey (online) 
Knowledge of oral 
cancer risk factors 
- 60% knew human papillomavirus is a risk 
factor for oral cancer 
Dodd, Riley, 
& Logan, 
2012 
USA 
93 community members 32% 
Cross-sectional 
survey (telephone) 
Knowledge of oral 
cancer risk factors 
- 34% knew having human papillomavirus 
‘increases the risk of getting mouth or 
throat cancer’ 
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Table 4.3: Included studies measuring knowledge of HPV and head and neck cancer (contd.) 
Reference 
Country 
Sample 
Response 
rate 
Study Design Outcomes/measures Relevant Findings 
Dumitrescu, 
Ibric, & Ibric-
Cioranu, 
2014 
Romania 
192 1st-6th year dental 
students; 139 female, 53 
male 
100% 
Cross-sectional 
survey (in person) 
Oral cancer risk factors 
- Almost 54% recognised HPV as a risk 
factor for oral cancer 
Dwojak et al., 
2015 
USA 
205 American Indian 
community members 
recruited via two 
community events; 70% 
female 
Not 
reported 
Cross-sectional 
survey (in person) 
Knowledge of the risk 
factors of head and 
neck cancer including 
HPV  
(e.g. Do you think that 
HPV can cause head and 
neck cancer?) 
- 32% had heard of head and neck cancer 
- 23% identified having multiple sexual 
partners as a risk factor 
- 36% thought HPV related to head and 
neck cancer  
Hassona, 
Scully, 
Shahin, 
Maayta, & 
Sawair, 2015 
Jordan 
 
330 primary healthcare 
professionals 
87% 
Cross-sectional 
survey (face-to-face 
interview) 
Knowledge of oral 
cancer risk factors 
- 43.3% recognised human papillomavirus 
as a risk factor 
Hertrampf, 
Wiltfang, 
Koller, Klosa, 
& Wenz, 
20104 
Germany 
306 dentists in 
Schleswig-Holstein 
14% 
Cross-sectional 
survey (postal) 
Knowledge of risk 
factors for oral cancer 
(e.g. Which of the 
following factors places 
an individual at high risk 
for oral cancers? Human 
papillomavirus as 
yes/no/don’t know option) 
- 57.8% recognised human papillomavirus 
as a risk factor 
 
                                                     
4 These two papers include data from the same study 
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Table 4.3: Included studies measuring knowledge of HPV and head and neck cancer (contd.) 
Reference 
Country 
Sample 
Response 
rate 
Study Design Outcomes/measures Relevant Findings 
Hertrampf, 
Wenz, Koller, 
Grund, & 
Wiltfang, 
2011 
Germany 
394 dentists in 
Schleswig-Holstein 
17% 
Cross-sectional 
survey (postal) 
Knowledge of risk 
factors for oral cancer 
(e.g. Which of the 
following factors places 
an individual at high risk 
for oral cancers? Human 
papillomavirus as 
yes/no/don’t know option) 
- 61.2% recognised human papillomavirus 
as a risk factor; 63.4% in those 
participating at re-evaluation and 
attending a continuing education course 
on oral cancer 
Hertrampf, 
Wenz, Koller, 
& Wiltfang, 
20123 
Germany 
306 dentists in 
Schleswig-Holstein; 1000 
members of the public 
14% 
Cross-sectional 
survey (postal and 
telephone) 
Knowledge of risk 
factors for oral cancer 
(e.g. Which of the 
following factors places 
an individual at high risk 
for oral cancers? Human 
papillomavirus as 
yes/no/don’t know option) 
- 57.8% dentists recognised human 
papillomavirus as a risk factor; 29% public 
Hertrampf et 
al., 2014 
Germany 
388 medical practitioners 
in Schleswig-Holstein 
13% 
Cross-sectional 
survey (postal) 
Knowledge of risk 
factors for oral cancer 
(e.g. Which of the 
following factors places 
an individual at high risk 
for oral cancers? Human 
papillomavirus as 
yes/no/don’t know option) 
- Human papillomavirus recognised as risk 
factor by 70% otorhinolayngology, 54% 
GPs, 50% Internal medicine (continuing 
education for general medical care), 51% 
internal medicine, 82% dermatologists 
Gilbert, 
Brewer, 
Reiter, Ng, & 
Smith, 20112 
USA 
609 men: 312 gay and 
bisexual, 296 
heterosexual 
70% 
Cross-sectional 
survey (online) 
Perceived knowledge 
of HPV-related disease 
- 21% of heterosexual men and 25% of 
gay/bisexual men knew HPV can cause 
oral cancer 
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Table 4.3: Included studies measuring knowledge of HPV and head and neck cancer (contd.) 
Reference 
Country 
Sample 
Response 
rate 
Study Design Outcomes/measures Relevant Findings 
Jaber, 
Shaban, & 
Hariri, 2012 
Saudi Arabia 
236 healthcare 
professionals 
Not 
reported 
Cross-sectional 
survey (in person) 
Knowledge of risk 
factors for oral cancer 
- 39.1% knew human papillomavirus was a 
risk factor for oral cancer 
Kujan, 
Abuderman, 
Azzegahiby, 
Alenzi, & 
Idrees, 2013 
Saudi Arabia 
167 undergraduate 
medical students (all 
students in year 4-6)  
100% 
Cross-sectional 
survey (in person) 
Knowledge of risk 
factors for oral cancer 
(e.g. Which of the 
following factors places 
an individual at high risk 
for oral cancers? Human 
papillomavirus as 
yes/no/don’t know option) 
- 65.7% overall recognised human 
papillomavirus as high-risk factor of oral 
cancer 
Men 4th yr 19%; 5th yr 17%, 6th yr 16% 
Female 4th yr 5%, 5th yr 4%, 6th yr 4% 
Kujan et al., 
2014 
Saudi Arabia 
479 undergraduate 
dental students (all 
students in year 4-6) 
87.1% 
Cross-sectional 
survey (in person) 
Knowledge of risk 
factors for oral cancer 
- 83.7% recognised human papillomavirus 
as placing someone at high risk for oral 
cancer 
Men 4th yr 10%; 5th yr 15%; 6th yr 15% 
Female 4th yr 12%; 5th yr 15%; 6th yr 
16% 
Little, Ogilvie, 
& Mirwaldt, 
2015 
Canada 
176 males at 
postsecondary 
institutions in Greater 
Vancouver 
Not 
reported 
Cross-sectional 
survey (in person) 
Knowledge of HPV 
- 32.9% knew ‘HPV infections can cause 
oral cancers’ and 24.2% knew ‘HPV 
infections can cause pharyngeal (throat) 
cancers’ 
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Table 4.3: Included studies measuring knowledge of HPV and head and neck cancer (contd.) 
Reference 
Country 
Sample 
Response 
rate 
Study Design Outcomes/measures Relevant Findings 
Luryi et al., 
2014 
USA 
 
2126 USA adults from 
Harris Interactive online 
panel 
Not 
reported 
Cross-sectional 
survey (online) 
Awareness  
(e.g. Did you know that 
the virus HPV (human 
papillomavirus) that 
causes cervical cancer is 
also associated with 
throat cancer?) 
Knowledge  
(e.g. How knowledgeable 
are you about oral, head, 
and neck cancer?) 
- 66% considered themselves not very or 
not at all knowledgeable about head and 
neck cancer 
- Knowledge of HPV as a risk factor in 
0.8% 
- 12.8% were aware of this association 
when specifically queried about the 
association between HPV and throat 
cancer 
- Respondents with a college or university 
degree were more likely to associate HPV 
with throat cancer (14.8% vs 10%) 
- Older age was associated with less 
knowledge of HPV as a risk factor 
Malloy, 
Ellender, 
Goldenberg, 
& Dolan, 
2013 
USA 
297 American Head and 
Neck Society head and 
neck surgeons 
27.5% 
Cross-sectional 
survey (online) 
Assess clinical 
practices 
Assess attitudes 
Assess knowledge 
regarding HPV-related 
cancer of the head and 
neck 
- 90.9% said they discuss HPV as a risk 
factor with patients  
- Respondents specifically with daughters - 
about 85% discussed HPV as a risk factor 
- Scored very well on knowledge items of 
HPV - in 5 out of 7, over 92% of 
responses were correct  
Maybury, 
Horowitz, 
Yan, Green, 
& Wang, 
2012 
USA 
619 dentists in Maryland 53.6% 
Cross-sectional 
survey (postal) 
Knowledge of risk 
factors for oral cancer 
- 88% knew HPV a risk factor for oral 
cancer 
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Table 4.3: Included studies measuring knowledge of HPV and head and neck cancer (contd.) 
Reference 
Country 
Sample 
Response 
rate 
Study Design Outcomes/measures Relevant Findings 
Osazuwa-
Peters et al., 
2015 
USA 
 
303 Drag racers (28.3%) 
and fans (70%), vendors 
(1.7%) attending annual 
United Black Drag 
Racers drag racing event 
in St Louis 
Not 
reported 
Cross-sectional 
survey (in person) 
 
Knowledge of HPV and 
HNC  
(e.g. Please indicate 
whether you think that 
each of these things may 
or may not increase a 
person’s chance of getting 
head and neck cancer: 
Human papillomavirus 
infection; Certain types of 
HPV can lead to oral 
cancer: True) 
- 29.9% knew HPV definitely increases the 
risk of developing oral, HNC  
- M 49%; F 62.6% 
Patton, Elter, 
Southerland, 
& Strauss, 
2005 
USA 
584 licensed dentists in 
North Carolina 
52% 
Cross-sectional 
survey (postal) 
Knowledge of oral 
cancer risk factors  
(e.g. In the United States, 
which of the following 
factors places an 
individual at high risk for 
oral cancer?) 
- 60% recognised human papillomavirus as 
a risk factor for oral cancer 
Pelullo, Di 
Giuseppe, & 
Angelillo, 
2012 
Italy 
1000 lesbian, gay and 
bisexual men and women 
86.8% 
Cross-sectional 
survey (in person) 
Know that HPV can 
cause oropharyngeal 
cancer 
- 47% gay men, 44% lesbians, 31% 
bisexual men and 35% of bisexual women 
knew oral cancer is an HPV related 
disease 
- The vast majority knew unprotected sex 
was the main risk factor  
- 60.6% had heard of HPV  
Posorski, 
Boyd, Giblin, 
& Welch, 
2014 
USA 
62 senior citizens 66% 
Cross-sectional 
survey (in person) 
Knowledge of risk 
factors for oral cancer 
- 29.5% knew infection with HPV was a 
contributing factor for oral cancer 
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Table 4.3: Included studies measuring knowledge of HPV and head and neck cancer (contd.)
Reference 
Country 
Sample 
Response 
rate 
Study Design Outcomes/measures Relevant Findings 
Reed, Duffy, 
Walters, & 
Day, 2005 
USA 
450 medical students, 
South Carolina 
78.8% 
Cross-sectional 
survey (in person) 
Knowledge of risk 
factors for oral cancer 
- 61.4% overall knew human papillomavirus 
associated with an increased risk for oral 
cancer; 33.7% 1st yr; 58.7% 2nd yr; 
80.8% 3rd yr; 64.7% 4th yr 
Reed et al., 
2010 
USA 
269 dentists, 19 oral 
surgeons, 221 physicians 
57% 
dentists 
76% oral 
surgeons 
45% 
physicians 
Cross-sectional 
survey (postal) 
Knowledge of risk 
factors for oral cancer 
(e.g. Rank (high, medium, 
low) the association of 
known high-risk factors 
(human papillomavirus) 
with oral cancer) 
- Human papillomavirus ranked as high risk 
by 26% dentists, 37% physicians; medium 
risk by 49% dentists and 45% physicians; 
low risk by 26% dentists, 37% physicians 
Reiter, 
Brewer, & 
Smith, 20102 
USA 
 
609 men aged 18-59 
from national panel of US 
households 
70% 
Cross-sectional 
survey (online) 
Knowledge of HPV 
- 21% of those having heard of HPV 
responded yes to HPV can cause oral 
cancer 
Reiter, 
Brewer, 
McRee, 
Gilbert, & 
Smith, 20102 
USA 
 
306 men self-identified 
as gay or bisexual aged 
18-59 from national panel 
of US households 
70% 
Cross-sectional 
survey (online) 
Knowledge of HPV 
- 25% of those having heard of HPV 
responded yes to HPV can cause oral 
cancer 
Riley et al., 
2013 
USA 
2393 general population 
from rural areas 
Not 
reported 
Cross-sectional 
survey (telephone) 
Knowledge of risk 
factors for mouth and 
throat cancer 
- 40.2% Having human papillomavirus 
‘Yes-it increases the risk of getting mouth 
or throat cancer’ 
Saleh et al., 
2014 
Malaysia 
362 dentists 41.7% 
Cross-sectional 
survey (in person) 
Knowledge of risk 
factors for oral cancer 
- 67.2% knew human papillomavirus is a 
risk factor for oral cancer  
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Table 4.3: Included studies measuring knowledge of HPV and head and neck cancer (contd.) 
Reference 
Country 
Sample 
Response 
rate 
Study Design Outcomes/measures Relevant Findings 
Schuler & 
Coyne-
Beasley, 
2015 
USA 
267 parents of sons 
eligible to receive HPV 
vaccination 
Not 
reported 
Cross-sectional 
survey (in person) 
Parent’s knowledge of 
HPV in oropharyngeal 
cancer 
- 18% knew role of HPV in oropharyngeal 
cancer  
Sitheeque, 
Ahmad, & 
Saini, 2014 
Malaysia 
147 final year medical 
and dental 
undergraduates of 
Universiti Sains Malaysia 
73.5% 
Cross-sectional 
survey (in person) 
Aetiology of oral cancer 
- 59.6% of medical students and 75.6% of 
dental students knew or role of human 
papillomavirus in aetiology of oral cancer 
(not stat sig difference) 
Sledge, 2015 
USA 
68 male African 
American college 
students, St Louis 
Not 
reported 
Cross-sectional 
survey (online) 
Knowledge of HPV 
- 60.2% knew HPV can cause oral cancer 
in men; 61.7% knew HPV can cause oral 
cancer in women 
Trad, 
Reardon, & 
Caraveo, 
2013 
USA 
361 freshman students at 
Texas State University 
10.7% 
Cross-sectional 
survey (online) 
Knowledge: 
- HPV can be 
contracted through 
oral sex 
- HPV has a strong 
correlation with 
oropharyngeal cancer 
- HPV is associated 
with some head and 
neck cancers 
- 71.5% knew HPV could be contracted 
through oral sex 
- 51.6% knew of an association between 
HPV and oropharyngeal cancer 
- 18.2% knew HPV is associated with some 
head and neck cancers 
Wheldon, 
Daley, Buhi, 
Nyitray, & 
Giuliano, 
2011 
USA 
179 men self-identified 
as gay and bisexual 
Not 
reported 
Cross-sectional 
survey (online) 
Knowledge of HPV 
- 25% of those having heard of HPV 
responded yes to HPV can cause oral 
cancer 
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Table 4.3: Included studies measuring knowledge of HPV and head and neck cancer (contd.) 
Reference 
Country 
Sample 
Response 
rate 
Study Design Outcomes/measures Relevant Findings 
White, 
Creighton Jr, 
Wise, & 
Hapner, 
2014 
USA 
491 NASCAR fans, 158 
medical students, 186 
undergraduate students 
Not 
reported 
Cross-sectional 
survey (in person) 
Awareness of 
relationship between 
HPV and HNC  
(e.g. How much do you 
agree that HPV increases 
the risk of HNC?) 
- Mean score: Medical students 2.84; 
Undergraduates 2.31; NASCAR 2.63 
NASCAR=National Association for Stock Car Auto Racing 
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4.3.3 Studies assessing knowledge of HPV-related head and neck cancer 
Forty one papers from 37 studies assessed knowledge about HPV and HNC (Table 4.3). Over 
half (n=24) were conducted in the USA, with others from Germany (n=4), Saudi Arabia (n=3), 
Canada (n=2), Malaysia (n=2), Jordan (n=2), Italy (n=1), Puerto Rico (n=1), Romania (n=1) and 
Ireland (n=1). All were published between 2002 and 2015. Quantitative studies (n=40) used 
survey-based data collection methods and one qualitative study collected data using focus 
groups (Daley et al., 2011).  
Studies assessing knowledge of HPV and HNC included samples of dental students 
(Boroumand et al., 2008; Cannick et al., 2005; Dumitrescu et al., 2014; Kujan et al., 2014; 
Sitheeque et al., 2014), medical students (Kujan et al., 2013; Reed et al., 2005; Sitheeque et al., 
2014; White et al., 2014), general undergraduate students (Little et al., 2015; Sledge, 2015; 
Trad et al., 2013; White et al., 2014), oral health providers (dentists and dental hygienists; Ashe 
et al., 2006; Clovis et al., 2002; Daley et al., 2011; Decuseara et al., 2011; Hertrampf et al., 
2011, 2012, 2010; Maybury et al., 2012; Patton et al., 2005; Reed et al., 2010; Saleh et al., 
2014), head and neck surgeons (Malloy et al., 2013), healthcare professionals (Hassona et al., 
2015; Hertrampf et al., 2014; Jaber et al., 2012; Reed et al., 2010), a population-based sample 
of USA men (Brewer et al., 2010; Reiter, Brewer, & Smith, 2010) and a population-based 
sample of USA adults (Dodd et al., 2012; Luryi et al., 2014; Posorski et al., 2014; Riley et al., 
2013; Schuler & Coyne-Beasley, 2015). Some specific sample populations were included such 
as American Indian community members (Dwojak et al., 2015), bisexual and homosexual 
populations (Gilbert et al., 2011; Pelullo et al., 2012; Reiter, Brewer, McRee, et al., 2010; 
Wheldon et al., 2011) and National Association for Stock Car Auto Racing (NASCAR) fans 
(White et al., 2014). 
Knowledge of the association between HPV and HNC varied across study populations and the 
questions asked (Table 4.4). All the questions involved recognition of HPV as either a cause or 
risk factor for oral cancer, with no studies requiring participants to recall HPV as a risk factor for 
oral cancer. For example, Hertrampf and colleagues (Hertrampf et al., 2014, 2011, 2012, 2010) 
asked ‘Which of the following factors places an individual at high risk for oral cancers?’ with 
human papillomavirus listed as a response option, and Colon-Lopez and colleagues (Colón-
López et al., 2012) asked participants to respond ‘true’ or ‘false’ to the statement ‘HPV is 
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associated with oral cancer’. As the measures used different wording to test knowledge in their 
sample populations, it is difficult to compare directly across each study. Table 4.4 has 
accumulated these results into meaningful groups to allow some comparisons to be made.  
Knowledge of HPV as a risk factor for oral cancer ranged from 26% to 91% in medical or dental 
professional samples (Alami et al., 2013; Ashe et al., 2006; Clovis et al., 2002; Decuseara et al., 
2011; Hassona et al., 2015; Hertrampf et al., 2014, 2011, 2012, 2010; Jaber et al., 2012; Malloy 
et al., 2013; Maybury et al., 2012; Patton et al., 2005; Reed et al., 2010) compared to between 
1% and 44% in samples of members of the general population (Brewer et al., 2010; Colón-
López et al., 2012; Dodd et al., 2012; Dwojak et al., 2015; Gilbert et al., 2011; Hertrampf et al., 
2012; Luryi et al., 2014; Osazuwa-Peters et al., 2015; Pelullo et al., 2012; Posorski et al., 2014; 
Reiter, Brewer, McRee, et al., 2010; Reiter, Brewer, & Smith, 2010; Riley et al., 2013; Schuler & 
Coyne-Beasley, 2015; Wheldon et al., 2011). Knowledge among students ranged from 18% in 
general undergraduate students to 84% in undergraduate dental students (Boroumand et al., 
2008; Cannick et al., 2005; Dumitrescu et al., 2014; Kujan et al., 2014, 2013; Little et al., 2015; 
Reed et al., 2005; Sitheeque et al., 2014; Sledge, 2015; Trad et al., 2013). Measured in focus 
groups with oral health providers, knowledge of the link between HPV and oral cancer was 
found to range from no knowledge at all, to some knowledge about the elements of the HPV 
and oral cancer link (Daley et al., 2011), for example, knowing some of the HPV types involved 
in HPV-related oral cancer.  
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Table 4.4: Knowledge about HPV and oral cancer reported in 35* studies 
Question % Sample population Reference 
Heard of HPV…  59% General population (USA) Dwojak et al., 2014 
61% General population (Italy) Pelullo et al., 2012 
61% General population men (USA) Reiter et al., 2010a 
71% General population men (USA) Brewer et al., 2010 
79% General population men (USA) Reiter et al., 2010b 
93% General population men (USA) Wheldon et al., 2011 
80% College students (Canada) Little et al., 2015 
85% College students (USA) Sledge, 2015 
Knew HPV was 
a risk factor for 
oral cancer…  
26% Dentists (USA) Reed et al., 2010 
53% Dentists (Canada) Clovis et al., 2002 
58% Dentists (Germany) Hertrampf et al., 2010 
58% Dentists (Germany) Hertrampf et al., 2012 
60% Dentists (USA) Patton et al., 2005 
60% Dentists (Ireland) Decuseara et al., 2011 
61% Dentists (Germany) Hertrampf et al., 2011 
67% Dentists (Malaysia) Saleh et al., 2014 
88% Dentists (USA) Maybury et al., 2012 
47% Dental hygienists (USA) Ashe et al., 2006 
54% Dental students (Romania) Dumitrescu et al., 2014 
67% Dental students (USA) Boroumand et al., 2008 
80% Dental students (USA) Cannick et al., 2005 
84% Dental students (Saudi Arabia) Kujan et al., 2014 
34% 
Newly graduated medical and 
dental personnel (Jordan) 
Alami et al., 2013 
37% Physicians (USA) Reed et al., 2010 
39% 
Healthcare professionals 
(Saudi Arabia) 
Jaber et al., 2012 
43% 
Healthcare professionals 
(Jordan) 
Hassona et al., 2015 
50%-82% 
Medical practitioners 
(Germany) 
Hertrampf et al., 2014 
91% 
Head and neck surgeons 
(USA) 
Malloy et al., 2013 
61% Medical students (USA) Reed et al., 2005 
66% 
Medical students (Saudi 
Arabia) 
Kujan et al., 2013 
1% General population (USA) Luryi et al., 2014 
18% General population (USA) Schuler et al., 2015 
29% General population (Germany) Hertrampf et al., 2012 
30% General population (USA) Posorski et al., 2014 
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30% General population (USA) 
Osazuwa-Peters et al., 
2015) 
32% General population (USA) Dodd et al., 2012 
40% General population (USA) Riley et al., 2013 
44% General population (Italy) Pelullo et al., 2012 
Knew HPV can 
cause oral 
cancer/head 
and neck 
cancer 
 
13% General population (USA) Luryi et al., 2014 
21% General population (USA) Reiter et al., 2010a 
25% General population (USA) Reiter et al., 2010b 
36% General population (USA) Dwojak et al., 2014 
21-25% General population men (USA) Gilbert et al., 2011 
23% General population men (USA) Brewer et al., 2010 
27% 
General population men 
(Puerto Rico) 
Colon-Lopez et al., 2012 
39% General population men (USA) Wheldon et al., 2011 
18% College students (USA) Trad et al., 2013 
33% College students (Canada) Little et al., 2015 
60% in 
men 
College students (USA) Sledge, 2015 
62% in 
women 
College students (USA) Sledge, 2015 
 60% Medical Students (Malaysia) Sitheeque et al., 2014 
 76% Dental Students (Malaysia) Sitheeque et al., 2014 
Knew HPV is 
strongly 
associated 
with 
oropharyngeal 
cancer 
52% College students (USA) Trad et al., 2013 
*Two references not included as the studies did not use comparable methodology (Daley et al., 2011; White et 
al., 2014) 
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4.3.4 Quality assessment  
Psychosocial  
Based on the NICE quality appraisal checklists for the quantitative studies measuring the 
psychosocial impact of HPV-related HNC, three studies were designed or conducted in a way 
that minimised bias, three studies were partly designed or conducted to minimise bias and had 
aspects of the study design that were unclear, and three studies were either unclear on aspects 
of the study reported or may not have addressed all potential sources of bias. It was not 
relevant to perform power calculations in the samples in these studies because the patient 
population for HPV-positive patients is small. The one qualitative study was clear in the purpose 
of the study, carried out the data collection appropriately, was clear on the context in which the 
study was carried out, conducted reliable analysis, provided convincing findings and drew 
relevant conclusions. The study was unclear about whether the relationship between the 
researcher and participants had been considered. The study was considered to be designed to 
have minimised bias.   
Knowledge 
For those studies assessing knowledge of the relationship between HPV and HNC, 23 studies 
were designed or conducted in a way that minimised bias, six studies were partly designed or 
conducted to minimise bias and had aspects of the study design that were unclear, and 11 
studies were either unclear on aspects of the study reported or may not have addressed all 
potential sources of bias. The one qualitative study was clear in the purpose of the study, 
carried out the data collection appropriately, was clear on the context in which the study was 
carried out, conducted reliable analysis, provided convincing findings and drew relevant 
conclusions. The study was unclear about whether the relationship between the researcher and 
participants had been considered. The study was considered to be designed to have minimised 
bias.   
No studies were assessed as having significant sources of bias across all aspects of the study 
design. The majority of studies described the source population well, used reliable and valid 
outcome measures, measured outcomes that were relevant and used appropriate analytical 
methods. Out of 25 studies in which it was relevant to perform a power calculation, only eight 
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did so. Many of the studies had small samples and so could not be generalised to the source 
population.  
4.4 Discussion 
This review draws together the emerging literature on the psychosocial implications of an HPV-
related HNC diagnosis and awareness of the link between HPV and HNC. QOL was measured 
in the HPV-related HNC patient population, with inconsistent results found. QOL in those with 
HPV-positive cancer was found to be higher, lower or equivalent to those with HPV-negative 
HNC. In longitudinal studies, irrespective of the instrument used, QOL in patients was at its 
lowest 2-3 months after diagnosis. In some studies, QOL almost returned to pre-treatment 
levels after 12 months.  
The UWQOL was the instrument used in three of the ten studies included in this review. This 
scale is specific to HNC and measures 12 different domains as single item questions. To allow 
for comparisons across studies, it would be ideal to have a well-validated, standardised 
measure that could be used in all studies. All the HNC specific QOL measures used in the 
studies included in the review (EORTC HNC-35, HNCI, UWQOL) measure similar constructs 
tapping into the physical and the psychosocial effects of HNC. The UWQOL is a simple 
measure and has been described as a suitable measure for use in routine clinical practice 
(Lowe & Rogers, 2012). Due to its ability to breakdown its 12 domains into two subscales of 
physical and social-emotional, this allows comparisons both across the two subscales and the 
individual items. Future studies measuring QOL in HNC patients in the future should use the 
UWQOL for both HPV-related HNCs and non-HPV related HNCs. As previously reported, it is 
difficult to make generalised statements about QOL that can aid in clinical decision making, due 
to inconsistencies in the design of QOL instruments for HNC and a lack of unified reporting 
standards (Ojo et al., 2012).  
Use of other psychosocial measures was limited, with only two other primary research studies 
measuring domains other than QOL (Hess et al., 2014; Milbury et al., 2013). It is therefore 
difficult to draw conclusions based on the limited research which has currently been conducted 
around the psychosocial impact of HPV-related HNC. As discussed in chapter 2, psychosocial 
distress is common in HNC patients and future work is needed to explore the psychosocial 
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impact of a diagnosis of HPV-positive HNC for patients, as well as their partners and health 
professionals. One study found clinically meaningful levels of distress in 30% of patients but 
relatively low levels of self-blame (Milbury et al., 2013), suggesting there may be a need for 
interventions which may help alleviate distress levels. In the one qualitative study, a few 
survivors of HPV-positive HNC reported feelings of stigma and embarrassment about their 
diagnosis and this affected their sexual relationships (Baxi et al., 2012), consistent with findings 
from the cervical cancer literature (McCaffery et al., 2006).  
The relationship between HPV and HNC is not well known across most populations in the 
studies included here. The groups who were the most knowledgeable about HPV as a risk 
factor for HNC were 2nd year dental students, dentists and head and neck surgeons. Awareness 
levels ranged across a variety of samples of the general population, dentists, students and 
specific sexually orientated groups, from 1% to 88%. Almost half of the studies included 
dentists, dental hygienists or dental students, suggesting that the role dentists have to play in 
HPV and HNC is being increasingly recognised, and educating them about HPV as a risk factor 
is important. Dentists have been shown to express enthusiasm for continued education (Alonge 
& Narendran, 2004; Jaber et al., 2012; Malloy et al., 2013; Maybury et al., 2012). Many studies 
with dentists have acknowledged their importance in early detection of oral cancers (Clovis et 
al., 2002; Ford & Farah, 2013; Hertrampf et al., 2010), as well as general practitioners (Carter & 
Ogden, 2007; Holmes, Dierks, Homer, & Potter, 2003).  
All the questions used in the studies of HPV knowledge were recognition questions, where 
participants had HPV listed as a response option, rather than free recall where participants 
would have to list HPV in an open response, and so may not represent the true knowledge of 
participants as previous studies have found awareness to be higher in participants when 
responding to recognition questions when compared to recall (Low, Simon, Lyons, Romney-
Alexander, & Waller, 2012; Marlow, Waller, & Wardle, 2007). One study assessing knowledge in 
medical practitioners in Ireland found that when asked to list the risk factors they would 
associate with oral cancer, HPV was not listed (Ni Riordain & McCreary, 2009). There was also 
no standardised question assessing knowledge of the link between HPV and HNC, some asking 
it as a risk factor, while others were more specific (e.g. HPV is associated with some head and 
neck cancers). None of the studies assessing HPV knowledge were conducted in the UK, so no 
conclusions can be drawn about the level of knowledge in the UK. These studies were mainly 
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from the USA, indicating a wide range of knowledge across different population subgroups, but 
that generally, there is a need for greater awareness.  
As the research presented in chapter 2 demonstrated that QOL is an important outcome for 
HNC patients, it is appropriate that QOL is also being measured in HPV-related HNC patients. 
Although the results from this review are mixed for QOL, the results presented in chapter 2 
illustrate the factors which are influential in affecting QOL in HNC patients. There is scope for 
many more of these studies to be carried out in the HPV-OSCC patient population and to 
examine if there are similarities or differences between the two patient populations. It is also 
important to examine other psychological outcomes, as patients diagnosed with HPV-OSCC 
may feel additional stressors compared to HPV-negative patients due to the sexually 
transmitted nature of HPV. HPV-OSCC patients may also feel more optimistic and feelings of 
relief once given the information that HPV-OSCC has a better prognosis than HPV-negative 
cancers.  
4.5 Strengths and Limitations 
Adhering to PRISMA guidelines ensured my review was carried out systematically. By including 
quantitative and qualitative studies in the review, I avoided exclusion of any eligible and relevant 
studies and the qualitative studies provided a greater depth of understanding of both the 
psychosocial aspects of HPV-related HNC and also the knowledge of the relationship between 
HPV and HNC. Great effort was taken in an attempt to include any relevant conference 
abstracts which had been published as papers, to ensure that the data presented in the review 
was as current as possible.  
In terms of the limitations of this review, some eligible studies may not have been picked up in 
the forward citation searches if they had not yet been included on Scopus, but I am only aware 
of one such paper (Williams, Carr, & Goldenberg, 2015). The findings from this study concurred 
with the other results from my review, with 51% of military officer trainees and 25% of the 
general population knowing HPV was linked to oropharyngeal cancer. As a number of different 
instruments were used to measure QOL and at different points in the patient care continuum, it 
was difficult to compare across studies. Although the measures used were HNC-specific, they 
CHAPTER 4 – SYSTEMATIC REVIEW 
140 
 
were not developed for HPV and HNC patients and therefore there may be additional domains 
that are relevant, but have not been included in the measures. 
The inclusion of the studies was also restricted to those written in English, however given the 
range of countries included in the knowledge section of the review, this would suggest that most 
of the studies in this area are written in English. There were difficulties in the interpretation of 
some of the studies as they asked different questions to their participants; at different points of 
time across the patient’s disease trajectory for the psychosocial studies, and the differences in 
the wording of the questions for the knowledge studies. Studies which assessed knowledge 
through recall as opposed to recognition may not have been detected through the search terms 
if there was low awareness of HPV. The quality assessment of the studies was subjective and 
often difficult to conclude on its final rating. As a random selection were checked by Dr Laura 
Marlow and few disagreements were found, this strengthens the ratings given to each study. As 
nearly a third of studies were rated as being unclear on some aspects of the study or not 
addressing all potential sources of bias, it is important to take this into consideration when 
examining the results. I decided to include all studies to give an overview of all studies that had 
been conducted, but I do recognise that some of the studies may be affected by potential 
sources of bias.  
4.6 Conclusion 
This review shows a limited number of studies have measured the psychosocial impact of a 
diagnosis of HPV-positive HNC and those few that have, have mainly used QOL as their 
primary outcome measure. The previous chapters have shown that QOL is diminished in HNC 
patients, largely due to dysfunction and disfigurement associated with its treatment. This review 
provides support for those findings, but does not provide evidence of specific factors associated 
with the psychological impact of being diagnosed with HPV as well as HNC. Future work is 
therefore needed with patients to explore the impact of the diagnosis of HPV, as well as with the 
partners of HPV-positive HNC patients and health professionals caring for these patients. The 
limited knowledge of the association between HPV and HNC among the public also indicates 
the need for research to explore the information that these populations are receiving, 
particularly in the UK. None of the studies measuring knowledge of the relationship between 
HPV and HNC in this review were conducted in the UK and therefore we have no evidence of 
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knowledge in the UK. Chapter 5 explores the coverage of the relationship between HPV and 
HNC in the UK media and through examining the content, what information about HPV and 
HNC is being presented to the UK population through the media. This may be influential to how 
much is known about the relationship between HPV and HNC in the UK general population.  
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CHAPTER 5. UK MEDIA COVERAGE OF THE LINK 
BETWEEN HPV AND HEAD AND NECK CANCER (STUDY 2) 
5.1 Introduction5 
My systematic review (see chapter 4) showed limited knowledge of the link between HPV and 
head and neck cancer (HNC) among patients and the public, but greater knowledge among 
health professionals and medical/dental students. Prior to the start of my PhD, the American 
actor Michael Douglas disclosed to the media that his throat cancer was caused by HPV and as 
this was pertinent to my thesis, it was important to address what information about HPV-OSCC 
has been presented to the UK population through the media. As with the previous chapter, this 
chapter addresses all types of HNC and will therefore use the term HNC to encompass all 
anatomical sites, not just OSCC. As the media has been shown to influence patients’ opinions 
and feelings (Passalacqua et al., 2004) and is considered a major source of health information 
for many (James, James, Davies, Harvey, & Tweddle, 1999), it is possible that media coverage 
of the link between HPV and HNC may influence public awareness and perceptions of HPV.  
Prior to the introduction of the HPV vaccination in the UK in 2008, women’s awareness of HPV 
(primarily in the context of cervical cancer) was measured to be between 24-30% in the UK 
(Marlow et al., 2007; Pitts & Clarke, 2002; Waller et al., 2003). The HPV vaccination attracted a 
lot of media attention in the UK (Forster, Wardle, Stephenson, & Waller, 2010) and knowledge 
of HPV appears to have increased in the UK following its introduction (Marlow et al., 2013; 
Sherman et al., 2015).  
Human interest stories presented in the media (e.g. celebrity cancer stories) can engage the 
audience and can influence the extent to which further information is provided (Hilton, Hunt, 
Langan, Bedford, & Petticrew, 2010; Menashe, 1998). The British media is no stranger to 
reporting celebrities’ cancer stories, most notably the stories of Jade Goody (an English reality 
television personality), Kylie Minogue (an Australian singer/songwriter) and Angelina Jolie (an 
American actress). Metcalfe and colleagues reported that following a celebrity diagnosis, an 
                                                     
5 The search for this study was conducted in August 2014. A version of this chapter has been published in 
BMJ Open (Appendix 5.1). 
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increased public interest in disease prevention can follow (Metcalfe, Price, & Powell, 2011). This 
was demonstrated in the UK in the case of Jade Goody, a reality television personality who 
made her terminal cervical cancer diagnosis public. She died aged 27 years old and an 
increase in the number of women attending cervical screening was observed (Lancucki, 
Sasieni, & Patnick, 2012). In 2013, American actor Michael Douglas disclosed in an interview 
with The Guardian that his throat cancer was ‘caused by HPV which actually comes about from 
cunnilingus’. This disclosure received global media attention, giving the media an opportunity to 
discuss the link between HPV and HNC. However, media publications are sometimes criticised 
for the lack of detail they provide, for example surrounding the announcement of Angelina 
Jolie’s double mastectomy, they failed to give information about the rarity of her condition 
(Kamenova, Reshef, & Caulfield, 2014).  
Media priming may be used to strengthen the association between a person’s existing beliefs 
and their subsequent behaviour by making these beliefs more accessible (Fishbein & Yzer, 
2003). Awareness campaigns for cancers such as breast and lung (e.g. Public Health England 
Be Clear on Cancer campaign) have been shown to be effective in increasing awareness of key 
symptoms for these cancers and increases in general practitioner attendance (Cancer 
Research UK, 2014). Media coverage is one route through which public understanding of health 
issues might be improved and may prompt help-seeking behaviour, but little is known about UK 
media coverage of the link between HPV and HNC. The media has been shown to be a 
common source of information about HPV (Pitts, Dyson, Rosenthal, & Garland, 2007) and 
greatly influences public opinion, and as such it is important to examine how the link between 
HPV and HNC is portrayed by the UK media. As the media may play an important role in 
fulfilling the information needs of the public, examining the content of articles will establish what 
information is being conveyed and how this is being communicated. The aims for this study 
were to answer the next two research questions of my thesis: 
3) How frequently has the relationship between HPV and HNC received coverage in the 
UK media? 
4) What information is covered in media articles covering the relationship between HPV 
and HNC? 
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The first research question demonstrates the amount of coverage that the relationship between 
HPV and HNC has received in the media and therefore shows how often information is 
communicated to the general population through the media. Future policy and research could 
be guided by these findings as they will provide an indication as to how frequently the general 
population may have read messages about HPV and HNC and what messages they may have 
received.  
The second research question examined the content of the articles, providing an indication as to 
how the media may have shaped public perceptions about HPV and HNC and also by 
identifying the messages that the media are choosing to portray to the public. Examining these 
messages now, provides a basis on which we can work with the media in the future to ensure 
that in an era where the HPV vaccine may be introduced for boys or an oral cancer screening 
programme may be introduced, that the messages accompanying these are those which help to 
minimise any negative psychological associations. The findings from this research question 
could provide insight for future policy and research about which messages need to be 
addressed in any future publications reporting on the link between HPV and HNC. Future 
education strategies could also be influenced and policymakers could work together with the 
media in educating the public about the signs and symptoms of HNC and the relationship 
between HPV and HNC.  
5.2 Methods 
5.2.1 Reviewing media coverage 
In the context of news stories about cervical cancer, HPV and the HPV vaccination, previous 
research reviewing the media coverage of these topics have used online databases to search 
for articles (Anhang, Stryker, Wright, & Goldie, 2004; Forster et al., 2010; Hilton et al., 2010). 
Content analysis is a popular method of analysis for studies examining media coverage of news 
topics (Forster et al., 2010; Hilton & Hunt, 2010; Johnson, Sionean, & Scott, 2011). Content 
analysis is a method that combines both qualitative and quantitative methods, allowing both the 
frequency of categories to be reported, as well as the content (Weber, 1990).  
I used the NexisUK database (RELX Group, 2015) to search for print and online articles in the 
UK relating to HPV and HNC. NexisUK was chosen because it is a comprehensive online 
CHAPTER 5 – NEWSPAPER ANALYSIS 
146 
 
database providing full text access to all international, national and regional news sources, and 
is updated daily. This database has been commonly used in previous studies analysing the 
content of media articles (Anhang et al., 2004; Forster et al., 2010; Johnson et al., 2011). The 
search was conducted on the 20th August 2014 with no date limits applied. The search terms 
‘oral cancer’, ‘mouth cancer’, ‘throat cancer’, ‘oropharyngeal cancer’, and ‘head and neck 
cancer’ were entered into the database separately, limited to major mentions (in the headline, 
lead paragraph or indexing) and combined with [HPV OR human papillomavirus] within UK 
publications. Newswire and non-business news publications (e.g. obituaries, sports) were not 
searched. I reviewed the full text of each publication. Newspapers were categorised into 
broadsheet, middle-market and tabloids using Newsworks, which is an online marketing body 
for national newspapers and provides the categories of both local and national newspapers 
(Newsworks, 2015). Newspaper articles were categorised as “broadsheet” newspapers (more 
intellectual in content e.g. The Guardian, The Times), “middle-market” newspapers (coverage of 
entertainment and important news stories e.g. Sunday Express, London Evening Standard) and 
“tabloid newspapers” (reporting mostly on sensational material e.g. The Sun, Kidderminster 
Shuttle). Regional newspapers were categorised following discussion between Dr Alice Forster 
and myself. All stories reporting on the link between HPV and HNC were included. Articles were 
excluded if they were duplicates and/or were published in a specialist magazine or publication. 
Articles were excluded from the content analysis if they included less than 100 words about 
HPV and its link to HNC.  
5.2.2 Quantitative Analysis 
The frequency of reporting of the link between HPV and HNC was analysed using a frequency 
count. The number of articles per month reporting the link were plotted on a graph from the first 
publication to the most recent publication.  
5.2.3 Qualitative Analysis 
The headlines of all articles were analysed descriptively and the main text was analysed using 
content analysis. As with any qualitative analysis, content analysis can still be subjective due to 
its reliance on the researcher analysing the data.  
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The content of eligible articles was analysed using the five stages of Framework Analysis 
(Ritchie & Spencer, 1994). Firstly, I familiarised myself with the content by reading through all 
the eligible articles, making notes of recurring themes and summarising each article. Using the 
qualitative package NVivo 10 (QSR, 2012), I generated a list of codes and these codes were 
applied to the data (Appendix 5.2). The data were summarised and organised into a matrix of 
main themes and subthemes, with each row representing an article and each column 
representing a theme or subtheme. The codes were organised into a hierarchy of main themes 
and subthemes. Dr Alice Forster coded 20% of the articles to test inter-rater reliability. Second 
coding of 20% of the articles has been considered sufficient in similar studies (Johnson et al., 
2011; Penta & Baban, 2014). Cohen’s Kappa across all themes was 0.71 representing a 
substantial agreement (Cohen, 1960; Kreimer et al., 2013). Any disagreements were resolved 
by discussion and I coded the remaining articles.  
5.3 Results 
5.3.1 Article characteristics 
A total of 854 UK articles were identified. Articles were excluded if they i) were duplicates 
(articles published around the same time, with the same number of words in the same 
publication and duplicating text) (n=477); ii) were published in a specialist magazine or 
publication (n=80); or iii) did not mention the link between HNC and HPV (n=32). Following 
these exclusions, 265 articles were eligible for inclusion in the quantitative analysis. An 
additional 153 articles were excluded from the qualitative analysis because they included fewer 
than 100 words about the link between HNC and HPV. These articles tended to include a 
sentence about the link between HPV and HNC as part of a story with a different focus; they did 
not have sufficient text to merit qualitative analysis. Overall 112 articles were suitable for the 
qualitative analysis and a couple of examples are shown in Appendix 5.3. 
The newspapers with the greatest number of articles eligible for qualitative analysis were The 
Times (n=16), MailOnline (n=10), The Guardian (n=8) and The Independent (n=9). Broadsheet 
newspapers accounted for 54% of the articles, 21% were from middle-market newspapers and 
25% were from tabloid newspapers. With regard to average length, broadsheet articles tended 
to be longer (530 words average), followed by those in middle-market newspapers (472 words 
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average), with tabloid newspapers having the shortest (458 words average) articles. A fairly 
small proportion of articles (18/112; 16%) were published in regional papers.  
5.3.2 Quantitative analysis  
No UK publications reported the link between HPV and HNC prior to 2001. Figure 5.1 shows the 
number of articles published per month mentioning the link between HPV and HNC. There was 
a steady number of articles reporting on the link, but for most years from 2001 to 2014, on 
average, fewer than two articles were published per month across the newspapers. The largest 
number of articles reporting on the link between HPV and HNC was seen in 2013 (112/265). 
Broadsheet newspapers first reported that there was a link between HPV and HNC in October 
2001, followed by tabloid newspapers in February 2004 and middle-market newspapers in 
November 2009. 
There were a few small peaks in articles published in May 2007 (6/265), with 5/6 discussing a 
research paper which further demonstrated the link between oral sex and throat cancer 
(D’Souza, Kreimer, et al., 2007) and in March 2012 (7/265) reflecting the publication of figures 
demonstrating a rise in mouth cancers. There was a noticeable peak in June 2013 (45/265) with 
34/45 of these discussing Michael Douglas’ throat cancer being caused by HPV. In November 
2013 (16/265) there was another small peak with 10/16 articles reflecting on mouth cancer 
awareness month. 
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Figure 5.1: The number of UK media articles reporting on the link between HNC and HPV from 2001-2014 
0
5
10
15
20
25
30
35
40
45
50
2
0
0
1
2
0
0
2
2
0
0
3
2
0
0
4
2
0
0
5
2
0
0
6
2
0
0
7
2
0
0
8
2
0
0
9
2
0
1
0
2
0
1
1
2
0
1
2
2
0
1
3
2
0
1
4
N
u
m
b
e
r 
o
f 
a
rt
ic
le
s
 p
e
r 
m
o
n
th
Year of publication
CHAPTER 5 – NEWSPAPER ANALYSIS 
150 
 
5.3.3 Qualitative analysis 
5.3.3.1 Headlines 
About one third (35/112) of the headlines mentioned oral sex (e.g. ‘Oral sex can lead to mouth 
cancer’, Birmingham Post, 26 February 2004) and Michael Douglas was mentioned in a quarter 
(n=28/112) of the headlines (e.g. ‘Michael Douglas says cunnilingus gives you cancer but is he 
right?’ The Guardian, 2 June 2013). ‘Throat cancer’ was the most frequently used term for the 
disease, mostly reflecting the terminology used by Douglas himself, with ‘mouth cancer’ and 
‘oral cancer’ also used. Some headlines (33/112; 29%) emphasised the risk of oral sex and 
HPV (e.g. ‘Mouth cancer rise in young people is linked to oral sex’ The Metro, 16 March 2012), 
and some used the words ‘risk’, ‘alert’ and ‘dangers’ when referring to the link between HPV 
and HNC: 
‘Your life: Oral Sex cancer risk’ (Daily Mirror, 28 March 2010) 
‘Early alert for throat cancer’ (The Times, 22 July 2013) 
‘Stay alive to the dangers of mouth cancer’ (Kidderminster Shuttle, 6 November 2010) 
Others emphasised the sexual nature of the link using terms like ‘sex virus’, ‘will oral sex ever 
feel safe again’ and ‘struck a blow for oral sex’. 
5.3.3.2 Article content 
Four main themes emerged from the content analysis of the reviewed articles: Michael Douglas’ 
disclosure, the riskiness of oral sex, health information communicated about HPV, including 
HPV as a cause of HNC and its incidence, and the need to vaccinate boys against HPV. 
Michael Douglas’ disclosure 
In June 2013, Michael Douglas revealed that HPV was responsible for his throat cancer and 
that it was transmitted through oral sex. This disclosure was more commonly reported in 
broadsheet newspapers (50% broadsheet vs 28% middle-market and 22% tabloid). There was 
a peak in the number of articles covering this link (34/112; 30%) in June 2013, including those 
which reported on Michael Douglas’ subsequent assertion that he was talking about causes of 
HNC more generally, rather than being specific to him: 
Year of publication 
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‘Michael Douglas did not say cunnilingus was the cause of his cancer. It was discussed 
that oral sex is a suspected cause of certain oral cancers...but he did not say it was the 
specific cause of his personal cancer’. (MailOnline, 4 June 2013) 
There were suggestions in some of the articles that Michael Douglas had raised awareness of 
the link between HPV and HNC and had ‘broken the last taboo for men’ by raising the topic of 
oral sex: 
‘Even with statements from his publicist denying he had put the blame on oral sex 
specifically, this genie is not going back in the bottle. And perhaps that’s a good thing’. 
(The Telegraph, 4 June 2013) 
There was also scepticism by one newspaper (MailOnline) about the motives behind Michael 
Douglas’ disclosure, suggesting that he was ‘being paid by drug companies to boost HPV 
vaccine sales’ or that he is trying to cover up smoking as the cause of his throat cancer.  
Focus was also given to Catherine Zeta-Jones (Michael Douglas’ wife) suggesting Michael 
Douglas had contracted HPV from her: 
‘The actor appeared to suggest Catherine Zeta-Jones could have given him the sexually 
transmitted disease in a candid interview published last week’. (Belfast Telegraph, 7 
June 2013) 
One newspaper also suggested that Michael Douglas was criticised for his public honesty 
‘Namely, because it may embarrass his wife, Catherine Zeta-Jones’ (MailOnline, 3 June 2013). 
Concern was also expressed that his wife could be at risk of cervical cancer: 
‘She could contract several forms of cancer, including cervical, if she contracts HPV’. 
(Sunday Express,12 September 2010) 
Riskiness of oral sex 
A large number (84/112; 75%) of the articles mentioned oral sex as a cause of mouth cancer:  
‘Oral sex can lead to mouth cancer, according to new research’. (Birmingham Post, 26 
February 2004) 
HPV was mentioned as being transmitted through oral sex, with articles quoting Michael 
Douglas including the term ‘cunnilingus’ and stating that HPV is a sexually transmitted disease.  
‘Without wanting to get too specific, this particular cancer is caused by HPV, which 
actually comes about from cunnilingus...But yeah, it’s a sexually transmitted disease 
that causes cancer. And if you have it, cunnilingus is also the best cure for it’. (The 
Times, 5 June 2013) 
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This disclosure from Michael Douglas led some articles to discuss the risk of different sexual 
behaviours e.g. ‘Is cunnilingus inherently riskier than fellatio?’ (The Guardian, 2 June 2013) with 
a number of these providing research findings: 
‘A US study showed about 10 per cent of men aged 14 to 69 have an oral HPV 
infection, compared with 3.6 per cent of women. Because HPV-related oral cancer is 
twice as common in men as in women, cunnilingus is considered riskier than fellatio’. 
(London Evening Standard, 4 June 2013) 
Some articles (14/112; 13%) expressed the belief that the rise in throat cancer was due to 
changes in sexual practice: ‘the rise in HPV-related throat cancer is being seen as the legacy of 
the sexual revolution that began in the 1960s’ (The Independent, 21 January 2012), with an 
increase in oral sex practices leading to increases in oral HPV and therefore throat cancer: 
‘What is most strongly linked to oral HPV infection is the number of sexual partners 
someone has had in their lifetimes, in particular the number of individuals on whom they 
have performed oral sex’. (The Guardian, 21 February 2011) 
The link between oral sex and mouth cancer was not as clear cut, according to Cancer 
Research UK quoted to have said ‘it was unclear if it was linked with oral sex’ (The 
Independent, 16 March 2012). A few (5/112; 4%) of the articles suggested that HPV transmitted 
through oral sex ‘could overtake tobacco and alcohol as the main risk factor in the next decade’ 
(Western Morning News, 23 November 2010). 
It was also acknowledged that ‘oral sex is a topic which could not have been discussed openly 
even recently’ (The Telegraph, 4 June 2013). 
One article asked ‘should oral sex be off the agenda’ (Daily Mirror, 28 February 2014), with 
other articles terming oral sex as ‘now officially life-threatening’ (The Times, 26 May 2007) and 
that HPV is a ‘devastating virus’ (The Sun, 13 February, 2014). 
Health information 
Most of the articles providing health information focused on the link between HPV and HNC. 
Table 5.1 shows what health information was presented in each type of publication. The 
different types of information are discussed.  
HPV causes HNC: As mentioning the link between HPV and HNC was an inclusion criterion, all 
articles included this, with the majority (88/112; 79%) of the articles mentioning the link between 
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HPV and HNC within the first 100 words. The terms used were inconsistent, with mouth cancer, 
oral cancer and throat cancer used interchangeably. Some articles were more specific about the 
type of cancer caused:  
‘These striking results provide some evidence that HPV16 infection may be a significant 
cause of oropharyngeal cancer’. (The Times, 26 July 2013) 
The incidence of HNC: In total, 61/112 (54%) articles reported on the incidence of HNC, with 
57/112 (51%) reporting that the number of cases was increasing. One newspaper quoted a 
Cancer Research UK expert as describing ‘an emerging epidemic’ [in HNC] and 5/112 (4%) 
quoted Cancer Research UK as linking the HPV virus to the ‘rapid rise’ [in HNC cases]. 
‘In Britain, the number of mouth and throat cancers have increased by 40 per cent in just 
a decade’. (MailOnline, 3 June 2013) 
Table 5.1: Health themes mentioned in articles across the publication types 
 Number of articles including each theme 
Health information theme 
All 
publications 
(n=112) 
Broadsheet 
(n=61) 
Middle-
market 
(n=23) 
Tabloid 
(n=28) 
HPV causes HNC 112 (100%)  61 (100%) 23 (100%) 28 (100%) 
Incidence of HNC 61 (54%) 29 (48%) 13 (57%) 19 (68%) 
Information about HPV     
Cause of cervical cancer 63 (56%) 33 (54%) 12 (52%) 18 (64%) 
100 variants of HPV 11 (10%) 5 (8%) 3 (13%) 3 (11%) 
8/10 will contract HPV 12 (11%) 5 (8%) 3 (13%) 4 (14%) 
90% will contract HPV by 
age 25 
6 (5%) 6 (10%) 0 0 
Better prognosis and 
survival 
18 (16%) 4 (7%) 10 (43%) 4 (14%) 
Diagnosis and treatment 29 (26%) 10 (16%) 10 (43%) 9 (32%) 
Symptoms and screening 36 (32%) 15 (25%) 10 (43%) 11 (39%) 
Cited research findings 42 (38%) 23 (55%) 6 (14%) 13 (31%) 
NB: Percentages are for columns 
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A change in the demographic characteristics of those being diagnosed with HNC was also 
mentioned in a number of the articles (49/112; 44%), emphasising that patients are increasingly 
younger, male, non-smokers and from professional backgrounds. A few (9/112; 8%) articles 
also suggested that there was a shift towards more women getting HNC.  
Information about HPV: Over half of the articles also mentioned HPV as a cause of cervical 
cancer (63/112; 56%) and presented information about there being ‘more than 100 variants’ of 
HPV. In total, 19/112 (17%) articles highlighted that not all types of HPV cause cancer: 
‘Just a few strains cause problems, but one in particular, HPV-16, is known to cause cell 
changes which could develop into cancer’. (MailOnline, 16 March 2012) 
In 30/112 (27%) articles it was mentioned that most people will be infected with HPV at some 
point:  
‘HPV is really, really common - to the point that if you’re a sexually active adult, you’ve 
probably had it. By the age of 25, 90% of sexually active people will have been exposed 
to some form of genital HPV’. (The Guardian, 2 June 2013) 
A total of 16/112 (14%) articles expressed the need for increased awareness of the link 
between HPV and HNC, for example ‘few people can recognise its symptoms’ (Kidderminster 
Shuttle, 6 November 2010). Nigel Carter, Chief Executive of the British Dental Health 
Foundation was quoted as saying, ‘there is a clear gap in public knowledge about what causes 
mouth cancer’ (Daily Mirror, 28 February 2014). 
Better prognosis and survival: The positive prognosis and survival rates of HPV-related HNC 
were discussed (18/112; 16%), sometimes in the context of Michael Douglas’ own survival: 
‘[Dr Kumar] testified to increased recovery rates among this kind of cancer sufferer. This 
would help explain why Douglas was given an 80% chance of survival, despite the 
advanced stage of his illness’. (The Guardian, 2 June 2013) 
Survival was also discussed in comparison to HNCs without HPV as a cause:  
‘Treatments such as chemotherapy, radiotherapy and surgery are often more successful 
in mouth and throat cancers caused by the virus than those caused by tobacco and 
alcohol’. (MailOnline, 16 July 2013) 
Diagnosis and treatment: Early diagnosis of HNC was mentioned as giving a ‘better chance of 
successful treatment’ by 14/112 (13%) articles.  
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‘Mouth cancer survival rates of about 50% haven’t changed in decades, but if the 
disease is caught early patients can have a 90% chance of a cure’. (Daily Mirror, 28 
February 2014) 
Treatment methods, particularly chemotherapy and radiotherapy were mentioned, as well as the 
possibility for less invasive treatment in the future.  
‘Given that subgroups of people with HPV-related H&N [head and neck] cancers display 
excellent survival, these patients may in future be offered less aggressive treatment’. 
(The Western Mail, 25 February 2013) 
Symptoms and screening: Symptoms of HNC were reported more frequently in tabloids and 
middle-market newspapers than in broadsheets (Table 5.1). 
‘If you have an ulcer that doesn’t heal after three weeks, see your dentist or doctor’. 
(Daily Mirror, 28 March 2008) 
The importance of dentists was emphasised, explaining that they play a vital role in HNC 
diagnosis as well as doctors. Advice was given as a slogan ‘If in doubt, get checked out’ and 
ways to look for symptoms of HNC were suggested.  
‘Men are advised to check their neck for lumps when shaving and both sexes to look at 
the back of their throat while brushing their teeth’. (MailOnline, 13 November 2013) 
Case studies were also included and often illustrated the symptoms of HPV-related HNC, the 
invasive treatment involved, and the importance of regular dental check-ups.  
Cited research: Fewer than half (42/112; 38%) referred to research findings from peer-reviewed 
journals. Research that was cited included studies showing the increase in incidence and 
burden of HPV-related HNC, showing evidence for oropharyngeal cancer patients carrying 
antibodies to the E6 protein from the HPV16 virus (Kreimer et al., 2013) and evidence for 
number of oral sex partners as a risk factor for HPV (D’Souza, Kreimer, et al., 2007).  
HPV vaccination for boys 
The link between oral sex and HNC was given as a strong case for boys to be vaccinated 
against HPV. HPV Action, a group campaigning for the vaccination of boys, was mentioned in 
three articles. Many of the articles covering news of campaigns to vaccinate boys spoke of the 
opportunity for the vaccine to reduce the number of HNC cases in men, calling for it to be ‘a 
gender neutral vaccination’. 
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‘Campaigners are calling for boys to have the jab too in order to stem the "catastrophic 
rise" in cancers’. (Daily Mirror, 28 February 2014) 
Arguments were made about the cost effectiveness of introducing the vaccine for boys (5/112; 
4%) and that ‘the Government could save thousands of lives and hundreds of millions of pounds 
for the NHS by vaccinating boys against a cancer-causing virus at a cost of around £20m a 
year’ (The Independent, 2 February 2014). 
An argument for vaccinating boys against HPV was also made with reference to other countries 
as Professor John Ashton said ‘It makes sense to give teenage boys as well as girls the HPV 
vaccine, which is already happening in Australia’ (The Guardian, 19 September 2013). 
Men who have sex with men were also acknowledged as an unprotected group in a number of 
articles (7/112; 6%). 
‘We [Department of Health] recognise that the current vaccination programme does not 
offer protection against HPV-related cancers for gay men’. (The Independent, 2 
February 2014) 
It was acknowledged that the HPV vaccination would have to be repositioned, as parents 
currently know it as ‘the cervical cancer vaccine’. There was also recognition that HNC is not the 
only HPV-related cancer to affect boys and that the virus is linked to anal and penile cancers.  
Experts were quoted as being in favour of HPV vaccination for boys, including Professor Maura 
Gillison, who published evidence of the link between HPV and HNC: 
Professor Maura Gillison - ‘The time has come to have a more thorough discussion 
about the potential benefits of HPV vaccines in boys … When my patients ask whether 
they should vaccinate their sons [with the HPV vaccine], I say ‘certainly’. The vaccine 
will protect them against genital warts and anal cancer and - as a potential by-product of 
that - it may protect them against oral cancer caused by HPV … The time has come to 
consider offering the HPV vaccine to boys’. (The Independent, 21 February 2011) 
Professor Margaret Stanley – ‘It is not ethical, fair or socially responsible to have a 
public-health policy that forces men to rely on herd immunity, which won’t be reached for 
decades’. (MailOnline, 3 June 2013) 
Jamie Rae of The Throat Cancer Foundation and HPV Action, expressed the view that not 
vaccinating boys is ‘inequitable - in fact, I’d say it’s an infringement of human rights, for all boys’ 
(The Independent, 2 February 2014) and it is ‘a flawed and discriminatory policy’ (The Herald 
(Glasgow), 12 June 2013), in the campaign to vaccinate boys against HPV. 
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5.4 Discussion 
This study is the first to analyse print and online newspaper coverage of the link between HPV 
and HNC in the UK. Coverage of the link between HPV and HNC has increased in response to 
major news stories. Articles reporting the link between HPV and HNC increased in March 2012 
as figures showed HNC cases to be rising. Michael Douglas’ disclosure in June 2013 sparked 
an increase in media interest as well as discussions about vaccinating boys. The main themes 
found to be reported in UK publications were Michael Douglas’ disclosure, the riskiness of oral 
sex, health information including HPV as a cause of HNC and its incidence, and the need to 
vaccinate boys against HPV.  
All the articles tended to report similar content and the themes remained consistent across the 
types of publication (e.g. broadsheet or tabloid), but how this was presented did differ across 
publication type. Broadsheets were the first type of publication to report on the link in October 
2001, followed by tabloids in February 2004 and middle-market in November 2009. Results 
from peer-reviewed research were reported in fewer than half of the articles. Basic facts about 
HPV were not reported in all articles, indicating that the public does not always receive even 
basic information which could help relieve any anxieties. This was also found in an analysis of 
the coverage of information about cervical cancer following Jade Goody’s illness, with there 
being very little information included in these articles about HPV (Hilton & Hunt, 2010). Using 
‘human interest’ stories such as the story of Michael Douglas, has been reported previously to 
be an effective way to engage audiences and can influence what is included or excluded from 
the coverage (Hilton et al., 2010; Menashe, 1998). 
Articles focusing on Michael Douglas’ disclosure were more likely to appear in broadsheets than 
the other types of publication, which is probably due to the interview being conducted with a 
Guardian reporter. Previous research has suggested that events such as a celebrity cancer 
diagnosis can create news coverage substantial enough to influence health behaviours such as 
attending cancer screening (Lancucki et al., 2012; Stryker, Moriarty, & Jensen, 2008). Oral sex 
was said to be the cause of Michael Douglas’ cancer in articles talking about his disclosure, but 
there were not many articles addressing what HPV is and the risk factors associated with it. 
There was a missed opportunity to educate the public as many articles did not discuss the signs 
and symptoms of HNC and what individuals should do if they find a symptom. This supports 
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findings in a previous study analysing cervical cancer coverage where the media failed to 
provide the signs and symptoms of cervical cancer, or the risk factors (Hilton & Hunt, 2010). 
Tabloid and middle-market newspapers covered these more often than broadsheet 
newspapers, but only tabloid newspapers mentioned HPV in their coverage on Mouth Cancer 
Awareness Month, held in November every year. As different newspapers appeal to different 
demographics, it is important for communication of HPV and HNC to be consistent across all 
newspaper types to minimise inequalities in awareness and consequently health outcomes. 
Previous research has suggested that in general, individuals who are more frequent users of 
the media are better informed (Chew, Palmer, & Kim, 1995). Attending to health news in 
newspapers has been shown to be associated with age, income and education, with income 
and education being found to strongly predict cancer prevention knowledge (Stryker et al., 
2008).  
Many of the references to oral sex related to the transmission of HPV. Some of the articles 
placed emphasis on the risk of oral sex, reporting that those with HPV-related HNC are ‘more 
likely to be connoisseurs of cunnilingus and fellatio’. These comments risk HPV-related HNC 
being seen as a sign of promiscuity and sensationalise it rather than including facts and 
presenting an HPV infection as common. This, in addition to information based on the evidence 
presented in chapter 1 about the rising incidence of HPV-related HNC, could lead the public to 
overestimate the prevalence of HPV-related HNC. Findings from the cervical cancer literature 
have shown that normalising HPV by emphasising its high prevalence and association with 
normal sexual behaviour has been effective at minimising negative psychological outcomes 
such as stigma or embarrassment (McCaffery et al., 2006; Waller et al., 2007). This information 
is also important for the partners of those diagnosed; I found that some articles suggested 
Michael Douglas could have contracted HPV from his wife, Catherine Zeta-Jones and could 
suggest that she was to blame. 
As Michael Douglas affirmed that he was talking about causes of HNC more generally, rather 
than being specific to him, this could also cause stigma towards HPV-related HNC, as the public 
may feel that he was ashamed to admit his throat cancer was caused by oral sex. There is also 
the concern that those who have been diagnosed with HPV-related HNC will feel stigmatised 
(Baxi et al., 2012; Daley et al., 2010; Kahn et al., 2005; McCaffery et al., 2006; Milbury et al., 
2013), so it is important that appropriate messages are being given about HPV to reduce the 
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stigma associated with this sexually transmitted infection (Braun & Gavey, 1998). Including case 
studies may help the public empathise with the person in the case study and reduce stigma. 
However, case studies reported in the articles were used to illustrate some of the symptoms for 
HPV-related HNC and how invasive and challenging the treatment can be. Endorsements from 
case studies where symptoms were noticed, and highlighting good prognosis with early 
diagnosis may encourage the public to adopt health protective behaviours such as checking for 
lumps and attending the dentist regularly.  
Articles which included reasons for vaccinating boys used case studies, Michael Douglas and 
research to support their campaigns. The media has been shown to increase knowledge of HPV 
after coverage of the introduction of the HPV vaccination (Kelly et al., 2009; Patel et al., 2016). 
Media coverage of the campaigns and the connection to Michael Douglas’ disclosure has the 
opportunity to raise awareness among parents and as all the articles took a positive stance 
towards vaccinating boys, this may influence parents’ decisions about vaccinating their sons 
against HPV. Including endorsements from leading researchers in the field of HPV and HNC 
may have enhanced the credibility of messages in the articles and encouraged parents to 
vaccinate their boys should they have the opportunity. Parents of boys will need to be able to 
communicate to their sons the link between HPV and sex, given that the vaccine is currently 
positioned as the ‘cervical cancer vaccine’. The media could play a role in facilitating this. 
5.5 Strengths and limitations   
This study showed both the trends in coverage of the link between HPV and HNC in UK 
publications and also gives further detail on the content of these publications. The use of the 
NexusUK database ensured the search was up-to-date at the time it was conducted. Using 
NexusUK database to search for media coverage has been shown to be as effective as 
conducting the search by hand (Wells, Marshall, Crawley, & Dickersin, 2001). As with any 
qualitative research, the analysis and interpretation was subjective. The interpretation could be 
influenced by my pre-existing perceptions, but by including others in the analysis process it is 
hoped that this will have minimised any personal biases and idiosyncrasies. Also by presenting 
quotes in the results section, this enables others to assess my interpretation of the data and 
provides data transparency (Moravcsik, 2014). The overall reliability of the coding of the content 
of the publications represented substantial agreement between myself and Dr Alice Forster, and 
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these methods for validating the interpretation of the data followed those used in previous 
research.  
This study is limited to UK publications and to print and online media, with broadcasts on 
television not examined, and so the results may not be representative of wider information 
available to the public. Different content may have been presented in television broadcasts 
which have not been picked up in this study. It is also important to recognise that although the 
media is a common source of information, it is not the only source. The internet is becoming 
increasingly popular as a source of health information, with over 154 million websites containing 
health information (Young, 2011). This figure is likely to have now increased since the 
publication of these statistics five years ago. The increasing use of social media could play a 
significant role in the dissemination of health information and an interesting area of research to 
explore would be the content of blogs and social networking sites, such as Facebook. Through 
Facebook, it is also possible to search for health information and to join patient groups (Young, 
2011). 
The articles in the study were only examined for content and not for accuracy of the information 
presented as this was not an aim of the study. Therefore it is not possible to determine if the 
health information covered in these publications was completely accurate, but this would be an 
interesting area to examine in future research. Assessing public knowledge about the link 
between HPV and HNC would also be useful, and an important first step towards raising public 
awareness and designing appropriate information for patients diagnosed with the disease. 
5.6 Conclusion 
This study is the first to show that the link between HPV and HNC has received coverage in the 
UK media, but an opportunity was missed to educate the public and influence health 
behaviours, through the disclosure of Michael Douglas. It is important for researchers not only 
to monitor media coverage of the link, but to work with journalists to ensure the content of 
articles is accurate and appropriate. Transmission of HPV via oral sex was regularly discussed, 
along with the link between HPV and HNC, which could raise public anxieties about oral sex. It 
is therefore important for journalists to aim to minimise stigma and blame associated with these 
messages, normalising HPV and portraying it as associated with normal sexual behaviour.  
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Examining responses to articles presenting the link between HPV and HNC through analysis of 
the discourse of online comments made on these articles would be an interesting area for future 
research. Patients diagnosed with HPV-OSCC may have read about the relationship between 
HPV and HNC in the media and there may be differing levels of knowledge when they are 
diagnosed. As health professionals are a trusted source of information and are likely to be a key 
source of information for patients, chapter 6 interviews health professionals directly caring for 
HNC patients, some of whom are now being diagnosed with HPV, to assess the information 
given to patients when they are given a diagnosis of HPV-OSCC. 
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CHAPTER 6. AN EXPLORATORY INTERVIEW STUDY WITH 
HEALTH PROFESSIONALS (STUDY 3) 
6.1 Introduction6 
The systematic review in chapter 4 showed that knowledge of HPV and head and neck cancer 
(HNC) was generally low in general population samples, and the previous chapter has shown 
that UK media covering the link between HPV and HNC did not always provide detailed 
information about HPV and often lacked basic facts the public may want to know. As these 
basic facts are often missing, it is possible that if diagnosed with HPV-OSCC, patients are also 
not aware of the relationship between HPV and OSCC and this may create unnecessary 
anxieties. Based on these results, it was deemed important to explore what health professionals 
tell their patients about HPV and HNC and what information they think is important to give them. 
The term OSCC will be used in this chapter as the majority of the HPV-positive patients that 
health professionals will have discussed HPV with will have been diagnosed with OSCC, 
although I recognise that health professionals will have also treated patients with other HNCs.    
Sharing the diagnosis of HPV-OSCC imparts not only a cancer diagnosis, with all the 
associated psychological implications that were discussed in chapter 2, but also conveys the 
information that the cancer was caused by a sexually transmitted infection. In the USA, HPV 
testing has been introduced as a clinical standard of care in oropharyngeal cancer in the 
National Comprehensive Cancer Network guidelines (Pfister et al., 2012). HPV tumour 
detection is also taking place in some UK centres (Roe et al., 2014), and guidelines have been 
published recently in the UK by NICE (National Institute for Care and Excellence, 2016; see 
section 1.6). Now HPV testing of tumours is more commonly carried out, the HPV status of the 
tumour is available to be communicated to patients.  
The sexually transmitted nature of HPV creates a potential challenge for health professionals 
with little experience of discussing sexual behaviour (Daley et al., 2011; Kahn et al., 2007; 
Riedesel et al., 2005). Evidence from the cervical cancer literature suggests that general 
practitioners and practice nurses often lack knowledge of HPV and find the topic sensitive, 
                                                     
6 A version of this chapter has been published in Head and Neck (Appendix 6.1) 
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awkward, and difficult to explain in a way patients can understand (McSherry et al., 2012). 
Some also questioned the need to mention HPV at all (McSherry et al., 2012). As described in 
chapter 3, an HPV diagnosis in the cervical cancer screening context has the potential to cause 
feelings of stigma and shame in addition to the anxiety and health concerns usually associated 
with abnormal cervical screening results (McCaffery et al., 2006). In the absence of any formal 
recommendations for discussing HPV test results with OSCC patients, a recent review (Fakhry 
& D’Souza, 2013) suggested that the cervical cancer literature could be used as a starting point. 
A small amount of research with HPV-OSCC patients has begun in the USA and results from 
these studies could be used in conjunction with the cervical cancer literature in providing a 
starting point for health professionals when discussing HPV test results with OSCC patients. A 
qualitative study with male HPV-OSCC survivors (n=10) in New York found physicians were the 
primary source of information for all participants who wanted to know about HPV (Baxi et al., 
2012). In a larger study (n=62) exploring the information needs of HPV-OSCC patients in Texas 
(Milbury et al., 2013), around half reported that their oncologist did not discuss issues related to 
HPV with them. Many of these patients sought information about HPV and their cancer 
elsewhere.  
It has been argued that health professionals have an ethical obligation to ensure accuracy and 
transparency when disclosing HPV as the cause of a patient’s cancer (Shuman & Wolf, 2010), 
but as yet there have been no studies exploring the discussion of HPV-OSCC among health 
professionals themselves. Therefore, I carried out an exploratory qualitative interview study with 
health professionals treating patients with HPV-OSCC (as well as other HPV-HNCs), exploring 
their experiences and the perceived challenges of talking to patients about HPV in this context. 
This work aimed to help identify needs for information materials which may encourage the 
discussion between health professionals and their patients.  
Qualitative research is valuable in behavioural science as it allows full exploration of the 
experiences, attitudes and beliefs of participants and the data are not constrained by closed 
questions. Qualitative research involves the use of open-ended questions and participants are 
probed in response to their answers (Guest, Namey, & Mitchell, 2013). It allows rich and 
detailed data to be collected in often very new areas of research that require exploration and 
description (Pope & Mays, 1995; Yardley, 2000). In behavioural science, qualitative research is 
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often used in this way, to explore new areas of research which can then later be used to help 
inform future research and data collection through quantitative measures.  
This study aimed to answer the fifth research question of my thesis:  
5) What are the experiences and views of health professionals in the UK who care for 
patients with HPV-OSCC? 
6.2 Methods 
6.2.1 Ethics 
This study was approved by the UCL Research Ethics Committee, reference 4577/002 
(Appendix 6.2). 
6.2.2 Recruitment 
I recruited health professionals from different disciplines caring for patients with HPV-OSCC, 
using purposive sampling to explore a range of perspectives. Participants were recruited from 
eight research-active hospitals in England and Wales (see Table 6.1), where HPV is discussed 
with patients. Potential participants were initially identified through existing contacts of Dr Jo 
Waller (two surgeons and two oncologists) and contacted via email. Snowballing is a method to 
identify new participants. It involves asking participants who are already taking part in a study, 
to contact others who they think might also be willing to take part. This method was 
subsequently used to recruit further health professionals as at the time, I did not have many 
contacts with health professionals working with OSCC patients. I also attended multidisciplinary 
team meetings at two hospitals in London to introduce the study and recruit participants.  
My relationship with the participants prior to the interviews involved contacting them to arrange, 
and later confirm the interviews. The participants were aware that I was a researcher interested 
in their experiences of discussing HPV with their patients, which was explained on the study 
information sheet (Appendix 6.3) provided to them prior to them consenting to take part.  
Initially I aimed to purposively recruit 10 participants to include oncologists, surgeons and 
nurses, as they have the most contact with HPV-OSCC patients. There are no set guidelines for 
sample size in qualitative research, but one such recommendation is to include between six and 
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eight interviews for homogeneous samples and 12 to 20 when looking to find maximum 
variation (Kuzel, 1992). As this was an exploratory study interviewing different subgroups of 
health professionals and I was unsure whether the results were likely to be homogeneous, I 
decided to aim for 10 interviews as a starting point. The emerging themes were noted for each 
interview. As the study progressed additional professional groups were included as other health 
professionals expressed that they were also key to HPV-OSCC patients’ care, and to try to 
maximise the range of views.  
Prior to the interview, each participant was provided with a study information sheet and 
completed a short demographic questionnaire which included questions about their age, sex, 
ethnicity, highest level of qualifications, profession, how many years they had been practicing in 
their profession, where they work, an approximation of how many HPV-positive HNC cases are 
seen in their centre each year and how many of these they are involved in (Appendix 6.4), and 
provided written consent (Appendix 6.5). Participants were also given a short debrief at the end 
of the interview (Appendix 6.6). Emerging themes from the interview transcripts were noted 
simultaneously with carrying out the interviews. Once I was satisfied that no new themes had 
emerged from three consecutive interviews, this suggested that saturation had been achieved. 
Data collection ceased at this point (Francis et al., 2010).   
6.2.3 Procedure 
I carried out semi-structured interviews with the health professionals following a topic guide that 
I developed using the existing literature on patient experiences and previous work on HPV and 
cervical cancer. It covered the participants’ professional background and experience of working 
with HNC patients, and their experiences of and attitudes towards communicating with patients 
about HPV-OSCC (Appendix 6.7). Suggestions for facilitating communication in the future were 
also discussed. 
Interviews took place face-to-face at the participant’s workplace (n=7) or over the telephone 
(n=8), lasted 20-40 minutes and were digitally recorded. I conducted all the interviews and 
transcribed them verbatim. Transcripts were not returned to the participants for comment or 
correction as this is time-consuming, participants’ perspectives may have already changed due 
to experiences since the interview, and it is possible they might want to change their responses 
to be more socially desirable.   
CHAPTER 6 - INTERVIEWS WITH HEALTH PROFESSIONALS 
167 
 
6.2.4 Analysis 
The interviews were analysed using Framework Analysis (Ritchie & Spencer, 1994), which is a 
popular method of analysing qualitative data in health research (Gale, Heath, Cameron, Rashid, 
& Redwood, 2013). This approach involves the five stages of familiarisation, identifying a 
thematic framework, indexing, charting and mapping, and interpretation. The data are organised 
into a thematic framework which enables close inspection of the data by theme and by 
participant. The matrix produced in Framework Analysis also enables the data to be easily 
analysed by either the participant or theme. This approach was considered more suitable than 
other qualitative analytical methods because the data was not aligned with a particular 
theoretical approach. Other qualitative approaches include Grounded Theory which focuses on 
generating theory; Interpretive Phenomenological Analysis (IPA) which focuses on the individual 
experience; Discourse Analysis which focuses on interpreting language and how it has been 
constructed; and Ethnography which focuses on the individual in the wider social and cultural 
context.  
I became familiar with the interviews by listening to, transcribing and reading the transcripts. I 
made notes on recurring themes and each interview was summarised. Each transcript was 
coded, after which themes were identified and developed into a thematic framework with 
subthemes under each main theme. Using the qualitative package NVivo 10 (QSR, 2012), the 
data were summarised and charted into a matrix, where each column represented a subtheme 
and each row represented a participant. Initial codes were developed with input from Dr Jo 
Waller and Dr Laura Marlow and then later checked for agreement against the final coding 
framework. There were few disagreements in interpretation and those that did occur were 
resolved by discussion.  
6.3 Results  
Thirty health professionals were approached and I interviewed 15 from a range of professional 
groups in June 2013, yielding a response rate of 50%. Three of the 15 health professionals who 
were not interviewed were willing to take part if they were needed and consisted of one male 
surgeon, one female surgeon and one male oncologist. The other 12 non-responders consisted 
of three males and nine females. These were a mix of clinical nurse specialists and surgeons. 
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There was an equal mix of male and female health professionals working in hospitals, with most 
being from White British backgrounds. Characteristics of the sample are shown in Table 6.1. 
Table 6.1: Sample characteristics 
 
 Sample characteristics (n=15) 
Age [median (range)]  47 (33-59) 
Sex [n]  
   Male 8 
   Female 7  
Ethnicity [n]  
   White British 13 
   Other  2 
Profession [n]  
   Surgeon 5 
   Clinical oncologist 3 
   Specialist nurse 4 
   Research nurse 1 
   Specialist radiographer 1 
   Speech and language therapist  
Geographic place of work [n] 
   North West England 
   North East England 
   South West England 
   London  
   South East England 
   Wales 
1 
 
4 
2 
1 
4 
3 
1 
 
Representing the views and experiences of these health professionals, seven main themes 
emerged: The significance of HPV in OSCC, attitudes to discussing HPV, challenges to 
discussing HPV, dealing with the impact of HPV on relationships, patients concerns and 
questions about HPV, key messages and professional development (Table 6.2). 
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Table 6.2: Framework of themes and subthemes 
Theme Subtheme 
Background 1 Background with head and neck cancer 
patients  
2 Research 
3 HPV testing 
4 Vaccination 
5 Perceptions of colleagues 
The significance of HPV 1 Patient characteristics  
2 Important topic 
3 Epidemiology 
4 Survivorship and treatment 
5 Impact on the future 
Attitudes to discussing HPV 1 Reasons for discussing HPV 
2 Reasons against discussing HPV 
Challenges to discussing HPV 1 Lack of knowledge 
2 Talking about sexual health 
Dealing with the impact of HPV on 
relationships 
 
Patient concerns and questions about HPV  
Key messages 1 Normalising HPV 
a. High prevalence 
b. Normal sexual behaviour 
c. Link with cervical cancer/HPV 
vaccination 
2 No need to change behaviour 
3 Positive prognosis  
Professional development  1 Learning from experience 
2 Learning from others  
3 Training 
6.3.1 The significance of HPV in OSCC 
All participants regarded the role of HPV in OSCC as an important issue, describing HPV-OSCC 
as a ‘different disease entirely’ (P9, female, specialist radiographer), affecting younger, 
otherwise healthy patients. The rise in incidence was a key concern. Participants reported being 
able to tell which patients had HPV due to their appearance and demographic background, 
which differed from the patients they usually treated. As one oncologist reported:  
‘When I first started in head and neck cancer practice, the stereotype of the head and 
neck cancer patient was pretty well fulfilled in that most of our patients were alcohol 
dependent, nicotine dependent and had developed head and neck cancer as a 
consequence of those two risk factors, but we have seen a change … over the last … 
decade where increasingly we’re seeing younger, non-smoking, non-drinking patients 
who are on average 10 years younger and recognising in that patient group that their 
HPV associated disease is the main risk factor for that’. (P3, male, clinical oncologist) 
The clinical implications of HPV-positive OSCC were discussed by a number of participants, 
including patients living longer with the after-effects of treatment and patient demands for 
expedited rehabilitation. One participant explained the impact of this: 
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‘We’ve got a longer period of survivorship for younger people who are still actively 
employed and so their functional rehabilitation becomes a bigger issue so that’s going to 
be a bigger part of our case load’. (P12, female, speech and language therapist)  
6.3.2 Attitudes to discussing HPV  
Almost all participants had talked about HPV with their patients, but even those who did not 
have direct experience of discussing HPV were able to express their opinions on the issue. 
Views about disclosing HPV as the cause of a patient’s cancer varied, perhaps reflecting the 
lack of guidelines for discussing HPV. There was a range of views on the possible benefits of 
discussing HPV status with patients.  
Participants who felt it important to discuss HPV status believed it was ‘helpful for the patient’s 
psyche’ (P4, male, surgeon) to understand the cause of their cancer. Sometimes patients had 
done their own research about HPV and had become ‘scared about it’ (P10, female, clinical 
oncologist), making it important to provide them with accurate and reassuring information. A 
clinical oncologist described how patients would search for information about HPV on the 
internet, and felt that avoiding the issue in the clinic was unhelpful. 
In centres running clinical trials, it was viewed as difficult not to mention HPV, because HPV 
status determined eligibility which ‘forces the issue’ (P2, male, surgeon). One reason for 
discussing HPV was the positive prognosis of HPV-OSCC, which participants felt had a direct 
impact on the patient and was seen as ‘one of the major bits of information they want to know’ 
(P6, male, surgeon).  
Participants who did not discuss HPV status with patients felt it unnecessary to mention HPV 
because it is ‘not offering a modifiable risk factor’ (P3, male, clinical oncologist) and focusing on 
the cause may contribute to self-blame for past behaviour:  
‘When it comes to HPV disease, I mean what can you tell them? … There’s nothing that 
they need to adapt in their lifestyle which is going to make any difference to their 
outcome at all’. (P7, male, surgeon) 
One view was that patients were not concerned about the cause of their cancer during the 
diagnosis consultation, where other worries and discussions about treatment took priority: ‘not a 
single patient that I’ve met so far has asked me what’s caused their cancer’ (P7, male, 
surgeon). It was sometimes felt to be best to ‘leave it at that stage, to the patient and their family 
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[to raise]’ (P1, male, surgeon) due to the fact that it does not change the clinical management. 
The consultation was sometimes described as being patient-directed and if patients did not ask 
about it, HPV ‘may just not come up’ (P3, male, clinical oncologist). Some participants said they 
were increasingly raising the issue of HPV with their patients, whereas others described patient-
led consultations. Mentioning clinical trials prompted patients to ask questions, but one surgeon 
reported ‘less than 10% of patients coming back at a later stage to discuss the implications [of 
HPV] in a social context’ (P1, male, surgeon).  
Variations in attitudes towards communicating about HPV among health professionals were 
described, including a difference between surgeons and clinical oncologists: 
‘I would say the oncologists talk about it much more easily and freely and openly, 
whereas the surgeons might mention it, but they don’t go into how it’s caused, the whole 
thing about HPV. No, I’d say oncologists are better at communicating about it’. (P8, 
female, specialist nurse) 
6.3.3 Challenges to discussing HPV 
Health professionals described two main concerns when talking to patients about HPV: the 
limitations of their own knowledge about the virus and discomfort talking about sexual health 
matters. 
Lack of knowledge 
It was apparent that some of the health professionals felt they lacked knowledge to respond to 
some of the questions patients asked about HPV, with a specialist nurse reporting ‘no bottom to 
those questions’ (P11, female, specialist nurse). It appeared there was some uncertainty about 
where to find accurate information, with consultants sometimes reported as giving different 
information to that printed in journals: ‘he [consultant] said ‘Oh it’s not an epidemic’ … am I 
supposed to go with what he says, or am I supposed to go with what’s in the journals?’ (P11, 
female, specialist nurse). The issue was raised of not feeling well informed, while it was 
suggested that some questions are difficult to answer due to the limits of scientific knowledge: 
‘They [the patients] start asking questions about how I caught HPV and when I caught it 
and who I caught it from, how will I have caught it. And some of those questions are 
difficult to answer because we don’t have the scientific knowledge at the moment … it’s 
still quite confusing I think both for the doctors and for the patients’. (P5, male, clinical 
oncologist) 
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Being honest with patients about not knowing the answers was advocated, since there is still 
scientific uncertainty: 
‘One of the questions I have been asked is ‘So now the cancer’s gone, if I have oral sex 
again, is it going to come back?’ I don’t know that answer, I don’t know if anybody does 
know that answer … if the questions are difficult like that, I tend to say there’s a lot of 
research on the go at the moment and we don’t have all the answers to the questions’. 
(P13, female, research nurse) 
There was some evidence of discomfort talking about HPV with patients. A specialist nurse 
said: ‘I’d feel out of my depth pretty quickly if people had been on the internet and they’d heard 
this and heard that’ (P11, female, specialist nurse). However, confidence appeared to increase 
with experience of discussing HPV with patients, with an oncologist describing how she felt she 
could now honestly say ‘nobody knows the answer’ (P10, female, clinical oncologist).   
Talking about sexual health 
Health professionals working with head and neck cancer patients are not used to discussing 
sexual health and some participants were very aware of this: 
‘You end up getting into the field of how was the virus transmitted and you say well it’ll 
be broadly speaking through sexual contact and actually it’s uncommon for patients to 
want that spelt out, but just occasionally I’ve got into a conversation between like as it 
were vaginal sex, oral sex, kissing and all of that. People want it spelt out in words of 
one syllable, but I think to be honest most head and neck consultants get pretty 
squeamish about that’. (P2, male, surgeon) 
Observations were raised about participants’ colleagues:  
‘I’m very lucky to work with some extremely talented surgeons, … but I think talking 
about HPV takes them out of their comfort zones somewhat … they are empathetic 
enough communicators to know what they’re not good at and I think they’d know that 
they’re straying out of their comfort zone; better not to get into it’. (P3, male, clinical 
oncologist) 
In addition, the issue of potential blame or ‘finger pointing’ (P6, male, surgeon) in relation to 
sexual transmission was raised. One participant observed that ‘it can be particularly difficult 
when you have couples in a session’ (P12, female, speech and language therapist). There were 
also concerns about not wanting to give the information in the ‘wrong manner’ and worry about 
patients leaving the consultation blaming themselves. 
Not all participants reported difficulties talking about sexual matters, with the speech and 
language therapist being experienced in, for example, dealing with ‘difficult questions about … 
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engaging in sexual practice when I have a stoma’ (P12, female, speech and language 
therapist). 
6.3.4 Dealing with the impact of HPV on relationships 
It was suggested that consultations could be influenced by the presence of the patients’ 
partners and that some patients were more open to discussion about HPV without their partners 
present. For example, one couple had researched HPV prior to the consultation and the partner 
was concerned about whether HPV indicated infidelity: 
‘Both husband and wife had done their homework, they knew about HPV, they knew he 
was likely to be HPV-positive before the consultation started … but the main crux of this 
issue was that … the wife was [saying] ‘How’s he got it, when did he get it’. As far as the 
wife was concerned they’d been in a monogamous relationship for 15 years and she felt 
… this must be a sign that he’d been unfaithful and had other partners outside of the 
marriage … that was obviously causing some problems between the two of them’. (P5, 
male, clinical oncologist) 
The techniques described for normalising HPV, through emphasising its high prevalence, 
explaining it is a result of normal sexual behaviour, linking it to cervical cancer and the HPV 
vaccination, explaining to the patient there is no need to change their behaviour and giving a 
positive prognosis, were used to try and diffuse the issues around past and/or present sexual 
activity (see section 6.3.6). Surgeons and oncologists often tried to help patients realise it was 
not their fault and that there was nothing they could have done to prevent their cancer.  
Fear of transmission and self-blame among partners were also described. In one case, a couple 
had ceased sexual activity following a consultation, which had led the clinical oncologist to re-
assess how issues of sexual transmission should be communicated: 
‘We’ve been on a real learning curve with that [discussing HPV] and I know I got it 
wrong initially … we talked about it with a patient and in subsequent discussions with 
the support workers, that patient was not having sex with his wife anymore because he 
was worried he would infect her with HPV’. (P3, male, clinical oncologist) 
A surgeon also recognised the nature of the relationship as important when deciding how much 
to discuss in the consultation:  
‘I was just slightly cautious … about discussing with partners the number of partners 
someone else has had … because obviously it was a newer relationship, not a sort of 
you know 20 years married type one’. (P6, male, surgeon)  
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6.3.5 Patient concerns and questions about HPV 
Almost all participants gave examples of concerns and questions patients had expressed about 
HPV. Views differed amongst health professionals about what patients’ primary concerns were. 
Some participants reported concerns mainly about diagnosis and treatment; with others 
reporting concerns and questions about HPV and transmission (see previous section). One 
specialist nurse reported an experience with a patient worried about transmitting HPV to his wife 
and re-infecting himself if he continued to practice oral sex. This patient was also worried about 
his son and talked about getting him vaccinated: 
‘I had this one guy who was HPV-positive and obviously he was really worried about 
passing this onto his wife or being re-infected by HPV if he continued to practice oral 
sex… He also was really worried about his son … because he knew that girls are being 
vaccinated against the HPV virus. He was worried that his genetic makeup, that he’s 
developed a cancer by the HPV virus, that his son was going to and he was looking into 
getting his son vaccinated privately’. (P15, female, specialist nurse) 
Specialist nurses described how some patients ‘come armed with’ (P8, female, specialist nurse) 
lots of questions about implications for transmission and the chances of becoming re-infected, 
but also noted that others ‘probably wouldn’t ask many questions’ (P11, female, specialist 
nurse). Some nurses thought that patients felt more comfortable asking them questions than the 
surgeon or clinical oncologist. This was acknowledged by some surgeons who said that it was 
the specialist nurses who were asked follow-up questions. Nurses and allied health 
professionals tended to see it as their role to be ‘the patients’ advocate’ (P8, female, specialist 
nurse), checking whether they had any questions following the consultation.  
6.3.6 Key messages  
Several key messages about HPV were highlighted by participants, suggesting an agreement 
about core messages perceived to be useful to the patient. These focused on trying to minimise 
possible negative psychological responses to HPV and presenting the diagnosis in a way that 
was easy to understand, and emphasised its positive implications. Recognising the amount of 
information each patient could understand and tailoring communication to avoid overloading 
them was mentioned by participants as important. It was suggested that delivering information 
about HPV in a factual manner ‘can distance any emotive element’ (P12, female, speech and 
language therapist), with the aim of ‘not making a big deal of it’ (P10, female, clinical 
oncologist). 
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Normalising HPV 
Participants reported a range of ways they would try to normalise HPV infection and reduce its 
psychological impact. This included describing the high prevalence of HPV, highlighting that 
transmission is through normal sexual behaviour and using the context of cervical cancer and 
HPV vaccination.  
High Prevalence 
HPV was often normalised by explaining that anyone who is sexually active will have been 
exposed to it: ‘it’s just really a difference between how the body deals with it in different people’ 
(P4, male, surgeon). The importance of communicating the fact that HPV is ‘a ubiquitous 
problem’ (P5, male, clinical oncologist) was emphasised; a surgeon reported telling his patients 
that HPV is as common as flu, calling it ‘genital flu’ (P6, male, surgeon).  
Normal sexual behaviour 
Participants emphasised that HPV was caused by normal sexual behaviour and was not an 
indication that the patient was promiscuous: ‘this is something which is associated with probably 
any sexual relationship … it’s not like getting a dose of gonorrhoea or chlamydia’ (P4, male, 
surgeon). It was suggested that by being deliberately vague about the nature of transmission, it 
was possible to reassure the patient that almost anything could have caused it: ‘I say you can 
get it from kissing somebody … that may not be the most common way to get it but you could 
do’ (P5, male, clinical oncologist). Participants also emphasised the fact that HPV is an infection 
likely to have occurred a long time ago and that the patient had ‘not gone out and slept with an 
infected individual’ (P4, male, surgeon).  
Link with cervical cancer/HPV vaccination 
Referring to HPV in the context of cervical cancer was reported to help patients understand that 
the same virus is involved in both cancers. Mentioning the HPV vaccination programme was 
thought to convey to the patient that this virus ‘isn’t something special’ (P3, male, clinical 
oncologist) and one surgeon described how he would explain this: 
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‘I always explain that it’s the same virus that’s related to cervical cancer and that anyone 
that’s sexual active will have been exposed to it, hence the vaccination programme for 
pre-sexually active individuals’. (P4, male, surgeon) 
No need to change behaviour 
When patients were concerned that they had ‘caused’ their cancer, participants reassured them 
that there was no need to modify their behaviour. Participants explained how they would tell 
patients with cancer related to tobacco and alcohol use to change their behaviour as this was 
important for their prognosis, whereas for HPV-OSCC patients ‘there’s no change in their 
behaviour related to the sexual practice right now that you’re advising them to take’ (P2, male, 
surgeon), as this would not affect the outcome.  
Positive Prognosis 
Participants tried to convey the positive prognosis of HPV-OSCC, with one clinical oncologist 
reporting how this information is useful: 
‘I think where knowledge of HPV status is useful to the patient, is enabling them to 
understand yes, you’ve got head and neck cancer, but we know that this particular head 
and neck cancer carries a much better prognosis than other forms of head and neck 
cancer’. (P3, male, clinical oncologist) 
Conveying the message about prognosis was viewed by most of the health professionals to 
help counter any feelings of blame and guilt among patients seeing this as ‘a bit of good news 
for them’ (P7, male, surgeon) and was sometimes accompanied by a comparison to HNC 
related to smoking and other risk factors, using terms such as doing ‘better in the long-term’ 
(P4, male, surgeon) and a ‘better prognosis’ (P6, male, surgeon). 
It was recognised that the positive prognosis of HPV-OSCC could lead to less intensive 
treatment in the future which is less toxic and leads to less dysfunction in these patients: 
‘More people are realising this is a separate disease and that we may be over treating 
them with that and as 80% of these patients tend to survive, we need to be looking at 
long term survivorship and functional outcomes that they survive with’. (P7, male, 
surgeon) 
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6.3.7 Professional development 
Learning from experience 
As health professionals saw an increasing number of HPV-OSCC cases, they felt they had 
begun to learn what is relevant for patients. One clinical oncologist described how in the past he 
had ‘mentioned unnecessarily orogenital transmission and that’s not actually relevant’ (P3, 
male, clinical oncologist). 
A transition was evident, from participants previously talking about contracting HPV through oral 
sexual behaviours, to now talking about most sexually active people contracting HPV. In some 
cases, participants reported having identified areas of discussion they avoided because of their 
lack of knowledge. They had since made an effort to find out more, resulting in increased 
confidence and more open discussions about HPV. Knowing the latest research and reading 
the literature was of upmost importance:  
‘I mean for us it was finding out more information and having the knowledge to answer 
questions … then also just learning from experience about the types of things that 
people are asking, … doing your best to find out what the answer to that question is for 
the next person to ask. Because if one’s [patient] going to ask, the next are’. (P15, 
female, specialist nurse) 
Learning from others 
Regular team updates and feedback with colleagues were mentioned as useful to improve 
dissemination of information to the patient in the future. It was acknowledged that colleagues 
‘think differently’ (P1, male, surgeon) so working as a multidisciplinary team was viewed as very 
important. 
Attending conferences was also perceived as a valuable way to both increase knowledge about 
the area and learn alternative ways to discuss HPV-OSCC. 
There was agreement over the need to add to and provide consistent information to patients 
with HPV-OSCC:  
‘Incorporating it in our … patient information … I certainly think that there will be serious 
room for improvement in that’. (P14, male, specialist nurse)  
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It was also suggested that a leaflet and/or guidelines offering advice for health professionals 
would be useful. Another suggestion was learning from colleagues working in cervical cancer, 
as they have ‘done a very good job in that women with cervix cancer don’t get immediately 
vilified for being sexually promiscuous and that’s not the public conception of cervix cancer’ (P5, 
male, clinical oncologist).  
Training 
Communication workshops and training were mentioned as a way of developing further skills: 
‘we would be best off receiving some degree of training in terms of how to communicate this 
information to patients’ (P7, male, surgeon). In some centres, communication workshops had 
already been carried out and participants from these centres felt they had benefited.  
6.4 Discussion 
This study explored the views and experiences of health professionals talking to patients about 
HPV in the context of OSCC. Views about discussing patients’ HPV status were mixed. Some 
felt it was beneficial for the patient to know the cause of their cancer, others felt that as clinical 
management is not currently determined by HPV status, discussing HPV in consultations was 
not necessary. Most health professionals in this sample did talk to their patients about HPV, 
with discussions sometimes initiated by the health professional and sometimes by the patient.  
HPV was recognised as being significant to the HNC field and was something health 
professionals described as a ‘different disease entirely’, and it has been described as this 
elsewhere and in chapter 1 (Chua, 2014; Scudellari, 2013). It is important to recognise the 
implications HPV has for health professionals, in particular the changing demographic of 
patients as they are now younger and are having to live with the after-effects of their treatment 
for longer. Health professionals also recognised the pressures on themselves for the 
requirement of expedited rehabilitation in these younger patients, as they are keen to return to 
their lives as soon as possible (Chua, 2014).  
Participants agreed on several key messages about HPV that they felt were important to 
incorporate into their discussions with patients. Describing the high prevalence of HPV and its 
link with normal sexual behaviour, and explaining HPV using the context of cervical cancer and 
HPV vaccination helped to normalise the infection. There is increasing recognition of the need 
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for appropriate messages and guidance to be developed to aid health professionals in their 
discussions. The HPV Core Messages study developed messages about HPV vaccination and 
HPV testing in the context of cervical cancer and recognises the need for appropriate messages 
to be adapted for patients with other HPV-related cancers (Hendry et al., 2016). The messages 
developed have not been published and therefore I am unable to compare them to the key 
messages found in this study. Their current work aims to develop scripted consultations that are 
‘offering messages that are succinct, salient, reassuring and relevant’ (Hendry et al., 2016, p5).  
The findings in this study found that discussion of oral sex specifically was deemed unhelpful as 
it can add stress to relationships as well as create awkward situations where the patient may 
feel stigmatised. However, recent UK evidence confirms that oral sex is commonplace, with the 
majority of people reporting oral sexual contact in the last year, and numbers rising in younger 
age-groups (Mercer et al., 2013). In the cervical cancer literature, the high prevalence of HPV 
has been an important message to convey to patients and has been shown to reduce stigma 
and embarrassment (McCaffery et al., 2006; Waller et al., 2007), although the psychosocial 
implications for HPV-OSCC patients may be different. These participants also felt it was 
important to explain that HPV-OSCC tends to have a positive prognosis. Qualitative work with 
HPV-OSCC patients suggests that they are encouraged by this information as patients 
expressed relief that this was good news for their recovery (Baxi et al., 2012), supporting this as 
a key message for health professionals to convey. A potential implication of explaining the good 
survival rates to HPV-OSCC patients is a resulting preference for de-escalation of treatment, as 
one surgeon described. As mentioned in chapter 1, on-going clinical trials (Mehanna et al., 
2012) are exploring the possibility of de-escalating treatment for HPV-OSCCs, so that patients 
are presented with less intensive treatment options with the hope that the after-effects of 
treatment may be lessened. Once the results of these trials are published, clinical guidelines 
should be available. Until then, health professionals may still need to be prepared for 
conversations about de-escalating treatment, especially with highly informed patients.  
Qualitative work with HPV-OSCC patients suggests that questions about HPV are 
overshadowed by concerns about cancer (Baxi et al., 2012), also described by some of the 
participants in this study. Some of the nurses I interviewed described a lack of confidence 
answering questions about HPV largely due to their own lack of knowledge. Given that nurses 
are often the first point of contact for patients with questions, it is important that information and 
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training is available to increase their knowledge and improve their confidence for these 
discussions. Surgeons and clinical oncologists also felt there was a general lack of knowledge 
about HPV and OSCC, but understood this was due to limited scientific knowledge and were 
generally confident explaining this to patients. As found in chapter 5, knowledge of the 
association between HPV and OSCC was higher in health professionals than the general 
population. It was evident that confidence in discussing HPV with patients increased with their 
experience of doing so. 
Most of the health professionals interviewed felt that additional training could help them improve 
their knowledge about HPV and communication with their HPV-OSCC patients, supporting 
previous research with dentists and dental hygienists who expressed a desire for more 
knowledge and training to improve their communication, as well as improving their comfort 
levels in discussing sexual behaviour with patients (Daley et al., 2011). Participants in this study 
acknowledged that these discussions were outside some of their colleagues’ comfort zones. 
This training could take place through communication workshops with a diversity of health 
professionals. These findings could also contribute to the development of information for health 
professionals that could be used with patients to communicate about this sensitive topic. This 
information could include responses to some of the questions posed by patients that have been 
mentioned by health professionals in this study and help improve the knowledge of health 
professionals when discussing this with their patients. 
Some of the participants interviewed felt that communicating with HPV-OSCC patients was very 
different from communicating with patients whose cancer was related to tobacco and alcohol 
use. It was advocated that it was important when communicating with HPV-OSCC patients, to 
correct the perception that they have done something to cause their cancer, whereas this would 
not be the case in cancers caused by tobacco and alcohol use. HPV-OSCC patients would 
usually be given more information about the cause of their cancer, due to the cause being less 
obvious than with tobacco and alcohol. Communicating about the cause of HPV-OSCC often 
brought with it the need to discuss sexual behaviour. These discussions have the potential to 
cause problems in relationships, demonstrated by some of the cases described in this study 
and previous findings from Baxi and colleagues (Baxi et al., 2012). This should therefore be 
something health professionals consider when planning treatment and recommending support 
for patients. 
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The themes presented can be interpreted within the ‘cognitive representation’ component of 
Leventhal’s Common Sense Model (CSM) (Leventhal et al., 1980). The identity of the cancer as 
HPV-related was important for health professionals, distinguishing these patients from those 
with alcohol/tobacco-related disease. Understanding that HPV was the cause of the cancer led 
some patients to question how they had acquired the virus, raising issues of sexual 
transmission and fidelity which some health professionals found challenging to address. 
Timeline, curability and controllability were salient because prognosis is better in HPV-related 
cancers, leading to the potential de-escalation of treatment. Consequences included longer 
survivorship, which was an issue raised by health professionals, and impact on sexual 
relationships, which was recognised as important for some patients. Consequences were 
influenced by the demographic of this patient group, who are generally younger. The CSM may 
provide a useful structure for discussing HPV with OSCC patients, and could be used to inform 
the development of clinical guidance for HCPs and information for patients about HPV-related 
OSCC. 
The findings from this study mirror those of similar studies in the cervical cancer literature, 
finding health professionals recognise HPV as a sensitive topic and are reluctant to discuss it, 
that some patients do not want to know anything about HPV and that there are gaps in health 
professionals’ knowledge (McSherry et al., 2012). This suggests significant overlap in the 
concerns of health professionals from the two fields. Research into common questions asked by 
patients (Gilbert, Alexander, Grosshans, & Jolley, 2003; Marlow, Wardle, Grant, & Waller, 2009) 
and educational needs of health professionals from the cervical cancer literature (Szarewski, 
2009) could therefore be useful to HNC health professionals. It is important to consider, 
however, that the needs and concerns of HPV-OSCC patients are likely to differ from those of 
women being screened for cervical cancer due, in part, to that fact that a high proportion of 
HPV-OSCC patients are men (Blomberg et al., 2011; Mehanna et al., 2012) and that in the 
cervical cancer screening context they are not being treated for cancer.   
6.5 Strengths and Limitations  
A range of health professionals across England and Wales were sampled to gain perspectives 
on communicating about HPV-OSCC from different disciplines. This work offers a useful starting 
point for the development of information for health professionals and potentially to inform larger 
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quantitative work with HPV-OSCC patients, with the ultimate goal of developing information for 
patients. Qualitative research is a good starting point for fields of research where there has 
been currently little research conducted. The findings from this study provide key information 
about what patients are currently being told and what health professionals are finding difficult to 
communicate with patients, providing a basis for which further information for these health 
professionals and their patients can be developed.  
Conducting this study using qualitative methods enabled the complexities of the consultation to 
be discussed which would not be possible in quantitative studies; however I acknowledge a 
number of limitations to the study. The subjectivity of qualitative analysis has long been 
recognised, but by involving other researchers in the analysis process this should provide 
greater reliability of the interpretation of the data. The transparency of the data described in the 
results and supported by quotes from the participants also helps to enhance the ability of others 
to understand the interpretations from the data. The health professionals in this study may have 
been those who are more comfortable talking about HPV, so it is possible that additional 
themes may have arisen in those who do not talk about HPV, as these were difficult to sample. 
Conversely, the health professionals in this sample may have been interested in receiving more 
information about HPV in the context of HNC and might have been hoping to learn something 
through their participation. Participants may also have personal biases which could influence 
the discussion of sensitive topics such as sexually transmitted infections. Comparisons were not 
able to be drawn between the different professional groups because of small numbers, but this 
could be an important avenue of future research. Patients’ views were not explored in this 
study, so caution is also needed when interpreting the data about patients’ concerns, as these 
are all from the perspective of the health professionals.  
6.6 Conclusion 
This exploratory study has gained insight into the challenges faced by health professionals 
caring for HNC patients. The demographic characteristics of patients with HPV-OSCC present 
new challenges for health professionals in terms of the questions being asked, the factors 
important to the patients, and their rehabilitation and treatment needs. Experiences among 
health professionals differed, suggesting a need for clinical guidance for communication about 
HPV in this context to ensure that patients are receiving consistent messages. Due to the 
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exploratory nature of these findings, it is important to use these to develop larger quantitative 
studies, which leads into my next study in chapter 7. It is also important to carry out research 
with patients to explore how being diagnosed with HPV-OSCC impacts them, which leads to my 
study conducted in chapter 8.
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CHAPTER 7. DISCUSSING HPV WITH PATIENTS: A SURVEY 
OF HEALTH PROFESSIONALS IN THE UK AND IRELAND 
(STUDY 4) 
7.1 Introduction 
The findings from chapter 6 alongside other qualitative research conducted with health 
professionals suggests that many of the psychological and communication challenges 
associated with cervical HPV may also apply in the head and neck cancer (HNC) context (Daley 
et al., 2011). Research has shown sexual behaviour through both oral sex and open mouth 
kissing are associated with acquisition of oral HPV infection (D’Souza et al., 2009) and both a 
USA study (Daley et al., 2011), and my findings from chapter 6 (Dodd, Marlow, & Waller, 2016), 
suggested these health professionals find it difficult to talk to their patients about their HPV-
OSCC due to the sexual nature of the acquisition of the virus. Some health professionals in 
chapter 6 also expressed concern that their knowledge about the role of HPV in OSCC was 
limited and that this impacted their ability to respond to some of the questions that were being 
asked by patients. For the reasons stated in the previous chapter, the term OSCC will be used 
in this chapter, unless referring to specific studies and to the survey, where HNC was used to 
encompass all anatomical sites.    
Current evidence suggests that not all health professionals involved in the diagnosis and 
treatment of HNC are aware of the risk factors for the disease, in particular the link with HPV. As 
the systematic review in chapter 4 showed, knowledge of the association between HPV and 
HNC among health professionals ranges from 26-88% in dentists (Maybury et al., 2012; Reed 
et al., 2010) and 34-91% in other medical professionals (Alami et al., 2013; Malloy et al., 2013). 
None of this previous research was conducted in the UK. A previous study with oral health 
professionals in the USA assessed knowledge of HPV and attitudes to discussing HPV (Daley 
et al., 2011) and found a range in knowledge of HPV-related HNC from complete lack of 
knowledge, to understanding of some details, and that they wanted more knowledge and 
training to aid in communicating with patients. 
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There is no available literature focusing on attitudes of medical professionals when discussing 
HPV in the context of oropharyngeal squamous cell carcinoma (OSCC), but there has been a 
great deal of previous work focusing on health professionals’ attitudes towards the HPV 
vaccination. Studies exploring HPV in the context of the HPV vaccination are referred to here to 
provide some examples of barriers to discussing HPV. Studies have found the discussion of the 
sexual nature of HPV as a barrier to physicians recommending the HPV vaccination (Bynum et 
al., 2014; Daley et al., 2010). In contrast, those who routinely discuss sexual health issues and 
who feel comfortable doing so, are more likely to recommend the HPV vaccine to their patients 
(Allison et al., 2013; McCave, 2010), showing a clear need for an intervention around sexual 
health which aims to improve patient-provider communication about the topic (Bynum et al., 
2014).  
Previous research around the HPV vaccination has found that those health professionals with 
greater knowledge about HPV and the HPV vaccination are more likely to recommend it 
(Holder, Katzenellenbogen, & Middleman, 2013). Doctors have previously reported self-rated 
knowledge as an important determinant of their willingness to recommend the HPV vaccination 
(Hopkins, Wood, West, & Darling, 2009). These findings demonstrate that knowledge is an 
important component with regard to health professionals being willing to discuss HPV and is 
important for answering patients’ questions, which could also apply in the OSCC context.  
The key messages to discuss with patients about HPV that were raised by health professionals 
in chapter 6 were to normalise HPV by emphasising its high prevalence, relating it back to its 
relationship with cervical cancer and explaining that HPV is a result of normal sexual behaviour. 
Explaining to patients that there is no need to change their behaviour and that the prognosis for 
HPV-OSCC patients is much better than other forms of HNC were other key messages.   
Qualitative studies, such as my previous study in chapter 6, are limited in their ability to assess 
how widespread these concerns are. Qualitative studies also do not produce measureable 
results to enable comparisons across groups and relationships among variables. Therefore, this 
study aimed to assess knowledge of HPV and experiences of discussing HPV with patients 
among a larger sample of different health professionals involved in the treatment of OSCC. This 
study contributes to the sixth research question of this thesis: 
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6) What are the experiences and attitudes of different groups of health professionals in the 
UK and Ireland who care for patients with HPV-OSCC? 
7.2 Methods 
7.2.1 Study Design 
This was a cross-sectional survey completed online through the platform Opinio or on paper.  
7.2.2 Ethics  
This study was approved by the UCL Research Ethics Committee, reference 4577/003 
(Appendix 7.1). 
7.2.3 Participants  
Health professionals [surgeons, oncologists, specialist nurses and allied health professionals 
(all other health professionals including speech and language therapists, dietitians and staff 
nurses)] in roles working directly with HNC patients in the UK and/or Ireland completed a 
survey. 
7.2.4 Recruitment 
Health professionals were recruited through several of the NHS cancer networks (e.g. London 
Cancer Alliance) (Appendix 7.2) and other professional organisations (National Cancer 
Research Institute, National Cancer Intelligence Network), as well as through existing contacts 
in the NHS and previous research studies (Table 7.1). NHS cancer networks were contacted if a 
contact name was available and delegate lists available from relevant conferences were used to 
help provide the names of HNC health professionals and email addresses were sourced for 
these names where possible. When contacting health professionals directly through email, 
snowballing techniques were used as they were asked to disseminate it within their teams. 
Health professionals were also recruited at three HNC specific conference days where data 
were collected using a paper questionnaire. Participants were told that they were consenting to 
their data being used by completing the survey (Appendix 7.3) and participants read a short 
debrief at the end of the survey (Appendix 7.4). Where possible, reminders were sent to those 
who received the online link to the survey two and four weeks after the initial email. A sample 
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size calculation with α=0.05 and a power of 0.8, suggested that for the chi-square tests 220 
participants were needed to detect a medium effect size of r=0.3. The chi-square tests were 
conducted to test for differences in experience and attitudes across the five health professionals 
groups: surgeons, oncologist, specialist nurses, speech and language therapists and ‘other’ 
health professionals.  
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Table 7.1: Details of the sources of recruitment 
Recruitment 
source 
Details about the source 
Which health 
professionals 
Online/paper 
NHS Cancer 
networks (e.g. 
London Cancer 
Alliance) 
Strategic Clinical Networks focus 
on priority service areas to bring 
about improvement in the quality 
and equity of care and outcomes 
of their population, both now and 
in the future. There are 14 cancer 
networks across England and 
Wales. Three of the 14 networks 
sent out information and the link 
to the survey.  
All disciplines Online 
National Cancer 
Research 
Institute 
The National Cancer Research 
Institute is a UK-wide partnership 
between research funders 
working together to make faster 
progress against cancer. 
All disciplines Online 
National Cancer 
Intelligence 
Network (NCIN) 
The NCIN is a UK-wide initiative, 
working to drive improvements in 
standards of cancer care and 
clinical outcomes by improving 
and using the information 
collected about cancer patients 
for analysis, publication and 
research. 
All disciplines Online 
Head and Neck 
Cancer 
Masterclass 
This masterclass offered the 
opportunity for all professional 
groups working with head & neck 
cancer patients to come together 
to hear about the latest 
developments in treatment and 
care and to discuss issues of 
mutual interest. The meeting was 
attended by around 80 – 100 
health professionals from across 
the multi-disciplinary team. 
Predominantly 
Clinical Nurse 
Specialists, 
Speech & 
Language 
Therapists, 
Radiographers 
and Dietitians  
Paper  
Joint Meeting of 
the Northern 
and Southern 
Clinical 
Excellence 
Networks for 
Head and Neck 
Cancer 
The purpose of this joint study 
day was to enhance participants’ 
knowledge of HPV in the context 
of head and neck cancer, critical 
issues in the management of 
acute and late swallowing 
toxicities and clinical trials aiming 
to ascertain optimal treatment 
delivery aimed at minimising late 
dysphagia.  
Predominantly 
Clinical Nurse 
Specialists, 
Speech & 
Language 
Therapists, 
Radiographers 
and Dietitians 
Paper 
Head and Neck 
Study Day – 
The Royal 
Marsden 
Hospital 
This meeting explored the issues 
surrounding cutaneous 
malignancy of the head and neck. 
It included: evidence-based 
lectures that focused on the 
management of a variety of skin 
and adnexal cancers including 
non-invasive diagnostic testing, 
Specialist 
Registrars and 
Consultants in 
Head and Neck / 
Maxillofacial / 
ENT / Plastic 
Surgery, 
Dermatologists, 
Paper  
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7.2.5 Materials and Measures 
Awareness of HPV 
Health professionals were asked to respond ‘yes’, ‘no’ or ‘don’t know’ to the question ‘Have you 
ever heard of HPV?’ Health professionals were also asked, ‘Have you ever looked for any 
information on human papillomavirus (HPV) and head and neck cancer?’ (yes; no; don’t 
remember) and ‘If yes, where have you looked?’ (other colleagues; internet; journals; media; 
conferences; professional organisations; medical textbooks; other; not applicable). 
  
the assessment of regional 
nodes, the role of adjuvant 
treatment and targeted therapies, 
a discussion on how surgeon-
level reporting might influence the 
delivery of head and neck cancer 
care.  
Clinical and 
Medical 
Oncologists, 
Pathologists and 
all members of 
the extended 
Head and Neck 
Team 
British 
Association of 
Head and Neck 
Oncologists 
Annual 
Scientific 
Meeting 2015 
Email addresses were searched 
for online for the names on the 
delegate lists.  
Clinical 
oncologists, 
surgeons, clinical 
nurse specialists, 
maxillofacial 
oncologists, ENT 
Online 
British 
Association of 
Oral and 
Maxillofacial 
Surgeons – list 
of hospital units 
Email addresses were searched 
for online for the names on the 
delegate lists. 
Oral and 
Maxillofacial 
Surgeons 
Online 
A list of 
contacts from a 
researcher in 
Ireland 
A researcher who works closely 
with my research group provided 
a list of health professionals who 
had been involved in previous 
research with them and were 
happy to be involved in future 
research. All health professionals 
were emailed.  
Clinical 
oncologists, 
surgeons, clinical 
nurse specialists, 
maxillofacial 
oncologists, ENT 
Online 
Multidisciplinary 
teams (MDT) 
Some health professionals 
distributed it to their hospital MDT 
All disciplines Online 
British 
Association of 
Head and Neck 
Oncology 
Nurses website 
The study was advertised on the 
website 
Head and neck 
cancer oncology 
nurses 
Online 
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Knowledge about HPV 
Health professionals were asked to respond ‘true’, ‘false’ or ‘don’t know’ to seven selected items 
from a validated measure of HPV knowledge including, ‘HPV often has no visible signs or 
symptoms’ and ‘Having many sexual partners increases the risk of getting HPV’ (Waller, Ostini, 
Marlow, McCaffery, & Zimet, 2013). This measure includes 16 items, but these items were 
selected because they were about HPV in general and were not specific to genital HPV. An 
additional five items specifically about HPV and HNC were included, such as ‘The oral tongue is 
the principal head and neck cancer site associated with HPV’ from a previous study (Malloy et 
al., 2013) which measured knowledge of HPV and HNC in head and neck surgeons. The 
reliability of the 12 item scale in this study sample was questionable (α=0.62) (George & 
Mallery, 2003). 
Experiences of discussing HPV with patients 
Four items assessed health professionals’ experiences of informing HNC patients about HPV: 
‘Thinking about the patients you treat with HPV-related head and neck cancer, how many of 
them have you told that their cancer was caused by HPV?’ (all; most; some; none) and ‘If you 
have informed a patient about their HPV status, have you discussed HPV in detail with a 
patient?’ (yes; no; not sure). Health professionals were also asked, ‘Generally, how willing are 
you to discuss HPV with your patients in the future?’ (not at all willing; not very willing; neither 
willing or unwilling; somewhat willing; very willing) and ‘If you discuss HPV during consultations, 
who usually initiates the discussion?’ (myself; patient; sometimes me, sometimes the patient; 
other; not applicable). These items were developed from the findings in chapter 6.  
Attitudes to discussing HPV with patients  
Thirty-two items assessed how health professionals think and feel about discussing HPV with 
patients’, such as ‘Discussing HPV with patients is important’ and ‘I am confident that I can 
initiate a discussion about HPV with a patient’, about discussing HPV with a patients’ partner 
present, such as ‘I would use a different approach if the patient was alone’, about their attitudes 
to discussing HPV such as, ‘I don’t want to pass judgement on patients’ sexual behaviour’ and 
how it would be helpful for them to keep up-to-date with the latest information about HPV such 
as ‘Have regular team updates’. Responses to these questions were on a 5-point likert scale 
(strongly disagree, disagree, neither agree nor disagree, agree, strongly agree). These items 
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were developed based on the findings from chapter 6 and existing literature (Malloy et al., 2013; 
McSherry et al., 2012).  
Socio-demographics 
Health professionals completed measures assessing their demographic and professional 
background developed for this study. These included: age, sex, country of training, ‘Did you 
train in the UK?’ (yes; no); ‘If no, where did you train?’ (open response); profession, ‘What is 
your profession?’ (surgeon; oncologist; specialist nurse; other); years in profession, ‘How many 
years have you been practicing in this profession?’ (open response) and their main place of 
work (hospital; hospice; rehabilitation centre; other).  
The full questionnaire can be found in Appendix 7.5.  
7.2.6 Analysis 
Descriptive statistics were analysed for each of the measures assessing awareness of HPV (n/%), 
knowledge of HPV (n/%), experiences of discussing HPV (n/%), attitudes and beliefs of health 
professional groups (n/%) and socio-demographics (n/%). Chi-square tests were used to compare 
individual items from the knowledge scale across health professional groups and ANOVA was 
used to compare across health professional groups for total scale score for knowledge of HPV 
and for their scores on each factor. 
Factor analysis was run with the items tapping into attitudes and beliefs to reduce the large 
number of items into factors which could be compared across groups more easily and 
meaningfully. Cronbach’s alpha was calculated for each factor. Pearson’s correlations were run 
to explore the relationships between the factors produced in the factor analysis. Independent t-
tests were used to compare differences on the factors by gender.  
When converting the paper-based questionnaire into an online version, the item ‘I am confident 
that I can reassure patients that HPV is a result of normal sexual behaviour’ was missed. This 
error was only noticed after 85 responses had already been received through the online survey, 
but was immediately rectified. In addition, the list of information sources in the online 
questionnaire included ‘medical textbooks’ as a response, whereas the paper-based version did 
not and so responses for this are only available for 193 participants.  
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7.2.7 Missing data 
Using an online survey meant that the questions could be set as being mandatory and 
participants could not move onto the next question unless they had answered each question. 
This meant for the participants who responded through the online survey (n=193), there were no 
missing data. For the remaining participants (n=67) who completed the paper survey, there was 
very little missing data (less than 1%) on all variables. Cases where missing values occurred 
were coded as missing and included in the analyses. An exception to this included the variable 
mentioned above which had missing responses for 85 participants online. This variable was 
included in the descriptive analyses, but excluded from the factor analysis.  
7.3 Results 
7.3.1 Sample characteristics 
The response rate is unknown, as the survey was sent through a number of cancer networks, 
organisations and also by personal email. The size of the cancer networks and organisations 
was not possible to track and some health professionals may have received the survey from 
multiple sources. I was therefore unable to calculate an accurate denominator and do not have 
any data available for those who chose not to respond to the survey. 260 health professionals 
from the UK and Ireland completed the survey. Table 7.2 shows the sample characteristics. The 
majority of the sample were female (59.6%, n=155), had trained in the UK (91.2%, n=237) and 
mostly worked in a hospital (97.3%, n=253). Surgeons were the profession most represented in 
the sample (36.9%, n=96). Some examples of professionals in the ‘other’ group of health 
professionals include dieticians, staff nurses, research nurses and radiographers (Table 7.3).  
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Table 7.2: Sample characteristics 
Characteristic Number of participants 
(n=260) 
Age [median(range)] 45 (21-66) 
Sex [n(%)] 
  Male 
  Female 
 
105 (40.4) 
155 (59.6) 
Profession [n(%)] 
  Surgeon 
  Oncologist 
  Specialist nurse 
  Speech and language therapist 
  Other* 
 
96 (36.9) 
28 (10.8) 
40 (15.4) 
59 (22.7) 
37 (14.2) 
Years practising in profession [median(range)] 17 (0-45) 
Trained in the UK [n(%)] 
  Yes 
  No 
 
237 (91.2) 
23 (8.8) 
Main place of work [n(%)] 
  Hospital 
  Other  
 
253 (97.3) 
7 (2.7) 
*includes dieticians, radiographers, staff nurses, research nurses (Table 7.3) 
 
The median age of the sample was 45, ranging from 21 years through to 66 years. Health 
professionals had worked in their profession for a median of 17 years, which ranged across the 
sample from 0 to 45 years. Almost all (99.2%) had heard of HPV and 94.2% said they had 
looked for information about HPV and HNC. The internet, medical journals and other colleagues 
were the top three places health professionals looked for information (Figure 7.1). 
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Table 7.3: Specific health professions in the ‘other’ group 
Professions in the ‘other’ group Number of participants (n=37) 
Dieticians 
Staff nurse 
Therapy radiographer 
Oral medicine 
Dentist 
Research nurse 
Allied health professional (did not specify) 
Unknown 
Specialist radiographer 
Research radiographer 
GP 
Radiologist 
Clinical psychologist 
Dermatologist 
Dental nurse specialist 
7 
7 
4 
3 
3 
2 
2 
2 
1 
1 
1 
1 
1 
1 
1 
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Figure 7.1: Frequency of information sources searched for HPV and head and neck cancer 
 
 
7.3.2 Knowledge of HPV  
The proportion of respondents giving the correct answer to each individual knowledge item is 
shown in Table 7.4, with statistical tests and p values, indicating differences by profession. 
Across all health professional groups, knowledge of HPV was high. Most participants correctly 
answered the item ‘a person could have HPV for many years without knowing it’ (97.7%, 
n=253), while the item ‘HPV usually goes away without needing any treatment’ was answered 
correctly by the fewest number of participants (45.8%, n=119).  
The mean knowledge score in the whole sample was 9.97 out of a possible 12. Total knowledge 
score was highest in oncologists, followed by surgeons, specialist nurses, speech and language 
therapists and the ‘other’ group of health professionals (F (4,246) = 10.48, p<0.001). Surgeons 
had a significantly higher mean knowledge score than the ‘other’ group of health professionals 
(p=0.001) and speech and language therapists (p<0.001); and oncologists had a significantly 
higher mean score than specialist nurses (p=0.017), speech and language therapists (p<0.001) 
and the ‘other’ group of health professionals (p<0.001). 
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For four of the items (Having many sexual partners increases the risk of getting HPV; the oral 
tongue is the principal head and neck cancer site associated with HPV; HPV is a relatively 
uncommon sexually transmitted infection; most patients with oral HPV experience symptoms of 
the infection), a greater proportion of surgeons and oncologists answered these correctly 
compared to speech and language therapists and the ‘other’ group of health professionals and 
for two of the items (HPV often has no visible signs or symptoms; HPV is very rare), a greater 
proportion of surgeons, oncologists and nurses answered these correctly compared to speech 
and language therapists and the ‘other’ group of health professionals.  
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Table 7.4: Correct responses (n/%) to individual knowledge of HPV items amongst all professional groups (n=260)* 
 Overall Surgeons Oncologists 
Specialist 
nurses 
Speech and 
language 
therapists 
Other 2 (p value) 
  (n=96) (n=28) (n=40) (n=59) (n=37)  
HPV often has no visible signs or 
symptoms  239 (91.9) 91 (94.8) 28 (100) 38 (95.0) 49 (83.1) 33 (89.2) 10.66 (0.031) 
HPV is very rare (F)  244 (93.8) 94 (97.9) 28 (100) 38 (95.0) 52 (88.1) 32 (86.5) 11.48 (0.022) 
A person could have HPV for many years 
without knowing it  253 (97.7) 95 (99.0) 27 (96.4) 38 (97.4) 56 (94.9) 37 (100) 3.77 (0.438) 
Having many sexual partners increases 
the risk of getting HPV  230 (88.8) 91 (94.8) 28 (100) 30 (76.9) 49 (83.1) 32 (86.5) 14.69 (0.005) 
HPV can cause cervical cancer  253 (97.3) 96 (100) 28 (100) 39 (97.5) 55 (93.2) 35 (94.6) 8.24 (0.083) 
HPV usually goes away without needing 
any treatment  119 (45.8) 47 (49.0) 17 (60.7) 18 (45.0) 25 (42.4) 12 (32.4) 5.85 (0.211) 
Most sexually active people will get HPV 
at some point in their lives  159 (61.9) 62 (65.3) 21 (75.0) 25 (65.8) 31 (52.5) 20 (54.1) 5.89 (0.207) 
HPV can cause oral cancer  240 (92.7) 85 (88.5) 27 (96.4) 38 (97.4) 53 (89.8) 37 (100) 7.92 (0.095) 
The oral tongue is the principal head and 
neck cancer site associated with HPV (F)  191 (93.7) 83 (86.5) 26 (92.9) 24 (60.0) 39 (66.1) 19 (52.8) 27.15 (<0.001) 
HPV is a relatively uncommon sexually 
transmitted infection (F)  201 (78.2) 84 (87.5) 27 (96.4) 26 (68.4) 40 (67.8) 24 (66.7) 19.02 (0.001) 
HPV is associated with a much improved 
prognosis for patients with head and neck 
cancer  
229 (88.1) 87 (90.6) 27 (96.4) 34 (85.0) 53 (89.8) 28 (75.7) 8.41 (0.078) 
Most patients with oral HPV experience 
symptoms of the infection (F)  223 (85.8) 91 (94.8) 27 (96.4) 34 (85.0) 42 (71.2) 29 (78.4) 20.96 (<0.001) 
Total knowledge score: mean(standard 
deviation) 9.97 (1.82) 10.48
ab (1.32) 11.11cde (0.83) 9.74 (1.85)c 9.22 (2.06)bd 9.14 (2.2)ae 
F(4,246)=10.48
, p<0.001 
*n varies slightly between items due to missing data; (F) indicates items for which ‘false’ is the correct response. All other items are true; abcde indicates which groups are 
significantly different from each other in post hoc tests. 
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7.3.3 Experiences of discussing HPV 
Across three of the items asking about the participants’ experiences of discussing HPV with 
their patients, a greater proportion of surgeons, oncologists and specialist nurses had more 
experience in telling their patients that their cancer was caused by HPV (2 (12)=78.49, 
p<0.001), had discussed this in detail with their patients (2 (8)=23.48, p=0.003) and they were 
more willing to discuss HPV with their patients in the future (2 (16)=51.79, p<0.001) compared 
to the speech and language therapists and the ‘other’ group of health professionals.  
Of the health professional groups, a greater proportion of oncologists reported initiating the 
discussion about HPV themselves (67.9%), followed by surgeons (54.8%) and specialist nurses 
(25.7%; 2 (12)=95.94, p<0.001). In those speech and language therapists who had discussed 
HPV with patients (n=40), 55% (n=22) reported that the patient had initiated the discussion. All 
health professional groups reported that sometimes it was them who initiated the conversation 
and sometimes it was the patient.  
7.3.4 Attitudes and beliefs about discussing HPV 
The results of chi-square tests for each individual survey item are included in Appendix 7.6. The 
questionnaire was designed to measure attitudes about discussing HPV with patients and I was 
interested in which latent variables may contribute to attitudes to discussing HPV. A principal 
components analysis (PCA) was conducted with orthogonal rotation (Varimax) (Field, 2009). 
PCA was conducted as this was an exploratory factor analysis and the goal was to reduce the 
larger set of variables into a smaller set of new variables. The conclusions from PCA are 
restricted to the sample collected and therefore may not be generalisable to other sample 
populations. Orthogonal rotation (Varimax) was used as the factors were expected to not be 
correlated with each other. The item, ‘I am confident that I can reassure patients that HPV is a 
result of normal sexual behaviour’ was not included in the analysis as there was missing data 
(as explained in section 7.2.6). After checking the correlation matrix, two items were removed (I 
would use a different approach than if the patient was alone; I don’t want to pass judgement on 
patients’ sexual behaviour) from the analysis due to low correlations with other items.  
PCA was conducted primarily and principal axis factoring was conducted to test the content 
validity of the factors. The analysis was also conducted forcing the items into five factors and 
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the items in each factor were assessed to examine whether they made sense in the factors they 
had been forced into, but the factors did not make as much sense as when loaded onto seven 
factors. Running the factor analysis both with orthogonal rotation (varimax) and oblique rotation 
(direct oblimin) also allowed the component correlation matrix to be assessed against whether 
the factors in the analysis were correlated or uncorrelated. As the component correlation matrix 
showed low correlations between the factors (Appendix 7.7), an orthogonal rotation was 
deemed appropriate. Cronbach’s alpha was run on each factor subscale.  
A PCA was conducted on 29 items with orthogonal rotation (Varimax) and found seven factors 
with eigenvalues over Kaiser’s criterion of 1 (Kaiser, 1960) and in combination explained 
63.03% of the variance (Table 7.5). The scree plot showed inflexions that would justify retaining 
these seven factors (Appendix 7.8). The Kaiser-Meyer-Olkin measure verified the sampling 
adequacy for the analysis, KMO=0.826. Bartlett’s Test of Sphericity (2 (406)=3241.44, p<0.001) 
indicated that the correlations were sufficiently large for PCA. An initial analysis was run to 
obtain eigenvalues for each component in the data. The items that cluster on the same factor 
suggest that factor 1 represents confidence in discussing HPV (α=0.89), factor 2 represents 
ways to facilitate the discussion of HPV (α=0.81), factor 3 represents negative attitudes to 
discussing HPV (α=0.75), factor 4 represents positive attitudes to discussing HPV (α=0.76), 
factor 5 represents personal barriers for health professionals not discussing HPV (α=0.71), 
factor 6 represents the need for more information (α=0.64) and factor 7 represents attitudes to 
talking about sexual relationships (α=0.83). All items had a factor loading of greater than 0.45 in 
their respective factors (Table 7.5). The item ‘I don’t have enough information on HPV-related 
head and neck cancer’ was reversed before computing the factors and calculating the mean of 
the items that loaded onto each of the factors, which was then taken as the score and reported 
in Table 7.6.  
Factor 1: Confidence in discussing HPV  
There were five items loading onto factor 1, with an overall mean score of 3.41 (scale 1-5) and 
standard deviation of 0.83, suggesting overall health professionals are fairly confident in 
discussing HPV. There was a significant positive correlation between knowledge (M=9.97, 
SD=1.82) and confidence (M=3.41, SD=0.83), r=0.435, p<0.001 (Table 7.7), and between years 
practising in their profession (M=18.11, SD=9.62) and confidence (M=3.41, SD=0.83), r=0.138, 
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p=0.027. There was a significant main effect across professional groups in their confidence 
talking about HPV (F(4,253) = 22.80, p<0.001; Table 7.6). Post hoc tests (Appendix 7.9) found 
significantly lower average scores in confidence in both speech and language therapists and 
health professionals in the ‘other’ group, compared to surgeons, oncologists and specialist 
nurses. Confidence was also significantly higher in males than in females (t(254.56) =6.26, 
p<0.001; Table 7.8). 
Factor 2: Ways to facilitate the discussion of HPV 
There were four items loading onto factor 2, with an overall mean score of 3.97 and standard 
deviation of 0.56, suggesting health professionals mostly agreed with the methods suggested 
as ways to facilitate the discussion of HPV. A significant main effect was found across health 
professional groups in their agreement to the methods suggested for facilitating the discussion 
of HPV (F (4,254) = 12.01, p<0.001; Table 7.6). Speech and language therapists and specialist 
nurses had greater average scores for methods to facilitate the discussion of HPV, indicating 
they agreed more strongly with the methods suggested. Post hoc tests found these scores to be 
significantly higher for both these health professional groups than in surgeons and oncologists 
and between the health professionals in the ‘other’ group and speech and language therapists 
(Appendix 7.9). 
Female health professionals had greater average scores for ways to facilitate the discussion of 
HPV (t(257)=-5.63 , p<0.001; Table 7.8), indicating they agreed more strongly with the methods 
suggested to facilitate the discussion of HPV than men.  
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Table 7.5: Summary of PCA results for the survey (n=254) 
Item 
Rotated 
factor 
loadings 
Eigenvalue 
(% of 
variance) 
α 
Confidence in discussing HPV 5.91 (20.4) 0.89 
I am confident that I can deal with patients’ questions 
and concerns when I talk to them about HPV  
0.848 
  
I am confident that I can explain HPV in a way that 
patients can understand 
0.848 
  
I am confident about initiating a discussion about HPV 
with a patient 
0.836 
  
I would feel confident discussing the transmission of 
HPV 
0.731 
  
I don’t have enough information on HPV-related head 
and neck cancer 
-0.614 
  
Ways to facilitate discussing HPV 5.07 (17.5) 0.81 
Have regular feedback of experiences with patients from 
colleagues 
0.784 
  
Have regular team updates 0.777   
Attend further training 0.754   
Attend conferences 0.733   
Negative attitudes to discussing HPV 1.85 (6.4) 0.75 
I don’t think patients want to know about HPV-related 
head and neck cancer 
0.756 
  
I don’t see any reason to discuss HPV with patients 0.731   
It is not necessary to tell patients whether they have 
HPV because it doesn’t change their clinical 
management 
0.669 
  
My patients are not concerned about the cause of their 
cancer 
0.657 
  
It is not necessary to tell patients that they have HPV 
because there’s no implications for behaviour  
0.556 
  
Positive attitudes to discussing HPV 1.63 (5.6) 0.76 
It is helpful for the patient to understand the cause of 
their head and neck cancer 
0.706 
  
Information about HPV is reassuring to patients 0.696   
It is important to convey the positive prognosis of HPV-
related head and neck cancer to patients 
0.640 
  
Discussing HPV with patients is important 0.610   
It is important to provide accurate information about 
HPV to the patient 
0.563 
  
Personal barriers to discussing HPV 1.5 (5.2) 0.71 
Talking to a patient about HPV is embarrassing 0.823   
Talking about HPV with a patient is not easy because 
it’s about their sexual behaviour 
0.792 
  
I don’t have enough time to discuss HPV-related head 
and neck cancer 
0.498 
  
I am not used to talking about sexual health with my 
patients 
0.466 
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Item 
Rotated 
factor 
loadings 
Eigenvalue 
(% of 
variance) 
α 
Need for more information 1.28 (4.4) 0.64 
HPV-related head and neck cancer is an evolving area 
so it’s hard to keep up-to-date 
0.655 
  
Having a clear plan of what I was going to say would 
help me discuss HPV with patients 
0.592 
  
I might not have all the answers to patients’ questions 
about HPV-related head and neck cancer 
0.585 
  
Having a leaflet to pass onto patients would help me 
discuss HPV with them 
0.524 
  
Attitudes to talking about sexual relationships 1.05 (3.6) 0.83 
I would feel comfortable talking about infidelity if this 
was raised 
0.815 
  
I would feel comfortable talking about their sexual 
relationship 
0.770 
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Table 7.6: Average score (mean/SD; 1-5) for factors reflecting attitudes and beliefs about discussing HPV with oropharyngeal cancer patients 
 Surgeons Oncologists Specialist 
nurses 
Speech and 
language therapists 
Other F (p value) 
 (n=96) (n=28) (n=40) (n=59) (n=37)  
Confidence in discussing HPV  3.74 (0.65)
ab 3.88 (0.58)cd 3.59 (0.74)ef 2.74 (0.82)ade 3.10 (0.80)bcf 22.80 (<0.001) 
Ways to facilitate discussion of HPV  3.78 (0.51)
ab 3.70 (0.57)cd 4.24 (0.55)ac 4.24 (0.46)bde 3.91 (0.52)e 12.01 (<0.001) 
Negative attitudes to discussing HPV 1.98 (0.53)
a 1.90 (0.47) 1.66 (0.55)abc 2.00 (0.42)c 2.02 (0.60)b 3.49 (0.009) 
Positive attitudes to discussing HPV 4.12 (0.50)
a 4.10 (0.46)b 4.52 (0.48)abc 4.26 (0.42) 4.18 (0.48)c 5.59 (<0.001) 
Personal barriers to discussing HPV 2.69 (0.71)
ab 2.76 (0.71) 2.30 (0.70)acd 3.05 (0.66)bd 2.81 (0.70)c 6.92 (<0.001) 
Need for more information  3.69 (0.52)
a 3.66 (0.60)b 3.95 (0.38) 4.18 (0.41)abc 3.77 (0.64)c 9.83 (<0.001) 
Attitudes to talking about sexual 
relationships 
2.79 (0.94)a 3.11 (0.97) 3.46 (0.81)abc 2.57 (0.92)b 2.82 (0.72)c 6.76 (<0.001) 
n for items varies slightly due to missing data 
abcdef indicates across rows which groups are significantly different from each other in post hoc tests (Appendix 7.9) 
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Table 7.7: Correlation matrix for all factors and total knowledge score and willingness to discuss HPV 
 Confidence 
in 
discussing 
HPV 
Ways to 
facilitate 
discussion 
of HPV 
Negative 
attitudes to 
discussing 
HPV 
Positive 
attitudes 
to 
discussing 
HPV 
Personal 
barriers to 
discussing 
HPV 
Need for 
more 
information  
Attitudes to 
talking about 
sexual 
relationships 
Knowledge Willingness 
to discuss 
HPV 
Confidence in 
discussing HPV  
1       
  
Ways to facilitate 
discussion of HPV  
-0.181** 1      
  
Negative attitudes to 
discussing HPV 
-0.097 -0.235** 1     
  
Positive attitudes to 
discussing HPV  
0.132* 0.307** -0.508** 1    
  
Personal barriers to 
discussing HPV 
-0.484** 0.050 0.244** -0.251** 1   
  
Need for more 
information  
-0.415** 0.431** -0.213** 0.156* 0.294** 1  
  
Attitudes to talking 
about sexual 
relationships 
0.473** -0.066 -0.133* 0.193** -0.485** -0.206** 1 
 
 
Knowledge 0.435** -0.107 -0.071 -0.033 -0.164** -0.154* 0.183** 1  
Willingness to discuss 
HPV 
0.582** -0.059 -0.232** 0.201** -0.456** -0.149* 0.381** 0.347** 1 
*correlation is significant at the 0.05 level (2-tailed) 
**correlation is significant at the 0.01 level (2-tailed)  
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Table 7.8: Independent t-tests of factors by gender 
Factor Males (mean;SD) Females (mean;SD) Significance 
Confidence in 
discussing HPV  
3.76 (0.64) 3.18 (0.87) <0.001 
Ways to facilitate 
discussion of HPV  
3.74 (0.54) 4.12 (0.52) <0.001 
Negative attitudes to 
discussing HPV 
1.98 (0.54) 1.90 (0.51) 0.246 
Positive attitudes to 
discussing HPV 
4.12 (0.48) 4.28 (0.48) 0.008 
Personal barriers to 
discussing HPV 
2.71 (0.74) 2.76 (0.72) 0.604 
Need for more 
information  
3.68 (0.53) 3.96 (0.52) <0.001 
Attitudes to talking 
about sexual 
relationships 
2.80 (0.96) 2.93 (0.91) 0.292 
 
Factor 3: Negative attitudes to discussing HPV  
There were five items loading onto factor 3, with an overall mean score of 1.93 and standard 
deviation of 0.53, suggesting health professionals disagreed with the items about why they 
would not discuss HPV. Negative attitudes for not discussing HPV differed significantly across 
the health professional groups (F (4,252) = 3.49, p=0.009; Table 7.6). Post hoc tests found 
surgeons, the ‘other’ group of health professionals and speech and language therapists to have 
significantly higher average scores for this factor than specialist nurses, indicating they had 
more negative attitudes towards discussing HPV (Appendix 7.9). No significant differences were 
found across gender and negative attitudes to discussing HPV (Table 7.8).  
Factor 4: Positive attitudes to discussing HPV 
There were five items loading onto factor 4, with an overall mean score of 4.22 and standard 
deviation of 0.49, suggesting health professionals had positive attitudes towards discussing 
HPV. The factor representing positive attitudes to discussing HPV were significantly different 
across professional groups (F (4,254) = 5.59, p<0.001; Table 7.6), with scores being higher in 
specialist nurses than surgeons, oncologists and the ‘other’ health professional group (Appendix 
7.9). 
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Female health professionals scored higher than male health professionals (t(257)=-2.68, 
p=0.008; Table 7.8). 
Factor 5: Personal barriers to discussing HPV 
There were four items loading onto factor 5, with an overall mean score of 2.74 and standard 
deviation of 0.73, suggesting some level of disagreement from health professionals about 
personal barriers to discussing HPV. Personal barriers represented in the factor included talking 
about HPV being embarrassing and HPV not being easy to talk about because it’s about their 
sexual behaviour. A significant main effect was found (F (4,253) = 6.92, p<0.001; Table 7.6), 
with surgeons, speech and language therapists and the ‘other’ group reporting significantly 
higher scores for personal barriers than specialist nurses and surgeons reporting significantly 
lower scores for personal barriers than speech and language therapists (Appendix 7.9). No 
significant gender differences were found for this factor (Table 7.8).  
Factor 6: The need for more information 
There were four items loading onto factor 6, with an overall mean score of 3.85 and standard 
deviation of 0.54, suggesting health professionals agreed with the need for further information 
about HPV. The factor representing the need for more information showed a significant main 
effect between health professional groups (F (4,254) = 9.83, p<0.001; Table 7.6). Speech and 
language therapists had a significantly greater need for information than surgeons, oncologists 
and the ‘other’ group of health professionals (Appendix 7.9).    
Females expressed a greater need for information than men (t(257)=-4.30 , p<0.001; Table 
7.8). 
Factor 7: Attitudes to talking about sexual relationships 
There were two items loading onto factor 7, with an overall mean score of 2.88 and standard 
deviation of 0.93, suggesting some level of disagreement with these items and that health 
professionals are not comfortable talking about sexual relationships. The final factor which 
represented health professionals’ attitudes in talking about patients’ sexual relationships, 
showed a significant main effect across health professional groups (F (4,254) = 6.76, p<0.001; 
Table 7.6), with specialist nurses being significantly more comfortable than surgeons, the ‘other’ 
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health professional group and speech and language therapists (Appendix 7.9). No significant 
gender differences were found for this factor (Table 7.8). 
Correlations among factors and other variables 
The correlation matrix (Table 7.7) shows significant associations between most of the factors. 
Most notably, knowledge was significantly positively associated with confidence (r=0.435, 
p<0.001), reasons it is important to discuss HPV (r=0.132, p=0.034), willingness to discuss HPV 
in the future (r=0.347, p<0.01) and negatively associated with personal barriers to discussing 
HPV (r=-0.164, p<0.01). Willingness to discuss HPV in the future was positively associated with 
confidence (r=0.582, p<0.01), reasons it is important to discuss HPV (r=0.201, p<0.01), comfort 
in talking about sexual relationships (r=0.381, p<0.01) and negatively associated with personal 
barriers to discussing HPV (r=-0.456, p<0.01). Personal barriers to discussing HPV were also 
negatively associated with confidence (r=-0.484, p<0.01), reasons it is important to discuss HPV 
(r=-0.251, p<0.01), comfort in talking about sexual relationships (r=-0.485, p<0.01) and 
positively associated with the need for more information (r=0.294, p<0.01). 
7.4 Discussion 
This study measured knowledge, attitudes and beliefs about discussing HPV-OSCC with 
patients among health professionals in the UK and Ireland. Almost all (99.2%) had heard of 
HPV and 94.2% said they had looked for information about HPV and HNC. The internet, 
medical journals and other colleagues were the top three places health professionals looked for 
information, supporting findings from previous research (Daley et al., 2011). Oncologists had 
the greatest knowledge, followed by surgeons, specialist nurses, speech and language 
therapists and the health professionals in the ‘other’ group, demonstrating a need to increase 
knowledge among allied health professionals. The item ‘HPV usually goes away without 
needing any treatment’ was the item answered correctly by the fewest number of participants 
overall and suggests health professionals may incorrectly believe that HPV always needs 
treating. The proportion of surgeons answering the specific HNC questions correctly was slightly 
lower than in a previous study with head and neck surgeons (Malloy et al., 2013), but 
knowledge was high in both studies.  
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Supporting previous research about discussing HPV in the context of the HPV vaccination, 
health professionals in this study with greater knowledge also had the confidence to discuss 
HPV and were those most willing to do so in the future (Hopkins et al., 2009). Factors with the 
greatest association with willingness to discuss HPV in the future were confidence, comfort in 
talking about sexual relationships, knowledge and positive attitudes to discussing HPV. Health 
professionals reporting personal barriers to discussing HPV were less willing to discuss HPV, 
had lower knowledge of HPV and reported the need for more information about HPV. The 
results from this study identify areas which could be targeted to increase health professionals’ 
confidence to discuss HPV and also their willingness to do so. To increase health professionals’ 
confidence in discussing HPV, improving knowledge and meeting their information needs, as 
well as addressing their personal barriers for not discussing HPV and their negative attitudes 
towards discussing HPV, could result in more health professionals discussing HPV with their 
patients.  
A greater proportion of allied health professionals agreed that having a leaflet, regular team 
updates, regular feedback and attending training would be useful, suggesting that they 
recognise there is a gap in their knowledge and they are keen to address this. This is supported 
by previous research with oral health professionals, finding that patient education materials 
increase comfort levels during patient interaction (Daley et al., 2011). Previous research with 
oral health professionals has shown great enthusiasm for continued education (Jaber et al., 
2012; Malloy et al., 2013; Maybury et al., 2012). Educational materials could be used in future 
interactions which may help increase knowledge and comfort levels about having these 
conversations with patients. Didactic approaches such as information booklets, videos and 
interactive lectures have been found to be effective at increasing knowledge in dentists 
(Hertrampf et al., 2010). These findings demonstrate that it is not only oral health professionals 
who are enthusiastic to continue their education, but medical health professionals, especially 
allied health professionals, are also keen to address gaps in their knowledge.  
Some factors demonstrated gender differences between health professionals, where females 
were less confident, more strongly agreed with the methods to facilitate discussing HPV, had 
more positive attitudes to discussing HPV and had more information needs than males. As 
some health professions are more likely to be female-orientated professions and some male, 
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this could affect the differences in results between the health professional groups. For example, 
speech and language therapists are more likely to be female than male (Boyd & Hewlett, 2001), 
therefore the results reflecting gender differences could explain why speech and language 
therapists exhibit these differences in comparison to some of the more male-oriented 
professions such as the surgeons.  
There are several models of behaviour change that could be useful when thinking about health 
professionals discussing HPV with their patients, e.g. the Information-Motivation-Behaviour 
(IMB) model or Capability Opportunity Motivation-Behaviour (COM-B) model. The COM-B 
model is particularly useful because it can be applied to a broad range of behaviours. Although 
this model was not used to design the survey, due to the survey being developed based on the 
results of the qualitative interview study (study 3) and other relevant surveys, the results from 
this study appear to fit the components of the COM-B model (Michie et al., 2011). As previously 
discussed in section 3.4.3.1, this model asserts that capability, opportunity and motivation all 
interact to result in a behaviour, which then impacts upon the three components. In this context 
the model may help understanding of the skills health professionals need to discuss HPV with a 
patient (Figure 7.2) and identify which components and which health professional groups could 
be targeted for future intervention and training.  
Assessing the results from this study against the components of the COM-B model show that 
surgeons and oncologists have the capability, motivation and opportunity to discuss HPV, and 
that they are discussing HPV. Speech and language therapists and other allied health 
professionals who do not hold all the components of the COM-B model, are not discussing 
HPV.  
The first component of the COM-B model is capability. Knowledge was shown to be the highest 
in surgeons and oncologists, and lowest in speech and language therapists and the ‘other’ 
group of health professionals. The questions assessing capability demonstrated surgeons and 
oncologists to have a greater confidence about discussing HPV than the other health 
professional groups. Knowledge was also found to be associated with confidence in discussing 
HPV, with previous research in dentists finding associations between level of confidence and 
the performance of oral examinations or providing advice to patients about risk habits (Saleh et 
al., 2014).  
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The second component is motivation. The questions in the survey that assessed attitudes to 
discussing HPV (motivation), showed speech and language therapists and health professionals 
in the ‘other’ group reported more personal barriers to discussing HPV such as talking about 
HPV being embarrassing, and these groups were less willing to discuss HPV. Specialist nurses 
were the most comfortable talking about sexual health with patients and feel comfortable talking 
about their patients’ sexual relationships.  
The third component is opportunity. Greater proportions of oncologists, surgeons and specialist 
nurses than allied health professionals in this sample had told all or most of their patients their 
cancer was caused by HPV, had discussed HPV in detail with those patients, and were more 
willing to discuss HPV in the future. These health professionals are ideally situated to have this 
discussion with patients as they are likely to see patients more frequently than allied health 
professionals. As there was still a proportion of allied health professionals who had discussed 
HPV in detail with these patients, this demonstrates that it is possible for questions to come up 
at any point during patients’ diagnosis, treatment and aftercare and has been found previously 
(Catt, Fallowfield, Jenkins, Langridge, & Cox, 2005). It is therefore important that all health 
Opportunity 
Acceptability and 
time to discuss HPV 
 
Capability 
Knowledge and skills 
to discuss HPV and 
HNC 
Motivation 
Attitudes towards the 
importance of 
discussing HPV 
Behaviour change 
Discussing HPV with 
patients diagnosed 
with HPV-OSCC 
Figure 7.2: The COM-B model in the context of these results 
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professionals dealing with these patients feel informed enough, have the necessary skills, are 
motivated enough, and have the opportunity to have these discussions with patients. Further 
training could be targeted at increasing these three components in these health professional 
groups, to help facilitate the discussions of HPV with patients. 
Reasons suggested in chapter 6 for not disclosing HPV as the cause of a patient’s cancer 
support those found in previous research of HPV having no clinical relevance and there being a 
lack of available prevention and treatment for HPV (Turbitt, Wiest, Halliday, Amor, & Metcalfe, 
2014). The Theoretical Domains Framework (TDF) (Michie et al., 2005) has been used 
previously with regards to health professionals discussing HPV in the cervical cancer context as 
a basis for developing a theory-based intervention to support primary care practitioners 
(McSherry et al., 2012). The TDF was developed to synthesise the key constructs used in 
relevant behaviour change theories and can be used to identify what behaviours need to 
change with the aim of developing behaviour change interventions. The TDF would be a useful 
framework to use in future research designed to identify which HPV-related clinical behaviours 
need to be targeted and to determine what influences these behaviours, to develop an 
intervention to support HNC health professionals in their discussions about HPV with patients.  
7.5 Strengths and limitations 
As the factors all had high reliability, the items used in this survey could be replicated in other 
studies. The range and sufficiently powered large sample of health professionals completing the 
survey helped in the understanding of different health professionals’ positive and negative 
attitudes for discussing HPV with their patients. The results from this survey support those 
found in chapter 6 and give more information about specific areas that could be targeted with 
health professionals working with HNC patients. Due to the nature of the delivery of how the 
survey was sent to participants, it was not possible to calculate a response rate and therefore it 
is difficult to assess the representativeness of the responses. Further research would also be 
needed to determine whether these results extend to other countries, beyond the UK and 
Ireland. As some of the participants completed the survey at study days, it is possible that some 
of them completed it following the talks given that day and this could have influenced their 
responses. Participants were encouraged to complete these at the beginning of the day, before 
talks commenced. The ‘other’ professional group contained a mix of health professionals and it 
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may have been the case that experiences and attitudes differed within the group, but each 
profession within this group was too small to be able to conduct any meaningful analysis.  
PCA as a method of factor analysis has some limitations and the results can be subjective. For 
example, in this study one of the factors included only two items. A number of arbitrary rules are 
followed in PCA and there are a number of stages where I had to use my own discretion in the 
interpretation of factors, in the decision of how many factors to retain and which items load onto 
which factors. As I did this in collaboration with my supervisors, this should have helped validate 
my interpretations.  
The study was cross-sectional and therefore causation cannot be determined. The items 
included in the survey were developed from the findings of chapter 6 and from previous 
literature and so were not validated. Many of the constructs were measured using only one 
item, such as willingness to discuss HPV in the future. Although some of the questions 
assessing participants’ knowledge were from a validated scale, not all of the questions were 
taken from validated scales and the internal reliability was found to be questionable and so the 
results should be interpreted cautiously. Future work should look at validating a measure 
assessing knowledge of HPV-related HNC.  
7.6 Conclusion 
This study shows that knowledge, attitudes and beliefs about HPV-related HNC, vary across 
health professionals, with surgeons, oncologists and specialist nurses having more experiences 
discussing HPV-related HNC with their patients. These results suggest that knowledge is an 
important component to discussing HPV and could be targeted in future training with health 
professionals to increase their confidence in discussing HPV. The COM-B model could be a 
useful model on which to base future training and interventions to equip all health professionals 
with the vital components to be able to discuss HPV-related HNC with their patients. Chapters 6 
and 7 have provided insight into the impact that the emergence of HPV-OSCC has had on 
health professionals’ clinical practice and their experience of discussing HPV. Health 
professionals have their own attitudes about discussing HPV and beliefs about what patients 
want to know and so it is important to explore directly with HPV-OSCC patients what they want 
to know, as well as their partners who are also shown to be significantly affected. 
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CHAPTER 8. A QUALITATIVE INTERVIEW STUDY WITH 
PATIENTS AND THEIR PARTNERS (STUDY 5) 
8.1 Introduction 
As the previous chapters have presented, the potential for psychosocial distress in patients with 
HPV-oropharyngeal squamous cell carcinoma (HPV-OSCC) is high. This is due to the diagnosis 
of cancer itself and the potential of disfigurement and dysfunction after treatment. In addition, a 
diagnosis of cancer caused by HPV, a sexually transmitted infection, may also contribute. Not 
only does this impart a great burden on the patient, but also on the partner of the patient, who 
may inevitably become a carer for their partner. Partners are usually involved from the 
beginning, as they may be the first person the patient discloses their illness to and the rates of 
psychological distress in partners of HNC patients have been shown to be higher than any other 
type of cancer (Manne & Badr, 2010). Summarised in chapter 2 is previous research with the 
partners or carers of HNC patients which has shown them to have their own informational 
needs alongside their fears and concerns. As chapter 6 presented, sexual relationships with 
partners may also be affected due to the sexual transmission of HPV.  
As patients diagnosed with HPV-OSCC are typically younger, they may also face greater 
psychosocial challenges associated with long-term survivorship following treatment. HPV-OSCC 
patients will be required to manage family life, potentially with young children, while managing 
the challenges associated with the diagnosis and treatment of their cancer (Gold, 2012). As 
treatment for HNC has been shown to be associated with significant dysfunction and 
disfigurement, HPV-OSCC patients may need to manage these consequences of treatment 
long into survivorship. Findings from chapter 6 suggested that these patients also seek 
expedited rehabilitation for their lives to return to normal as quickly as possible.   
To date, there has been little research examining the impact of a HPV-OSCC diagnosis on 
patients and none of these have examined the impact on the patients’ partners. The increasing 
incidence of HPV-OSCC worldwide highlights the need for research exploring the impact of the 
diagnosis on patients and their partners to enable us to understand the implications of the 
diagnosis, and possibly help alleviate any anxiety by developing an information and support 
CHAPTER 8 – INTERVIEWS WITH PATIENTS AND PARTNERS 
216 
 
package for patients and their partners. There is a need for clear and consistent health 
messages aimed at diminishing stigma, fear and self-blame (Daley et al., 2010). This interview 
study (study 5) aimed to explore the psychosocial impact of being diagnosed with HPV-OSCC 
on both the patient and the patient’s partner. This study contributes to the seventh and eighth 
research questions:  
7) What is the psychosocial impact on patients being diagnosed with HPV-OSCC? 
8) What is the psychosocial impact on partners of patients who have been diagnosed with 
HPV-OSCC? 
8.2 Establishing a Participatory Advisory Group 
Prior to beginning recruitment for study 5, I established a Participatory Advisory Group (PAG). 
The involvement of patients and the public in research and development is increasingly being 
recognised as important, with the Department of Health supporting the role of the public in the 
processes of health research (Department of Health, 1999). Patients and the public can provide 
different perspectives to researchers about what research is important and the best strategies 
for achieving the research outcomes. The National Health Service (NHS) has a clear policy 
directive to involve patients and the public in research and development (Department of Health, 
1999) and it is encouraged to support ethical applications for research with NHS patients. Due 
to the planned involvement of NHS patients in some of my research, I decided to establish an 
advisory group to ensure high quality acceptable and clinically relevant research. 
This PAG was established prior to designing study 5 with the intention of members being 
involved in testing and commenting on the acceptability of research materials and procedures 
for this study and future research studies. Recruitment to the PAG was approved by the UCL 
Research Ethics Committee, reference 4577/002 (Appendix 8.1).  
8.2.1 Recruitment of PAG 
An advert was placed on The Throat Cancer Foundation website in August 2014 (Appendix 8.2) 
to recruit HNC patients ‘to help us try out research materials for studies exploring experiences of 
being diagnosed with head and neck cancer’. Responses to the advert were received until 
August 2015. Potential participants were advised that they could be asked to take part in 
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practice interviews or focus groups, comment on questionnaires which could be used in larger 
studies, and/or advise on future research studies (Appendix 8.3). Participants were eligible if 
they had been diagnosed with HNC and were able to communicate in English. Interested 
participants were asked to complete a short online questionnaire and consent form (Appendices 
8.4 and 8.5). The online screening questionnaire helped determine their eligibility for different 
pilot studies and provided information about what types of pilot studies they were happy to be 
involved in. The participants gave their contact details at the end of the questionnaire so that I 
was able to contact them regarding involvement in pilot studies or another PAG activity, and this 
also indicated consent.  
8.2.2 Characteristics of the PAG 
Nineteen patients completed the screening questionnaire. Three patients did not include their 
contact details and had to be removed from the PAG list. Patients were diagnosed between 
October 1999 and December 2014. In terms of treatment, one patient received surgery alone, 
nine patients had surgery combined with chemoradiation, one patient had surgery combined 
with radiation, one patient received only radiation and four patients received only 
chemoradiaton. There was an even split of male and female patients, most were married, with a 
mix of employment status, most being either employed full-time, disabled or too ill to work or 
retired. Six of the 16 patients knew that their tumour was tested and confirmed as HPV-positive. 
Characteristics of the PAG are shown in Table 8.1.   
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Table 8.1: Characteristics of the PAG 
 Patient characteristics (n=16) 
Age at diagnosis [median (range)]  53 (34-67) 
Sex [n]  
Male 8 
Female 8 
Marital Status [n]  
Married/Civil Partner 9 
Long term partner but not married 3 
Widowed 1 
Separated 1 
Single 2 
Employment status [n]  
Employed full-time 4 
Employed part-time 1 
Retired 5 
Disabled or too ill to work 4 
Carer 1 
Full-time homemaker 1 
Primary cancer [n]  
Oropharynx 1 
Larynx 2 
Base of tongue 5 
Throat 2 
Tonsil 6 
Smoking status [n]  
Current 2 
Former 9 
Never 5 
Knew their cancer was HPV-positive [n] 6 
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8.3 Methods: Main study  
8.3.1 Participants  
Eligible participants were identified by medical staff from patient’s medical records at Aintree 
University Hospital, Liverpool and Brighton and Sussex University Hospital, Brighton. Patients 
were also going to be recruited through University College London Hospital, but due to 
organisational difficulties, no patients were recruited from this site. Patients were eligible if: they 
tested positive for HPV; were at least one year post diagnosis of HPV-OSCC; they could 
communicate in English both orally and through writing; and they were able to give informed 
consent. Partners were eligible if: their partner (the patient) met the patient inclusion criteria; 
they were also able to communicate in English both orally and through writing; and they were 
able to give informed consent. Eligibility was established using the patients’ medical records by 
members of staff at Aintree University Hospital and Brighton and Sussex University Hospital. 
Ethical approval was granted by South East London NHS Research Ethics Committee 
(Reference: 15/LO/0803) (Appendix 8.6).  
8.3.2 Materials 
The interviews followed a topic guide that I developed using the existing literature on patient 
experiences and previous work on HPV and cervical cancer. The interviews began with an open 
question about the participant’s experience of being diagnosed or of their partner being 
diagnosed. The rest of the interview was prompted by responses to this question, but included 
questions about symptoms, diagnosis, any psychosocial impact and information needs 
(Appendices 8.7 and 8.8). 
Piloting 
PAG members were recruited to the pilot study on the basis of their responses to the online 
questionnaire. If participants had indicated they knew that their tumour had been tested for HPV 
and that this was positive, they were contacted about taking part in pilot interviewing to test the 
interview topic guide for the main study. Three patients were contacted and two responded to 
say they were interested in taking part. These patients also indicated that they had partners and 
were asked if they would be happy if they also took part. Consent was obtained from the 
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partner. One partner took part and the other patient’s partner was not available at the time of 
the interview. As all participants were happy with the questions asked in the interview and did 
not think any changes needed to be made, the interviews of these three participants were 
included in the larger study. 
8.3.3 Procedure  
Sixty eligible participants at Aintree University Hospital and 29 eligible participants at Brighton 
and Sussex University Hospital were invited to take part in the study through an information 
pack sent in the post. Similar protocols were run at each NHS site (Figure 8.1). The information 
pack contained an invitation letter addressed from the hospital, an information sheet, a short 
questionnaire and a consent form with a Freepost envelope enclosed for the return of the 
questionnaire, consent form and contact details form (Appendices 8.9, 8.10, 8.11, 8.12). If 
patients had not returned their questionnaire and consent form after three weeks, a second 
invitation letter (Appendix 8.13) with the information pack was sent out. The participants were 
aware that I was a researcher studying for a PhD and was interested in their experiences of 
being diagnosed with HPV-OSCC or of their partner being diagnosed with HPV-OSCC, which 
was explained on the study information sheets (Appendices 8.10, 8.14) provided to them prior 
to them consenting to take part.  
If patients had indicated on their questionnaire they knew that their tumour had been tested for 
HPV and that this was positive, primarily it was those patients whom I contacted about taking 
part. Once the patient had returned their contact details form, I contacted them to ask if they 
had any questions about the study and then if they were happy to take part, I arranged an 
interview date with them. Patients indicated on their consent form whether they were willing for 
their partner to be contacted to take part in the study. When I contacted the patient, I asked 
those who had indicated they would be happy for their partners to be contacted whether they 
were happy for me to send their partner an information pack in the post (Appendix 8.9, 8.14, 
8.15, 8.16). Patients were still able to take part regardless of whether they had a partner or not, 
or if their partner was not taking part. I contacted partners who had been sent an information 
pack in the post after giving them time to read it and if they were happy to take part, arranged 
an interview with them for the same time as the patient. Consent from partners was collected at 
the time of the interview. My relationship with the participants prior to the interviews involved 
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contacting them to arrange the interviews and confirming the interviews closer to the interview 
date. 
I carried out in-depth interviews with the patients and, where possible, their partners. Patients 
and their partners were interviewed separately. Interviews with patients took place face-to-face 
at their home (n=18) or over the telephone (n=2) and lasted 35-84 minutes. Interviews with 
partners took place face-to-face at their home (n=11) or over the telephone (n=1) and lasted 26-
55 minutes. One interview that was arranged had to be cancelled for personal reasons of the 
participant. I conducted and digitally recorded all the interviews. They were transcribed verbatim 
by an external transcription company as soon as they has been conducted. Emerging themes 
from the interview transcripts were noted simultaneously with carrying out the interviews. Once I 
was satisfied that no new themes had emerged from three consecutive interviews, I took this to 
indicate that saturation had been achieved. Data collection ceased at this point (Francis et al., 
2010). For the same reasons as previously explained in chapter 6, transcripts were not returned 
to the participants for comment or correction. Information about patients’ diagnosis were 
obtained from their medical records.  
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Figure 8.1: Recruitment at Aintree Hospital (A) and Brighton and Sussex Hospital (B) 
  
YES 
An interview was 
arranged with the 
partner for the 
same day as the 
patient if possible 
(n=8A; 3B)   
NO 
No further 
contact was 
made  
(n=2A; 1B) 
Somerset Cancer Database screened for eligible 
patients (A) 
Eligible patients drawn from a list of patients 
accumulated by oncologist (B) 
Eligible patients were assigned an ID number and 
sent the information pack: invitation letter, 
information sheet, consent form, questionnaire 
(n=60A; 29B) 
Patient returned the consent form, questionnaire 
and contact details via post  
(n=7A; 4B) 
YES 
Patient contacted to arrange an 
interview 
(n=14A; 6B) 
Patient was asked if they think their 
partner would like to take part 
(n=8A; 3B) 
An interview was arranged with the 
patient   
(n=12A; 6B) 
NO 
A second invitation letter was sent 
after 3 weeks  
(n=53A; 25B) 
Partner would like to take part in the 
interview 
(n=8A; 3B) 
Patient returned 
the consent 
form and 
contact details 
via post  
(n=7A; 9B) 
NO 
No further 
contact was 
made  
(n=46A; 16B) 
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8.3.4 Analysis  
The audio recordings of the interviews were sent to a transcription company to transcribe. On 
their return, I uploaded the transcripts to NVivo 11 (QSR, 2015). Data was coded into common 
themes in NVivo. Dr Jo Waller and Dr Alice Forster read 10% of the transcripts each (n=3) and 
developed codes independently. All coding was then discussed and any disagreements were 
resolved before I coded all of the transcripts. Once all of the data had been coded in NVivo, the 
framework matrix included all participants in rows and themes in columns, with the cells 
showing summarised data. This enabled me to view the sections coded for each participant and 
view which themes were most prevalent. This method is known as Framework Analysis (Ritchie 
& Spencer, 1994) and was chosen because it aims to generate themes and make comparisons 
both within and between cases and is not aligned with a particular theoretical approach (Gale et 
al., 2013). Patients and partners were all treated as separate participants as I was interested in 
each participant’s individual experience. Dr Laura Marlow read a further 10% of the transcripts 
and checked her agreement against the coding framework. 
This analysis of data allowed me to gain an understanding of the experiences and psychosocial 
impact of a diagnosis of HPV-OSCC on both the patient and their partner.  
8.4 Results 
Out of 89 patients sent an information pack, 27 sent their consent forms back, giving a response 
rate of 30% (Figure 8.1). The characteristics of the non-responders are not available as I had no 
access to any of their data due to them being approached by the clinical teams at each NHS 
site. I interviewed 18 patients and 11 partners across two NHS sites between September and 
November 2015. Interviews with two patients and one partner were included from the pilot study 
and were interviewed in September and October 2014. Patients were diagnosed between June 
2011 and September 2014, with an average time since diagnosis being 22.85 months (range 
12-53 months). All were diagnosed with a primary tumour in either their tonsil (n=14) or base of 
tongue (n=5) and all except one at the most advanced stages of IV A to C. In terms of 
treatment, one patient received surgery alone, five patients had surgery combined with 
chemoradiation, five patients had surgery combined with radiation and eight patients received 
only radiation. The medical records for one patient were not obtainable. The majority of the 
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patients were male, white British, married or cohabiting, with a mix of employment status, most 
being either employed full-time or retired. Characteristics of the patients are shown in Table 8.2 
and partners in Table 8.3.  
Table 8.2: Patient characteristics 
 Patient characteristics (n=20) 
Age at diagnosis [median (range)]  57 (40-82) 
Age at interview [median (range)] 59 (41-83) 
Sex [n]  
Male 14 
Female 6 
Ethnicity [n]  
White British 19 
Other 1 
Marital Status [n]  
Married/Cohabiting 14 
Widowed 2 
Divorced 2 
Separated 1 
Single 1 
Employment status [n]  
Employed full-time 7 
Employed part-time 2 
Unemployed 1 
Retired 8 
Disabled or too ill to work 2 
Knew their cancer was HPV-positive [n] 12 
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Table 8.3: Partner characteristics 
 Partner characteristics (n=12) 
Age [median (range)]  59.5 (45-74) 
Sex [n]  
Male 2 
Female 10 
Ethnicity [n]  
White British 12 
Marital Status [n]  
Married/Civil Partner 12 
Employment status [n]  
Employed full-time 1 
Employed part-time 5 
Retired 5 
Disabled or too ill to work 1 
Knew partner’s HPV status 5 
 
A large quantity of data emerged from the interviews and the entire framework which includes 
the themes generated from all participant interviews is presented in Figure 8.2. Themes 
interpreted from the data which are not referred to in this chapter relate to experiences with the 
healthcare system, person factors (e.g. lifestyle, comorbidities) and other cancer-related 
impacts. Experiences with the healthcare system reflected participants’ direct experiences with 
healthcare professionals and their experiences of symptoms, diagnosis and treatment for which 
participants gave much factual detail. Person factors reflected other individual aspects which did 
not impact upon perceptions of HPV-OSCC. The final theme reflected other ways in which the 
diagnosis had an impact, which were not psychological. These themes do not relate directly to 
the research question and therefore are not discussed here.  
The data were examined to understand the psychosocial impact of being diagnosed with HPV-
OSCC, looking at individual experiences for both the patient and their partner, and to explore 
how this varied between participants. Initial reactions to being diagnosed with cancer included 
shock, panic, being destined to the diagnosis, thinking they were going to die, feeling vulnerable 
and frightened. A small number of patients said that the diagnosis was not a shock and a few of 
them felt like it was not happening to them.  
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For this thesis I have focused on the themes and subthemes that related to the aim of the study 
which was to explore the psychosocial impact of being diagnosed with HPV-OSCC for both the 
patient and the patient’s partner. Therefore this chapter focuses on: beliefs about the cause of 
their cancer, disclosure of results to others, being diagnosed with HPV, prognosis, questions 
and information about HPV and their cancer, the psychosocial impact and impact on others. 
Two case studies are included to provide context of two patients who were aware of being HPV-
positive and demonstrate how the context is relevant to the impact of being diagnosed with 
HPV-OSCC (Yin, 2003). For the themes which focus on HPV, the data presented here focuses 
on the 12 patients and their partners who knew they were HPV-positive. Where quotes are 
used, participants are described using their gender (M/F), unique identifying number and age. 
Partners are distinguished with the use of a ‘P’ at the end of the unique identifying number.    
  
CHAPTER 8 – INTERVIEWS WITH PATIENTS AND PARTNERS 
227 
 
Included themes 
Beliefs about the cause of their cancer 
1 HPV or virus 
2 Does not know the cause of their 
cancer 
3 The cause of their cancer did not 
matter  
Disclosure to others 
1 Disclosure of the cancer 
i. Keeping others informed 
2 Disclosing HPV as a cause to 
others 
Being diagnosed with HPV 
1 Reactions to being diagnosed with 
HPV 
2 When and how to be told about 
HPV 
3 HPV vaccination 
Prognosis of HPV-related cancers 
Questions and information about their 
cancer 
1 Information given about diagnosis 
and treatment 
2 Understanding of HPV 
i. Searching for information 
about HPV 
3 Need for more information 
4 No need for more information 
Psychosocial impact of the diagnosis 
and treatment 
1 Responses to the diagnosis 
2 Partners: Feelings about their 
partners cancer 
3 Partners: Taking control 
4 Social 
5 Work 
6 A different perspective on life 
7 Feelings about the future 
Impact on others 
1 Impact on family members 
2 Effect on partner 
 
Not included themes 
Experiences in the healthcare system 
Health professionals and hospital 
1 Attitudes 
2 Experiences with health 
professionals 
3 Trouble with services 
4 Positive experience 
Check ups 
Symptoms and diagnosis 
1 Symptoms and attributions 
2 Diagnosis 
3 Help-seeking 
4 Misdiagnosis 
5 Reaction to diagnosis 
6 Reaction of others 
Timelines 
1 Time to diagnosis 
2 Move quickly 
3 Timeline to normality 
Treatment and medication 
1 Preparing for treatment 
2 Involvement in decisions 
3 Radiotherapy and chemotherapy 
i. During treatment 
4 Feeding tube 
5 Medication 
6 Finishing treatment 
Waiting for something to happen 
Person factors 
Comorbidities 
Lifestyle 
Other experiences with cancer 
Other stresses  
Awareness and beliefs about cancer 
Other cancer-related impact  
Impact 
1 Effects of treatment 
2 Financial 
3 Physical 
4 Practical 
Recovery 
Support 
1 Support from family and friends 
2 Support from health professionals 
3 Support from hospital and 
organisations  
4 Support of partner 
5 Support available 
6 Practical support 
7 No external support 
8 Support groups 
Figure 8.2: Framework with the themes focused on in this chapter in the left-hand column 
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8.4.1 Beliefs about the cause of their cancer 
This theme is directly linked to the research question and distinguishes between patients who 
knew about HPV and those that did not. It covers the cause of patients’ cancer, whether it was 
talked about, whether patients knew or wanted to know the cause, and whether knowing the 
cause mattered.  
HPV or virus 
All patients discussed the cause of their cancer; almost a third of patients brought up the cause 
and the other cases were prompted by the researcher. Some patients were told that their 
cancer was caused by HPV or ‘by a virus’: 
‘I was probably midway through my hospital stay when the doctor mentioned it was 
because of HPV, which opened up even more questions to me because I didn’t even 
know that it can cause that’. (F02, 41 years) 
Patients did not always find out about HPV being the cause of their cancer from their doctor. A 
couple of patients found out after being approached by a member of a clinical trials team asking 
about them taking part in research:  
‘I only found out because... they didn’t... nobody told me. Erm, he was doing, erm, err, 
you know, kind of like a survey looking into, erm, things, and will I be interested 
afterwards in, you know, taking part in that because my diagnosis was HPV? And, erm, I 
had no idea what he was talking about … So, yeah, that’s how I found out’. (F58, 61 
years) 
HPV was not always accepted as the cause of cancer, with one partner describing a 
conversation with her friend who was a nurse and dismissed HPV as the cause of her partner’s 
cancer: 
‘I sort of Googled it and I know [name of friend] made the joke about, uhm, it - it could be 
done - it - it’s something that’s often caused by oral sex, or something or other. Uhm, but 
it - that’s a load of nonsense in his case, or something or other. So, other than that, no, 
absolutely no idea of the how or why or anything’. (F06P, 64 years) 
Some patients were still not being told about HPV as the cause of their cancer despite having 
been tested for it. A patient whose brother-in-law had also been diagnosed with HPV-OSCC 
specifically asked his doctor if he had HPV and was told he had ‘been unlucky’ and that they 
had not found HPV. Another patient was angry that she had not been asked if she wanted a test 
for HPV: 
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‘Well, it doesn’t make me feel any better, because even... you know, still even then, if I 
have been tested for something, nobody’s given me any results or, you know, or even 
told me I’ve been tested for it. Um. Don’t get me wrong, I wouldn’t refuse, but by the 
same token I think I should have been asked, or been told, ‘We’re going to test, and..’ … 
You think it’s just general’. (F20, 58 years) 
Does not know the cause of their cancer 
A number of patients had not been told what the cause of their cancer was and so in searching 
for a causal attribution, some attributed it to smoking, related it to work or genetics.  
‘You know, dusty, dirty atmospheres: am I breathing that in? Because me first one 
was… me primary was me tonsil. Erm, chemicals, nasty stuff. And back in the 70s and 
80s when I was working, there was nothing… PPE and all that, you just got on with it. 
You know, you didn’t have all the stuff you have on now. I mean, I’ve worked with 
asbestos’. (M59, 56 years) 
Another patient described it as a ‘self-inflicted illness’ and believed ‘it’s pointless doing 
something [smoking] for pleasure which is gonna ruin your health’ (M50, 83 years). 
There were some patients who had not been told the cause of their cancer and expressed the 
view that they wanted to know.  
‘Like I say, I would have loved, "Yeah, that’s what’s caused it." But to this day, I don’t 
know. I don’t know what it is’. (M59, 56 years) 
The cause of their cancer did not matter 
Nearly half of the patients said it did not matter what had caused their cancer, the most 
important thing was that they had got rid of it. The cause was also seen as something that could 
not be changed, ‘I can’t go back and say I’ll not do that’ (F55, 66 years) and that it did not affect 
the treatment. This partner expressed her relief that her husband’s cancer was now gone: 
‘I don’t care how it was caused. It was just that it’s gone, we hope, you know. We know 
we don’t get an all-clear for five years but, erm, fingers crossed, you know’. (F06P, 64 
years) 
One patient thought that as HPV had not been discussed, that means ‘it can’t be much of a 
problem’. One patient believed nobody was really bothered how they had got their cancer: 
‘Umm, I know the HPV’s really interesting and different and people need to know about 
your lifestyles, and stuff, to try and stop other people getting it, but, erm, I think the 
people who do get it don’t give a damn about the HPV, or most of them’. (F58, 61 years) 
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8.4.2 Disclosure to others 
Disclosure of the cancer 
Participants took different approaches to telling other people that they had been diagnosed with 
cancer. Some participants did not want to tell anyone their diagnosis, wanting to keep it to 
themselves and being aware that this was something with an immediate impact on others. 
Disclosing their diagnosis of cancer was something that patients did not look forward to doing, 
or sometimes even want to do.  
‘[Name of patient] didn’t want to tell anyone. I don’t know why. I don’t know... I mean he 
did eventually, obviously. And he didn’t really want to talk about it … I mean, him and his 
brother [name of patient’s brother] were quite close, and I couldn’t understand why he 
wouldn’t want to tell his brother’. (F56P, 59 years) 
Reasons given for not telling people were around not feeling comfortable, waiting for the 
prognosis before telling people and not wanting to burden other people. This often delayed the 
disclosure of their cancer diagnosis to other people, but the disclosure would happen 
eventually. One couple decided not to tell anybody until after the operation.  
‘Uhm, possibly cause it was Christmas-ish it helped, because we have a fabulous social 
life, uhm, and we decided not to tell anybody, apart from [name of friend] and her now 
husband [name of friend’s husband]. We didn’t tell anybody else at all. We kept it to 
ourselves’. (F06P, 64 years)  
Some participants minimised what was happening when they told people about their cancer 
diagnosis and wanted to be able to keep them calm and reassure them everything would be 
okay. One patient waited until he saw people to tell them, as he did not want to tell people over 
the phone. Another patient had found out his diagnosis on the day of a friend’s birthday and his 
partner explained that they ‘didn’t want to ruin his birthday’ (F12P, 51 years). 
Keeping others informed 
Another aspect relevant to participants was the need to keep everyone informed, which was 
described as ‘emotionally draining’ (F59P, 49 years). Participants recognised the importance of 
both being kept informed and keeping the family informed about how the patient was. One 
couple, when referring to their children, said they ‘kept them regularly updated every time I went 
to clinics and things’ (M31, 61 years), but think ‘it’s probably still in the back of their minds, if you 
know what I mean’ (F31P, 56 years). Being honest was seen as important. Some partners 
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found keeping people up-to-date was tiring, having to answer people’s texts and phone calls. 
One partner adopted a strategy to keep everyone updated at once: 
‘I didn’t want to leave it off the hook because people would think, I’m in and not 
answering it or I’m, there’s something wrong, so I told everybody when they rang me, I 
said, don’t call me again, I’ve got your email address, I’ll send out an email’. (M61P, 74 
years) 
One of the partners recognised that perhaps sometimes she and her husband forgot to keep 
people updated, ‘because we were so cocooned in together in what was going on’ (F47P, 45 
years).  
Disclosing HPV as the cause to others 
A couple of patients gave examples of why they thought others did not ask them about the 
cause of their cancer, believing that ‘the cancer word’s enough for most people’ (F58, 61 years) 
and ‘they think well you get cancer and you just get it, it’s one of those things that happens’ 
(M31, 61 years). Some patients who knew that HPV was the cause, felt uncomfortable talking 
about it with others: ‘It’s not a conversation you really want to have with your daughter’ (F20, 58 
years). One patient described telling people ‘It’s viral, in my throat, very treatable, a type of skin 
cancer, it comes from HPV’ and that ‘you don’t go around broadcasting that something’s 
sexually transmitted’ (M9, 49 years). 
One patient said she found it easier to tell other people than her partner and that she had told 
others about HPV before she had told her partner: 
‘I don’t think I told [name of partner], my partner, what it was… When they told me it was 
because of HPV I don’t think I told him for ages … I think it was easier to tell other 
people why as opposed to him. And I don’t really know why on that one. I don’t know’. 
(F02, 41 years) 
One partner described how everyone assumes HNC is caused by smoking and how people 
reacted when she and her partner told them about HPV and that most friends said they looked it 
up on the internet after they had explained: 
‘They were quite sort of, ooh. It’s a bit like anything you’ve never heard of before, you 
think, gosh, now that’s an eye opener, didn’t know that could happen or exist’. (F10P, 60 
years) 
Reluctance to discuss HPV as a cause of their cancer with others was evident, not fully 
disclosing their diagnosis to others and viewing it as a ‘medical thing’ so only felt comfortable 
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talking about HPV with medical people. One patient explained how she feels ‘stigma attached to 
it [HPV]’, due to the negative reactions of other people and how this has prevented her from 
disclosing where her cancer had come from. This patient did then disclose that compared to 
before, she felt more comfortable talking about HPV after her consultant had told her:  
‘This is the most contagious virus in the world, er, 95% of people manage to disperse it 
through their immune system, 5% don’t and unfortunately, 5% of that 5% it turns to 
cancer and you’re unlucky’. (F13, 42 years) 
Some participants also brought up Michael Douglas and viewed what he had said as ‘not 
helpful’ and there was a ‘sensationalist aspect’ surrounding the sexually transmitted nature of 
HPV. One partner described how she was happy telling people that her partner’s cancer was 
caused by HPV before Michael Douglas said that ‘it’s caused by oral sex’. 
‘Well, to start with probably I was quite open telling people that [name of patient]’s 
cancer was caused by HPV but, after that, a bit more reluctant to discuss it. Which is a 
shame, because I think that more people need to be aware of this, but it’s difficult’. 
(F01P, 62 years) 
8.4.3 Being diagnosed with HPV 
This theme describes reactions to being diagnosed with HPV, preferences for being told about 
HPV and about the HPV vaccination. 
Reactions to being diagnosed with HPV 
Patients’ reactions to news of their cancer being caused by HPV were embarrassment, 
confusion, surprise, disappointment, shock and feeling unlucky. One patient described how she 
still has ‘got a little bit of an issue still with it’ and how her husband had ‘said something that 
made me feel really dirty’ (F13, 42 years).  
‘Yeah, pretty disappointed really, um, and, you know, slightly, I don’t know slightly 
concerned that I’d got it, you know, either from my wife or from a previous partner’. (M9, 
49 years) 
One patient explained how she was embarrassed about the HPV aspect of her cancer, but how 
it feels less relevant now, with the cancer being most important, not the cause: 
‘I think that was the worst… I was embarrassed at first, but then, yes, after a little while 
you just… again, whichever way I got throat cancer, I got throat cancer. So now I think, 
two years on, or nearly two years on, I think it’s less relevant’. (F02, 41 years)  
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Transmission of HPV to their partner was a concern for some patients and one of the partners 
decided to get tested privately for HPV.  
‘And I’m thinking, I don’t want to pass this thing on to my wife, or if she’s got it and I’ve 
cleared and she passed it back to me, it’s potentially passing it backwards and 
forwards’. (M01, 59 years) 
When and how to be told about HPV 
There were mixed opinions from patients about when would be the best time to have been told 
about HPV as the cause of their cancer. Patients recognised that the initial diagnosis stage 
might not be the best time, but other participants thought it would have been helpful to know at 
the beginning, when they were first told about their diagnosis. 
‘So yeah, just clear information when you are diagnosed or at the point of… Maybe 
when you’re diagnosed is an awkward one, because, like I said, that appointment to me 
went through in a blur. But maybe a doctor somewhere just having a half an hour chat, 
being able to have half an hour with you to talk through everything when things are a bit 
clearer in your head. Which, you know, they’re so busy’. (F02, 41 years)  
This patient also described how she was told about HPV and how this was not how she 
believes she should have been told:  
‘When I found out I had it because of HPV, it came out… it was like a midnight 
conversation of the doctor doing his rounds and I was awake so we got chatting. And it 
wasn’t… at the time and everything, but it was like… how it just came out totally at 
random. Now, whether it’s because it’s not relevant to how they treat. But, to me, if you 
are gonna be told something like that, which psychologically becomes very relevant, it 
would have probably been better to have known in a proper way not just a chat’. (F02, 
41 years) 
HPV vaccination 
The HPV vaccination was brought up by a few participants with children who are boys and will 
not receive the vaccination, and one couple had got themselves vaccinated against HPV. 
‘What, an, angers me is the fact that boys aren’t, don’t have the HPV vaccine, um, 
because when I was talking to [name of doctor] he said, you know, this, this will be null 
and void when I’m in my rocking chair, he said, because obviously down to the, to the 
injections the girls have now, but that clinic was full of men. You know? And it just 
seems a bit unfair that, in fact I even looked at, um, getting my son immunised, um, 
privately for that reason’. (F13, 42 years) 
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8.4.4 Prognosis of HPV-related cancers  
Most of the patients given information about their prognosis were told that it was treatable, 
curable and they could expect to recover completely. The statistics given to patients ranged 
from 50-85% survival, with research showing higher survival rates for HPV-related diagnoses: 
‘So I mean, the oncologist told me I had a 60% to 70% chance of survival, erm, unless it 
was HPV then it was 70% to 80%. So I’d just been given an extra 10% survival. That’s 
very nice!’ (M01, 59 years) 
Patients were reassured by the better prognosis given to HPV-related diagnoses and one 
patient described how he focused on the words ‘it’s treatable’ (M59, 56 years). One patient 
interpreted 80% as good, but then put the statistics into real life when he saw the radiotherapy 
masks lined up in the room. 
‘She [radiographer] said, we’ve got 42 masks at the moment. And I’ll tell you what 
kicked in then, there’s eight of us not going to make it then. That, that’s what was in my 
mind. Whether she, that was just the way I think anyway’. (M12, 53 years) 
Finding out the cause was HPV was seen as something positive due to finding information from 
research studies showing that it is a much more treatable cancer. This partner indicated her 
relief of finding out this information: 
‘So once we did find, it took a little while, that he was HPV-positive, and I think all the 
signs were he was, erm, that we felt a lot better about that’. (F01P, 62 years) 
8.4.5 Questions and information about their cancer 
This theme relates to discussion around information the patients and their partners were given 
about their diagnosis and treatment, their understanding of HPV, searching for information 
about HPV, their need for more information and there being no need for more information.  
Information given about diagnosis and treatment 
A number of the participants described having been given information in the format of books or 
leaflets. One patient also reported having been given a CD with pictures and stories of people 
following surgery who had had mouth cancer, which ‘frightened the pants off me, which I don’t 
think they should have done!’ (M01, 59 years). A couple of participants reported on where they 
kept the information, such as organising them onto a table or into a box file. The information 
given tended to reflect general information about HNC, on treatment and side effects, 
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rehabilitation exercises and other health conditions. One patient also described how he was 
given a leaflet to use as a prompt for any questions he wanted to ask: 
‘Yeah. Err, he gave me a leaflet and what he said to me was to write it all down on a 
piece of paper. He said, “Now, after I’ve saw you, you’ll be coming in to see me again,” 
and he gave me a fact file on everything’. (M22, 59 years) 
Many of the participants described how information about the treatment plan and what they 
were going to do was explained to them, with the aim of keeping them calm. Some patients 
were also told about some of the effects they could experience following treatment, such as 
restricted movement of the neck, tiredness, and possible future thyroid issues. Some patients 
also mentioned things that happened that they were not told about, such as loss of saliva, how 
bad they were going to feel after the treatment and potential effects of morphine.  
Understanding of HPV 
In terms of information participants were given about HPV, this very much varied. Information 
patients described getting when they were told about HPV included it being discussed in 
relation to cervical cancer, that ‘the HPV virus is in all of us’, and that ‘it has been written up that 
it can be from cunnilingus’. Most participants had never heard of HPV before they were 
diagnosed. Those that were already aware of HPV tended to be women who had heard about it 
in the context of cervical cancer.  
‘Obviously, I heard about HPV but not in this context. Erm, I’d always been for my 
cervical smears and they’d always been fine’. (F01P, 62 years) 
Some of the understanding about HPV that participants came away with from their doctors were 
that it’s ‘a virus’, ‘it’s sexually transmitted’, it ‘seems to affect anybody’, ‘you could have it for 
years’, it’s ‘the most contagious virus in the world’, ‘it’s on the increase’ and it’s ‘becoming more 
and more common in all ages’.  
‘He explained then that it was this papilloma virus and I asked if I could get it and he 
said, you know, it’s in all of us, anyone can but that they didn’t know really what 
specifically caused it … it’s in people that are sort of sexually active, um, and that it can, 
that they’ve realised that there’s a lot more cases … Um, and that, I know that they said 
it was quite sort of, it was becoming more and more common in all ages’. (F10P, 60 
years) 
Questions participants had about HPV included whether HPV is likely to travel around their 
body, ‘what’s the chance of it coming back’, ‘where has this [HPV] come from’, ‘how’s it taken so 
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long to come through’, have they still got HPV, ‘is it only sexually transmitted’, how long have 
they been carrying HPV, what is the prognosis, will the treatment get rid of HPV and are their 
children more at risk of HPV. 
‘I mean, I know [name of patient] does an awful lot of swimming, and a few years ago he 
had a dreadful bout of verrucas, and they spread to his hands. He had a lot of warts and 
things like that. So I think, well has he got some sort of susceptibility to this sort of thing? 
Could it have been that we’ve been passing it between ourselves for years and years? I 
mean I’ve actually got some warts on my hands as well that I can’t get rid of, which I’ve 
had for quite a while. I didn’t realise it was a wart until I went the doctor quite recently 
and had this thing on my hand’. (F01P, 62 years) 
One patient was reassured by a friend who works in a hospital, that people’s interpretation of 
HPV being down to oral sex, ‘is their naivety’. One patient believed that there were ways, other 
than oral sex, that HPV could be transmitted.  
‘I mean surely if you can transmit the virus around, there’s going to be other ways of 
doing it as well, surely? It could be a cut on your hand, it could be a kiss, it could be 
anything, couldn’t it really? You just don’t know really. I don’t think the authorities do yet 
either, that’s the impression I get’. (M01, 59 years) 
Searching for information about HPV 
Although the internet was a popular source of information for participants, there was an 
understanding that this should be done with caution: ‘I know you shouldn’t, but you look online, 
don’t you?’ (F20, 58 years). It was also recognised that the information is not always trustworthy 
or ‘regulated’: 
‘There’s no real, kind of, er, evidence to support a lot of the, kind of, things that are said 
online’. (M9, 49 years) 
A few did not want to look for any more information and not on the internet for reasons such as 
that they did not want to ‘panic’ or read the wrong information. 
‘No. I never look on the Internet for anything like that, because I don’t think... rightly or 
wrongly and umm... it’s no disrespect to anyone who put it on there, but they don’t know 
like the professionals’. (M22, 59 years) 
Some patients looking for more information found information that confirmed what they had 
been told by their doctor.  
‘And they [websites] were saying basically the same as, as he did, you know, that, err, 
there are various ways you can get it, that it can lie sort of within your body for years. 
Some people, most people get rid of the, the virus within a couple of weeks or a month 
of, of contracting it, and sort of perhaps 99% of the population have had it at some time 
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and don’t realise, and that there’s just some people for some reason it, err, it stays 
within the body, you know, it doesn’t, err, it doesn’t disappear like it should do, sort of, in 
a normal situation. So yes, I had some idea and he sort of just confirmed what I’d, what 
I’d read’. (M31, 61 years) 
The internet was used to look for information on HPV, information about the best treatment 
options, researching symptoms, causes, information on their doctor, explanations of tests and 
for further information about their particular cancer. It was recognised that there was not much 
information out there on the Cancer Research UK website about HPV, but that the Mouth 
Cancer Foundation had more information. 
‘And it was him that, and his exact words were, because, when you get home, being told 
it’s HPV, you Google everything, and I Googled it and I broke down, because I just 
thought, I can’t believe what, it, er, it was all over the internet that it was all down to oral 
sex, etc, etc’. (F13, 42 years) 
For those that did further research into HPV, the level of research undertaken also varied. One 
partner read research papers on HPV from the USA and took away the information that the 
prognosis is good, and that it affects men in their 40s and 50s ‘who are quite healthy’ (F01P, 62 
years).  
‘Unless somebody had another type of cancer, it seemed like the chances of recurrence 
were pretty low after the sort of standard treatment, which was what [name of patient] 
had had. So I was pretty reassured by that’. (F01P, 62 years) 
Some participants expressed concern that the information currently available was not very 
applicable to them. One patient pointed out how information about HPV seems to be ‘centred on 
teenagers’ and being ‘either aimed at young people not contracting HPV or old people not 
getting cancer through HPV’. This particular patient was a female, in her 40’s, so she felt like 
the information available about throat cancer was aimed at ‘that sort of age group – 60 plus. 
And you are like, well, that’s not me’ (F02, 41 years).  
Need for more information  
In terms of getting more information from health professionals, some partners felt like they could 
ask anything, with one partner feeling guilty because she was ‘asking all the questions and it’s 
not me that’s affected’ (F56P, 59 years). More specifically participants would have liked to have 
known more about the effects of the treatment, follow-up treatment plan, radiation burns, and 
ideas about food for the patient. Questions also came up with regards to what the treatment 
was going to involve and feeding tubes, as well as whether it was curable and what the main 
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effects of the treatment would be. Some patients also acknowledged that they were not sure 
what questions to ask.  
One of the partner’s also recognised the challenges with giving information in that ‘everybody’s 
different’. 
‘I’ve been, I’ve been thinking about that, the thing is everybody’s different, and if you 
start, start saying, you know, your hair’s gonna come out, you’re gonna lose your voice 
and things like that, you’re, you’re waiting for it to happen’. (M61P, 74 years) 
It was acknowledged that there was a need for more research to be done in the area and that 
there will be more known about HPV-OSCC in a few years’ time, and that further research may 
lead to different and ‘milder treatment’ for HPV cancer, with this one partner hoping this would 
mean people ‘wouldn’t have had to go through the dramatic treatment he did have to go 
through’ (F01P, 62 years).  
‘I think it just needs more research doing, but I think, at the moment, we’re just happy 
that [name of patient]’s going to get over this thing. But I just think there’s so much that’s 
unknown’. (F01P, 62 years) 
No more information needed 
There were a number of participants who were satisfied with the amount of information they had 
been given, with a few patients giving examples of all their questions being answered.  
‘He [doctor] said, “But if there’s nothing on there, there’s no answer to your question, 
write it down on a piece of paper, bring it in and ask me.” And that’s what I did. And he 
just answered everything completely, completely’. (M22, 59 years) 
Some participants also did not want any more information because they did not want to know 
the details of what they were going to go through and they did not want to get frightened. One 
partner also believed that ‘sometimes too much information is bad, because you’re looking for 
the things to occur’. (M61P, 74 years) 
8.4.6 Psychosocial impact of the diagnosis and treatment  
Patients discussed in detail many psychosocial aspects of their diagnosis that were not directly 
related to having HPV. In some cases, HPV did play a role in this (e.g. by influencing 
prognosis), but largely these aspects were related to dealing with a cancer regardless of the 
cause. As the previous research in chapter 2 illustrated, there are a number of factors which 
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can influence the psychological impact of HNC and so it was important to discuss those brought 
up by participants. This theme represents all the ways in which participants discussed the 
cancer diagnosis had a psychosocial impact on them. Subthemes that relate directly to the 
research question include psychological responses, feelings of the patient’s partners, partners 
taking control, social, work, having a different perspective on life and feelings about the future. 
Responses to the diagnosis 
This was a major theme that included a variety of responses from patients and their partners. 
Accepting it and getting on with it were common responses: 
‘But anyway, that’s, you know, we had to… you’ve got to take it, haven’t you, one step at 
a time. Accept it, fight it and pray that everything is gonna be all right. That’s all you can 
do. With any cancer it’s a shock but you’ve got it and what can you do about it? Accept it 
and be positive that this will… the cure, he’ll have the cure, he’ll have the treatment. So 
far, so good’. (F50P, 73 years) 
There was a mix of trying to be positive and not being frightened about the diagnosis, with 
others not feeling sure they would survive and wondering if they would see their children grow 
up. Some patients described cancer as a ‘battle’ and how the diagnosis had been a ‘blur’ and 
they had ‘blanked it out’. Cancer was still perceived as a ‘scary word’, with one patient saying, 
‘it’s like, kind of, Voldemort, you know what I mean, you’re not allowed to say the word, it’s, it’s 
like so powerful and no one can joke about it’ (M9, 49 years). Patients described having dark 
times, being in denial and having depression and anxiety.  
‘But, um, I did have a few dark times, you know, waking up in the middle of the night and 
saying, "Oh, I’ve had enough now." Because, um... There was one particular day where 
I just woke up and burst into tears in the middle of the morning, which I don’t normally 
do. I said, I’ve just had enough. Sleep deprivation and everything else, treatment and 
feeling rough’. (M47, 49 years) 
Other feelings expressed by patients and their partners included feeling alone or isolated, 
forgetting about cancer for a while, embarrassment over how things had changed, relief about 
clear results, stress and trying to go on as normal. A couple of patients also expressed that they 
had trouble sleeping due to the stresses associated with their cancer diagnosis. Some 
participants expressed that they felt lucky: 
‘You’ve come out the other side. You’ve been lucky. You’ve been unlucky, but lucky’. 
(M59, 56 years) 
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Feeling that nothing is normal anymore was described by some participants, as well as 
expectations from other people and unrealistic expectations about how long the recovery would 
take were also described by some patients.  
Loss of confidence was described by a few participants, with this one partner describing losing 
confidence in her partner’s health and in his ability to do things: 
‘And I think it has knocked me confidence a bit really, because I didn’t think he was 
invincible as such, but with coming out of the blue, you know, it just wasn’t expecting it’. 
(F31P, 56 years) 
Appearance was a worry for some participants; not knowing what they were going to look like 
after the treatment. One partner said he ‘went a bit cold then because I thought a lady does not 
like to have a disfigured face, and especially [name of patient]’ (M61P, 74 years).   
A few participants had ‘a fear of the unknown’ and ‘didn’t have a clue what really was going on’. 
One patient described not knowing what was going on as being the hardest bit.  
Partners: Feelings about their partners’ cancer 
One partner explained how he felt inadequate when his wife came home, as he did not know 
what to do. Partners also wanted to protect the patient and their children by being strong and 
not showing when they were upset. Another partner described how his partner (the patient) was 
worrying more about him and how he had taken control and things had been excellent since she 
had come home from hospital, demonstrating a positive effect of his caregiving role empowering 
him to be more independent.   
‘I then got myself ready for when she came home, and things have been fine since she 
has been home. Um, I’m not drinking so, um, that’s fine. Um, but things have been very 
good since she’s been back. Yes, excellent, I would say’. (M55P, 58 years) 
Partners also described the difficulties around HNC being ‘a dreadful illness’ and other people 
lacking understanding. 
‘And when the, um, when the treatment finished, people, it, it, that was something that 
was quite interesting actually, that er, just occurred to me, all the time [name of patient] 
was having his treatment it was as though, [name of patient]’s got cancer now. When his 
treatment finished, some people just thought that’s it, he’s, he’s, that’s it, it’s done, so 
it’s, which was quite interesting. Then, you know, again that’s just, it wasn’t that they 
didn’t care, it was just lack of, um, their understanding’. (F10P, 60 years) 
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Seeking further support, such as through Macmillian, was at times considered by a couple of 
partners. 
‘I felt worse… I felt… started feeling worse and I didn’t know… I was on the point of… I 
was just bursting into tears, and I was on the point of ringing the Macmillan support line 
to talk to somebody because I was thinking, well, why am I feeling like this, he’s getting 
better’. (F31P, 56 years) 
One patient explained how she was made to feel like she was ‘in the way’ and was treated as 
though she ‘wasn’t there’ when she was with her partner at the hospital.  
‘And like sometimes I’ve tried to ask questions, and they look at you as if to say it’s not 
you that’s got the cancer, it’s him. It’s just get out, just out of the way. And I’ve felt like 
that a lot of times … And then when, um, when he was going, going, when he was going 
for the diagnosis and things like that, I was going with him, and I was just, they was just 
treating me as if, as if I wasn’t there’. (F37P, 61 years) 
Partners: Taking control 
Partners described ways in which they took control by ‘dragging’ patients out of the house to go 
for treatment and searching for as much information as possible: 
‘I had to make him go. You know, "I’m dragging you out of the house for more treatment. 
But, err, no, I suppose I saw the bits that people didn’t see. The times when really, he 
just didn’t want to do anything. "I’m not going. I’m not going to [name of cancer centre] 
today." "Yes you are." So then I had to say something different to yesterday [laughs]. 
"Yes, you are coming to the car." (F56P, 59 years) 
Partners were also influential when it came to the patient going back to work. One partner was 
not happy about her husband going back to work, believing he had gone back too early. She 
also said:  
‘But, I says, "If you can’t eat," I says, "You can’t drive." Because he works in [name of 
town], you know, so he’s got 100 miles a day to drive, if he’s not eating as well, so. So I 
sort of, "No you can’t, until you can actually eat properly. Have breakfast, bit of dinner, 
something for tea." So that was me putting my foot down!’ (F56P, 59 years) 
One of the patients also wanted to return to work after he had been diagnosed but this partner 
stopped him: 
‘And he thought he was going to continue going back out to work and I’d always say, 
“Ha-ha, no you’re not! You’re going to sick health,” cause this was on, sort of, the 
Friday, “you’re going sick Monday morning.” (F06P, 64 years) 
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Social 
Some of the negative impacts of the diagnosis included having to cancel things such as 
holidays, not being able to cook like they used to and not being able to do the things they loved 
doing. One patient did not want to be treated differently socially as a consequence of his 
diagnosis: 
‘And I found that really oppressive, I couldn’t stand the fact that I was out, people 
weren’t taking the mickey out of me, I really wanted people to take the mickey out of me 
and treat it lightly, and it’s, you know, just like other things in life and, you know, people 
joke about death and lots of other things’. (M9, 49 years) 
The most common way in which participants spoke about their social life being negatively 
affected was through the effect of the treatment on eating and drinking, as this reduced their 
desire to eat out and in front of other people, therefore they felt it was ‘a waste of money’: 
‘Everything affects your social life, seriously, because, let’s be honest, when he was ill 
he got tired very quickly, so you couldn’t go far really, and he couldn’t have a drink. He’ll 
tell you the first gin and tonic he had was just like soap’. (F50P, 73 years) 
One partner described how it affected her social plans as she did not spend as long out of the 
house as she used to: 
‘And as for social life, not really, we still go to the theatre, um, and I still go for lunch with 
my friends, but I tend to only be away a couple of hours, whereas if I’d gone for lunch 
with friends, I’d probably go shop, around the shops, but now I’ll… I probably go out 
nearly every day for a couple of hours, because [name of patient] reads the paper 
from… every single word. So I thought, well, I might as well be out’. (F50P, 73 years) 
Some participants described how their diagnosis had an effect on their hobbies, with one patient 
saying ‘swimming was the furthest thing from my mind’ (F13, 42 years).  
‘Well, initially, after all me treatments… we’re strong rugby league fans, [name of 
hospital], and we go home and away games. We go all the away games of a weekend, 
and I couldn’t do that at the time because I couldn’t eat. I was having milk, and I 
couldn’t… I sort of couldn’t be anywhere away from these protein drinks, and I couldn’t 
physically take them all with me. [Laughter] I’d be going round with a suitcase as if I was 
going on holiday. So, a big impact, social-wise, erm, but I didn’t want to go out anyway. I 
just wanted to sit in here and…’ (M59, 56 years) 
One patient said that he is not a sociable person anyway so it did not affect him too much. Two 
patients described how it paused their hobbies temporarily but that they are doing them again 
now, with one patient saying he is playing golf more now than he was before.  
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A positive impact reported was the opportunity to spend time with family; however some had so 
many visits from friends and family that, at times, they just wanted to be left alone.  
Work 
Work came up in a lot of the interviews, primarily as this was something that was impacted upon 
in the majority of cases (for those who were still working and not retired). Some of the patients 
described how they enjoyed going to work and the normality of it, how they liked ‘having that 
purpose’, how the money gives them some freedom and keeps them occupied, with some 
describing being bored without work.  
‘Well, the treatment had finished, it was like it’s either sit round the house or get, get 
back to work sort of thing. And, as far as I was concerned, that bit’s done now, let’s get 
back, life back to normal, look forwards and carry on’. (M56, 61 years) 
Work was seen as a distraction from their partner’s treatment for a couple of the partners, to 
‘keep busy’ and ‘take your attention’. A number of the patients and partners described how they 
stopped working after their diagnosis or their partner’s diagnosis. In some cases, the patients 
were not able to return to their same job following effects of their treatment.  
‘Erm, certainly work-wise, er, ‘cause I work on the gas industry. And because I’ve no 
saliva glands now on this side, I’ve always got water to… and gels to keep me mouth 
lubricated. Erm, you wear breathing apparatus if you’re working in a gaseous 
atmosphere and I can’t do that now, so I can’t fulfil that side of my job’. (M59, 56 years) 
Two partners described how they were not able to do the same job as they had previously 
worked with cancer patients and it was too close to home now.  
‘I work in a GP surgery, I’m a nurse, and part of my role is, um, every month we have a 
monthly meeting, err, with patients with cancer and end of life and I always used to take 
the minutes and things like that. Well, I’ve, I’ve not been in since because I can’t, it’s too 
close to home’. (F31P, 56 years) 
Another partner who had worked with cancer patients described some of her experiences and 
how it had helped. 
‘So, yes, so yes I think it did help in some ways, you know. Uhm, perhaps if I hadn’t had 
all those experiences I would have been more scared, but I wasn’t, cause I saw so 
many people live with cancer for a lot of years and – and live with it and continue 
working and doing everything else in their normal lives. So I knew that we were on that 
same road’. (F06P, 64 years) 
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Another partner described how she was pleased when she was able to go back to work and 
how ‘work ethic’s very important’ and that she’s much happier now she’s back at work.  
Two of the partners described continuing working, but one ended up being signed off work with 
stress, later returning to work part-time.  
‘I worked with a particularly challenging pupil at the time and it kind of pushed me over 
the edge and I broke down in work and I got fetched home … In a nutshell, I basically 
ended up being off work for three months. The doctor signed me off with stress’. (F59P, 
49 years) 
Feelings about work were a mixture of patients missing their friends at work, thinking that their 
health is more important than work and wanting to go back to work as soon as the treatment 
had finished. One patient described how he could not wait to retire and how he does not ‘go for 
the love of it’. 
A different perspective on life 
Some of the participants described how the diagnosis had given them ‘a different perspective 
on life’, most of these being positive. A couple of patients explained how they were now more 
focused on and more aware of their health.  
‘So yeah, just a general acknowledgement that your body is, you know, more fragile 
than you realise and needs to be looked after probably more than it did when you were 
young and you were doing before you got ill, so yeah, just a general keeping healthy 
and, you know, just keeping it going’. (M9, 49 years) 
One partner described how she now felt ‘more empathetic’ towards cancer patients, as she 
could now understand more about what they were going through. Some participants also 
described themselves as being ‘a better person’ and how they appreciate things more since the 
cancer diagnosis.  
‘It’s totally changed my way of thinking about life. You know, and, err, I suppose in some 
respects for the better because sometimes you can be a bit cruel or, you know, you see 
somebody walking past and they drop something, “Oh, let them pick it up.” Or they don’t 
notice. But now I don’t, I stop somebody’. (M22, 59 years) 
The realisation that life is short was brought up by many of the participants, that you have to 
enjoy it, not worry about the cancer, do things you want to do and ‘get on with it’. One patient 
also described how cancer had ‘made me harder … life’s too short to fill it with A holes’ (F13, 42 
years). 
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Feelings about the future 
Most of the patients and their partners were positive about the future, making plans and looking 
forward to the future.  
‘Err, pretty optimistic really. Yeah. As I say, even more so since, you know, being told 
that the prognosis is much better, um, for somebody with, you know, oral cancer, if it is 
HPV-related. But yes, um, [pause] you know, as I say, I’ve never, I’ve never had a 
thought that it’s a terminal thing. So yeah, you know, quite optimistic for the future’. 
(M31, 61 years) 
Two patients were not as positive about the future, one feeling like they cannot plan ahead and 
the other feeling like the future was bleak.  
‘Umm, yeah, umm, I suppose we all, without thinking about it, plan things ahead 
constantly, and you can’t at all. Or you feel like you can’t, you know’. (F58, 61 years) 
Fear of recurrence was common among patients and their partners. This was sometimes 
related to HPV, such as this patient wondering ‘is it [HPV] more likely to come back because of 
this? Is it something that stays in your body?’ (F58, 61 years) 
8.4.7 Impact on others 
This theme covers the impact that the patient’s cancer diagnosis had on their family and more 
specifically their partner.  
Impact on family members 
Patients described the reactions of family members being that of devastation, scared, worry, 
upset, concern, shock and being stoic. Many of the patients brought up the effect on their 
children and grandchildren:  
‘My daughter handled it pretty well, I think my son was affected by it a bit, he, he felt that 
I was a kind of a superman before that, you know, I was, I was a big bear and, you 
know, kind of, you know, really, really kind of invincible and that whole period made me 
very, you know, mortal’. (M9, 49 years) 
Participants with children mainly talked about the effect on their children, with older children 
being supportive and wanting to be involved, and those with younger children advocating being 
honest with them. One patient tried to keep herself away from her children as she was visibly 
deteriorating.  
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One couple described the diagnosis as having a positive effect in that it ‘brought family more 
together’ and that previous conflict in the family got resolved and their daughter ‘started 
speaking to us again’.  
There were some stories of arguments between family members and mealtimes were especially 
stressful between the patient and their partner, as the partner would prepare food and the 
patient could not eat it.  
‘She had to try and cook food, which I couldn’t manage to eat because my mouth was 
obviously sore. And of course we had rows about that, because I never got the things 
which... well, not never’. (M50, 83 years) 
Preparing food and eating were described as some of the most stressful experiences. Partners 
struggled finding things that the patients would eat and then one partner explained that ‘[the 
patient] would get fed up eating the same thing’ (F58, 61 years). Loss of appetite, the struggle 
eating, intermittent taste and dry mouth were described as the worst parts of the cancer. This 
partner describes how she used to prepare her husband’s food.  
‘And on a Sunday, well that was hilarious because [clears throat] we kept trying to keep 
to the roast dinner … mine was in the oven, and I bought, what you call a Bullet. Have 
you ever heard…? I bought a Bullet, which you can make into smoothies, and I also 
bought a hand mixer as well to get the food pulped down. Anything to get the food, so 
that he could just take it off a teaspoon. Mmm. It wasn’t, it wasn’t easy at all’. (F50P, 73 
years) 
Effect on partner 
One of the evident impacts of patients’ partners was them becoming a carer and spending an 
increasing amount of time at home. Partners described their experiences as a carer as ‘doing 
the mum bit’, being ‘bossy’, caring for them and taking them to their treatment appointments. A 
few of the partners saw it as their role and they did not want anyone else to take them:  
‘I didn’t want anybody else doing it. I know that sounds a bit weird, but... I knew what he 
was gonna go through, or imagined what he was gonna go through, and I thought that is 
the one thing I could do. I could take him’. (F56P, 59 years) 
Patients recognised the impact that their diagnosis had on their partner, recognising that it was 
hard for them, that they were worried and that they were tired and ‘run-down’. One patient 
recognised that with her partner ‘there’s definitely issues there, but we’ve got different issues’ 
(F13, 42 years) and that her partner did not want her to get involved as a cancer support 
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worker. Another patient recognised that ‘she needs more support than me, if you know what I 
mean’ (M10, 63 years). 
Partners expressed the effect it had on the patients’ weight, their sleep and how upsetting it 
was.  
‘And sometimes I would be thinking to myself, [name of patient] was very quiet because 
his throat hurt all the time, he didn’t do much talking, um, and sometimes I think, well 
how am I, how am I doing this every day, because it was very tiring, it was six weeks. 
But you kind of do, just get on with it’. (F10P, 60 years) 
For one partner, his wife’s diagnosis amplified some psychological problems, saying ‘I was 
[pause] distressed like I’ve never been distressed before’. But it also had a positive impact on 
him regarding him becoming more independent, getting a bus pass and his driving licence back 
in preparation for his wife coming out of hospital. He saw himself as ‘quite a positive person 
now’. 
There was recognition that the diagnosis affected both of them, but that sometimes the patient 
just wanted to be left alone.  
8.4.8 Case studies  
As the data interpreted through framework analysis have many cross-cutting themes, two case 
studies have been chosen to illustrate the way in which patients reacted differently to their 
diagnosis of HPV-OSCC and how this impacted upon them. They have been selected as they 
represent contrasting experiences and reactions of testing positive for HPV. 
Case study 1 
The first patient is a 42 year-old woman who is married, with four children and is employed part-
time. Her partner was not interviewed as he does not want to talk about her cancer and ‘he kind 
of wants to put it in a box and put the lid on’. She was in a previous marriage before marrying 
her current partner. She described being shocked that she could have HPV, ‘felt dirty’ and was 
worried that she had passed HPV onto her partner. She described feeling very unlucky and 
worried about issues that an HPV diagnosis caused in her relationship with her husband, with 
her husband making her ‘feel dirty’ about the fact that HPV is sexually transmitted. She was 
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reassured by information given to her by her oncologist about HPV being the most contagious 
virus in the world and in a small number of people HPV turns into cancer.  
Reluctance to tell others that her cancer was caused by HPV was demonstrated because she 
did not believe it was anyone else’s business and even though she still has ‘a bit of an issue’ 
with having HPV because of the stigma attached to HPV by other people, she is now more open 
about HPV with the information she has been given by her oncologist. A friend who worked in a 
hospital reassured her that other people will not think that HPV is down to oral sex and if they 
do then it is due to their naivety.  
Concerns about the HPV vaccine not being offered to boys were expressed, as she has two 
sons and believes it is unfair that boys are not vaccinated. She had looked at getting her older 
son vaccinated privately.  
This patient did not mention any information she was given about the prognosis of her cancer. 
She found the medical staff very informative about what she wanted to know about HPV and the 
treatment for her cancer. Her husband was also kept well informed. She was not told 
information about HPV at her diagnosis and would have preferred to have heard information 
about HPV when she was diagnosed. After she had been told about HPV, she had looked HPV 
up on the internet and described ‘breaking down’ as all the information on the internet said that 
HPV was all because of oral sex. This patient also mentioned Michael Douglas and how he had 
contributed to the stigma attached to the diagnosis of HPV-OSCC. 
Case study 2 
The second patient is a 61 year-old man who has been married for 34 years, with two children 
and is retired. He described not feeling shocked about being diagnosed with cancer and never 
felt he was going to die. He was not concerned about the cause of his cancer and the most 
important thing was that his cancer had gone. He had not even thought about HPV being the 
cause. He would have liked to have been told about HPV being the cause of his cancer right at 
the beginning because he believes in honesty. His wife suggested a good time for them to have 
been told about HPV would have been at one of the follow-ups after they found HPV. He did not 
disclose HPV as the cause of his cancer to others and nobody had asked, but was honest and 
kept his children up-to-date about his treatment. His wife explained how they had told their 
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children about taking part in the research, but not disclosed that it was because his cancer was 
HPV-related, mainly due to not wanting to ‘bring it all up again for them’. 
Being told the prognosis was much better for HPV-OSCC, this patient and his wife felt optimistic 
about the future. He was reassured by the prognosis being better and felt happier once he had 
been told this. His wife felt a sense of relief when they found out that his cancer being HPV-
related meant that the prognosis was better.  
Information the patient described being given about HPV included that he could have had it for 
years, but was not concerned about how he had got HPV as he had been with his wife for 34 
years and was secure in the knowledge that neither of them had ever been with anyone else. 
The partner also recounted that they were told that it is very unlikely that HPV would be passed 
on to her as ‘usually the virus disappears’. The internet was used to look up information about 
HPV and he learned that most people get rid of the virus, but that in some people it does not go 
away like it would normally. This information was confirmed by the doctor. Questions he had 
about HPV included whether he was still carrying the virus and whether that means it can come 
back. Michael Douglas was also mentioned by this patient and his wife; the patient was not 
aware of what he had said about HPV and throat cancer, but his wife believed Michael Douglas’ 
disclosure did not help. His wife had some understanding about HPV already, but described 
having any questions they did have, answered by the doctor.  
These two case studies illustrate the different ways that people respond to a diagnosis of HPV 
and the possible implications that this might have. Although both patients were aware of the 
sexually transmitted nature of HPV, the first patient experienced emotional responses of shock, 
worry and stigma and the second patient was not concerned about HPV, and was secure in the 
knowledge that neither he nor his wife had been unfaithful. The first patient also focused more 
on the suggestion of HPV having been transmitted through oral sex, whereas this was not 
specifically mentioned by the second patient. These differing reactions to HPV may be due to 
the differences in their life circumstances, with the first patient being married for a second time, 
being younger, female and having four young children, compared to the second patient who has 
been married for 34 years, is older, male and has two grown up children. Both patients would 
have liked to have been told about HPV as soon as they had been diagnosed. Both patients 
had looked for HPV information on the internet, with the first patient ‘breaking down’ when it was 
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suggested that oral HPV was transmitted through oral sex, whereas the second patient was 
reassured by the information that the prognosis was better. 
8.5 Discussion 
This study explored the psychosocial impact of being diagnosed with HPV-OSCC for patients 
and their partners. The demographics of the sample were representative of the ‘typical’ HPV-
OSCC patient, being mostly male, married, a median age of 57 at diagnosis and white (Gillison 
et al., 2008; Marur et al., 2010). The youngest patient was diagnosed at 40 years of age, 
reflecting the younger age of these patients. Although the medical records of all patients 
showed their tumour was HPV-positive, not all the patients were informed of this. Reactions 
were mixed among those who knew their cancer was caused by HPV. Some participants felt 
embarrassed and recognised stigma associated with HPV. Other participants were not 
concerned about the cause of their cancer and were more interested in knowing the survival 
rates were better and they were going to get better, suggesting concerns were more cancer-
related than HPV-related. The two case studies presented suggest that these differing reactions 
may be due to life circumstances. Patients and partners who were told about HPV as the cause 
had a number of questions about HPV and some sought out further information. Psychosocial 
effects were similar to those described in previous qualitative research with HNC patients (Baxi 
et al., 2012; De Boer et al., 1999; Lang et al., 2013), with patients describing times of 
depression, anxiety and denial, but also feelings of optimism and relief.  
Participants reactions to finding out that their HNC was caused by HPV varied. In line with 
findings from the cervical cancer literature, some patients reported feelings of embarrassment, 
confusion and concerns of transmission to their partner (McCaffery et al., 2006). As reported in 
chapter 6 by health professionals, there was also concern among patients who had young 
children, boys in particular, about them being more at risk of HPV and not receiving the HPV 
vaccination as part of the national immunisation programme. One couple had paid to have the 
vaccine themselves after concerns about transmission, with evidence now emerging that the 
vaccine can help prevent future infections or infections with different HPV types (Joura et al., 
2012). Michael Douglas was also mentioned, and supporting findings from chapter 5, 
participants perceived what he had said as unhelpful and that it had also added a ‘sensationalist 
aspect’ to HPV-OSCC. This had changed one of the partner’s attitudes about being so open 
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about the diagnosis, and others described giving factual information about HPV being the cause 
when discussing with others, suggesting they were trying to avoid attaching stigma to it.  
Supporting the key messages from chapter 6 where health professionals expressed the 
importance of normalising HPV, patients reported health professionals relating HPV back to 
cervical cancer and normalising HPV by telling them it is becoming more and more common 
and that it seems to affect anybody. Some participants did search for more information about 
HPV and found that the information available was not applicable to them and was targeted at 
young girls in relation to the HPV vaccination. Information sought from patients and their 
partners about HPV was specific about where HPV had come from and around transmission 
and future HPV risk, supporting previous research which showed 62 HPV-OSCC patients 
sought causal information and information about vaccinations, prevention of transmission and 
available treatments (Milbury et al., 2013). The internet was a popular source of information for 
participants, which has been found previously in this population (Baxi et al., 2012) although 
patients did recognise that the information is not always trustworthy and reliable. Findings from 
a previous study with the same population showed patients wanted more information about 
HPV and that ‘a cohesive, comprehensive, and trusted source would be valuable’ (Baxi et al., 
2012, p5). These findings suggest that there is a need for information to be available about HPV 
and HNC which is targeted at these patients and developed in line with evidence-based 
research. Previous research in the USA has confirmed that less than half of oncologists discuss 
HPV with their patients (Milbury et al., 2013) and this study showed just over half had been told 
of their HPV diagnosis. As it is becoming more recognised that patients should be informed 
about HPV being the cause of their cancer (Shuman & Wolf, 2010), health professionals need 
to decide on the best time to discuss this with patients, with patients in this study suggesting the 
earlier the better.  
Previous research with a small sample of male HPV-OSCC survivors also found that HPV was 
often overshadowed by the cancer itself and that patients were encouraged by the positive 
prognosis (Baxi et al., 2012). Unlike previous studies (Baxi et al., 2012; Low et al., 2009; Manne 
& Badr, 2008), no patients or partners in this study reported decreases in intimacy, but this may 
be because they were not specifically probed about their sexual relationships. Similarly, both 
studies showed HPV to be relevant, but that this was secondary to the concerns about 
treatment of their cancer.  
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Findings from my systematic review in chapter 4 showed mixed results for the psychological 
impact of HPV-OSCC, with these studies mainly comparing QOL between HPV-positive HNC 
and HPV-negative HNC patients. The results from this study show the impact of the cancer 
diagnosis itself and the impact of the treatment are still significant for HPV-positive patients. 
One study from the systematic review showed the ‘social’ domain on a measure of QOL to 
reach its lowest at 3 months (Dziegielewski et al., 2013). This is the time when patients are 
receiving treatment, and patients in this study described being unable to and did not want to eat 
out or be sociable due to issues with eating, talking and being tired.  
The Transactional Model of Stress and Coping could be a useful framework to consider when 
designing further studies with this patient group to understand how patients appraise their 
diagnosis of HPV-OSCC, and this model has been used previously with cancer patients to 
examine psychological adjustment to cancer (e.g. Hulbert-Williams, 2009; Parelkar, Thompson, 
Kaw, Miner, & Stein, 2013). In the context of these results, the way in which a patient appraises 
their diagnosis of HPV-OSCC (the stressor) influences their method of coping, which impacts 
upon their adjustment to their diagnosis. Perceptions about the severity of the diagnosis, how 
much this will impact their life and how much they perceive themselves to blame for their 
diagnosis are all elements of primary appraisal in these patients. The amount of perceived 
control over the outcomes and emotions, as well as their confidence in their ability to deal with 
their diagnosis are all secondary appraisals which also influence the patient’s choice of coping 
strategy. Social support can moderate the secondary appraisals of patients and a study with 
HNC patients found those with less social support adopted less effective coping strategies 
(Moore et al., 2014). It is likely that HPV-OSCC patients will perceive high motivational 
relevance and there could also be the potential for some patients to have a high causal focus if 
they perceive their diagnosis to be a result of their sexual behaviour. It may be possible that 
patients’ appraisals of a diagnosis of HPV-OSCC could be adapted as a result of the 
information presented to them by health professionals, such as by using the key messages from 
chapter 6. For example, informing patients of the better prognosis and that HPV is a result of 
normal sexual behaviour may reduce patients’ motivational relevance, causal focus and also 
increase their perceived control over their diagnosis.  
The impact of an HPV-OSCC diagnosis on patients’ partners was significant. Many of these 
partners had to stop working and become a carer for their partner, feeling it was their role, 
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supporting findings from previous research interviewing 31 caregivers in Ireland that identified 
‘lifestyle restrictions and competing demands’ and ‘financial problems’ (e.g. as a consequence 
of having to give up work) as two relevant themes associated with psychological distress (Balfe 
et al., 2016). Partners were also often the source of information for others, being the one who 
had to keep the rest of the family informed about the patient. Partners also sought information 
about HPV and other aspects of their partners’ cancer, in the effort to be as prepared as they 
could be, supporting previous findings from a study in New Zealand with 73 caregivers that 
found in a need to improve their understanding of the situation, caregivers requested 
information (Richardson et al., 2015a). Partners also thought about others, trying to hide their 
feelings from either the patient or the rest of their family. Patients recognised that their diagnosis 
had a significant impact on their partners, which supports previous findings from two studies in 
New Zealand carried out with HNC patients and their caregivers (Richardson et al., 2015a; 
Richardson, Morton, & Broadbent, 2015b). The findings from this study also support previous 
research with partners and carers of patients with HNC who have found carers to report 
restrictions to their lifestyle and frustrations around providing food for the patient at home (Balfe 
et al., 2016; Longacre et al., 2012). 
8.6 Strengths and limitations 
This study is the first in the UK to interview patients diagnosed with HPV-OSCC, as well as their 
partners. By interviewing patients and partners separately, this enabled each individual to share 
their experiences from their own perspective without being influenced by their partner. By 
interviewing both patients and their partners, this also allowed me to capture the individual 
within the dyad, without taking into consideration the perspective from the dyad (Eisikovits & 
Koren, 2010). This method also allowed me to address HPV, which may have been too 
sensitive to bring up in joint interviews. Other approaches which could be taken to interviewing 
these dyads include conducting two separate simultaneous interviews, conducted by different 
interviewers; joint interviews; both separate and joint interviews with the same participants; and 
separate interviews with some dyads and joint interviews with others (Eisikovits & Koren, 2010). 
Due to time and cost constraints, the simultaneous separate interviews and the combination of 
separate and joint interviews, were not possible. As I was not aiming to analyse interactions 
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between the patient and their partner, joint interviews were not appropriate, as well as for 
reasons of sensitivity of the topic.     
As I was a stranger to these participants and they were interviewed in a naturalistic setting, this 
may have enabled participants to feel more comfortable disclosing details about their 
experiences. Qualitative research provides a wealth of rich data, a lot of which could not be 
presented in this chapter. Qualitative interviews give a much greater depth to providing an 
understanding and description of people’s personal experiences. 
There were a number of ethical considerations which limited part of the research design for this 
study. Although all patients had been screened as HPV-positive on the basis of their medical 
records, not all these patients had been told of their HPV status, despite having indicated this 
on a pre-screening questionnaire. These discrepancies have been found previously in this 
population, where 62 patients were identified by their medical records as having an HPV-
positive tumour, but only 66% of the patients reported that they had an HPV-positive tumour 
(Milbury et al., 2013). This limited the scope of some of the interviews, as HPV could not be 
discussed as it would not have been ethical for me to disclose this to them. There is also the 
ethical problem of presenting quotes of participants alongside their partner’s quotes, revealing 
information which has been conducted in confidential interviews (Forbat & Henderson, 2003), 
but I have taken efforts to avoid doing this. Although the interviews were conducted separately, 
it is possible that patients and their partners may have discussed the interview between the 
interviews being arranged and when it was conducted, which may have influenced their 
response. Conversely, this may have triggered some memories in the participants which they 
may have otherwise forgotten. Conducting the interviews separately ensured that the 
participants would not interact within the interviews, but this may not have stopped the patient 
thinking about their partner when giving their responses during the interview. As with any 
qualitative research, the results cannot be generalised due to the sample size and recruitment 
being non-random, although the data in this study did reach saturation and no further themes 
were emerging. The interpretation of the data can also be influenced by the researcher, but by 
including others in the analysis process, it is hoped that this will have minimised any personal 
biases and idiosyncrasies. There is also the limitation of time since diagnosis with these 
patients. Patients were interviewed at least one year post diagnosis to ensure that they were 
post-treatment and were now in recovery. This may have affected the results in that issues 
CHAPTER 8 – INTERVIEWS WITH PATIENTS AND PARTNERS 
255 
 
pertinent to the participants at the time of diagnosis may no longer be pertinent now, or they 
may have forgotten their feelings at the time of diagnosis. It is not possible to know whether the 
responses of these patients at one year would be similar to those patients who may not have 
survived for one year. However, given the survival rates for HPV-OSCC patients are good, it is 
hoped that most patients would survive at least one year.    
8.7 Conclusion 
This study suggests that HPV-OSCC has a significant psychosocial impact on patients and their 
partners, but that most of the concerns are related to dysfunction that occurs from their cancer 
treatment and not to their HPV status. There are concerns and uncertainties about the sexually 
transmitted nature of HPV which need to be addressed and this information should come from a 
trustworthy and reliable source such as the patient’s doctor. As participants used the internet as 
an information resource for HPV, written information for patients and their partners is likely to be 
a useful resource and from a resource that is trustworthy, which leads to my final study. This 
written information should be discussed with the patient around the time of diagnosis. Further 
work is needed with a larger number of HPV-OSCC patients across different time points in their 
treatment pathway to establish their immediate responses to HPV and their feelings at different 
time points.
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CHAPTER 9. THE DEVELOPMENT OF PATIENT 
INFORMATION MATERIALS (STUDY 6) 
9.1 Introduction 
Communicating health information can be challenging (US Department of Health and Human 
Services, 2009). The previous chapters of this thesis have shown some health professionals to 
have a lack of confidence in discussing HPV with oropharyngeal squamous cell carcinoma 
(OSCC) patients (see chapters 6 and 7) and also that patients search for answers to questions 
they have about HPV (see chapter 8). Health professionals have also responded positively to 
the idea of having a clear plan of what to say to their patients about HPV and also welcomed 
the idea of having a leaflet that can be used with patients (see chapters 6 and 7). As previous 
research with HPV and cervical cancer has shown that there are key pieces of information 
about HPV that help reduce negative psychological consequences (see chapter 3), it is 
important that these messages are also communicated with HPV-OSCC patients. This chapter 
will use the term OSCC as the information developed is specifically aimed at HPV-OSCC 
patients. The term throat cancer is used in the information for reasons explained in the 
development process.  
There is substantial evidence that chronically ill and cancer patients obtain health information 
from sources other than physicians (Czaja, Manfredi, & Price, 2003; Wagner, Baker, Bundorf, & 
Singer, 2004). In a small USA study of 62 HNC patients, 58% of HPV-OSCC patients reported 
seeking information from sources other than their oncologist (Milbury et al., 2013). Since the 
introduction of the internet, a substantial number of people now use it to search for health 
information. In the UK, the use of the internet to access health information has risen from 18% 
in 2007 to 49% in 2015 (Office of National Statistics, 2015). The rates have been found to be 
even higher in the USA, with 72% of internet users reporting looking online for health 
information in the last year (PewResearchCenter, 2013) and in rural Canada the internet was 
reported to be frequently consulted for health information by 59% of responders (Harris, 
Wathan, & Fear, 2006). Searching online has been reported to improve people’s understanding 
of health care issues (Baker, Wagner, Singer, & Bundorf, 2003) and empower patients as a 
result of increasing their knowledge (Ziebland et al., 2004). However, there is the problem of 
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inaccuracies associated with information found on the internet and difficulties in finding high 
quality websites (Eysenbach, Powell, Kuss, & Sa, 2002). In contrast to printed educational 
materials, information on the internet can also be found across a number of different web pages 
and not on one website alone. The information found on the internet may also require higher 
literacy than printed educational materials (Eysenbach et al., 2002). Health information on the 
internet therefore may present inaccurate information which is not written at accessible 
readability levels and may cause unnecessary patient anxiety.  
Although the internet is becoming a huge resource of health information, it is still not used by all 
as a source for health information. Health professionals remain an important and a trusted 
source of health information and patient information leaflets are important in healthcare (Garner, 
Ning, & Francis, 2012). The Pew Internet Project found 70% of US adults still received 
information from their doctor the last time they had a serious health issue (PewResearchCenter, 
2013). Health professionals have an important role to play in checking patient comprehension 
and initiating an open discussion about health information (Colledge, Car, Donnelly, & Majeed, 
2008). Written information is still important to ensure that those who are without access to the 
internet and other new technologies are not unduly disadvantaged (Eng et al., 1998; Hsu et al., 
2005). Those more likely to use the internet to seek health information are younger, female and 
have more education (Bundorf, Wagner, Singer, & Baker, 2006). The 2004 UK White Paper 
‘Better information, better choices, better health’ stated that ‘everyone should have improved 
access to high quality information, health professionals should communicate more effectively 
with patients and there should be a nationally coordinated process to produce and deliver info’ 
(Colledge et al., 2008, p447).  
Health literacy is an important determinant of patients’ understanding of information given to 
them, and the percentage of adults in the UK below the literacy level expected at 16 years of 
age has been reported to be 43% (Harding et al., 2012), with the same percentage without the 
literacy skills to be able to understand the text in health materials (Rowlands et al., 2015). 
Good information provided to patients following the consultation can help remind patients what 
they have been told if, due to stress or language difficulties, they are unable to remember. By 
providing this information, it also gives patients the opportunity to go away and read the 
information that is relevant to them and think about the issues involved. Good information can 
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reduce patient anxiety, increase understanding of their diagnosis and result in patients being 
more satisfied with their care (Ong, de Haes, Hoos, & Lammes, 1995; Stewart, 1995). This 
information can also be useful for patients’ partners and other family members. High quality 
information is a key aspect of support for cancer patients and their families and as shown in 
chapter 8, caregivers search for information about the diagnosis. 
Previous experimental studies communicating HPV in the cervical cancer context have found 
key messages important to be communicated (Lloyd, Marlow, Waller, Miles, & Wardle, 2009; 
Waller et al., 2007). A study with female students randomised to receive information about HPV, 
Chlamydia or the environment, found that although HPV information was rated as more scary, it 
was also rated as more reassuring than environmental information and did not increase anxiety 
(Lloyd et al., 2009). A study manipulating knowledge of HPV in four experimental conditions 
found participants receiving messages about the high prevalence of HPV rated lower stigma 
and anxiety compared to participants who only received information about the sexually 
transmitted nature of HPV (Waller et al., 2007). Shame was also rated higher in this group 
compared to all other groups. The group with lowest anxiety was the group receiving basic facts 
about HPV, its high prevalence and its sexually transmitted nature. Lower stigma and shame 
scores in those receiving the messages about the high prevalence suggest there may be a 
normalising effect associated with this information. As these studies were either hypothetical or 
in student samples, it is not possible to know if these can be generalised to a clinical setting. 
However these studies provide important findings as to what messages about HPV may be best 
received and may mitigate negative psychological consequences associated with its sexually 
transmitted nature.  
Information currently available 
When conducting a Google search online using an incognito window for ‘HPV’, the top links 
were for NHS Choices, Cancer Research UK, Wikipedia, Centers for Disease Control and 
Prevention, Macmillan, Jo’s Trust, and the National Cancer Institute. All these links were mostly 
in the context of cervical cancer, with the National Cancer Institute including oropharyngeal 
cancer as a cancer caused by HPV. Information materials available through some of these links 
include titles such as ‘Human Papillomavirus (HPV)’ published by Jo’s Trust and ‘The HPV 
Vaccine’ published by the NHS. These information materials included information about the 
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prevalence of HPV, how HPV is transmitted, reducing the risk of having persistent HPV 
infection, HPV and cervical cancer, cervical screening and the HPV vaccine. The NHS booklet 
about the HPV vaccine also presented more detailed information about the vaccine, including 
who is eligible and potential side effects.  
When searching online for ‘head and neck cancer’, the information available from Macmillan, 
NHS Choices, Wikipedia, the National Cancer Institute and Cancer Research UK was 
presented on the first page of results. This is general information, such as ‘Mouth Cancer’ 
published by Cancer Research UK and there is also a wealth of information online, with some 
hospital trusts having information on their websites (e.g. Liverpool Head and Neck Centre, 
University Hospitals of Leicester). As found in the previous chapter, a lot of the information 
provided to patients was around their treatment. Some websites have begun to acknowledge 
the role of HPV in HNC, but there is either still a lot of information lacking from these websites, 
or the information provided is not targeted at the right readability and comprehension levels.  
Conducting an online search for ‘HPV and head and neck cancer’ uncovered a questions and 
answers leaflet resource from the USA based on a peer-reviewed paper (Fakhry & D’Souza, 
2013). This was a comprehensive leaflet, but was all text and does not include diagrams. 
Although it included some basic information about HPV, this was incomplete. Many of the other 
results from this search however, included links to research papers which were not 
understandable to all users. Specific UK-based charity websites were not easily found during 
this search and only when ‘HPV and throat cancer’ was searched for did The Mouth Cancer 
Foundation become evident, suggesting UK-based HNC charities do not use the terms 
commonly enough for them to be picked up as keywords.  
Information booklets have begun to be developed in the UK about HPV and its relationship with 
HNC, but these were not always appropriate in communicating messages that are aimed at 
reducing any possible negative psychological consequences. An example is ‘HPV and Mouth 
Cancer’ published by The Mouth Cancer Foundation, which included information about what 
HPV is, HPV and mouth cancer, getting HPV and the HPV vaccination. The leaflet provided a 
quote which says, ‘The only currently available preventive measure is to practise sensible 
sexual behaviour’. This has the potential to suggest that those who have HPV-OSCC had not 
been practising ‘sensible sexual behaviour’. The Throat Cancer Foundation website gives 
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information on what is HPV and information on why HPV is a problem, including information on 
high and low risk types of HPV and why it causes cancers, but does not give much information 
about HPV and throat cancer. The information about HPV on this website was very detailed and 
may not be suitable for all literacy levels, especially as this is only available online where higher 
readability levels are required than in printed materials (Eysenbach et al., 2002). Ideally, 
information presented online should have higher readability levels than printed materials to 
account for lower reading speed, comprehension and fatigue (Redshaw, 2003). Despite the 
increasing prevalence of HPV-OSCC, there is a lack of appropriate and reassuring information 
available to help patients and their family members understand the role of HPV in their disease. 
The aim of this study therefore was to develop an information booklet that is clear and 
accessible, would aid in the discussion of HPV-OSCC between health professionals and 
patients, and also provide information that patients could take home with them where it could 
facilitate the discussion with other family members. The booklet aimed to be clear, concise, 
relevant and accurate, and written in everyday language. The booklet also aimed to facilitate 
information about HPV-OSCC being communicated in a way which minimises any negative 
psychological outcomes to the patient.   
9.2 Methods 
The approach taken for the development of these information materials broadly followed the 
framework laid out in ‘Simply Put: A guide for creating easy-to-understand materials’ (US 
Department of Health and Human Services, 2009). The steps taken are illustrated in Figure 9.1. 
Steps seven and eight were not carried out due to time constraints.   
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Steps for Developing Health Communication Materials That Are Evidence-Based 
and User Friendly 
1. Identify intended audience and define/research the key health problems or interests  
2. Engage the intended audience- determine what their needs, beliefs/values, and 
interests are, and their level of knowledge of the identified health topic  
3. Determine key concepts and messages based on knowledge of the audience  
4. Design a draft of the material  
5. Pretest materials with intended audience  
6. Tweak draft according to feedback from the audience  
7. Publish and distribute materials  
8. Evaluate the audience’s satisfaction and understanding 
Figure 9.1: Steps followed in development of the information materials (US Department of Health and 
Human Services, 2009) 
9.2.1 Process of gathering information 
Health Professionals: The findings from the interview study with health professionals (chapter 6) 
and the survey with health professionals (chapter 7) contributed to an understanding of the 
components and key messages most useful to include in the booklet.  
Patients and Partners: The interviews conducted with patients and their partners (chapter 8) 
enabled an understanding of what information they had already received and an identification of 
their key information needs.  
The key information about HPV was extracted from the themes interpreted in the qualitative 
analysis from the interviews with health professionals and patients. This was information from 
the health professionals which was interpreted as being important to communicate to patients, 
and from patients and their partners as being the key information they wanted to know. Recent 
research and best evidence to answer these questions was then searched for using large, 
international databases to search for guidelines, systematic reviews or published research 
studies. The references for these information sources were noted.  
A search was also conducted for any other relevant patient material already in circulation about 
HPV, including information materials explaining HPV and cervical cancer. This search was 
looking for any materials that already gave specific information about HPV and oropharyngeal 
cancer. These materials were also used to develop the structure and design of the booklet. 
None of the materials found were suitable as they currently stood. All the evidence from the 
interviews, the recent literature and relevant materials was gathered together and assessed to 
decide what to include in the booklet. This was assessed against the questions patients wanted 
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answered and most frequently searched for. This information was designed to be handed to the 
patient following the consultation and used as a discussion tool for health professionals. The 
booklets could also be available on a rack in the waiting room of the clinic and the information 
included in the booklet could be available online.  
9.2.2 Writing the content for the booklet and measures of assessment 
Using the information gathered from the interviews and from the research evidence, the content 
of the booklet was drafted to answer frequently asked questions and also provide important 
summary points for health professionals. The content includes key messages from health 
professionals, basic information about HPV and more specific information about HPV and 
OSCC and signposts to other useful websites.  
Once drafted, the booklet went through a series of iterations, checking drafts against the 
guidance from the Plain English Campaign and checking with members of my supervisory team 
until it seemed easy to read. The Plain English Campaign strives for everyone to have access to 
clear and concise information (Plain English Campaign, 2016) and since 1990 has implemented 
the Crystal Mark on documents which the Plain English Campaign have worked with to make as 
clear as possible. The Plain English Campaign provides guidelines which were used in the 
development of this information to ensure that the information is as clear as possible. The 
Flesch Readability formula was applied to the content (Flesch, 1948). The Flesch Reading 
Ease7 rates text on a 100-point scale, with higher scores representing the text being easier to 
understand. A score of 60-70 is interpreted as Plain English and can be understood by 13-15 
year olds. The Flesch-Kincaid Grade Level8 test indicates at which grade level in the USA the 
text is suitable for. A lower score indicates a lower grade level and reading age. Microsoft Word 
also gives a percentage for the number of passive sentences in the text. The score is calculated 
by the number of passive sentences divided by the number of active sentences. The lower the 
score the better as this indicates more active sentences in the text. The guidance included in 
Lord Moser’s 1999 report ‘A Fresh Start’ (Department for Education and Employment, 1999; 
                                                     
7 The formula for calculating the reading ease is [206.835 – 1.015 (total words/total sentences) – 84.6 
(total syllables/total words)] 
8 The formula for calculating the grade level is [0.39 (total words/total sentences) + 11.8 (total 
syllables/total words) – 15.59] 
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National Health Service, 2010) was also followed throughout the development of this 
information. Table 9.1 outlines the guidance followed in the development of the information.  
Table 9.1: Guidelines followed in the development of the information 
Plain English Campaign Lord Moser’s ‘A Fresh Start’ 
Keep your sentences short: Short 
sentences, in general no more than 15 to 
20 words long 
Using patient-friendly text - ‘We’ and ‘you’, 
create a sense of inclusion and trust 
Prefer active verbs 
Being relevant - Make sure information is 
relevant to and appropriate for the patient 
group it is aimed at 
Use ‘you’ and ‘we’ Making sure the information is consistent 
Use words that are appropriate for the 
reader 
Making sure the information is helpful 
Do not be afraid to give instructions Do not confuse people 
Avoid nominalisations: an abstract noun, 
the name of something that is not a 
physical object such as a process, 
technique, or emotion e.g. discussion, 
completion  
Signpost additional resources 
Use lists where appropriate Be evidence-based and up-to-date 
Lowercase letters are easier to read  
Present and active tense will make text 
more direct and engaging - aim for 80-90% 
active 
 
Be concise  
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Content developed 
Readability checked 
Expert review 
Patient review 
Design by Resonant 
Content and design 
adapted 
Content and design 
adapted 
Readability checked 
Readability checked 
Leaflet finalised and readability 
checked 
Figure 9.2: Flowchart of the stages in the development of the booklet 
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9.2.3 Process of developing the booklet 
Resonant are a social marketing company and behavioural insight team who have been 
involved in the development of information materials for a number of health related projects 
within the Health Behaviour Research Centre at UCL and for Cancer Research UK. I met with 
Resonant to communicate the brief of the project (Appendix 9.1) and the content of the 
information was sent to Resonant at the same time as it was sent to experts for review (Figure 
9.2). Resonant were responsible for the design and layout of the information booklet and took 
into consideration the intended audience, key information, helping patients to navigate the 
information, use of colour, and use of diagrams to aid in the understanding of key pieces of 
information. The content and design were adapted following expert review and patient review. 
The information booklet went through five rounds of iterations before patient review to ensure 
the vocabulary was simple, re-writing sentences so they were less complex and used active 
sentences rather than passive. The readability score was assessed on a number of occasions 
as a marker for an improvement in the readability of the language (Figure 9.2). The final booklet 
was developed with a final iteration following the patient review.    
Expert evaluation 
Once my supervisory team and I were happy with the first draft, the content was sent to experts 
to check accuracy and that it reflected the best evidence available. This was a group of five 
experts who included: a field-based expert (British virologist and epithelial biologist working in 
HPV and cervical cancer), two HNC clinical experts (one surgeon, one speech and language 
therapist), a communications expert (academic working in health literacy) and an expert in 
psycho-oncology and healthcare communications (academic behavioural scientist). The booklet 
was sent with a deadline for feedback. The experts were asked to comment on: 
 Their overall impressions of the booklet 
 The order of the information presented 
 The use of headings throughout the booklet 
 If the booklet answers the questions they feel are important 
 If there are any other questions that should be included 
 If any of the information is unhelpful 
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 If the information is accurate  
 If relevant, whether they would be happy going through the booklet with patients 
 Whether any of the information was unnecessary 
 Any other comments/changes they would like to see 
 
Where there was disagreement about different information, I took responsibility for finding 
empirical evidence and made the final decision.  
  
2
6
8
 
C
H
A
P
T
E
R
 9
 –
 D
E
V
E
L
O
P
M
E
N
T
 O
F
 IN
F
O
R
M
A
T
IO
N
 M
A
T
E
R
IA
L
S
  
 
Figure 9.3: Draft 1 – Developed after receiving feedback from the experts 
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Figure 9.3: Draft 1 – Developed after receiving feedback from the experts (contd.) 
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Patient evaluation 
Following expert review, the booklet (Figure 9.3) was adapted before being tested with HNC 
patients to assess its ease of use, its relevance and accessibility. Five patients from my PAG 
were asked to rank a selection of front cover options (Figure 9.4) in order of preference and 
comment on the revised booklet (Figure 9.5). Three of the patients were recruited to the PAG 
through the online advertisement on The Throat Cancer Foundation website and two of the 
patients had joined the PAG following being interviewed for the study conducted in chapter 8. 
The patients were asked to comment on: 
 Their overall impressions of the booklet 
 The language used in the booklet /is it written in words they can understand 
 The order of the information presented 
 The use of headings throughout the booklet 
 If the booklet covers the things they feel are important 
 If there is any information missing that they would have liked to be included 
 If any of the information is unhelpful 
 Whether any of the information was unnecessary 
 Any other comments/changes they would like to see 
Patients were followed up with a short telephone interview to explore their feedback. Any 
barriers to patients’ understanding of the information presented and comments were carefully 
considered and changes to the booklet were made to improve it. Including patients in the design 
of the booklet helped to ensure that the information will be read and understood.  
 
  
0 
 
 
2
7
1
 
C
H
A
P
T
E
R
 9
 –
 D
E
V
E
L
O
P
M
E
N
T
 O
F
 IN
F
O
R
M
A
T
IO
N
 M
A
T
E
R
IA
L
S
  
  
 
Figure 9.4: Draft 2 - Front cover options presented to patients for feedback 
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Figure 9.5: Draft 2 - Booklet sent to patients for feedback  
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Figure 9.5: Draft 2 - Booklet sent to patients for feedback (contd.) 
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9.3 Results 
The information booklet was designed to provide answers to questions most frequently asked 
by patients in a question and answer format, and to provide a tool for health professionals to aid 
in communicating about HPV as a cause of OSCC to HPV-OSCC patients. Patients and health 
professionals were also signposted to websites which contain further information should they 
want to look further.  
The title of the booklet was chosen to be HPV and Throat Cancer. This was because when 
examining the patient interviews conducted in chapter 8, this was the most commonly used term 
to refer to their cancer. The throat was also thought to be the place where patients are most 
likely to attribute their cancer to as symptoms typically start there.  
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Figure 9.6: Final booklet - page 1 
The first page of the booklet (Figure 9.6) gives an overview of the focus of the booklet and some 
basic information about HPV. As many of the patients interviewed in chapter 8 had not heard of 
HPV before being told their diagnosis, it was important to include an explanation about the virus 
and to reassure patients that this is a common virus and that in the case of throat cancer, it is 
more treatable. Including a diagram of the throat was also to help explain to patients where their 
cancer is located as they are likely to have been told by their doctor where their primary tumour 
was found, as was the case for the patients in chapter 8. This is also included to facilitate the 
discussion of HPV between health professionals and patients.  
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Figure 9.7: Final booklet - page 2 
The second page of the booklet (Figure 9.7) includes further basic information about HPV which 
was included as evidence has shown basic information about HPV to be beneficial (Waller et 
al., 2007) and patients in chapter 8 who had been given information about the high prevalence 
of HPV felt reassured. Additionally, including information about the low-risk and high-risk types 
of HPV was important to include to explain to patients that not all types of HPV cause cancer. 
Including a pie chart to demonstrate that a very small percentage of those who have HPV go on 
to get cancer, was suggested by the health literacy expert, explaining some concepts through 
diagrams.  
CHAPTER 9 – DEVELOPMENT OF INFORMATION MATERIALS 
277 
 
 
Figure 9.8: Final booklet - page 3 
The third page of the booklet (Figure 9.8) begins to answer some of the specific questions 
patients had about HPV. How they had got HPV and whether HPV could be transmitted were 
common questions expressed to health professionals in chapter 6 and by patients in chapter 8. 
There was also a worry from patients and also from partners, as to whether they could be at 
heightened risk. An important message to reiterate was that HPV is a result of normal sexual 
behaviour as this has been found to be reassuring and was specifically mentioned in the 
feedback from patients. The information about partners being at increased risk is aimed at 
reassuring couples that HPV-related cancers are rare and so they are at low risk of getting a 
cancer caused by HPV. Information was also included about future partners, for patients not 
currently with a partner.  
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Figure 9.9: Final booklet - page 4 
Page four (Figure 9.9) continues to answer questions posed by patients, progressing from how 
they might have got HPV, to how HPV turned into cancer. As there are still many unknowns 
around this question, these were acknowledged and expressed. One of the patients in chapter 8 
quoted what her oncologist had told her about the progression of HPV which had really 
reassured her and she found it straightforward to follow. That explanation was adapted for use 
in answering this question. Patients also wanted to know whether they still have HPV after they 
have been treated for their cancer, and it was important to acknowledge that there is no clear 
evidence to suggest whether they have or they have not, and also that there is no reliable test 
available yet for oral HPV. The health literacy expert contributed to the wording of the response 
to ‘Do I still have HPV?’ to help make this as simple and straightforward as possible.  
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Figure 9.10: Final booklet - page 5 
Page 5 (Figure 9.10) of the booklet included another two questions posed by patients. The HPV 
vaccine was mentioned in chapter 8 by some of the patients who have children and also a 
couple who had chosen to pay for the vaccine privately themselves. Health professionals also 
said that patients asked them about the HPV vaccine. As all the information about the HPV 
vaccine has been conducted with cervical cancer, the evidence for the efficacy of the vaccine 
against oral HPV has not yet been established and it was important to say this. Patients had 
demonstrated relief and reassurance in chapter 8 when they were told about the positive 
prognosis of HPV-OSCC and general lifestyle advice was included to inform patients of other 
ways to help prevent cancer in the future.  
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Figure 9.11: Final booklet - page 6 
The final page of the booklet (Figure 9.11) reiterated some of the key messages interpreted 
from the health professional interviews, to reassure patients and help minimise any negative 
psychological impact. This included some of the key messages from health professionals in 
chapter 6.  
The back cover of the booklet (Figure 9.12) also included reliable and trusted websites where 
patients and/or their family members could look for further information. 
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Figure 9.12: Final booklet - back cover 
9.3.1 Expert review  
The Flesch Reading Ease score, Flesch-Kincaid Grade Level score and percentage of passive 
sentences in the content sent to the experts was 71.7/100, 6.6 (ages 11-12), and 20% 
respectively. The lower the percentages of passive sentences the better, as this indicates more 
active sentences in the text. One health professional said ‘it will be an extremely useful 
document’. Feedback from the expert review was very thorough and included advice about the 
language used and clarifying the accuracy of some of the information used (Appendix 9.2). For 
example, this one health professional commented on the section ‘What is HPV?’ that it could be 
expanded to explain that the majority of people will clear the infection and that only a very small 
number go on to get cancer.  
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‘Maybe expand this to highlight that the vast majority of us will clear the infection, a 
small number will set up a chronic infective/inflammatory state while only a very small % 
of us will go on to get cancer’. (Male, health professional) 
Other comments from this expert included clarifying information about the HPV vaccine, 
particularly around the effectiveness of being vaccinated after being infected with HPV, the 
approval of the vaccine for men who have sex with men (MSM) and reasons for girls being 
included in the national immunisation programme. The evidence behind the inclusion of 
information about behavioural actions such as cervical screening, condom use and attending a 
dentist regularly were questioned.  
The health literacy expert commented on the content of the information and also the use of 
graphics. This expert helped simplify the language used and made suggestions of techniques to 
use to do this. For example, spelling oropharyngeal cancer out phonetically, ‘The medical term 
for these cancers is oropharyngeal (or-o-far-an-gee-al) cancer’. Other specific comments from 
this expert included simplifying the diagram showing where oropharyngeal cancers are located, 
clarifying low and high-risk HPV types and including more information about the HPV vaccine, 
such as whether it is free and if they can get their boys vaccinated if they are willing to pay for it, 
and simplifying information about whether the HPV vaccine will prevent against throat cancers 
in the future.   
Specific advice came from the speech and language therapist working with HNC patients about 
how patients might feel about some of the language used based on her experiences of 
communicating with them. An example included a comment based on the section about the 
prognosis being ‘good news’. The speech and language therapist explained that some of her 
HNC cancer patients expressed the view that cancer can never feel like good news.  
‘I am a bit cautious about the “good news” - My PPI [Patient and Public Involvement] 
group think that getting cancer can never feel like good news, so being told that your 
cancer may respond better and therefore this is good news may be construed differently 
by different patients. Might be best to keep to fact’. (Female, speech and language 
therapist) 
Further comments included moving some of information from under one heading to another 
heading and simplifying the diagrams included, in particular the diagram illustrating the 
progression of oral HPV to throat cancer.   
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9.3.2 Patient review  
After all the amendments and improvements made conjointly between Resonant, my 
supervisory team and I, the Flesch Reading Ease score, Flesch-Kincaid Grade Level score and 
percentage of passive sentences for the draft of the booklet sent to the patients for feedback 
was 78.5/100, 3.9 (ages 9-10) and 7% respectively. Encouragingly all the patients were very 
positive about the booklet and would have liked to have received it when they were diagnosed. 
Some of the comments that came from patients about the content included clarifying some of 
the information about the vaccination, in particular whether the vaccine works only for women 
and MSM, and whether the vaccine prevents throat cancer. Some patients also wanted some 
additional explanation for the diagram demonstrating the progression of oral HPV to throat 
cancer to aid in their understanding (Appendix 9.3).  
The front cover labelled number 4 in Figure 9.4 which shows two men and two women from 
different ethnic backgrounds was the most favoured for the front cover, ranked first by two 
patients, third by two patients and fifth by one patient. The reasons patients favoured this cover 
were because it had a mixture of men and women and ‘because it reflected the broad spectrum 
of people that can and do get HPV-related cancers’. Some patients found the options with just 
the person’s throat ‘a bit creepy’. Two patients liked the covers with four people on the front, 
with one patient preferring those covers which focused on the throats as he said, ‘personally I 
think the one that spoke out to me was everyone’s throats, because that is the initial, that is 
what we’re talking about’. Some patients said they did not feel that strongly about the cover.  
All patients were asked for their overall impressions about the booklet and all patients were 
positive.  
‘Thanks for sending me this brochure. It is extremely good, I wish my wife and I had 
access to this when I was first diagnosed. I think this brochure is excellent, and will be 
very useful for people diagnosed with these cancers, and for their family and friends’. 
(Male, patient) 
One of the patients commented that this would have been a useful resource to have had 
available to help communicate to her family that her HNC was HPV-related.  
‘Excellent to have a resource, I would have found this really useful at the point of 
diagnosis, especially to share with family as HPV-related cancer is very difficult to talk 
about, especially with children and older relatives. I didn’t share the specific details of 
my cancer for exactly this reason’. (Female, patient) 
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The patients said it was easy to read, one particularly commenting that they liked the ‘guide on 
how to pronounce oropharyngeal’. The order of the information was well accepted by all 
patients, with just a few small suggestions about repeating one of the key messages that having 
HPV is a result of normal sexual behaviour. The headings were said to be useful, but one of the 
patients commented that one of the questions (Should I be vaccinated?) posed was not 
answered.   
Patients were asked to express their preference between a pie chart and a pyramid depicting 
that less than one per cent of those who get HPV go on to get cancer. The preference was for 
the pie chart.  
All patients believed the booklet covers the things they believe are important, but made some 
suggestions about additional websites that could be signposted, about considering listing the 
high and low-risk HPV types, more information about the vaccine (as discussed above), a more 
detailed explanation of what HPV is, whether they can be tested to see if they still have HPV 
and if there are any implications for patients’ children.  
9.3.3 Examples of amendments 
A printed copy of the final draft of the information booklet is appended. The Flesch Reading 
Ease, Flesch-Kincaid Grade Level score and percentage of passive sentences for the final 
information booklet were 77.3, 4.2 (ages 9-10) and 5% respectively. Resonant asked questions 
about the content in the beginning stages to clarify the content and become familiar with the 
available evidence. Table 9.2 gives some examples of changes made from paragraphs in the 
original content, to changes made through input from Resonant, after the expert review and 
what they are now following both expert and patient review. This section includes some 
examples of sections which were amended through an iterative process following both expert 
and patient feedback and explains why and how these sections were changed.  
The information under the heading, ‘How did I get HPV?’ was amended following comments 
received from experts and input from Resonant. One expert suggested including the word 
‘probably’ prior to open mouth kissing because the real risk is transmitting HPV through the 
tongue or oral skin on the penile skin. Another expert was also cautious as individual sexual 
practice is difficult to quantify in terms of risk. The heading of the section was amended after 
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review by my supervisory panel and I to ‘How can HPV be passed on?’ After the feedback from 
patients just one sentence was added. One patient commented that they would like the 
prevalence of HPV to be reiterated and so the sentence ‘Having HPV is a result of normal 
sexual behaviour’ was added to the beginning of the paragraph.   
The second example given is under the heading, ‘Is my partner at risk of getting HPV?’ At first 
this contained information about cervical screening being important for the patients’ partner, but 
this was removed after comments that it was not relevant in this context. The content was 
amended through iterations between Resonant, myself and my supervisory team aiming to 
simplify the vocabulary and make the sentence less complex. When designed by Resonant, the 
paragraph relating to condom use with new partners was highlighted in a box as this is a 
behaviour patients can adopt to help prevent transmission of HPV.  
The final example in the section, ‘Should I be vaccinated against HPV?’ went through a number 
of iterations. A key comment from one of the patients was that the question had not been 
answered and so the title of the heading was changed so that some background about the 
vaccine could be explained, and to also acknowledge that there are currently no clear 
recommendations. The information in this section was also clarified to include a sentence about 
the effectiveness of the vaccine on current HPV infections, future infections and infections with 
different HPV types.  
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Table 9.2: Examples of original paragraphs and what they were amended to 
Original paragraph Paragraph after expert feedback Final paragraph (following expert and patient feedback) 
How did I get HPV? 
HPV is passed through 
skin-to-skin contact with 
someone who has the 
virus. This can include 
genital, oral and anal 
contact. Open mouth 
kissing and oral sex can 
be risk factors for oral 
HPV. Risk of getting 
HPV goes up with the 
number of sexual 
partners a person has 
but you can get it from 
just one partner. 
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Table 9.2: Examples of original paragraphs and what they were amended to (contd.)                   
 
Is my partner at risk 
of HPV? 
If you have been 
together for several 
years it is likely that you 
and your partner have 
passed HPV between 
you lots of times. HPV 
infections are very 
common but HPV-
related cancers are not 
common. So the 
chance of your partner 
getting an HPV-related 
cancer is low.  
It is important that all 
women aged 25-64 
years go for cervical 
screening when invited 
to reduce the risk of 
cervical cancer.  
Using condoms for all 
sexual behaviours with 
future partners can 
reduce the risk of HPV 
being passed on but 
does not provide 
complete protection. 
HPV is passed through 
skin-to-skin contact.  
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Table 9.2: Examples of original paragraphs and what they were amended to (contd.)                         
 
Should I be 
vaccinated against 
HPV?  
We still do not know if 
the HPV vaccine stops 
throat cancer. 
Researchers are 
working to find out if the 
HPV vaccine might also 
work for throat cancers 
as it does for cervical 
cancers. We do know 
that the HPV vaccine 
can stop HPV infection 
from staying for a long 
time in the mouth and 
throat. 
As a large number of 
HPV-related throat 
cancers are caused by 
HPV-16, researchers 
are hopeful that 
vaccinating children 
now will protect them 
against HPV-related 
throat cancers in the 
future. 
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9.4 Discussion 
The objective of this study was to design an information booklet which provides answers to 
questions HPV-OSCC patients frequently ask or think about, as well as to facilitate discussion 
between patients and health professionals. The booklet includes responses to frequently asked 
questions and includes basic information about HPV, its sexually transmitted nature and 
emphasises its high prevalence, as previous research has shown these messages can lower 
feelings of anxiety, shame and stigma (McCaffery et al., 2006; Waller et al., 2007). This booklet 
adds to the existing literature already available to patients as it is up-to-date with the latest 
evidence and provides a resource which can be used by health professionals to ensure 
messages communicated to patients about HPV and HNC are consistent. It is not unusual for 
patients to seek the same information from a range of professionals involved in their care and 
so it is vital that consistent information is provided no matter who patients speak to (Catt et al., 
2005). 
The Flesch Reading Ease score was 77.3 and the Flesch-Kincaid Grade Level score was 4.2, 
illustrating a high score which indicates ease of understanding and the grade level to be that of 
a 4th grader in the USA, which is ages 9-10 years old. This demonstrates that the information 
booklet should be accessible for all levels of health literacy, as the average reading age in the 
UK is 9 years of age (See A Voice, 2010). The percentage of passive sentences was 5%, 
adhering to and exceeding the Plain English Campaign guidelines of aiming for 80-90% of 
sentences being active (Plain English Campaign, 2016).  
Comments provided by both experts and patients were valuable to the development of the 
booklet and the booklet was generally well received. All patients would have liked to have 
received this booklet when they were diagnosed and could use this booklet to facilitate the 
discussion about HPV and their cancer with their family. Patients particularly liked the guide on 
how to pronounce ‘oropharyngeal’, which to the best of my knowledge, has not been used in 
previous literature for this patient group. Patients commented on the language used in the 
booklet being easy to read and the use of headings in the design of the booklet being helpful to 
signpost to specific sections. As good information is also important for patients’ families, this 
booklet could also prove to be effective and useful for them too.  
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It is important to involve patients in the development of information booklets such as this to 
assess their understanding of the content and to amend the content based on their feedback 
(Rudd, Kaphingst, Colton, Gregoire, & Hyde, 2004), and it is becoming increasingly common to 
do so with the introduction of a clear NHS policy directive (Department of Health, 1999). As 
there has been a significant increase in the use of the internet in the search for health-related 
information (Office of National Statistics., 2015), it is also important that this information booklet 
is made available online.  
Through the development of the information booklet, it was apparent that there are still areas of 
the literature where there are not yet definitive answers. The literature about whether oral HPV 
can be transmitted through open mouth kissing is still hesitant (D’Souza et al., 2009; Pickard et 
al., 2012). There are also uncertainties about whether HPV remains in patients after they have 
been treated for their HPV-OSCC (Agrawal et al., 2008; Frakes et al., 2016; Rettig et al., 2015), 
and there is still a need for a reliable test for oral HPV (see section 1.2.2). The literature about 
whether the HPV vaccine prevents HPV-OSCC is also uncertain (see section 1.4), but the HPV 
vaccine has now been shown to prevent future infections or infections with different types of 
HPV if you have contracted and cleared HPV previously (Joura et al., 2012). It is also not 
possible to say for certain if a patient will not get another cancer caused by HPV.  
It is also important to be aware that there is increasing recognition that each individual is 
different and there may be a need for information to be tailored to the unique needs of 
individuals, which may be something which becomes more commonplace in the future 
(Colledge et al., 2008; Kreuter, Strecher, & Glassman, 1999). Providing alterative formats of 
information has been shown to improve knowledge, user-satisfaction and health behaviour 
(Berkman et al., 2004). Tailored information in HNC patients has also been shown to lower 
levels of anxiety and depression (D’Souza et al., 2013). Tailoring the information in the booklet 
to alternative mediums of accessibility and to different demographics, may be something to 
consider for this booklet in the future.   
Prior to this information being used within HNC clinics in the NHS, a formal evaluation with 
patients and health professionals would be optimal. An evaluation with patients would include 
testing the readability and comprehensibility of the booklet through cognitive interviews and 
assessing the acceptability of the information booklet. An evaluation with health professionals 
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would involve multidisciplinary team members piloting the information materials with HPV-
OSCC patients at a number of NHS sites for a short period (e.g. three months) with the aim of 
understanding how the booklet could be used in practice and how feasible it is to use in 
practice. Once the evaluation is complete, if shown to be comprehensible and acceptable to 
patients, and feasible to implement in practice, this booklet could be used across the NHS.  
9.5 Strengths and Limitations  
To my knowledge, this is the most up-to-date, evidence-based information booklet available for 
patients diagnosed with HPV-OSCC. This resource is valuable for both patients and health 
professionals, as some health professionals lack the confidence to discuss HPV because of 
their limited knowledge (see chapters 6 and 7). The development of the information was 
strengthened by the inclusion of both experts and patients in the development process. 
Involving experts in the early stages ensured that the information included in the booklet was 
accurate and they also provided some useful insights into how patients might respond to certain 
pieces of information. The inclusion of the patients for user-testing enabled the information to be 
tested for its ease of understanding and also for the design of the booklet to be commented on. 
As the booklet was well received, this provides some confidence that the booklet will be a useful 
addition to HNC clinics.  
It is important to not place too much emphasis on the readability scores of the booklet as 
readability scores are not designed to take into account the design and layout of the information 
and does not indicate comprehension. There is the possibility of social desirability bias in that 
the patients included in the user-testing of the booklet were less likely to criticise the booklet as 
they knew I developed it. The booklet needs to be evaluated formally with a larger sample size 
of patients and the comprehension of the booklet assessed, but this was not possible for the 
current study due to time constraints. According to Mayberry and Mayberry, an evaluation of 
patient information must comprise tests of readability, comprehensibility and the long-term 
effects of written materials (Mayberry & Mayberry, 1996). The booklet would also benefit from 
being evaluated for its feasibility of use in HNC clinics, by piloting its use in a number of clinics 
and getting feedback from the health professionals in these clinics. It is also important for this 
information to be made available online, given that a large number of people now look for health 
information online.  
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There are still some areas of uncertainty with HPV-OSCC and further research is needed. The 
information will need to be reviewed regularly and updated if new evidence has emerged that 
needs to be included or changed.  
9.6 Conclusion  
The feedback from experts and patients suggests that this information booklet will be well 
received by patients and a useful resource for health professionals. The development of this 
information booklet for HPV-OSCC patients and health professionals demonstrates where there 
are still gaps in our knowledge and so will need updating and reviewing. This resource also has 
the potential to help minimise any negative psychological consequences in patients and may 
increase health professionals’ confidence to discuss HPV and encourage more health 
professionals to discuss HPV.  
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CHAPTER 10. GENERAL DISCUSSION AND CONCLUSIONS  
10.1 Initial aims 
A wealth of research has been undertaken around the psychosocial impact of being diagnosed 
with head and neck cancer (HNC) associated with the well known causes of tobacco and 
alcohol. With the incidence of HNC increasing due to the rise in those diagnosed with HPV as a 
causal factor, it was important to investigate the psychosocial impact of this subgroup of HNC 
patients and whether this was amplified with the additional dimension of HPV.  
My thesis was based on eight research questions, which were addressed in five research 
studies, with my final study accumulating the findings from all previous chapters to produce an 
information booklet. Study 1 was a systematic review assessing the current literature measuring 
the psychological impact of an HPV diagnosis in the context of HNC in studies with patients 
(n=10 studies) and current knowledge of the link between HPV and HNC across a range of 
sample populations (n=41 studies). Study 2 was a content analysis examining media coverage 
in the UK of the link between HPV and HNC (n=112 articles). Study 3 was a qualitative study 
which purposively sampled health professionals from a range of disciplines who work with HNC 
patients (n=15) to explore their experiences of, and attitudes towards discussing HPV. Study 4 
was an extension of study 3, developing a survey for dissemination among different health 
professional groups working with HPV-OSCC patients (n=260) to explore their knowledge of 
HPV, their experiences of and attitudes to discussing HPV with their patients. Study 5 was a 
qualitative study with patients diagnosed with HPV-OSCC (n=20) and with some of these 
patients’ partners (n=12) to explore their experiences around the diagnosis of HPV-OSCC. 
Study 6 involved the development of an information booklet for use as a discussion tool 
between health professionals and patients, using evidence-based research and the other 
studies from my thesis towards its development. The following section summarises the findings 
of these eight research questions along with the implications for this field of research. 
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10.2 Summary of main findings and their implications 
10.2.1 What is the psychological impact of an HPV diagnosis in the context of head and neck 
cancer according to the existing literature? 
Study 1 which is presented in chapter 4, is the first systematic examination of the existing 
literature about the psychosocial impact of HPV diagnosis in the context of HNC. Study 1 
followed the PRISMA guidelines for conducting a systematic review and found 10 papers from 
the existing literature examining the psychosocial impact of HPV-related HNC. The outcome 
measured most frequently in these studies was quality of life (QOL), albeit using a number of 
different QOL scales. These results demonstrated QOL in HPV-positive patients was reduced 
from diagnosis and throughout treatment, supporting previous research with HNC patients 
(Morton, 2003). Comparing QOL between HPV-positive patients and HPV-negative patients, the 
differences between the two patient groups were inconclusive, with HPV-positive patients 
having greater QOL at some time points and HPV-negative patients having greater QOL at 
other time points, although these differences were not always significant. There were also no 
significant differences in levels of anxiety or depression found in HPV-positive or HPV-negative 
patients, finding levels of anxiety and depression in both patient groups to be lower than in 
previous studies with non-HPV patients (e.g. Hassanein et al., 2005; Hutton & Williams, 2001). 
HPV-positive patients demonstrated moderate levels of distress, but encouragingly, low levels 
of self-blame. The one qualitative study with a small number of HPV-positive HNC survivors 
found 3/10 to express feelings of stigma or shame associated with their diagnosis. These 
patients also expressed optimism and relief after being informed of the better prognosis 
associated with HPV-positive HNC.  
The findings from study 1 suggest that currently we know little about the psychosocial impact of 
HPV-related HNC and that the field is in relative infancy. Only one small qualitative study had 
been conducted, suggesting the need for further qualitative work to enable the experiences of 
HPV-OSCC patients to be explored in depth and to develop a greater understanding of the 
psychosocial impact in this HNC subgroup. This sets the scene for my thesis and demonstrates 
that there is therefore a need for studies to investigate the psychosocial impact of a diagnosis of 
HPV-related HNC further. The implications of a diagnosis of HPV-related HNC are currently 
uncertain and it is important to establish so that patients can be offered appropriate support or 
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resources. Using a standardised measure with all patients to assess psychological variables of 
anxiety, depression and QOL would be useful to enable firm conclusions to be drawn in the 
future.  
10.2.2 What is known about HPV-related head and neck cancer in different population groups 
according to the existing literature? 
The systematic review in chapter 4 (study 1) also searched the existing literature for research 
studies examining knowledge of the relationship between HPV and HNC. The systematic review 
found 41 studies examining knowledge of HPV as a cause of, or a risk factor for HNC. These 
studies consisted of samples from a number of different populations, across 10 different 
countries. Over half of these studies were conducted in the USA and none conducted in the UK, 
so it is not possible to draw any conclusions on knowledge of the relationship between HPV and 
HNC in the UK. Some of the samples included in these studies were in the medical profession; 
some being oral health providers, head and neck surgeons, healthcare professionals and some 
were in-training medical or dental students. These samples had the greatest knowledge of the 
relationship between HPV and HNC, with one study finding 88% of dentists and another study 
finding 84% of dental students were aware of HPV as a risk factor for oral cancer, which could 
be suggestive of this information now being included in their training. Knowledge in samples of 
the general population was found to be as low as 1% and no higher than 44%, with the lowest 
level similar to that found for knowledge of HPV as a risk factor for cervical cancer (Waller, 
McCaffery, & Wardle, 2004). The samples of the general population varied, with the lowest 
awareness being found in an online panel and the highest in gay and bisexual samples of the 
population. The huge variation in knowledge across samples of the general population may 
partly be explained by the variation in how the question was asked. The sample with the lowest 
awareness were asked about the most common risk factors of mouth and throat cancer, and 
only 4.8% of this sample also selected alcohol and 54.5% selected smoking (Luryi et al., 2014), 
suggesting awareness of all risk factors was low. 
The results from this systematic review show there are wide disparities in knowledge that HPV 
can cause HNC, but it is promising that knowledge is high in health professionals, as chapter 7 
(study 4) found confidence of discussing HPV to be associated with knowledge. Knowledge of 
the relationship between HPV and HNC is also important in clinical practice so that health 
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professionals do not dismiss any potential symptoms of HNC due to the demographic of the 
patient (Dahlstrom et al., 2013; Gillison et al., 2000). These results also have implications for 
public health campaigns and oral cancer awareness, giving an indication as to where 
knowledge is the lowest and could be targeted by these campaigns. As with HPV in cervical 
cancer, it is important for there to be a greater awareness of the role that HPV can play in HNC, 
with the hope that the more widely this is known, the less stigma will be attached to HPV, with 
people understanding that this is a widespread infection in those who are sexually active. This 
would also then have implications for patients diagnosed with HPV-related HNC as they would 
have a greater understanding of their diagnosis and this could help alleviate any potential 
negative psychosocial outcomes. Awareness of HPV as a cause of HNC could also have 
implications for any future oral cancer screening programmes, as if the general population are 
aware that they could be at risk then this could influence the uptake to these initiatives.  
10.2.3 How frequently has the relationship between HPV and HNC received coverage in the 
British media? 
The disclosure of Michael Douglas that his throat cancer was caused by HPV was timely for my 
PhD, occurring a few months prior to the start of my PhD. It was therefore deemed pertinent to 
examine what information about HPV and HNC was covered by the media, to assess what 
information members of the general public may have received about the relationship between 
HPV and HNC. The media has been found to report on a number of celebrity diagnoses of 
cancer, as these engage the public (Hilton et al., 2010) and there is the opportunity to educate 
the public. The publication search of media articles in the UK conducted in chapter 5 (study 2) 
revealed 265 articles that had reported on the relationship between HPV and HNC from 2001 
until the date the search was conducted in August 2014. More articles were found to report on 
the relationship between HPV and HNC in June 2013, following Michael Douglas’ interview 
about his throat cancer being caused by HPV. On average, there were less than two articles a 
month published which mentioned the relationship between HPV and HNC, showing that very 
little information has been presented in the media.  
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10.2.4 What information is included in media articles covering the relationship between HPV 
and HNC? 
Chapter 5 (study 2) also examined the content of 112 of the articles. The sexual nature of the 
link between HPV and HNC was sometimes emphasised in the headlines of the articles, 
immediately opening up the potential for this to be sensationalised or stigmatised. Some articles 
suggested that this disclosure by Michael Douglas has raised awareness that HPV can cause 
HNC and that by mentioning oral sex, this was opening up the lines of communication for a 
sexual behaviour that has in the past been ‘taboo’. Oral sex was mentioned in three quarters of 
the articles and specifically the term cunnilingus. HPV was also mentioned and described as a 
sexually transmitted disease and linked as a cause of HNC. Mentioning oral sex led some of the 
articles to suggest that oral sex might be riskier for men than for women and that also an 
increase in oral sex was linked to the sexual revolution of the 1960’s, with this resulting in 
greater prevalence in oral HPV and consequently throat cancer. Although there is evidence that 
it may be the case that performing oral sex on a woman may result in a higher level of oral HPV 
exposure due to higher viral load in the female genital mucosa than in men (Fakhry et al., 2013; 
Pytynia et al., 2014), there is a need to decide upon the important messages which should be 
conveyed to the public. A few articles placed particular emphasis on the riskiness of oral sex, 
suggesting that it should be off the agenda and that it is life-threatening. Oral sex has been 
reported as becoming more commonplace and it should be framed as ‘normal sexual 
behaviour’, as most people in the UK reported having had oral sexual contact within the last 
year (Mercer et al., 2013).   
In terms of the health information presented in these articles, just over half gave statistics about 
the increasing incidence of HPV and HNC and just over half also linked HPV back to being a 
cause of cervical cancer. Articles did fail however, to communicate the high prevalence of HPV 
and how common it is, with just 11% of articles giving the information that 8 out of 10 sexually 
active people will contract HPV. This lack of basic information about HPV was also found in 
media coverage about cervical cancer and HPV in relation to Jade Goody (Hilton & Hunt, 2010), 
a reality television personality who was publically diagnosed with terminal cervical cancer and 
died aged 27. The better prognosis and survival rates of patients diagnosed with HPV-related 
HNC was also only communicated in 16% of the articles. Articles also covered some of the 
campaigns about vaccinating boys against HPV and recognised that should this happen, the 
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vaccine would have to be re-marketed as currently it is known more often as the cervical cancer 
vaccine, due to it being developed primarily to prevent cervical cancer in girls. The media could 
be utilised to help re-market the vaccine, as when the HPV vaccination was first introduced, it 
attracted a lot of media attention (Forster et al., 2010). 
This study demonstrates what information the media convey about the link between HPV and 
HNC and has advanced our understanding of some of the information that the general public 
have received about the link between HPV and HNC. As one of the themes interpreted from the 
data was the riskiness of oral sex, this suggests that the media coverage of HPV and HNC may 
be sensationalised or stigmatising, whereas it could be normalising the behaviour based on 
data showing oral sex is commonplace in the UK (Mercer et al., 2013). This could have 
implications for practice and the psychological health of patients diagnosed with HPV and HNC, 
as this could affect others people’s reactions towards them and it could also affect their own 
feelings about themselves. This study also gives us some indication as to what information 
patients may have already seen when they are diagnosed with HPV-OSCC, which could 
provide a baseline on which to build discussions between health professionals and their patients 
and prepare health professionals for some of the information they may be asked questions on. 
The lack of basic information about HPV and its prevalence in the population, which has been 
shown to be important information to help alleviate anxiety and stigma (Waller et al., 2007) 
needs to be addressed in any future publications reporting on the link between HPV and HNC. 
As events such as celebrity cancer diagnoses have been shown to create a substantial amount 
of news coverage, this would be the most effective time to include reassuring and normalising 
information about HPV. The media could also use this as an opportunity to educate the public 
about the signs and symptoms for HNC and recommendations about what to do upon finding a 
symptom. It is also imperative that these messages are broadcast across broadsheet, middle-
market and tabloid newspapers to minimise inequalities and consequently health outcomes.  
10.2.5 What are the experiences and views of health professionals in the UK about discussing 
HPV with HPV-OSCC patients and how do these differ across different health 
professional groups? 
Interviewing health professionals caring for patients with HPV-OSCC allowed me to explore 
their experiences and views about discussing HPV in depth. All the health professionals 
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interviewed in chapter 6 (study 3) regarded the role of HPV in OSCC to be an important issue 
and that the increasing incidence was a concern. The distinctive demographic of these patients, 
particularly that they are a younger group of patients, has clinical implications. These patients 
will have to live longer with the after-effects of their treatment and due to many of them still 
being actively employed, there is a greater demand for expedited rehabilitation. Regarding 
health professionals’ attitudes towards discussing HPV, these were mixed. Some health 
professionals believed that it is important to discuss HPV with their OSCC patients, whereas 
others thought there was no clinical relevance to discussing HPV. Chapter 7 (study 4) found 
that specialist nurses had less negative attitudes towards discussing HPV than surgeons, 
speech and language therapists and the group of ‘other’ health professionals, which may 
indicate that specialist nurses feel strongly that patients should be told about their diagnosis of 
HPV. Chapter 6 (study 3) found one health professional suggested that patients are not 
concerned about the cause of their cancer, but when asked to 260 health professionals in 
chapter 7 (study 4), 75% strongly disagreed or disagreed with the item ‘My patients are not 
concerned about the cause of their cancer’. The difference suggested in chapter 6 (study 3) that 
surgeons are less likely to discuss HPV than oncologists was not supported in chapter 7 (study 
4), where there were no significant differences between surgeons and oncologists on any of the 
factors reflecting attitudes and beliefs about discussing HPV.  
Limitations of knowledge about HPV and discomfort in talking about sexual health matters, 
which they are not used to doing, were two main concerns expressed by health professionals in 
chapter 6 (study 3) and these were also supported by findings in chapter 7 (study 4). 
Knowledge has been shown previously to be an important determinant in health professionals’ 
discussions of the HPV vaccination (Holder et al., 2013) and recommendations of the HPV 
vaccination have been influenced by health professionals’ comfort in discussing the sexual 
nature of HPV (Allison et al., 2013; Bynum et al., 2014; Daley et al., 2010; McCave, 2010).  
Although knowledge of HPV was found to be quite high among all health professional groups in 
chapter 7 (study 4), specialist nurses were those who expressed the greatest comfort in talking 
to their patients about sexual health matters, but were not those with the greatest knowledge of 
HPV. It was also a greater proportion of specialist nurses and speech and language therapists 
who agreed that having booklets to pass onto patients would help them to discuss HPV with 
them, more so than surgeons, oncologists and the ‘other’ health professional group. It was also 
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these two health professional groups who agreed that attending further training would facilitate 
them discussing HPV with patients. These limitations of knowledge were associated with a lack 
of confidence to discuss HPV with patients and also a lack of willingness to do so, indicating 
that simply by increasing health professionals’ knowledge, this could result in an increase in 
confidence and a willingness to discuss HPV. As shown in chapter 7 (study 4), these results 
could be interpreted using the Capability Opportunity Motivation-Behaviour (COM-B) model 
(Michie et al., 2011), which asserts that individuals must have the capability, motivation and 
opportunity for behaviour change to occur. Developed as a model of behaviour which is 
purposefully broad that it can be applied to any behaviour, in the context of these results, the 
behaviour change is health professionals discussing HPV with patients. Regarding the 
limitations to health professionals’ knowledge, it is also important to recognise that there are still 
a number of uncertainties around HPV and HNC and some of the questions patients ask may 
still be unanswerable. Health professionals recognise that they may not have all the answers 
and that they need more information. 
Key messages to normalise HPV and reduce its psychological impact were interpreted from the 
health professional interviews in chapter 6 (study 3) as explaining the high prevalence of HPV, 
that HPV is a result of normal sexual behaviour, that they do not need to change their 
behaviour, that HPV has a positive prognosis and referring to HPV in the context of cervical 
cancer and the HPV vaccination. These key messages have also been reported in an overview 
paper (Evans & Powell, 2014). Communicating the message that HPV is highly prevalent has 
been found in previous research to be associated with lower levels of anxiety, shame and 
stigma (Waller et al., 2007) and is reassuring (Baxi et al., 2012; McCaffery & Irwig, 2005; Waller 
et al., 2005). Health professionals could also influence patients’ cognitive representations of 
their HPV-OSCC though the five dimensions of the CSM and this could also help in developing 
guidance around discussing the key messages found in chapter 6 (study 3). The identity of the 
illness and the cause are determined when patients are told they have HPV-OSCC, and the 
timeline, curability and controllability dimensions are influenced by the better prognosis of HPV-
OSCC. In terms of consequences, this may include longer survivorship in younger patients and 
an impact on sexual relationships.  
In terms of experience of health professionals, as they had been seeing more and more cases 
of HPV-OSCC, health professionals reported that they had begun to learn what is relevant and 
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helpful to tell patients. Confidence was also associated with experience of discussing HPV, 
found in both the findings in chapter 6 (study 3) and in chapter 7 (study 4). In chapter 6 (study 3) 
health professionals had described their efforts to find out more information about HPV and this 
resulted in them feeling more confident about discussing HPV and being more open about 
those discussions. Chapter 7 (study 4) presented results that showed associations between 
years practising in their profession and confidence in discussing HPV; those with more years of 
experience in their profession being more confident about discussing HPV.  
The findings from chapters 6 and 7 provide some first insight into the attitudes of medical health 
professionals about discussing HPV. The implications of the findings from chapters 6 and 7 
demonstrate that there is a need for further education in health professionals, as well as the 
need for information that they can use as a plan and that they can give to their patients. 
Discussing HPV with patients is important not only for ethical reasons (Shuman & Wolf, 2010), 
but also to ensure they have a trustworthy and reliable source of information, and health 
professionals have been viewed as such (Garner et al., 2012). The findings from chapter 7 also 
demonstrate areas to target for facilitating the discussions between health professionals and 
their patients about HPV. The three components of the COM-B model that were shown to be 
associated with willingness to discuss HPV in the future should be the areas focused on for 
behavioural interventions and training with health professionals.  
10.2.6 What is the psychosocial impact on patients being diagnosed with HPV-OSCC? 
Chapter 8 (study 5) presents findings from a qualitative interview study with patients diagnosed 
with HPV-OSCC. Only 12 of the 20 patients interviewed knew that their OSCC was caused by 
HPV, demonstrating that patients are not being routinely told the cause of their cancer despite 
health professionals knowing this as it is on their medical records, which has also been found 
previously (D’Souza et al., 2016; Milbury et al., 2013). All patients were diagnosed with 
oropharyngeal cancers with primary tumours in their tonsil or the base of tongue. Ten patients 
received multimodality treatment, eight received radiation alone and one received surgery 
alone.  
Cancer is still perceived as a ‘scary word’ and feelings described by the patients in chapter 8 
(study 5) were a mixture of being positive and being frightened by the diagnosis. Findings 
presented in chapter 2 demonstrated the challenges associated with HNC and that HNC 
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patients may isolate themselves (Dhooper, 1985) and may struggle with a loss of meaning in 
the context of their illness (Moore et al., 2004). Those patients who knew they were HPV-
positive did not always find out from their health professional, which led to feelings of confusion 
and embarrassment. Reactions to their HPV diagnosis were mixed and some patients 
recognised stigma against HPV, supporting findings from the cervical cancer screening 
literature (McCaffery et al., 2006), whereas other patients were not bothered about the cause of 
their cancer and they were more concerned about their prognosis. Previous work with a small 
number of men in the HPV-OSCC population found concerns to be more cancer-related than 
HPV-related (Baxi et al., 2012) and the findings from chapter 8 (study 5) would also suggest 
this. Patients who also had young children, especially boys, were concerned about them being 
at greater risk of HPV and that they would not be offered the HPV vaccine as part of the current 
national immunisation programme. There is the potential that if the vaccine is proven to be 
effective against oral HPV as well as genital HPV, as some preliminary results may suggest 
(Grun et al., 2015; Herrero et al., 2013), vaccinating boys could eradicate HPV-OSCC in the 
future. Some patients were reluctant to discuss HPV with others, some due to the negative 
reactions of other people and some due to only being comfortable discussing HPV with medical 
professionals. This supports previous findings from the cervical cancer screening literature, 
where women have chosen not to disclose their HPV-positive test result as they were 
concerned about the reactions of others regarding stigma and shame, and that it could be a 
sign they had been unfaithful (Kahn et al., 2005). 
The information given to patients about HPV varied, but there was a good level of 
understanding of HPV among the patients and they expressed that they would like to be told the 
information at the beginning, once they have been given their diagnosis. Patients were 
reassured by the information that the prognosis was better and that HPV is so common, 
supporting previous research (Baxi et al., 2012; D’Souza et al., 2016). Some patients also 
worried about the transmission of HPV to their partner, which has also been found in the 
cervical cancer literature (Clarke et al., 1996; McCaffery et al., 2006; McCaffery & Irwig, 2005).    
Patients described how their diagnosis had given them “a different perspective”, being more 
focused and aware of their health, realising that life is too short and some described themselves 
as being ‘a better person’. These feelings around ‘seeing the world differently’ have been 
described in previous research with HNC cancer patients (Parker et al., 2013). The 
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psychological impact described by the patients in chapter 8 (study 5), were similar to those 
found in previous qualitative research with HNC patients (Baxi et al., 2012; De Boer et al., 1999; 
Lang et al., 2013). 
Patients also described loss of confidence, feeling alone and isolated, embarrassment about 
how things had changed, relief about clear test results, stress and the feeling that nothing is 
normal. Some patients also described themselves as feeling lucky. Patients explained how 
socially they had to cancel plans they had made, felt that people acted differently following their 
diagnosis and how the difficulties with eating and drinking affected their social plans. Hobbies 
were also affected. These findings reiterate some of the previous research with HNC patients, 
particularly the dysfunction associated with HNC and the associated difficulties experienced as 
a result (Chaukar et al., 2009; De Boer et al., 1999). 
The Transactional Model of Stress and Coping could be used to predict adjustment in HPV-
OSCC patients and could be utilised in future research. The model suggests that patients’ 
primary appraisal of HPV-OSCC would involve their perceptions of susceptibility and severity of 
their diagnosis, how much this may impact their lives, and how much they are to blame for their 
diagnosis. Patients also perceive how much control they have over their prognosis and their 
emotions as well as their ability to deal with their diagnosis. These two appraisal systems in turn 
influence how patients cope and how they adapt. Therefore interventions with patients at an 
early stage and ensuring they have all the information to meet their concerns may in turn 
influence their appraisal of the stressor and consequently their coping strategies, and how they 
adjust to their diagnosis.  
The findings from chapter 8 (study 5) suggest that there are few concerns about HPV in those 
diagnosed with HPV-OSCC, but that they do seek further information about what HPV is. As 
many of the concerns associated with the psychosocial impact of HPV-OSCC were those 
related to dysfunction associated with its treatment, it is important to consider that if the de-
escalation trials (see section 1.6) demonstrate that HPV-OSCC patients can receive less 
intensive treatment, then the treatment effects may not be as great and this could alleviate 
some of the psychological impact of HNC. These findings therefore have implications for 
practice, as to be able to offer HPV-OSCC patients a less intensive treatment would require 
health professionals to discuss HPV with patients at the time of their diagnosis.  
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10.2.7 What is the psychosocial impact on partners of patients who have been diagnosed with 
HPV-OSCC? 
Chapter 8 (study 5) also presents findings from interviews with 12 partners of patients who had 
been diagnosed with HPV-OSCC. There were differing reactions to the cause of their partners’ 
cancer, with one partner dismissing HPV as the cause, whereas other partners were open to 
talking about it with their friends especially when their friends assumed it was related to 
smoking. The disclosure from Michael Douglas was mentioned in some of the interviews as 
having a negative impact on how open partners were to their friends once Michael Douglas had 
disclosed his throat cancer was caused by oral sex. This demonstrates the altering perceptions 
of HPV through the information presented in the media, such as that shown in study 2. The risk 
of transmission was brought up in some interviews. 
Partners became carers, but saw this as their role and that they did not want anyone else to do 
it. Concerns and feelings expressed by partners were most often about their ability to be strong 
for their partner and their family. A couple of participants had expressed wanting to talk to 
someone but did not use any support, supporting previous research that found 40% of 
caregivers who would have liked to have received psychological support (Richardson et al., 
2015a). Active coping strategies, such as taking control, were apparent in some partners as a 
way of coping and to find out as much as they could. This has been found previously, as 
caregivers want to improve their understanding about HNC and its treatment (Richardson et al., 
2015a). This would involve ‘dragging’ patients out of the house to go for their treatment when 
they did not want to go and searching for further information about HPV to help to reassure their 
partner and to find out as much as possible. Some patients felt like they were in the way during 
consultations and sometimes felt guilty if it was them asking all the questions. It was also 
evident that partners were essential in the dissemination of information to other family members 
and the need to keep them up-to-date. Another impact evident from the interviews with partners 
was their role in preparing food for the patient, how this was stressful and not easy.  
The impact of being a carer for their partner did not always have negative implications, with one 
partner demonstrating it having a positive effect as he was now more independent. Positive 
experiences of caregiving have been found across a range of caregiving types (e.g. Cohen, 
Colantonio, & Vernich, 2002; Mackenzie & Greenwood, 2012). 
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The findings from interviewing partners of patients diagnosed with HPV-OSCC details a unique 
perspective which has not yet been studied in the field of HPV and HNC. As with previous 
research with caregivers, the impact upon these partners is substantial, as they take on the role 
of carer as well as managing everything else in their day-to-day lives (Röing et al., 2008; Watt-
Watson & Graydon, 1995). The implications of the findings of this study are that support should 
not only be available for patients, but also for their partners. Partners and caregivers should 
also be involved in the dissemination of information about HPV and other aspects of HNC, as 
they often seek out this information to provide a supportive role for their partner.  
10.2.8 The development of an information booklet 
The results from all the research studies were considered in the development of the information 
booklet in chapter 9 (study 6). This information booklet aimed to accumulate evidence from the 
existing literature to answer frequently asked questions from patients and to develop an 
information resource that could be used by health professionals with their patients in 
consultations to aid the discussion of HPV. The information booklet was well received by 
patients, with every patient who reviewed the booklet saying that they would have liked to have 
received the booklet when they were diagnosed. Aspects of the booklet that patients particularly 
liked were that although the language was easy to read it remained professional, the layout of 
the booklet such that the order of the questions in the booklet are in the order they are likely to 
be asked, and the use of headings allows you to find sections easily and quickly. One patient 
particularly liked the guide on how to pronounce oropharyngeal. Patients were also very helpful 
in their feedback about additional information they would like to see in the booklet and also 
when there was a need for something to be explained further. It is important to involve patients 
in the development of information booklets such as this so that their understanding of what is 
being communicated can be examined and the content of the materials can be revised based 
on their feedback (Rudd et al., 2004). 
The implications for the development of the information booklet are for further evaluation. As the 
information booklet has only been assessed against its readability and not for comprehension of 
the booklet, patients need to be involved in cognitive studies to assess how comprehensive the 
materials are. Previous studies have involved users in testing the comprehension of information 
materials (Hersch et al., 2014; Raynor, Knapp, Silcock, Parkinson, & Feeney, 2011) which have 
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involved interviews with users to assess comprehension of key content. For the information 
booklet to be used successfully within NHS consultations, it will be necessary for the information 
to also be assessed within this setting to measure its feasibility in this context. It will also be 
necessary to gain information on the views of health professionals using the information and 
whether this has increased their capability, opportunity and motivation for discussing HPV, and 
in turn increased their willingness to do so. The implications the provision of this information 
booklet could have include increasing knowledge of the relationship between HPV and HNC 
among the patient and health professional population and the potential to increase confidence 
of discussing HPV in health professionals. It is hoped that if implemented into HNC clinics in the 
NHS that patients will receive further information about their diagnosis as soon as they are 
diagnosed and this will help to prevent any negative psychological impact associated with HPV. 
It is also hoped that this booklet will become an important information resource for health 
professionals that could also facilitate training.  
10.3 Summary of implications 
The studies conducted in this thesis have shown that prior to this thesis, little was known about 
the psychological impact of HPV in HNC. These studies have demonstrated that the 
psychological impact of a diagnosis of HPV-OSCC is significant, but that it is usually 
overshadowed by concerns about OSCC and its treatment. This has implications for the 
importance of establishing appropriate support or resources for patients, as well as for their 
partners or caregivers. Knowledge of HPV as a cause or a risk factor for HNC in the general 
population is relatively low, but the level of awareness in the UK is still unknown and the basic 
facts about HPV and HNC were missing from coverage in the media. These findings could 
guide public health campaigns to generate a greater level of understanding and education 
among the public, which also has implications as there is currently no method through oral HPV 
testing of identifying populations who are at high risk of HPV-OSCC. This also has implications 
for possibilities of an oral cancer screening programme. Currently, HPV-OSCC fails to meet the 
criteria necessary for an effective and appropriate screening programme (Wilson & Jungner, 
1968). The incidence and natural history is not understood, there is no validated screening test, 
there is no effective intervention if oral HPV is detected, and there is no evidence from RCTs 
that a screening programme would be effective in reducing mortality or morbidity. Technological 
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advances could lead to developments towards meeting these criteria and population-level oral 
cancer screening may be possible in the future, or if it is possible to identify criteria which 
enables us to stratify individuals at high-risk, these high-risk groups could be the focus of the 
screening programmes.  
Health professionals are experiencing a different type of HNC patient now and this is having 
clinical implications for them in terms of patients’ need for expedited rehabilitation. The 
implications of the potential availability of de-escalated treatment bear promise for lessened 
after-effects from the treatment. Some health professionals lack the knowledge and confidence 
to discuss HPV with their patients and it is hoped that the provision of the information booklet 
developed in chapter 9 (study 6) will aid in their discussions about HPV with patients. Although 
the incidence of HPV-OSCC is increasing, it is still not a common cancer but may overtake 
cervical cancer by 2020 (Chaturvedi et al., 2011) and it may be that health professionals do not 
see that many patients. If the incidence trends continue to increase and surpass cervical 
cancer, a secondary prevention strategy will be needed. It is however vital that GPs are aware 
of the changing demographic of HNC patients so that patients are not dismissed if they attend 
to their GP with symptoms of HNC.  
10.4 Limitations 
I have discussed the limitations of my studies in each chapter, but I will highlight here some 
limitations that apply across my whole thesis.  
10.4.1 Participants  
Chapters 6, 7, 8 and 9 involved the recruitment of participants. Participants recruited to 
research studies are likely to be research driven and those most willing to participate. This has 
implications for response bias, as there is the potential that participants who took part may have 
different experiences and knowledge to those participants who were not recruited. For example, 
health professionals recruited in chapter 6 may be more positive about discussing HPV with 
patients compared to those health professionals who did not want to take part and therefore a 
full breadth of understanding may not be possible. Social-desirability is possible, but unlikely for 
the participants recruited in chapters 6 and 8 as these involved in-depth interviews where it is 
more difficult to answer questions in a socially desirable manner as opposed to with true 
CHAPTER 10 – DISCUSSION 
308 
 
experiences. Additionally, the participants recruited for chapter 7 were recruited anonymously 
and so this should have enabled the participants to feel comfortable answering truthfully and not 
as they thought I would like them to answer. The experts and patients recruited to provide 
feedback for the information booklet in chapter 9 may have been influenced by knowing that I 
developed the information, but as there were critical comments given by both experts and 
patients, this is unlikely.  
Participants recruited in chapter 6 were health professionals working with HPV-OSCC patients 
across the UK, but the subgroups of health professionals were not large enough to make 
comparisons across the health professions. Participants recruited in chapter 7 were recruited 
through opportunistic sampling and it was not possible to calculate a response rate, so the 
findings might not be generalisable to the population. The sample size achieved did reach the 
number needed to detect a medium effect size in the analyses. Participants recruited in 
chapters 6 and 7 may have been those already more interested in or knowledgeable about 
HPV. Participants in chapter 8 were recruited at least one year after they or their partner had 
been diagnosed with their cancer and therefore some of their recollections may not be as vivid 
or accurate as if they would have been interviewed closer to the time of their diagnosis.  
10.4.2 Methodology 
Methods used for analysis in some of the chapters in this thesis can be viewed as subjective. 
The methodology used to assess the quality of the studies eligible for inclusion in the systematic 
review in chapter 4 was subjective, although by a member of my supervisory panel also coding 
ten per cent of the eligible studies, this strengthens the ratings given to each study as we were 
in agreement. Chapters 5, 6 and 8 involved qualitative analysis. As this was a new field of 
research, the aim was to present a snapshot and a greater depth of experiences, thoughts and 
feelings. Although qualitative research is not aimed at producing findings that are representative 
of the whole population, this was the most appropriate methodology for four of the research 
questions addressed in this thesis. Reliability and validity in qualitative research are often 
termed as quality, trustworthiness and rigour (Golafshani, 2003). As the interpretation of the 
data is subjective, qualitative research requires methods of demonstrating trustworthiness of the 
findings (Noble & Smith, 2015). Measures were taken in chapters 5, 6 and 8 to demonstrate 
reliability of the findings by recognising any sources of bias in the sampling, including verbatim 
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descriptions from participants in the results to support the interpretive findings, and by engaging 
with members of my supervisory panel during the analysis to reduce researcher bias.  
There are also confounding factors which need to be considered in the studies conducted in this 
thesis. In chapter 4, the studies included were from a number of different countries, across a 
range of populations and so it is difficult to draw firm conclusions. The sample sizes in some of 
the studies included were also small and so may not be representative of the population in that 
country. There were also limits to the forward citation searches conducted as I was limited by 
which papers were currently included on Scopus which may have led to some of the most 
recent papers not being found and consequently not included. In chapter 5, the analysis of the 
content of UK media publications provides an overview of the information provided to the public, 
but no conclusions can be drawn from these findings to knowledge of the general population. 
The general population has access to many other media outlets, as well as the media in other 
countries, and in addition to social media. All these other outlets of information could affect 
knowledge in the UK of the relationship between HPV and HNC.  
10.4.3 Materials and measures  
The items used to assess health professionals knowledge, experience and attitudes in chapter 
7 were not from a validated scale. Seven of the items on the knowledge scale were selected 
from a validated scale, but then combined with items from an unvalidated scale. Measured 
using Cronbach’s Alpha, the reliability of the 12 item scale in this sample was questionable 
(α=0.62) (George & Mallery, 2003). Even when splitting these into two scales and measuring 
the reliability separately, the reliability did not improve. There is a need for a validated scale to 
measure knowledge of HPV and HNC in the UK, as there is currently no data available about 
levels of knowledge in the UK.   
In chapter 9 there was no formal evaluation of the information booklet due to time constraints. 
The readability scores should be interpreted with caution as they do not indicate any level of 
comprehension from the patients, but there was reassuring feedback from the patients 
indicating that they found the information presented easy to understand.  
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10.4.4 Research and researcher effects 
It is important to recognise the influence that research and myself as a researcher could have 
had on the research findings. As all the participants involved in any of the studies included in 
this thesis were aware that they were taking part in research towards my PhD, this may have 
influenced how they responded.  
As previously mentioned, qualitative analysis is subjective and so the results of chapters 5, 6 
and 8 are likely to have been influenced by my pre-existing perceptions of what may have been 
presented in the media, what experiences health professionals had had with patients and what 
patients and their partners may express as the impact of their diagnosis. These researcher 
effects should have been reduced by introducing members of my supervisory panel to also code 
some of the analysis and also by providing verbatim quotes as examples in the results sections 
of these three chapters, this will have enabled the reader to also interpret them.  
10.5 Future research 
10.5.1 Further psychosocial research with patients  
As discussed in the previous chapters of my thesis, this is only the beginning of research into 
the psychosocial impact of HPV in the HNC context in the UK. A great deal of further research 
needs to be done with a larger volume of patients, which would be possible if standardised 
psychological measures were part of standard clinical practice. It would also be useful, if 
ethically possible, to interview patients or ask them a few short questions shortly after they are 
told they have HPV-OSCC to gain insights on their immediate responses and not those at least 
one year post diagnosis. Alternatively, recruiting HPV-OSCC patients to complete a quantitative 
measure assessing their reactions to testing positive for HPV and the psychosocial impact of 
this, would enable an evaluation of the psychosocial impact of testing positive for HPV in a 
larger number of patients and so would provide a wider spread of data on which to base 
recommendations.  
10.5.2 Further evaluation of the information booklet  
As mentioned previously in chapter 9, the information booklet needs to be evaluated with 
patients and health professionals to assess its comprehension in patients and its feasibility of 
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use with health professionals. It would also be beneficial to investigate the impact of the booklet 
on patients’ understanding of HPV as well as on the emotional impact of testing positive for 
HPV. The booklet could be implemented into use into NHS head and neck cancer clinics as a 
discussion tool for health professionals.  
The information booklet could also be adapted for use in other populations such as the general 
public, to improve knowledge about HPV-OSCC.  
10.5.3 Knowledge of HPV and HNC 
As illustrated in this thesis, there has been no research published in the UK to assess 
knowledge of HPV as a cause of HNC. The development of a validated scale to measure 
knowledge of HPV-OSCC would be optimal so that knowledge could be compared across 
different populations and gaps in knowledge could be identified. By having a validated measure 
this could also assess knowledge in populations at different time points, in health professionals 
in particular and could be used to assess the effectiveness of interventions or training aimed at 
increasing knowledge. The Cancer Awareness Measure (CAM) is a validated, standardised 
measurement tool for assessing cancer awareness (Stubbings et al., 2009) and has since been 
developed for measurement of awareness of specific cancers (Linsell et al., 2010; Power, 
Simon, Juszczyk, Hiom, & Wardle, 2011; Simon, Juszczyk, et al., 2012; Simon, Wardle, et al., 
2012), but one has yet to be developed for HNC.  
It would also be interesting to assess knowledge in the patient population and whether 
knowledge is associated with improved psychosocial outcomes.  
10.5.4 Measure oral sex practices 
As one of the theories behind the increase in HPV-related HNC is the increase in oral sexual 
practices, it would be interesting to monitor whether the levels of oral sex are reported to have 
decreased with the increasing awareness that HPV is a cause of HNC and that oral sex is likely 
to be the reason why. The National Surveys of Sexual Attitudes and Lifestyles study in the UK 
asks about oral sex behaviour, but only takes place every ten years and so would not be due to 
be delivered again until 2020-2022. There is a possibility that in this time the relationship 
between HPV and HNC will be more widely known. Awareness of HPV as a risk factor for 
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cervical cancer in the UK increased in women from the general population from 0.9% (recall) in 
2002 (Waller et al., 2004), to 61.6% (recognition) in 2011 (Marlow et al., 2013) and there is the 
possibility that awareness of HPV as a risk factor for HNC could increase by similar margins 
over the next ten years. However, the rise in awareness of HPV as a risk factor in cervical 
cancer is likely due to the cervical cancer national screening programme and the marketing of 
the HPV vaccine as the ‘cervical cancer’ vaccine. Unless a screening programme is introduced 
to screen for oral HPV or the HPV vaccine is extended to be given to boys, awareness of the 
relationship between HPV and HNC to the same level of HPV and cervical cancer may not be 
likely.  
10.5.5 Interventions for health professionals  
As health professionals have demonstrated a lack of confidence in discussing HPV with their 
HNC patients, it would be warranted to develop some behaviour change interventions, possibly 
using the COM-B model. These interventions could focus on increasing knowledge, confidence 
and demonstrating the reasons it is important to discuss HPV with patients in an effort to 
facilitate the discussion of HPV. As discussed in chapter 7, the Theoretical Domains 
Frameworks could be a useful approach for identifying HPV-related clinical behaviours that 
need targeting to develop an intervention to support health professionals when discussing HPV 
with their patients.  
10.5.6 Future research using theory 
Theory can be useful to help guide and focus research and accumulate knowledge about health 
outcomes. As discussed in this thesis, models such as the CSM and the Transactional Model of 
Stress and Coping could be useful models in the design of future research studies to help 
explain the different ways patients appraise their diagnosis of HPV-OSCC and the ways in 
which coping strategies can influence patients’ adjustment to their diagnosis.  
Models of behaviour change such as the COM-B model or the IMB model could also be used in 
the design of future studies to identify key components to target in the development of 
interventions for health professionals to facilitate the discussions of HPV with their patients. 
There are a number of resources available using the components of the COM-B model which 
are designed to provide insight into what health professionals would need to do in order to 
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change their behaviour (Michie et al., 2005) in the development of interventions. This would be 
a useful starting point for future interventions developed for health professionals caring for 
patients with HPV-OSCC.  
10.6 Final conclusions 
Prior to starting my thesis, research examining the psychological impact of HPV-OSCC in the 
UK did not exist. My thesis neatly examines the literature currently available and firsthand the 
experiences of health professionals, patients and their partners affected by this particular type 
of HNC which is on the increase. It is evident that health professionals need further training for 
discussing HPV with HNC patients and that patients and their partners should be told the cause 
of their cancer if an HPV test of their tumour is conducted. The information needs of patients 
and their partners could begin to be met with the introduction of the information booklet 
developed as part of this thesis and this may go some way to providing a discussion tool for 
health professionals. As many of the patients’ concerns in this thesis were about their cancer 
and its treatment, it is also important that with the introduction of the HPV element, that this is 
not forgotten. It is uncertain whether this subgroup of HNC patients will begin to be offered less 
intensive treatment in the future, but if this is to be the case, some of the psychosocial effects 
on this patient group may be alleviated if the after-effects of the treatment are not so severe. 
Communicating to patients the key messages about HPV-OSCC found in this thesis could have 
implications for the psychological health of HPV-OSCC patients in the future. 
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APPENDICES 
APPENDIX 1.1: ONGOING DEINTENSIFICATION TRIALS IN HPV-OPSCC 
Permission to reproduce this has been granted by UBM. Source: Lewis et al., 2015 
  
Trial Primary 
Outcome 
HPV 
testing 
Inclusion Criteria Treatment Primary 
Completion 
Date 
ECOG 1308 
United States 
2-yr OS HPV 
PCR 
Stage III/IVA-IVB 
oropharyngeal 
SCC 
Low-dose IMRT 
(50 Gy x 27 
fractions) + 
cetuximab vs 
standard-dose 
IMRT (60 Gy x 33 
fractions) 
2015 
NRG 002 
United States 
2-yr PFS p16 
IHC 
Stage III/IV A, B, 
or C (T1-T2, N1-
N2b or T3, N0-
N2b); <10 pack-
years smoking 
IMRT (60 Gy x 30 
fractions) + 
cisplatin 
2018 
RTOG 1016 
United States 
5-yr OS p16 
IHC 
Stage III/IV 
oropharyngeal 
SCC 
IMRT (60 Gy, 
day1-4 once 
daily, day 5 twice 
daily) and high-
dose cisplatin 
day 1 and 22 vs 
weekly cetuximab 
x 7 weeks 
2020 
(primary 
accrual 
completed) 
UMCC 
Michigan, 
United States 
Recurrence 
rate 
HPV 
testing 
or p16 
IHC 
Stage III/IV 
(excluding N3 or 
T4); <10 pack-
years smoking 
Standard-dose 
RT (70 Gy x 35 
fractions) + 
cetuximab 
2020 
TROG 12.01 
Australia 
Symptom 
severity 
p16 
IHC 
Stage III 
(excluding T1-
2N1) or stage IV 
(excluding T4, N3 
and distant 
metastasis); < 10 
pack-years 
smoking (if > 10 
pack-years, must 
be N0-N2a) 
Standard-dose 
RT (70 Gy x 35 
fractions) + 
weekly cetuximab 
or cisplatin 
2020 
De-ESCALATE 
United 
Kingdom 
Severe 
toxicity 
p16 
IHC 
Stage III/IVA 
(T3N0-T4N0 and 
T1N1-T4N3), 
except N2b, N2c 
or N3; > 10 pack-
years smoking 
Standard-dose 
RT + weekly 
cetuximab or 3 
doses of cisplatin 
2017 
APPENDIX 1.1 
348 
 
Trial Primary 
Outcome 
HPV 
testing 
Inclusion Criteria Treatment Primary 
Completion 
Date 
ECOG 3311 
United States 
2-yr PFS p16 
IHC 
Stage III/IV A or 
B (low risk, 
intermediate risk, 
and high risk) 
 Low risk: 
surgery + 
observation 
 Intermediate 
risk: surgery + 
low-dose RT 
(50 Gy x 25 
fractions) vs 
standard-dose 
RT (60 Gy x 30 
fractions) 
 High risk: 
surgery + 
standard-dose 
RT (60-70 Gy x 
30-35 fractions) 
+ weekly 
cisplatin or 
carboplatin 
2016 
SIRS 
New York, 
United States 
3-yr and 5-yr 
DFS, 
locoregional 
control 
HPV 
PCR 
 Low risk: 
complete 
resection; no 
LVI, PNI, or 
ECS; no matted 
or low nodes 
 Intermediate 
risk: complete 
resection; +LVI, 
+PNI; < 3 
positive nodes; 
< 1-mm ECS 
 High risk: 
incomplete 
resection; 3+ 
nodes; > 1-mm 
ECS; matted or 
supraclavicular 
nodes 
 Low risk: 
observation 
 Intermediate 
risk: RT 
 High risk: 
concurrent 
chemotherapy 
2019 
ADEPT 
Multistate, 
United States 
2-yr DFS, 
locoregional 
control 
p16 
IHC 
T1-4a, N+, +ECS 
with negative 
margins after 
resection 
Standard-dose 
RT (60 Gy x 30 
fractions) + 
weekly cisplatin 
2018 
ORATOR 
Ontario, 
Canada 
1-yr QoL p16 
IHC 
T1-2, N0-2 with 
negative margins 
after resection 
(TORS) 
Standard-dose 
RT (70 Gy x 30 
fractions) + 
chemotherapy 
2021 
HPV-OPSCC=HPV-mediated oropharyngeal squamous cell carcinoma; DFS=disease-free survival; 
ECOG=Eastern Cooperative Oncology Group; ECS=extracapsular spread; IHC=immunohistochemistry; 
IMRT=intensity-modulated radiation therapy; LVI=lymphovascular invasion; ORATOR=oropharyngeal 
cancer radiation vs TORS; OS=overall survival; PCR=polymerase chain reaction; PFS=progression-free 
survival; PNI=perineural invasion; QOL=quality of life; RT=radiation therapy; RTOG=Radiation Therapy 
Oncology Group; SCC=squamous cell carcinoma; SIRS=Sinai robotic surgery; TORS=transoral robotic 
surgery; TROG=Trans Tasman Radiation Oncology Group; UMCC=University of Michigan Comprehensive 
Cancer Center 
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APPENDIX 4.2: SEARCH STRATEGY AND NUMBERS FROM EACH DATABASE
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APPENDIX 5.2: STUDY 2 - FRAMEWORK 
Michael Douglas’ disclosure 
1. HPV Sexually transmitted 
2. Awareness 
3. Transmission of HPV 
Riskiness of oral sex 
1. Oral sex 
2. HPV Sexually transmitted 
3. HPV 
4. Change sexual practice 
5. Lifestyle 
Health information 
1. HPV as cause of HNC 
2. Incidence 
3. Cervical cancer 
4. Screening for HNC 
5. Symptoms 
6. Case study 
7. Treatment  
8. Early diagnosis  
9. Detection of HNC 
10. Normalising HPV 
11. Better prognosis 
12. Survival rates 
13. Demographics 
14. Reference to research 
HPV vaccination 
1. Vaccination 
2. Vaccination of boys 
3. Vaccine against cervical cancer 
4. Ethics around the vaccine 
5. Research needed for vaccine effectiveness for HNC 
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APPENDIX 5.3: STUDY 2 - EXAMPLE NEWSPAPER ARTICLES  
Daily Mirror 
February 28, 2014 Friday   
Edition 1;  
Northern Ireland 
 
Sex link to worrying rise of mouth cancer 
BYLINE: MIRIAM STOPPARD 
SECTION: FEATURES; OPINION, COLUMN; Pg. 38 
LENGTH: 402 words 
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The Sun (England) 
February 13, 2014 Thursday   
Edition 1;  
Ireland 
 
Why boys should have cervical cancer jab too 
 
BYLINE: LAURA STOTT 
SECTION: ME;NEWS; Pg. 6,7 
LENGTH: 1080 words 
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APPENDIX 7.6: STUDY 4 – STRONGLY AGREE/AGREE RESPONSES (N/%) TO ATTITUDES AND BELIEFS ABOUT DISCUSSING HPV 
WITH OSCC PATIENTS 
 Surgeons Oncologists 
Specialist 
nurses 
Speech and 
language 
therapists 
Other 2 (p value) 
 (n=96) (n=28) (n=40) (n=59) (n=37)  
Discussing HPV with patients is important 83 (86.5) 25 (89.3) 38 (95.0) 55 (93.2) 31 (83.8) 4.27 (0.37) 
It is helpful for the patient to understand the cause 
of their head and neck cancer 
86 (89.6) 22 (78.6) 39 (97.5) 55 (93.2) 30 (83.3) 8.66 (0.07) 
It is important to provide accurate information about 
HPV to the patient 
87 (90.6) 26 (92.9) 40 (100) 58 (98.3) 37 (100) 10.22 (0.037) 
Information about HPV is reassuring to patients 47 (49.0) 14 (50.0) 27 (67.5) 34 (57.6) 17 (45.9) 5.34 (0.254) 
It is important to convey the positive prognosis of 
HPV-related head and neck cancer to patients 
84 (87.5) 28 (100) 37 (92.5) 56 (94.9) 34 (91.9) 5.72 (0.221) 
It is not necessary to tell patients that they have 
HPV because there’s no implications for behaviour  
11 (11.5) 2 (7.1) 3 (7.7) 1 (1.7) 2 (5.4) 5.37 (0.251) 
My patients are not concerned about the cause of 
their cancer 
4 (4.2) 0 0 2 (3.4) 2 (5.6) 3.30 (0.508) 
It is not necessary to tell patients whether they 
have HPV because it doesn’t change their clinical 
management 
1 (1.0) 1 (3.6) 0 1 (1.7) 1 (2.7) 1.86 (0.761) 
I am confident about initiating a discussion about 
HPV with a patient 
77 (80.2) 25 (89.3) 32 (82.1) 23 (39.0) 15 (40.5) 50.04 (<0.001) 
I am confident that I can explain HPV in a way that 
patients can understand 
79 (82.3) 24 (85.7) 33 (82.5) 26 (44.1) 21 (56.8) 35.4 (<0.001) 
I am confident that I can reassure patients that 
HPV is a result of normal sexual behaviour (n=174) 
59 (74.7) 11 (100) 23 (82.1) 22 (75.9) 15 (55.6) 9.81 (0.044) 
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 Surgeons Oncologists 
Specialist 
nurses 
Speech and 
language 
therapists 
Other 2 (p value) 
 (n=96) (n=28) (n=40) (n=59) (n=37)  
I am confident that I can deal with patients’ 
questions and concerns when I talk to them about 
HPV  
69 (71.9) 25 (89.3) 27 (67.5) 17 (28.8) 12 (32.4) 50.8 (<0.001) 
Talking about HPV with a patient is not easy 
because it’s about their sexual behaviour 
34 (35.4) 13 (46.4) 14 (35.9) 33 (55.9) 12 (32.4) 8.56 (0.073) 
Talking to a patient about HPV is embarrassing  7 (7.3) 2 (7.1) 3 (7.7) 11 (18.6) 6 (16.2) 6.65 (0.156) 
I am not used to talking about sexual health with 
my patients  
47 (49.0) 10 (35.7) 7 (17.9) 35 (59.3) 13 (35.1) 19.3 (0.001) 
I would use a different approach than if the patient 
was alone 
34 (35.4) 9 (32.1) 9 (23.1) 20 (34.5) 12 (32.4) 2.05 (0.726) 
I would feel confident discussing the transmission 
of HPV 
63 (65.6) 21 (75.0) 24 (61.5) 14 (23.7) 11 (29.7) 40.66 (<0.001) 
I would feel comfortable talking about infidelity if 
this was raised 
26 (27.1) 10 (35.7) 20 (51.3) 16 (27.1) 5 (13.5) 14.32 (<0.001) 
I would feel comfortable talking about their sexual 
relationship 
25 (26.0) 15 (53.6) 25 (64.1) 12 (20.3) 7 (18.9) 32.37 (<0.001) 
I don’t have enough information on HPV-related 
head and neck cancer  
17 (17.7) 9 (32.1) 20 (50.0) 35 (60.3) 15 (40.5) 32.25 (<0.001) 
HPV-related head and neck cancer is an evolving 
area so it’s hard to keep up-to-date 
35 (36.5) 9 (32.1) 20 (50.0) 43 (72.9) 12 (32.4) 25.86 (<0.001) 
I might not have all the answers to patients’ 
questions about HPV-related head and neck 
cancer 
71 (74.0) 20 (71.4) 33 (82.5) 54 (93.1) 33 (89.2) 12.15 (0.016) 
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 Surgeons Oncologists 
Specialist 
nurses 
Speech and 
language 
therapists 
Other 2 (p value) 
 (n=96) (n=28) (n=40) (n=59) (n=37)  
I don’t want to pass judgement on patients’ sexual 
behaviour 
82 (86.3) 26 (92.9) 33 (82.5) 48 (81.4) 31 (86.1) 2.35 (0.672) 
I don’t have enough time to discuss HPV-related 
head and neck cancer 
18 (18.8) 5 (17.9) 2 (5.3) 11 (18.6) 5 (13.5) 4.37 (0.36) 
I don’t think patients want to know about HPV-
related head and neck cancer 
1 (1.0) 1 (3.6) 0 0 1 (2.7) 3.38 (0.496) 
I don’t see any reason to discuss HPV with patients 0 0 0 1 (1.7) 2 (5.4) 7.89 (0.096) 
Having a leaflet to pass onto patients would help 
me discuss HPV with them 
77 (80.2) 22 (78.6) 39 (97.5) 56 (94.9) 31 (83.8) 12.75 (0.013) 
Having a clear plan of what I was going to say 
would help me discuss HPV with patients 
80 (83.3) 23 (82.1) 37 (92.5) 57 (96.6) 31 (83.8) 8.22 (0.084) 
Have regular team updates  73 (76.0) 16 (57.1) 36 (90.0) 54 (91.5) 29 (78.4) 17.54 (0.002) 
Have regular feedback of experiences with patients 
from colleagues 
67 (69.8) 19 (67.9) 35 (89.7) 58 (98.3) 31 (83.8) 24.66 (<0.001) 
Attend conferences 88 (91.7) 24 (85.7) 38 (95.0) 56 (94.9) 31 (83.8) 5.32 (0.256) 
Attend further training  65 (67.7) 23 (82.1) 39 (97.5) 57 (96.6) 33 (89.2) 31.28 (<0.001) 
n for items varies slightly due to missing data       
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APPENDIX 7.7: COMPONENT CORRELATION MATRIX FOR OBLIQUE ROTATION 
Component Correlation Matrix 
Component 1 2 3 4 5 6 7 
1 1.000 -.088 .093 .153 -.196 .073 .273 
2 -.088 1.000 .183 -.007 -.080 -.285 -.164 
3 .093 .183 1.000 .039 -.244 -.176 .027 
4 .153 -.007 .039 1.000 -.060 .098 .313 
5 -.196 -.080 -.244 -.060 1.000 .182 -.104 
6 .073 -.285 -.176 .098 .182 1.000 .218 
7 .273 -.164 .027 .313 -.104 .218 1.000 
Extraction Method: Principal Component Analysis.   
 Rotation Method: Oblimin with Kaiser Normalization. 
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APPENDIX 7.8: SCREE PLOT PRODUCED IN PRINCIPAL COMPONENTS ANALYSIS 
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APPENDIX 7.9: STUDY 4 – POST HOC TESTS FOR DIFFERENCES BETWEEN HEALTH PROFESSIONAL GROUPS ON EACH FACTOR 
Multiple comparisons: Bonferroni   
Dependent Variable (I) What is your profession (J) What is your profession 
Mean 
Difference (I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
Confidence in 
discussing HPV 
Surgeon Oncologist -.15030 .15494 1.000 -.5891 .2885 
Specialist nurse .14567 .13698 1.000 -.2422 .5336 
Other .63271* .13959 .000 .2374 1.0280 
Speech and Language 
Therapist 
.99749* .11997 .000 .6577 1.3372 
Oncologist Surgeon .15030 .15494 1.000 -.2885 .5891 
Specialist nurse .29597 .17868 .989 -.2100 .8020 
Other .78301* .18069 .000 .2713 1.2947 
Speech and Language 
Therapist 
1.14778* .16600 .000 .6777 1.6179 
Specialist nurse Surgeon -.14567 .13698 1.000 -.5336 .2422 
Oncologist -.29597 .17868 .989 -.8020 .2100 
Other .48704* .16555 .036 .0182 .9559 
Speech and Language 
Therapist 
.85181* .14938 .000 .4288 1.2748 
Other Surgeon -.63271* .13959 .000 -1.0280 -.2374 
Oncologist -.78301* .18069 .000 -1.2947 -.2713 
Specialist nurse -.48704* .16555 .036 -.9559 -.0182 
Speech and Language 
Therapist 
.36477 .15178 .170 -.0650 .7946 
Speech and Language 
Therapist 
Surgeon -.99749* .11997 .000 -1.3372 -.6577 
Oncologist -1.14778* .16600 .000 -1.6179 -.6777 
Specialist nurse -.85181* .14938 .000 -1.2748 -.4288 
Other -.36477 .15178 .170 -.7946 .0650 
 
 
 
 
4
1
9
 
A
P
P
E
N
D
IX
 7
.9
 
Ways to facilitate 
discussion of HPV 
Surgeon Oncologist .08743 .11032 1.000 -.2250 .3998 
Specialist nurse -.45974* .09754 .000 -.7359 -.1835 
Other -.12831 .09939 1.000 -.4098 .1531 
Speech and Language 
Therapist 
-.45343* .08497 .000 -.6940 -.2128 
Oncologist Surgeon -.08743 .11032 1.000 -.3998 .2250 
Specialist nurse -.54716* .12723 .000 -.9074 -.1869 
Other -.21573 .12866 .948 -.5801 .1486 
Speech and Language 
Therapist 
-.54086* .11787 .000 -.8747 -.2071 
Specialist nurse Surgeon .45974* .09754 .000 .1835 .7359 
Oncologist .54716* .12723 .000 .1869 .9074 
Other .33143 .11788 .053 -.0024 .6652 
Speech and Language 
Therapist 
.00630 .10600 1.000 -.2939 .3065 
Other Surgeon .12831 .09939 1.000 -.1531 .4098 
Oncologist .21573 .12866 .948 -.1486 .5801 
Specialist nurse -.33143 .11788 .053 -.6652 .0024 
Speech and Language 
Therapist 
-.32513* .10771 .028 -.6301 -.0201 
Speech and Language 
Therapist 
Surgeon .45343* .08497 .000 .2128 .6940 
Oncologist .54086* .11787 .000 .2071 .8747 
Specialist nurse -.00630 .10600 1.000 -.3065 .2939 
Other .32513* .10771 .028 .0201 .6301 
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Negative attitudes to 
discussing HPV 
Surgeon Oncologist .07684 .11089 1.000 -.2372 .3909 
Specialist nurse .32043* .09807 .012 .0427 .5982 
Other -.03982 .10093 1.000 -.3256 .2460 
Speech and Language 
Therapist 
-.02316 .08548 1.000 -.2652 .2189 
Oncologist Surgeon -.07684 .11089 1.000 -.3909 .2372 
Specialist nurse .24359 .12774 .577 -.1182 .6053 
Other -.11667 .12994 1.000 -.4847 .2513 
Speech and Language 
Therapist 
-.10000 .11834 1.000 -.4351 .2351 
Specialist nurse Surgeon -.32043* .09807 .012 -.5982 -.0427 
Oncologist -.24359 .12774 .577 -.6053 .1182 
Other -.36026* .11919 .028 -.6978 -.0227 
Speech and Language 
Therapist 
-.34359* .10642 .014 -.6450 -.0422 
Other Surgeon .03982 .10093 1.000 -.2460 .3256 
Oncologist .11667 .12994 1.000 -.2513 .4847 
Specialist nurse .36026* .11919 .028 .0227 .6978 
Speech and Language 
Therapist 
.01667 .10906 1.000 -.2922 .3255 
Speech and Language 
Therapist 
Surgeon .02316 .08548 1.000 -.2189 .2652 
Oncologist .10000 .11834 1.000 -.2351 .4351 
Specialist nurse .34359* .10642 .014 .0422 .6450 
Other -.01667 .10906 1.000 -.3255 .2922 
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Positive attitudes to 
discussing HPV 
Surgeon Oncologist .01875 .10170 1.000 -.2692 .3067 
Specialist nurse -.39625* .08911 .000 -.6486 -.1439 
Other -.05903 .09253 1.000 -.3211 .2030 
Speech and Language 
Therapist 
-.13888 .07833 .774 -.3607 .0829 
Oncologist Surgeon -.01875 .10170 1.000 -.3067 .2692 
Specialist nurse -.41500* .11667 .004 -.7454 -.0846 
Other -.07778 .11931 1.000 -.4156 .2601 
Speech and Language 
Therapist 
-.15763 .10866 1.000 -.4653 .1501 
Specialist nurse Surgeon .39625* .08911 .000 .1439 .6486 
Oncologist .41500* .11667 .004 .0846 .7454 
Other .33722* .10878 .022 .0292 .6452 
Speech and Language 
Therapist 
.25737 .09698 .085 -.0172 .5320 
Other Surgeon .05903 .09253 1.000 -.2030 .3211 
Oncologist .07778 .11931 1.000 -.2601 .4156 
Specialist nurse -.33722* .10878 .022 -.6452 -.0292 
Speech and Language 
Therapist 
-.07985 .10014 1.000 -.3634 .2037 
Speech and Language 
Therapist 
Surgeon .13888 .07833 .774 -.0829 .3607 
Oncologist .15763 .10866 1.000 -.1501 .4653 
Specialist nurse -.25737 .09698 .085 -.5320 .0172 
Other .07985 .10014 1.000 -.2037 .3634 
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Personal barriers to 
discussing HPV 
Surgeon Oncologist -.06882 .14942 1.000 -.4920 .3543 
Specialist nurse .38747* .13333 .040 .0099 .7651 
Other -.12071 .13462 1.000 -.5019 .2605 
Speech and Language 
Therapist 
-.36074* .11508 .019 -.6866 -.0348 
Oncologist Surgeon .06882 .14942 1.000 -.3543 .4920 
Specialist nurse .45630 .17327 .090 -.0344 .9470 
Other -.05188 .17426 1.000 -.5454 .4416 
Speech and Language 
Therapist 
-.29192 .15965 .687 -.7440 .1602 
Specialist nurse Surgeon -.38747* .13333 .040 -.7651 -.0099 
Oncologist -.45630 .17327 .090 -.9470 .0344 
Other -.50818* .16068 .018 -.9632 -.0532 
Speech and Language 
Therapist 
-.74822* .14470 .000 -1.1580 -.3384 
Other Surgeon .12071 .13462 1.000 -.2605 .5019 
Oncologist .05188 .17426 1.000 -.4416 .5454 
Specialist nurse .50818* .16068 .018 .0532 .9632 
Speech and Language 
Therapist 
-.24004 .14589 1.000 -.6532 .1731 
Speech and Language 
Therapist 
Surgeon .36074* .11508 .019 .0348 .6866 
Oncologist .29192 .15965 .687 -.1602 .7440 
Specialist nurse .74822* .14470 .000 .3384 1.1580 
Other .24004 .14589 1.000 -.1731 .6532 
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Need for more 
information 
Surgeon Oncologist .03199 .10941 1.000 -.2778 .3418 
Specialist nurse -.25729 .09587 .078 -.5288 .0142 
Other -.07756 .09857 1.000 -.3567 .2016 
Speech and Language 
Therapist 
-.48402* .08472 .000 -.7239 -.2441 
Oncologist Surgeon -.03199 .10941 1.000 -.3418 .2778 
Specialist nurse -.28929 .12552 .220 -.6447 .0662 
Other -.10956 .12760 1.000 -.4709 .2518 
Speech and Language 
Therapist 
-.51601* .11722 .000 -.8480 -.1841 
Specialist nurse Surgeon .25729 .09587 .078 -.0142 .5288 
Oncologist .28929 .12552 .220 -.0662 .6447 
Other .17973 .11619 1.000 -.1493 .5088 
Speech and Language 
Therapist 
-.22672 .10470 .313 -.5232 .0697 
Other Surgeon .07756 .09857 1.000 -.2016 .3567 
Oncologist .10956 .12760 1.000 -.2518 .4709 
Specialist nurse -.17973 .11619 1.000 -.5088 .1493 
Speech and Language 
Therapist 
-.40645* .10718 .002 -.7100 -.1030 
Speech and Language 
Therapist 
Surgeon .48402* .08472 .000 .2441 .7239 
Oncologist .51601* .11722 .000 .1841 .8480 
Specialist nurse .22672 .10470 .313 -.0697 .5232 
Other .40645* .10718 .002 .1030 .7100 
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Attitudes to talking 
about sexual 
relationships 
Surgeon Oncologist -.32068 .19086 .942 -.8612 .2198 
Specialist nurse -.67508* .16874 .001 -1.1529 -.1972 
Other -.03787 .17196 1.000 -.5248 .4491 
Speech and Language 
Therapist 
.21866 .14700 1.000 -.1976 .6349 
Oncologist Surgeon .32068 .19086 .942 -.2198 .8612 
Specialist nurse -.35440 .22012 1.000 -.9777 .2689 
Other .28282 .22259 1.000 -.3475 .9131 
Speech and Language 
Therapist 
.53935 .20393 .087 -.0381 1.1168 
Specialist nurse Surgeon .67508* .16874 .001 .1972 1.1529 
Oncologist .35440 .22012 1.000 -.2689 .9777 
Other .63721* .20394 .020 .0597 1.2147 
Speech and Language 
Therapist 
.89374* .18339 .000 .3744 1.4131 
Other Surgeon .03787 .17196 1.000 -.4491 .5248 
Oncologist -.28282 .22259 1.000 -.9131 .3475 
Specialist nurse -.63721* .20394 .020 -1.2147 -.0597 
Speech and Language 
Therapist 
.25653 .18635 1.000 -.2712 .7842 
Speech and Language 
Therapist 
Surgeon -.21866 .14700 1.000 -.6349 .1976 
Oncologist -.53935 .20393 .087 -1.1168 .0381 
Specialist nurse -.89374* .18339 .000 -1.4131 -.3744 
Other -.25653 .18635 1.000 -.7842 .2712 
*. The mean difference is significant at the 0.05 level. 
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APPENDIX 8.4: QUESTIONNAIRE FOR THE PAG 
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APPENDIX 8.6: STUDY 5 - NHS ETHICS APPROVAL
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APPENDIX 8.10: STUDY 5 – EXAMPLE PATIENT INFORMATION SHEET  
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APPENDIX 8.11: STUDY 5 – EXAMPLE PATIENT CONSENT FORM 
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APPENDIX 8.12: STUDY 5 – EXAMPLE PATIENT QUESTIONNAIRE 
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APPENDIX 8.13: STUDY 5 – EXAMPLE SECOND INVITATION LETTER  
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APPENDIX 9.2: STUDY 6 – FEEDBACK FROM EXPERTS  
Expert Page Section Comment 
Virologist 2 What is HPV? Insert scrotum skin (balls) after penis 
3 How did I get HPV? I would rephrase to read oral sex and 
probably open mouth kissing since the 
real risk for transmission is the 
tongue/oral skin on the penile skin 
4 Is my partner at risk of 
HPV? 
Change ‘can be passed through skin-
to-skin’ to ‘is passed through skin-to-
skin’ 
5 Should I be vaccinated 
against HPV? 
Rather cautious - the evidence is that 
vaccination prevents persistent 
infection in the oral cavity and 
oropharynx. The statement that we do 
not know if it prevents cancer is 
correct, but it does prevent infection 
7 There is no need to change 
your behaviour 
‘Using condoms for all sexual 
behaviours’ - insert ‘especially with 
new partners 
HNC surgeon 2 What is HPV? Change balls to testes (all other terms 
are medical) 
2 Can they cause cancer? Maybe a bit confusing - you give e.g. 
6 and 11 and give examples of 2 and 
1 
2 What is HPV? 
‘Most sexually active…’ 
Maybe expand this to highlight that 
the vast majority of us will clear the 
infection, a small number will set up a 
chronic infective/inflammatory state 
while only a very small % of us will go 
on to get cancer 
2 What is HPV? 
‘All 12-13 year old…’ 
Is this true? Are we not currently using 
the bivalent vaccine? I may be wrong 
here, I can never remember! 
3 What is HPV? 
‘Men who have sex with 
men…’ 
Has this been formally agreed by the 
JCVI yet - I was of the opinion that 
official sign off was awaited? Again, I 
may be wrong? 
2 How did I get HPV? 
‘Oral sex and probably 
open mouth kissing…’ 
Mmm… what’s the real evidence for 
this? I just wonder if you need to find a 
way of explaining the collinearity 
effects and how individual sexual 
practice is difficult to quantify in terms 
of risk. Maybe a statement beginning, 
‘It would appear… however…’? 
3 Do I still have HPV? 
‘When cancer is caused by 
oral HPV has been treated, 
oral HPV is still found in 
some patients and not 
others’ 
What data is this statement based on? 
3 How did my HPV infection 
turn into cancer? 
‘Most infections go away on 
their own’ 
This fits with my previous point 
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4 Figure 1 Maybe try and quantify in terms of 
most, many, few etc? 
4 Is my partner at risk of 
HPV? 
‘If you have been together 
for several years it is 
likely…’ 
Mmmm… most adults will not have 
active infection?? 
4 Is my partner at risk of 
HPV? 
Cervical Screening 
Why is this relevant here? 
4 Is my partner at risk of 
HPV? 
Condom use 
I’m not sure there is any evidence for 
this in the case of OPC? Seems to be 
a bit of confusion with Cx? 
5 Will I get another cancer 
from HPV? 
Going for regular dental 
appointments 
What’s the evidence for this? 
5 Will I get another cancer 
from HPV? 
Going for cervical screening 
Why is this relevant in this context? 
6 There is no need to change 
your behaviour 
‘Open mouth kissing might 
also be possible’ 
Evidence? 
Health literacy 
academic 
1 This booklet will help 
answer your questions 
about human 
papillomavirus (HPV) and 
how it is linked to 
oropharyngeal cancer. 
Oropharyngeal cancer is 
the medical term used to 
include cancers in parts of 
the mouth and throat shown 
in the picture below. In this 
leaflet we call it ‘throat 
cancer’ as you might know 
this word better.  
 
This booklet will help answer your 
questions about human papillomavirus 
(HPV) and how it is linked to cancers 
in parts of the mouth and throat. The 
medical term is for these cancers is 
oropharyngeal (or-o-far-an-gee-al) 
cancer. In this leaflet we call it ‘throat 
cancer’ as you might know this word 
better. 
1 Diagram showing the parts 
of the oropharynx  
Probably too detailed. A very simple 
sketch (without bone, muscle, sinus 
cavity) would do.  Also it is not clear 
where the cancers live. Are patients 
told they have “back 1/3 of the tongue 
cancer”? 
Suggest very basic schematic 
showing only detail of cancer 
locations, and text of cancer names. 
e.g. tongue cancer – shade back 1/3 
caption should explain what diagram 
illustrates 
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1 HPV, or human 
papillomavirus, is a family 
of common viruses that live 
on our skin and the moist 
areas that line some parts 
of the body. HPV affects 
the: 
 
HPV, or human papillomavirus, is a 
family of common viruses that live on 
our skin and moist areas of the body. 
HPV affects the: 
2 What is HPV? Include skin in list? 
2  They are so common that everyone 
(?) has been exposed to one. Most 
people never have any symptoms. (?) 
 
2  Next sentence lists sexually 
transmitted/cancer causing HPV.  
Then table lists other kinds of HPV in 
other parts of the body. 
 
2  There are many types of HPV and 
most people have at least one type. 
Each type has a number. Some are 
low risk (do not cause cancer) and 
others are high risk (can cause 
cancer). In 20XX a vaccine to stop the 
most common HPV infections was 
developed. We hope (expect?) this 
will avoid HPV cancers in future. 
 
2 Most people Everyone? 
2 Some are low risk… What does low risk mean in this 
context? Low risk of infection or low 
risk of cancer? Risk concepts are 
often not well understood 
Confusing above. Is it just the 2 types 
that cause all HPV cancer? Or are 
they 2 examples of high-risk types? 
 
Also confusing if cervical cancer is 
caused almost always by these 2 
types, or if there are non-HPV causes 
of cervical cancer? 
 
2 Almost all (90%) throat 
cancers caused by HPV are 
caused by HPV-16 
Seems out of place here? 
3  Low-risk types can cause obvious 
symptoms 
Perhaps include this info in graphic 
above? 
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3 All 12-13 year old girls are 
offered vaccination against 
HPV-16, HPV-18 (the high 
risk types), HPV-6 and 
HPV-11 (the low risk types) 
as part of a national school-
based programme. Men 
who have sex with men 
aged up to 45 years are 
also offered the vaccine in 
clinics.  
 
This does not flow from above…and is 
covered in last para 
 
3 HPV is passed through 
skin-to-skin contact with 
someone who has the virus. 
This can include genital, 
oral and anal contact. Oral 
sex and probably open 
mouth kissing can be risk 
factors for oral HPV. Risk of 
getting HPV goes up with 
the number of sexual 
partners a person has but 
you can get it from just one 
partner.   
HPV is passed through skin-to-skin 
contact with someone who has the 
virus. This can include genital, oral 
and anal contact. Oral sex and 
probably open mouth kissing can be 
increase the chance of passing on 
oral HPV. You can get HPV from just 
one partner but the Risk of getting 
HPV goes up with the number of 
sexual partners a person has. Most 
sexually active men and women will 
come into contact with a high risk type 
of HPV at some point in their life. 
People with a high risk HPV infection 
usually have no obvious signs or 
symptoms. 
 
3 Just one partner Ok phew I can relax 
3 Probably open mouth 
kissing 
? Is it or isn’t it? 
3 Risk of getting HPV goes 
up with the number of 
sexual partners a person 
has  
The more partners you have, the more 
chance one of them will pass it on to 
you 
3 No obvious signs  “I didn’t notice any warts…” 
3 It is not possible to know 
the exact time when 
someone got the virus. It 
can lie hidden for many 
years. You could have had 
HPV for years without 
knowing.  
It is not possible to know the exact 
time when someone got the virus 
because it can hide in the body. You 
could have had HPV for many years 
without knowing. 
3 You could have had HPV 
for years without knowing 
Is it always many years? Because if 
slow-growing, maybe I don’t need to 
panic about it coming back? 
3 How did my HPV infection 
turn into cancer? 
More logical directly under ‘when did I 
get HPV?’ 
3 Do I still have HPV? And do I need to be worried that I will 
get cancer again? 
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4 Do I still have HPV? 
When cancer caused by 
oral HPV has been treated, 
oral HPV is still found in 
some patients and not 
others. If HPV cannot be 
found it might be that it has 
gone away or you could still 
have HPV but your immune 
system is controlling it. 
There is need for more 
research in this area.  
 
At this stage we don’t know. Three 
things can happen: 
 HPV goes away 
 HPV hides from the test but 
stays in the body 
 HPV stays in the body and 
can be found with a test 
Your doctor can test for HPV, but 
sometimes HPV hides so the test 
can’t find it. When cancer caused by 
oral (mouth) HPV has been treated, 
oral HPV is still found in some patients 
and not others. If HPV cannot be 
found it might be that it has gone 
away or you could still have HPV but 
your immune system is controlling it. 
We don’t fully understand why this 
happens.  
4 Do I still have HPV? These are quite complicated 
concepts. Rethink how to phrase this 
para. Some suggestions above 
5 Is my partner at risk of 
HPV? 
Do we have prevalence estimates that 
you can illustrate with side-by-side 
icon arrays? 
5 Is my partner at risk of 
HPV? 
Inserted: How can I reduce risk - 
rephrase to cover self, partners, 
others. How can people avoid HPV 
cancer? 
5 Is my partner at risk of 
HPV? 
It is important that all 
women aged 25-64 years 
go for cervical screening 
when invited to reduce the 
risk of cervical cancer. 
Women aged 25-64 years should go 
for cervical screening to reduce the 
risk of cervical cancer.  
Is it free? Where do I get more info? 
5 Will I get another cancer 
from HPV? 
It is unlikely that you will 
develop another HPV-
related cancer but it is hard 
to tell after treatment if the 
infection has gone 
completely. Your immune 
system could be controlling 
the infection. You can also 
stay healthy by: 
 not smoking 
 not drinking too much 
alcohol 
 eating a balanced diet 
 going for regular dental 
appointments 
 going for cervical 
screening (for women)  
This is another complicated concept 
This para is about taking care of your 
health to support your immune system 
It is unlikely that you will develop 
another HPV-related cancer even if 
the virus stays in your body.  Here are 
some things you can do to stay 
healthy: 
 don’t smoke 
 limit alcohol to 2 drinks per day 
 eating a balanced diet 
 going to the dentist twice a year 
 going for cervical screening (for 
women) every 2 years 
5 Your immune system could 
be controlling the infection 
Meaning? 
This is another complicated concept 
5 Not drinking too much Or recommended amount 
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5 Eating a balanced diet What does this mean? Equal amounts 
of meat and potatoes? Fish and 
chips? 
5 Should I be vaccinated 
against HPV? 
Vaccine is a new concept here. 
Perhaps a section with overall 
heading about preventing HPV 
cancer, and subheadings on healthy 
living, screening, and vaccines? 
Quite unclear 
6 Should I be vaccinated 
against HPV? 
As a large number of HPV-
related throat cancers are 
caused by HPV-16, 
researchers are hopeful 
that vaccinating children 
now will protect them 
against HPV-related throat 
cancers in the future. 
Too complicated. Basically – we have 
a vaccine, we don’t know yet if it 
works for throat cancer (but we think it 
should). We do know it works for 
cervical cancer 
6 Should I get my children 
vaccinated against HPV? 
 
The NHS recommends that 
girls are vaccinated against 
HPV. The vaccination has 
not yet been recommended 
for boys in the UK, but men 
who have sex with men 
who are aged up to 45 
years can get the vaccine in 
clinics.  
The NHS recommends that girls are 
vaccinated against HPV. Men aged up 
to 45 years who have sex with men 
can also get the vaccine in clinics.  
Does this mean it is free? What if my 
girl is already 16? 
Can I get my boy vaccinated if I pay 
for it? 
 
6 Men aged up to 45 years Assume this refers to person seeking 
vaccine, not their partner? 
6 HPV is normal HPV is common? 
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7 There is no need to change 
your behaviour 
 Risk of oral HPV 
increases with the 
number of sexual and 
oral sex partners you 
have. But some people 
get HPV with only one 
sexual partner.  
 Getting HPV through 
open mouth kissing 
might also be possible.  
 You could not have 
stopped yourself getting 
HPV so there is no 
need to change your 
sexual behaviour.  
 Most people will 
probably get oral HPV 
at some point in their 
lives. It is very unlucky 
when this turns into 
cancer and we do not 
know why some people 
get cancer and other 
people do not.  
Nobody is telling you to 
change your sexual practice 
but using condoms for all 
sexual behaviours, 
particularly with new 
partners, could give you 
and your partner some 
protection against genital 
HPV  
There is no need to change your 
sexual behaviour 
 Most people will probably get oral 
HPV at some point in their lives. It 
is very unlucky when this turns 
into cancer and we do not know 
why some people get cancer and 
other people do not.  
 Risk of oral HPV increases with 
the number of sexual and oral sex 
partners you have. But some 
people get HPV with only one 
sexual partner.  
 Getting HPV through open mouth 
kissing might also be possible.  
 You could not have stopped 
yourself getting HPV so there is 
no need to change your sexual 
behaviour.  
 Nobody is telling you to change 
your sexual practice but using 
condoms for all sexual 
behaviours, particularly with new 
partners, could give you and your 
partner some protection against 
genital HPV.  
7 Nobody is telling you to 
change your sexual practice 
but using condoms for all 
sexual behaviours, 
particularly with new 
partners, could give you 
and your partner some 
protection against genital 
HPV. 
This sentence is complex and a bit 
contradictory. I’m not telling you what 
to do… but wear a condom! 
 
7 There is no need to change 
your behaviour 
 
There seem to be some contradictions 
in this paragraph.   
 
Also this is for a person who has had 
HPV cancer. 
7 Outlook 5 year survival, size of tumour, risk of 
metastasis…. Could mean so many 
things 
7 Better This is a relative term and a bit 
meaningless. Yes you have a 
disfiguring cancer …. But it could be 
worse!! 
7 Treatment Is there positive news about the 
treatments? E.g. targeted therapies? 
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7 Websites More context would help. Or can you 
put them next to relevant text? 
General  Know when you are informing vs 
instructing. Make sure the language 
matches your intent 
General  Perhaps a section on things we don’t 
know? There is quite a bit of hesitant 
language, which people find 
confusing, and healthcare providers 
might find difficult to explain 
General  Vaccine section looks like you can 
only get it if you are 12-13f or 
<45msm. Which seems a bit odd (and 
the reasons for this are complex to 
explain). Does NHS limit prescriptions 
to only those groups or just 
recommendations/funding? 
General  Reassurance section is not very 
reassuring. It is a bit confusing and in 
some places contradictory. Might be 
better as just a list of known facts? 
E.g. 1. you can get it from one person, 
2. vaccine might prevent it, 3. 
condoms can help but not completely, 
etc 
General        Can you leave the choice about 
changing behaviour to the individual? 
Or refer them to sexual or other 
counselling service? There might be 
guilt, shame, etc…I can’t see that any 
leaflet can really address those 
feelings. Suggest talking to partner 
about any changes to sexual 
behaviour? Partners are reading this 
leaflet too and may need help   
General         Also if they smoke, they should stop! 
No debate, right? There are other 
lifestyle behaviours they may want to 
change – cancer diagnosis can be a 
crisis point for people to change their 
lives. Can they talk to their GP about 
this, or are there other services 
available? 
General         How well understood is concept of 
“immune system” by lay people? How 
else can you explain this? 
General  Be wary of vagueness e.g. “don’t drink 
too much”. What does this actually 
mean? Give people information they 
can act on. You could also present 
lifestyle tips as an attractive graphic 
(making sure that the meaning is 
obvious from the picture and you are 
not relying on words to qualify) 
APPENDIX 9.2 
467 
 
HNC Speech 
and language 
therapist 
1 call it ‘throat cancer’ as you 
might know this word better 
Maybe could change this to ‘In this 
leaflet we will simply use the term 
throat cancer … original may sound 
patronising to some people.  I have a 
slight concern that people may think 
that the larynx cancer (more 
commonly what we (clinicians) may 
call throat cancer) is also a result of 
HPV… but I can see that you are 
trying to find one word that’s not too 
technical. Not a biggy. 
2 Can they cause cancer? 
(figure)  
Could this be ‘which types cause 
cancer?’ 
6 Nobody is telling you to 
change your sexual practice 
but 
Not sure we need this bit 
6 Compared with head and 
neck cancers caused by 
smoking and drinking 
alcohol the outlook for 
patients with HPV-related 
throat cancers is better.  
 
It may be worth sounding this out on a 
few people to get the wording 
right/precise. HPV may co-exist with 
smoking, and outlook is affected by 
several other factors too. 
 
6 This is good news. HPV-
related throat cancers 
respond better to treatment. 
This is good news. HPV-related throat 
cancers tend to respond better to 
treatment – this may therefore provide 
a better outlook than head and neck 
cancers that are linked to smoking 
and alcohol use. 
6 This is good news.  I am a bit cautious about the “good 
news” - My PPI group think that 
getting cancer can never feel like 
good news, so being told that your 
cancer may respond better and 
therefore this is good news may be 
construed differently by different 
patients. Might be best to keep to fact. 
Academic 
behavioural 
scientist 
2 Most sexually active men 
and women will come into 
contact with a high risk type 
of HPV at some point in 
their life. People with a high 
risk HPV infection usually 
have no obvious signs or 
symptoms. 
All 12-13 year old girls are 
offered vaccination against 
HPV-16, HPV-18 (the high 
risk types), HPV-6 and 
HPV-11 (the low risk types) 
as part of a national school-
based programme. Men 
who have sex with men 
aged up to 45 years are 
also offered the vaccine in 
clinics. 
Maybe list under a subheading: ‘how 
many people get HPV?’ 
Where it sits currently feels a little 
disconnected. 
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3 When did I get HPV?  
It can lie hidden for many 
years 
Would ‘stay’ be better term? 
5 Should I get my children 
vaccinated against HPV? 
Have you considered adding a 
sentence explaining that girls are 
vaccinated at 12-13 to achieve the 
best immune response as this is when 
their immune systems are developing 
rapidly. 
 
5 Should I get my children 
vaccinated against HPV? 
Figure  
Might rethink the presentation of this 
info. I worry that people will confuse 
the message about vaccination and 
read 12-13 year old girls having sex 
with men. 
6 There is no need to change 
your behaviour: 
 
Risk of oral HPV increases 
with the number of sexual 
and oral sex partners you 
have. But some people get 
HPV with only one sexual 
partner.  
Getting HPV through open 
mouth kissing might also be 
possible 
This loses the message that HPV can 
be transmitted through skin to skin 
contact not necessarily bodily fluids 
6 Most people will probably 
get oral HPV at some point 
in their lives. It is very 
unlucky when this turns into 
cancer and we do not know 
why some people get 
cancer and other people do 
not.  
Most people will probably get oral 
HPV at some point in their lives. It is 
very unlucky when this turns into 
cancer and we do not know why some 
people get cancer and others do not.  
General  Think a glossary of terms might be 
helpful to include with a list of all the 
medical jargon words defined. 
I’d include in that words like verrucas, 
genitals, etc. 
General  The section on should I get my kids 
vaccinated might benefit from a 
sentence explaining the rationale for 
vaccinating at the onset of puberty, 
I.e. To generate maximum immune 
response to vaccine. 
General  I haven’t commented in detail on the 
2nd and 3rd figures, but I found them 
a little more difficult to process. 
But I’m assuming that you will get 
graphic designer to help with that? 
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APPENDIX 9.3: STUDY 6 – FEEDBACK FROM PATIENTS  
Comments DS (Male)  DK (Female)  TB (Female)  TR (Male) MT (Male) 
Overall 
impressions 
Thanks for sending me 
this brochure. It is 
extremely good, I wish 
my wife and I had 
access to this when I 
was first diagnosed. 
I think this brochure is 
excellent, and will be 
very useful for people 
diagnose with these 
cancers, and for their 
family and friends. 
Excellent to have a resource, I 
would have found this really 
useful at the point of diagnosis, 
especially to share with family 
as HPV related cancer is very 
difficult to talk about, especially 
with children and older relative. 
I didn’t share the specific 
details of my cancer for exactly 
this reason. 
 
 
I loved the leaflet, I 
feel you have 
included every detail 
required for a newly 
diagnosed patient. 
I find your leaflet to be 
reasonably attractive and 
very organised. The color 
scheme could be a little 
more colorful, in my 
opinion. But, I am a 
graphic artist and enjoy a 
more vibrant 
color palette. 
I need to know who 
the leaflet is aimed at 
to do this properly. Is 
it post-diagnosis or 
post-treatment 
patients? Or others? 
Better than other info 
I was given. 
Straightforward 
explanations. Not too 
scary. 
 
The use of 
the language 
used in the 
leaflet/is it 
written in 
words you 
can 
understand 
The language used is 
fine, it was an easy 
read without the use of 
medical terms or being 
overly verbose. (I also 
liked your guide on 
how to pronounce 
“oropharyngeal”, it is 
hard not to sound like 
an idiot trying to repeat 
that word the first time 
you hear it) 
Good use of plain English, nice 
tone, easy to read but gives a 
sense of being very 
professional. The only part-
sentence I was a little 
uncomfortable with was 
"You’re not responsible for 
your throat cancer" - I would 
have preferred it to say 
something more along the lines 
of ‘getting cancer is not a result 
of your behaviour’ - but I’m still 
not sure why this sentence 
bothers me... 
 
 The use of the language 
in your leaflet is very easy 
to understand and 
answers most, if not all, 
the questions I would 
have if I was concerned 
about the HPS viruses 
and their association with 
throat cancer. I do like the 
way the brochure is laid 
out. 
Yes 
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Comments DS (Male)  DK (Female)  TB (Female)  TR (Male) MT (Male) 
The order of 
the 
information 
presented 
The order of topics 
correlates with the 
order of the questions 
is likely to ask. 
 
The ‘Things to remember 
about HPV’ was a really useful 
reminder, but some of the 
information could helpfully be 
repeated in the body of the 
document. The most important 
phrase for me was "Having 
HPV is a result of normal 
sexual behaviour" - I think this 
should really be in the ‘How 
can HPV be passed on’ as the 
first line - or even the heading 
(replacing ‘How can HPV be 
passed on’) 
It’s well organised 
and the order of info 
is correct, detailing 
the statistics, 
complete 
with diagram etc  
 Start with (viral?) 
cancer, then talk 
about HPV? 
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Comments DS (Male)  DK (Female)  TB (Female)  TR (Male) MT (Male) 
The use of 
headings 
throughout 
the leaflet 
The headings help you 
zoom in on the topics 
making the leaflet a 
useful reference guide. 
Aside from comment above, 
headings were helpful. My only 
critical comment would be that 
where a question is posed, it is 
not really answered. For 
example, ‘Should I be 
vaccinated..’ has information 
about vaccination for women, 
men over 45 and does not 
really give me an idea of 
whether I can or should be 
vaccinated. The ‘What types of 
HPV can cause cancer?’ 
heading is not really relevant 
as it doesn’t say which types of 
HPV cause what - it lists high 
risk and low risk things - HPV 
related cancers are high risk 
HPVs? Are warts etc type of 
HPVs? Found this a little 
unclear. 
 
 I do like the headings. 
They are a nice size and 
the font is easy to read. I 
would make all headings 
flush left instead of 
making some centered 
and others flush left. I just 
like consistency. 
Fine 
Whether the 
diagrams are 
easy to 
understand 
The diagrams do the 
required job, I prefer 
the pie chart to the 
pyramid on page 12. 
The only one I found a little 
tricky to understand was the 
MANY YEARS diagram. I 
found the pie chart easier to 
visualise. 
 
I think both pie chart 
and pyramid are 
effective and 
explanatory 
 
I like page 13 better than 
page 12. 
Yes 
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Comments DS (Male)  DK (Female)  TB (Female)  TR (Male) MT (Male) 
If the leaflet covers 
the things you feel 
are important 
Yes, I can’t think of anything 
missing 
Apart from its own 
unanswered 
questions 
 
 I feel you were 
pretty thorough in 
describing how 
HPV is transmitted. 
You might consider 
some symptoms 
people may look for 
to ascertain 
whether they may 
need to be checked 
for throat cancer. 
 
If there is any 
information 
missing that you 
would have liked to 
be included 
Links on page 16 could include 
reference to: 
www.mouthcancerfoundation.org 
and www.oralcancer.org (Very 
technical with lots of medical 
research info) 
The link on page 16 to Cancer 
Research UK: 
http://goo.gl/96Ppcv may have 
been replaced by  
http://www.cancerresearchuk.org
/about-cancer/causes-of-
cancer/infections-hpv-and-
cancer/hpv-and-cancer 
Not quite sure why 
the help yourself box 
next to ‘Will I get 
another cancer..’ 
mentions dental 
checks, but not 
regular follow-up 
oncology checks 
(especially as a great 
number are not 
visible in the mouth 
by a dentist) 
 
You have 
mentioned how 
treatable this 
type of cancer is 
but not exactly 
what the 
treatment is. I 
understand it 
differs per 
patient and this 
leaflet is an 
explanatory 
leaflet regarding 
HPV, if 
I had any 
comments it 
would be to 
mention 
radio and 
chemo but I 
understand why 
it’s not. 
One thing I think 
would be beneficial 
would be to list the 
types of HPV that 
are not high risk 
types for HPV. I 
had HPV 16. That 
is a high risk HPV 
type. You might 
want to consider 
listing the low risk 
types. 
More vaccine info 
More detailed explanation 
of what HPV is 
Differences between viral 
and genetic and other 
types of cancer 
Can I get any test to see if 
I still have HPV 
Implications for children. 
Do they have a propensity 
for this type of disease? 
More info on the different 
types of cancer associated 
with HPV 
Info around lymphatic 
system, nodes etc. 
Likely treatment 
Long term implications of 
treatment and things to do 
to combat them 
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Comments DS (Male)  DK (Female)  TB (Female)  TR (Male) MT (Male) 
Is any of the 
information unhelpful 
No, there is nothing unnecessary 
here. I’d think most people would 
want access to as much information 
as possible when they are trying to 
understand what a HPV Throat 
cancer diagnosis means. 
  I think all of the 
information is very 
helpful. I like the leaflet 
very much. I think it 
just needs a little more 
information, which I 
have mentioned. 
No 
 
Is any of the 
information 
unnecessary 
No, as per my last answer    No 
 
Any other comments/ 
changes you would 
like to see 
My only negative criticism is in the 
‘Should I be vaccinated’ section.  
The second last sentence states 
“We don’t know for certain whether 
the vaccine prevents throat cancer 
– researchers are still working on 
this”.  
This doesn’t make sense to me. If 
the vaccine had prevented me from 
getting the virus I couldn’t have got 
an HPV cancer, what further 
research needs to be done? 
Are they saying that the vaccination 
only works for women and gay 
men? If heterosexual men aren’t 
getting vaccinations offered to 
them, I assume that the incidence 
of HPV cancers in men is lower 
than in women and gay men, so it 
isn’t seen as economically 
worthwhile.  
 
 Other than that, it’s 
perfect! I only wish 
it was available to 
my husband and I 
when I was 
diagnosed! We 
perhaps wouldn’t 
of relied on google 
and read info that 
made our 
relationship suffer 
in the first couple 
of weeks until my 
planning 
appointment 
at the cancer 
centre. At this 
appointment we 
were then 
informed of all the 
contents of this 
leaflet. A very big 
well done to you! 
😊 publish it soon!! 
 
  
 
 
 
 
4
7
4
 
A
P
P
E
N
D
IX
 9
.3
 
Comments DS (Male)  DK (Female)  TB (Female)  TR (Male) MT (Male) 
Cover 
design 
6, 9, 4, 1, 10, 5, 8, 7, 
2, 3 
I would have thought 
that the majority of 
people being 
diagnosed with these 
cancers will be middle 
aged men. This 
demograph doesn’t 
seem to be 
represented on many 
of the options. (I’m not 
being sexist here, my 
wife mentioned this 
before I did!). 
4; 3; 2; 10; 5 ;7; 1; 6; 8; 9 
 
1, 6, 4, 7, 2 4, 3, 5, 7, 2, 1, 9, 10, 6, 8 
 
3, 2, 6, 5, 4, 7, 9, 8, 
10, 1 
 
 
 
  
